| Test Name | Order Code | Test Code | Method | Reference Ranges |
| 1, 5 ANHYDROGLUCITOL (GLYCOMARK) | GLYMAR | GLYMAR | Enzymatic | GlycoMark ug/mL
M 10.7-32.0
F 6.8-29.3
|
| 11-DEOXYCORTISOL, SERUM (QUANTITATIVE) | 11DQS | 11DQS | Tandem Mass Spectrometry | 11-Deoxycortisol, Serum ng/dL
Premature 26-28 wks 110-1376
Premature 29-36 wks 70-455
Term 1-5 mo 10-200
Term 6-11 mo 10-156
1-6 yrs 7-210
F 7-9 years 94 or less
10-12 years 123 or less
13-15 years 107 or less
16-17 years 47 or less
18 yrs & more LT 33
M 7-9 years 120 or less
10-12 years 92 or less
13-15 years 95 or less
16-17 years 106 or less
18 years & moe LT 50
By Tanner Stage
F Tanner 1 94 or less
Tanner 2 136 or less
Tanner 3 99 or less
Tanner 4-5 50 or less
M Tanner 1 105 or less
Tanner 2 108 or less
Tanner 3 111 or less
Tanner 4-5 83 or less
After metyrapone stimulation GT 8000 |
14-3-3 PROTEIN, CSF (PRION DISEASE) | PRION | PRION | Immunoassay | 14-3-3 Protein, CSF See separate report |
| 17-ALPHA-HYDROXYPROGESTERONE | 17AHYD | 17AHYD | RIA/Column | 17-Alpha-hydroxyprogesterone ng/dL
Premature 26-28 wks Day 4 range 124-841
Premature 31-35 wks Day 4 range 26-568
Full term newborn Day 3 range LT 78
M 1-11 months Levels increase to peak values
ranging from 40-200 between 30-60
days of age. Values then decline to
a prepubertal value of LT 91 before
one year of age.
LT 10 yrs LT 91
Tanner Stage 1 LT 91
Tanner Stage 2 LT 116
Tanner Stage 3 10-138
Tanner Stage 4 29-180
Tanner Stage 5 24-175
Adult 27-199
F 1-11 months 13-106
LT 9 yrs LT 91
Tanner Stage 1 LT 83
Tanner Stage 2 11-98
Tanner Stage 3 11-155
Tanner Stage 4 18-230
Tanner Stage 5 20-265
Adult-Follicular 15-70
Adult-Luteal 35-290
|
| 17-HYDROXYCORTICOSTEROIDS | 17OHQ | 17OHQ | Porter-Silber Reaction | Collection Period h
Volume mL
17-Hydroxycorticosteroids mg/d
Urine
4.0-14.0
17-Hydroxycoricosteroids mg/gCr
2.0-6.5
Creatinine, Urine mg/dL
Creatinine, Urine mg/d
M 3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81 yrs + 600-2000
F 3-8 yrs 140-170
9-12 ys 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
52-80 yrs 500-1400
81 yrs + 400-1300 |
| 17-HYDROXYPROGESTERONE | 17HPRG | 17HPRG | RIA | 17-Hydroxyprogesterone ng/dL
F Premature 26-28 weeks 124-841
Premature 29-35 weeks 26-568
Full term-day 3 7-77
4-29 days 7-106
1-5 mons 13-106
6-35 mons 211 or less
3-6 yrs 278 or less
7-9 yrs 71 or less
10-12 yrs 129 or less
13-15 yrs 9-208
16-17 yrs 178 or less
18 yrs + LT 207
Follicular 15-70
Luteal 35-290
Tanner Stage I 74 or less
Tanner Stage II 164 or less
Tanner Stage III 13-209
Tanner Stage IV-V 7-170
M Premature 26-28 weeks 124-841
Premature 29-35 weeks 26-568
Full term-day 3 7-77
4-29 days LT 200
1-5 mons 90 or less
6-35 mons 181 or less
3-6 yrs 205 or less
7-9 yrs 63 or less
10-12 yrs 79 or less
13-15 yrs 9 to 140
16-17 yrs 24 to 192
18 yrs + LT 139
Tanner Stage I 62 or less
Tanner Stage II 104 or less
Tanner Stage III 151 or less
Tanner Stage IV-V 20-173 |
| 17-KETOSTEROIDS, URINE | KETO | 17KSUQ | Spectrophotometric (Zimmerman Reaction) | Collection Period h
Volume mL
17 Keto Steroids mg/L
17 Keto Steroids mg/d
Up to 1 yr 0.0-1.0
1-5 yrs 1.0-2.0
M 6-10 yrs 1.0-4.4
11-12 yrs 1.3-8.5
13-16 yrs 3.4-9.8
17-50 yrs 5.3-17.6
50+ yrs 4.1-12.1
F 6-10 yrs 1.4-3.9
11-12 yrs 3.8-9.5
13-16 yrs 4.5-17.1
17-50 yrs 4.4-14.2
50+ yrs 3.2-10.6
Creatinine, Urine mg/dL
Creatinine, Urine mg/d
M 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81+ yrs 600-2000
F 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
50-80 yrs 500-1400
81+ yrs 400-1300 |
| 17-OH PREGNENOLONE | 17OHPG | 17OHPG | HPLC/TMS | 17-OH Pregnenolone ng/dL
0-15 yrs 44-235
16+ yrs 53-357 |
| 18-HYDROXYCORTICOSTERONE | 18OHCC | 18OHCC | HPLC/MS | 18-Hydroxycorticosterone ng/dL
Premature infant 10-670
(26-28 weeks) Day 4
Premature infant 57-410
(31-35 weeks) Day 4
Full-term infant
3 days 31-546
1-12 months 5-220
Children
1-2 years 18-155
2-10 years 6-85
10-15 years 10-72
Adults 9-58
Normal Na intake
8 am supine 4-21
8 am upright 5-46
Low Na intake
8 am supine 11-75
8 am upright 19-96 |
| 21-HYDROXYLASE ANTIBODIES | 21HYAB | 21HYAB | RIA | 21-Hydroxylase Antibodies 0.0-1.0 U/mL |
| 3-ALPHA-ANDROSTANEDIOL GLUCURONIDE | 3-AAG | 3AAG | Enzyme Digestion/Chrom/RIA | 3-Alpha-Diol Glucuronide ng/dL
M Adult 260-1500
F Adult 60-300
Prepubertal 10-60
F 33-244 Tanner Stages II-III
M 19-164 Tanner Stages II-III |
| 5' NUCLEOTIDASE | 5NT | 5NT | Enzymatic | 5' Nucleotidase 0-15 U/L |
| 5-FLUOROCYTOSINE, ANTIFUNGAL LEVEL | FUNAB | FUNAB | BA | 5-Fluorocytosine Level Peak serum 30.0-45.0 ug/mL
Any undisclosed antibiotics might affect the results. |
| 5-HIAA, URINE (QUANTITATIVE) | 5-HIAA | HIAAUQ | HPLC/Electrochemical Detection | Collection Period h
Volume mL
5-HIAA 0.0-10.0 mg/24h |
| 5-HIAA, URINE (RANDOM) | HIAUR | HIAUR | HPLC/Electro Det/Enzymatic (IDMS traceable) | Creatinine, Urine Random No reference range established mg/dL
5-HIAA, Urine Random No reference range established mg/L
5-HIAA, Urine Random mg/gCr
3-8 years 1.2-16.2
9-12 years 2.4-8.7
13-17 years 1.8-5.5
Adults 1.3-6.9
Please note: A 24-hr urine collection is the
preferred specimen. These reference ranges
for random urine collections are based on
literature review. |
| ABO & RH | ABO/RH | MABORH | Hemagglutination | ABO
RH |
| ABO GROUP | ABO | M1ABO | Hemagglutination | ABO |
| ACETAMINOPHEN | TYLEN | TYL | Enzymatic | Acetaminophen ug/mL
Therapeutic 10-25
Toxic GT 150 |
| ACETAMINOPHEN, URINE | ACETAM | ACETAM | GC/MS | Acetaminophen, Urine 2.5-200 ug/mL |
| ACETAZOLAMIDE SERUM/PLASMA | ACETAZ | ACETAZ | HPLC | Acetazolamide 10-15 ug/mL
Usual adjunct antiepileptic therapeutic range. |
| ACETONE | ACETONE | KET | Acetest/Semiquantitative/Nitroprusside | Acetone Negative |
| ACETYLCHOLINE BINDING ANTIBODY | AR-AB | ACETYL | RIA | Acetylcholine Binding Ab nmol/L
Negative 0.0-0.4
Positive 0.5 or greater
Approximately 85-90% of patients with
myasthenia gravis (MG) express anti-
bodies to the acetylcholine receptor
(AChR), which can be divided into
binding, blocking, and modulating
antibodies. Binding antibody can activate
complement and lead to loss of AChR.
Blocking antibody may impair binding of
acethlcholine to the receptor leading to
poor muscle contraction. Modulating
antibody causes receptor endocytosis
resulting in loss of AChR expression,
which correlates most closely with
clinical severity of disease.
Approximately 10-15% of individuals with
confirmed myasthenia gravis have no
measurable binding, blocking or
modulating antibodies. |
| ACETYLCHOLINE RECEPTOR BLOCKING ANTIBODY | AR.AB.BLOCK | ARAB | RIA | Acetylcholine Blocking Ab 0-15 %
Interpretive Criteria
Negative 0-15 % blocking
Indeterminate 16-24 % blocking
Positive 25 % blocking or more
Approximately 85-90% of patients with
myasthenia gravis (MG) express anti-
bodies to the acetylcholine receptor
(AChR), which can be divided into
binding, blocking, and modulating
antibodies. Binding antibody can activate
complement and lead to loss of AChR.
Blocking antibody may impair
binding of acetylcholine to
the receptor leading to
poor muscle contraction. Modulating
antibody causes receptor endocytosis
resulting in loss of AChR expression,
which correlates most closely with
clinical severity of disease.
Approximately 10-15% of individuals
confirmed myasthenia gravis have no
measurable binding, blocking or
modulating antibodies. |
| ACETYLCHOLINE RECEPTOR MODULATING ANTIBODY | ACHRMO | ACHRMO | Radioreceptor Assay | ACHR Modulating Antibody %
Negative 0-20
Indeterminate 21-25
Positive 26 or greater
Approximately 85-90% of patients with
myasthenia gravis (MG) express anti-
bodies to the acetylcholine receptor
(AChR), which can be divided into
binding, blocking, and modulating
antibody. Binding antibody can activate
complement and lead to loss of AChR.
Blocking antibody may impair binding of
acetylcholine to the receptor leading to
poor muscle contraction. Modulating
antibody causes receptor endocytosis
resulting in loss of AChR expression,
which correlates most closely with
clinical severity of disease.
Approximately 10-15% of individuals with
confirmed myasthenia gravis have no
measurable binding, blocking or
modulating antibodies. |
| ACETYLCHOLINESTERASE, AMNIOTIC FLUID | AACHE | AACHE | EIA | Acetylcholinesterase, Amniotic Fluid
Interpretation
Reviewed by
Date |
ACID FAST BACILLUS, MIC 12 DRUG PACKAGE | M12NJ | M12NJ | Bactec MIC | AFB MIC 12 Drug Package
See separate report |
| ACID FAST BACILLUS, MTB COMPLEX DNA, PCR | AFBPCR | AFBPCR | PCR | MTB Complex DNA by PCR Not detected
This assay is performed using the
Amplicor MTB test manufactured &
distributed by Roche Diagnostics
Systems, Inc. It is a target amplified
in vitro diagnostic test for the
qualitative detection of M. tuberculosis
complex DNA in concentrated sediments
prepared from sputum (induced/
expectorated), bronchial specimens
including bronchial alveolar lavages
and aspirates, or tracheal aspirates.
The MTB test is intended for use as an
adjunctive test for evaluating acid-
fast bacilli smear positive sediments
from untreated patients suspected of
having tuberculosis. It is specific
for, but does not differentiate among,
members of the M. tuberculosis complex,
i.e., M. tuberculosis, M. bovis,
M. bovis BCG, M africanum, & M. micoti.
A negative test result does not exclude
the possibility of isolating a M.
tuberculosis complex organism from the
specimen. The manufacturer has not
determined the efficacy of this test
for the detection of M. tuberculosis
from non-respiratory specimens. The
performance characteristics of the
test on non-respiratory specimens
have been determined by Focus
Technologies. |
| ACID MUCOPOLYSACCHARIDES, URINE | ACMPS | ACMPS | Colorimetric | Acid Mucopolysaccharides, mg/L
Urine 0-2 months LT 60
3-6 months LT 60
7-12 months LT 60
GT 1 year LT 60
Acid MPS (calc) 0-2 months LT 350 mg/gCr
3-6 months LT 250
7-12 months LT 150
GT 1 year LT 60
MPS Interpretation |
| ACID PHOSPHATASE WITH TARTRATE STAIN | SS.TRAP | TRAP | Cytochemical Stain; TRAP Stain | Source
Tartrate Resistant Acid Phosphatase Stain
TRAP Interpretation
Reviewed by |
| ACTIVATED PROTEIN C RESISTANCE | APCRES | APCR | Clot-based Assay | APC Resistance
Normal GT 2.0 ratio |
| ACYLCARNITINES, QUANTITATIVE | ACYQUT | ACYQUT | MS/MS | Acetylcarnitine, C:2 nmol/mL
1-7 days 2.14-15.89
8 days-7 years 2.00-27.57
8 yrs & older 2.00-17.83
Propionylcarnitine, C3 nmol/mL
1-7 days LT 0.55
8 days-7 years LT 1.78
8 yrs & older LT 0.88
Iso-/Butyrylcarnitine, C4 nmol/mL
1-7 days LT 0.46m
8 days-7 years LT 1.06
8 yrs & older LT 0.83
Isovaleryl-/2-Methylbutyrylcarnitine nmol/mL
C5
1-7 days LT 0.38
8 days-7 years LT 0.63
8 yrs & older LT 0.51
Hexanoylcarnitine, C6 nmol/mL
1-7 days LT 0.14
8 days-7 years LT 0.23
8 yrs & older LT 0.17
3-OH-hexanoylcarnitine, C6-OH nmol/mL
1-7 days LT 0.08
8 days-7 years LT 0.19
8 yrs & older LT 0.09
Octenoylcarnitine, C8:1 nmol/mL
1-7 days LT 0.48
8 days-7 years LT 0.91
8 yrs & older LT 0.88
Octanoylcarnitine, C8 nmol/mL
1-7 days LT 0.19
8 days-7 years LT 0.45
8 yrs & older LT 0.78
Decenoylcarnitine, C10:1 nmol/mL
1-7 days LT 0.25
8 days-7 years LT 0.46
8 yrs & older LT 0.47
Decanoylcarnitine, C10 nmol/mL
1-7 days LT 0.27
8 days-7 years LT 0.91
8 years & older LT 0.88
Glutarylcarnitine, C5-DC nmol/mL
1-7 days LT 0.06
8 days-7 years LT 0.10
8 yrs & older LT 0.11
Dodecenoylcarnitine, C12:1 nmol/mL
1-7 days LT 0.19
8 days-7 years LT 0.37
8 yrs & older LT 0.35
Dodecanoylcarnitine, C12 nmol/mL
1-7 days LT 0.18
8 days-7 years LT 0.35
8 yrs & older LT 0.26
3-OH-dodecanoylcarnitine, C12-OH nmol/mL
1-7 days LT 0.06
8 days-7 years LT 0.09
8 yrs & older LT 0.26
Tetradecadienoylcarnitine, C14:2 nmol/mL
1-7 days LT 0.09
8 days-7 years LT 0.13
8 yrs & older LT 0.18
Tetradecenoylcarnitine, C14:1 nmol/mL
1-7 days LT 0.16
8 days-7 years LT 0.35
8 yrs & older LT 0.24
Tetradecanoylcarnitine, C14 nmol/mL
1-7 days LT 0.11
8 days-7 years LT 0.15
8 yrs & older LT 0.12
3-OH-tetradecenoylcarnitine, nmol/mL
C14:1-OH
1-7 days LT 0.06
8 days-7 years LT 0.18
8 yrs & older LT 0.13
3-OH-tetradecanoylcarnitine, C14-OH nmol/mL
1-7 days LT 0.04
8 days-7 years LT 0.05
8 yrs & older LT 0.08
Hexadecenoylcarnitine, C16:1 nmol/mL
1-7 days LT 0.15
8 days-7 years LT 0.21
8 yrs & older LT 0.10
Hexadecanoylcarnitine, C16 nmol/mL
1-7 days LT 0.36
8 days-7 years LT 0.52
8 yrs & older LT 0.23
3-OH-hexadecenoylcarnitine, C16:1-OH nmol/mL
1-7 days LT 0.78
8 days-7 years LT 0.36
8 yrs & older LT 0.06
3-OH-hexadecanoylcarnitine, C16-OH nmol/mL
1-7 days LT 0.10
8 days-7 years LT 0.07
8 yrs & older LT 0.06
Linoleylcarnitine, C18:2 nmol/mL
1-7 days LT 0.12
8 days-7 years LT 0.31
8 yrs & older LT 0.24
Oleylcarnitine, C18:1 nmol/mL
1-7 days LT 0.25
8 days-7 years LT 0.45
8 yrs & older LT 0.39
Stearoylcarnitine, C18 nmol/mL
1-7 days LT 0.10
8 days-7 years LT 0.12
8 yrs & older LT 0.14
3-OH-linoleylcarnitine, C18:2-OH nmol/mL
1-7 days LT 0.04
8 days-7 years LT 0.06
8 yrs & older LT 0.06
3-OH-oleylcarnitine, C18:1-OH nmol/mL
1-7 days LT 0.03
8 days-7 years LT 0.04
8 yrs & older LT 0.06
Comment |
| ADAMTS13 EVALUATION (REFLEXIVE) | ADAM13 | ADAM13 | FRET with synthetic substrate | ADAMTS13 Activity 67 or greater %
ADAMTS13 Inhibitor 0.4 or less Inhibitor Units
ADAMTS13 Antibody 18 or less Arbitrary Units
|
| ADENOSINE DEAMINASE, BODY FLUID | ADEDFL | ADEDFL | Spectrophotometry | Adenosine Deaminase, Body Fluid U/L
Pleural transudate (total protein
LT 3.0 g/dL) 0.0-6.7
Pleural exudate (total protein GT
3.0 g/dL) 1.6-9.2
Tuberculosis 19.0-85.0
Neoplastic 0.0-22.0
Pneumonia 0.0-19.0
RA 23.0-42.0
Lymphoma 6.0-420.0
Peritoneal exudate or transudate
CSF LT 10.0 |
| ADENOSINE DEAMINASE, RBC | ADA.RBC | ADARBC | Spectrophotometry | Adenosine Deaminase, RBC 0.6-1.8 U/gHgb |
| ADENOVIRUS ANTIBODY, IGG & IGM | ADENGM | ADENGM | ELISA | Adenovirus Antibody, IgG IV
0.89 or less Negative-no significant
level of adenovirus IgG antibody
detected.
0.90-1.10 Equivocal-questionable
presence of adenovirus IgG antibody
detected. Repeat testing in 10-14
days may be helpful.
1.11 or more Positive-IgG antibody
to adenovirus detected, which may
suggest current or past infection.
Adenovirus Antibody, IgM IV
0.89 or less Negative-no significant
level of adenovirus IgM antibody
detected.
0.90-1.10 Equivocal-questionable
presence of adenovirus IgM antibody
detected. Repeat testing in 10-14
days may be helpful.
1.11 or more Positive-IgM antibody
to adenovirus detected, which may
suggest current or recent infection. |
| ADRENAL ANTIBODY, (REFLEXIVE) | ADREAB | ADREAB | IFA | Adrenal Antibody Negative in normal
individuals
Adrenal Antibody, Titer Titer |
| ADRENOCORTICOTROPIC HORMONE ASSAY | ACTH | ACTH | Chemiluminesence DPC Immulite | ACTH 0-46 pg/mL
Adults drawn between 0700 and
1000 AM |
| ALBUMIN | ALB | ALB | Colorimetric | Albumin g/dL
0-4 days 2.9-4.6
4 days-14 yrs 3.9-5.6
14-18 yrs 3.3-4.7
18-60 yrs 3.5-5.0
60-90 yrs 3.3-4.8
90 yrs+ 3.0-4.7 |
| ALBUMIN, CSF | ALB-C | ALBSF | Nephelometry | Albumin, CSF 5-30 mg/dL |
| ALBUMIN, FLUID | ALBFL | ALBFL | Colorimetric | Albumin, Fluid g/dL
No reference range established.
Values LT 1.2 g/dL will be reported as such.
Method not validated for body fluid.
Clinical correlation necessary. |
| ALBUMIN, GLYCATED | GLYCOALBUMIN | GLYALB | Turbidimetric Immunoassay | Albumin, Glycated 0.6-3.0 % |
| ALDOLASE | ALDOLASE | ALD | Enzymatic | Aldolase U/L
M 2.0-7.0
F 1.0-8.0 |
| ALDOSTERONE, SERUM | ALDOSTERONE | ALDOS | RIA | Aldosterone ng/dL
0-6 days 5.0-102.0
1-3 weeks 6.0-179.0
1-11 mo 7.0-99.0
1-2 yrs 7.0-93.0
3-10 yrs 4.0-44.0
11-14 yrs 4.0-31.0
15 yrs + 31.0 or less
Standing 4.0-31.0
Recumbent 16.0 or less |
| ALDOSTERONE, URINE | ALDOSTERONE-U | ALDUQ | RIA | Collection Period h
Volume mL
Aldosterone, Urine
Normal diet 6-25 ug/d
Low salt diet 17-44
High salt diet 0-6
Normal urine values of aldosterone
Normal sodium intake 100-200 mEq
Low sodium intake LT 25 mEq
High sodium intake GT 200 mEq
Creatinine, Urine mg/dL
Creatinine, Urine mg/d
M 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81+ yrs 600-2000
F 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
81+ yrs 400-1300 |
| ALDOSTERONE/RENIN RATIO | ALDREN | ALDREN | RIA | Aldosterone ng/dL
0-6 days 5.0-102.0
1-3 weeks 6.0-179.0
1-11 mo 7.0-99.0
1-2 yrs 7.0-93.0
3-10 yrs 4.0-44.0
11-14 yrs 4.0-31.0
15 yrs + 31.0 or less
Standing 4.0-31.0
Recumbent 16.0 or less
Renin ng/mL/h
(With unrestricted salt intake)
Random Ambulatory 0.8-2.5
Random Non-ambulatory 1.5-5.2
Child, supine with normal sodium intake
1-7 days 15-114
7 days-12 mo 18-120
12 mo-3 yrs 13-36
3-5 yrs 7.5-21.1
5-10 yrs 3.8-19.2
10-15 yrs 3.8-10.7
Aldosterone/Renin Ratio
An Aldosterone/Renin activity ratio
of GT 25 is suggestive of
hyperaldosteronism. |
| ALKALINE PHOSPHATASE | AKP | ALKP | Colorimetric | Alkaline Phosphatase U/L
0-6 yrs 72-307
6-9 yrs 133-340
9-15 yrs M 103-429
15-18 yrs M 49-210
9-13 yrs F 99-453
13-15 yrs F 53-186
15-18 yrs F 38-110
18 yrs+ 38-110 |
| ALKALINE PHOSPHATASE ISOENZYMES (HEAT STABLE) | AKP-ISO | AKPISO | Color w/ Heat Fract | Alkaline Phosphatase U/L
0-6 yrs 72-307
6-9 yrs 133-340
9-15 yrs M 103-429
15-18 yrs M 49-210
9-13 yrs F 99-453
13-15 yrs F 53-186
15-18 yrs F 38-110
18 yrs+ 38-110
Alkaline Phos, Heat Stable 30-85 U/L
Alkaline Phos, % Heat Stable %
LT 20% heat stable activity indicates
a predominance of bone isoenzyme.
25-55% heat stable activity suggests
a predominance of liver and/or in-
testinal isoenzyme.
GT 25% heat stable activity in a
patient with an elevated GGT
indicates a predominance of liver
isoenzyme. |
| ALKALINE PHOSPHATASE, BONE SPECIFIC | ALKPBS | ALKPBS | ICMA | Alkaline Phosphatase, Bone Specific ug/L
F 7-9 yrs 36.3-159.4
10-12 yrs 44.2-163.3
13-15 yrs 14.8-136.2
16-17 yrs 10.5-44.8
Premenopausal 4.5-16.9
Postmenopausal 7.0-22.4
M 7-9 yrs 48.6-140.4
10-12 yrs 48.8-155.5
13-15 yrs 27.8-210.9
16-17 yrs 15.3-126.8
18-24 yrs not established
25 yrs & older 6.5-20.1 |
| ALKALINE PHOSPHATASE, ISOENZYMES [ARUP] | AKPIAR | AKPIAR | Kinetic Heat Inactivation/Enzymatic | Alkaline Phosphatase U/L
M 0-30 days 60-320
1-12 mo 70-350
1-3 yrs 125-320
4-6 yrs 150-370
7-9 yrs 150-440
10-11 yrs 150-470
12-13 yrs 160-500
14-15 yrs 130-530
16-19 yrs 60-270
20+ yrs 40-120
F 0-30 days 60-320
1-12 mo 70-350
1-3 yrs 125-320
4-6 yrs 150-370
7-9 yrs 150-440
10-11 yrs 150-530
12-13 yrs 110-525
14-15 yrs 55-305
16-19 yrs 40-120
20 yrs + 40-120
Liver U/L
M 1-6 yrs 0-145
7-11 yrs 0-182
12-15 yrs 0-226
16-19 yrs 0-114
19+ yrs 0-94
F 1-9 yrs 0-148
10-15 yrs 0-162
16 yrs & older 0-94
Bone U/L
M 1-6 yrs 0-208
7-9 yrs 0-264
10-15 yrs 0-340
16-19 yrs 0-165
20+ yrs 0-55
F 1-6 yrs 0-189
7-9 yrs 0-246
10-13 yrs 0-340
14-15 yrs 0-91
16 yrs & older 0-55
|
| ALLERGEN, ACREMONIUM KILIENSE, IGE | ICMCP | ICMCP | FEIA | Acremonium Kiliense, IgE LT 0.35 kU/L |
| ALLERGEN, ACACIA TREE, IGE | ICTAC | ICTAC | FEIA | Acacia Tree, IgE LT 0.35 kU/L |
| ALLERGEN, ALFALFA, IGE [ARUP] | ICAFAR | ICAFAR | Immunocap | Alfalfa, IgE LT 0.35 kU/L |
| ALLERGEN, ALMOND, IGE | ICFAL | ICFAL | FEIA | Almond, IgE LT 0.35 kU/L |
| ALLERGEN, ALPHA-LACTALBUMIN [ARUP] | ICALAR | ICALAR | Immunocap | Alpha-Lactalbumin, IgE LT 0.35 kU/L |
| ALLERGEN, ALTERNARIA TENUIS (ALTERNATA), IGE | ICMAL | ICMAL | FEIA | Alternaria Tenuis (Alternata), IgE LT 0.35 kU/L |
| ALLERGEN, AMERICAN BEECH TREE, IGE | ICTAB | ICTAB | FEIA | American Beech Tree, IgE LT 0.35 kU/L |
| ALLERGEN, AMERICAN CHEESE, IGE [IBT] | ICACI | ICACI | RIA | American Cheese, IgE LT 0.35 kU/L |
| ALLERGEN, APPLE, IGE | ICFAP | ICFAP | FEIA | Apple, IgE LT 0.35 kU/L |
| ALLERGEN, APRICOT IGE (ARUP) | ICAPAR | ICAPAR | IMMUNOCAP | Apricot, IgE LT 0.35 kU/L |
| ALLERGEN, ASPERGILLUS FUMIGATUS, IGE | ICMAF | ICMAF | FEIA | Aspergillus Fumigatus, IgE LT 0.35 kU/L |
| ALLERGEN, ASPERGILLUS NIGER, IGE | ICMAN | ICMAN | FEIA | Aspergillus Niger, IgE LT 0.35 kU/L |
| ALLERGEN, AUREOBASIDIUM PULLULANS (PULLULARIA), IGE | ICMPU | ICMPU | FEIA | Aureobasidium Pullulans (Pullularia), IgE LT 0.35 kU/L |
| ALLERGEN, AVOCADO, IGE | ICFAVO | ICFAVO | FEIA | Avocado, IgE LT 0.35 kU/L |
| ALLERGEN, BAKERS YEAST, IGG4 [IBT] | ICBYG4 | ICBYG4 | ImmunoCAP FEIA | Bakers Yeast, IgG4 LT 1 mcg/mL
|
| ALLERGEN, BANANA, IGE | ICFBN | ICFBN | FEIA | Banana, IgE LT 0.35 kU/L |
| ALLERGEN, BANANA, IGG4 [IBT] | ICBNG4 | ICBNG4 | ImmunoCAP FEIA | Banana, IgG4 LT 10 mcg/mL
|
| ALLERGEN, BARLEY, IGE | ICFBA | ICFBA | FEIA | Barley, IgE LT 0.35 kU/L |
| ALLERGEN, BARLEY, IGG4 [IBT] | ICBAG4 | ICBAG4 | ImmunoCAP FEIA | Barley, IgG4 LT 1 mcg/mL
|
| ALLERGEN, BASIL IGE [IBT] | ICBASL | ICBASL | FEIA | Basil, IgE LT 0.35 kU/L |
| ALLERGEN, BEEF, IGE | ICFBF | ICFBF | FEIA | Beef, IgE LT 0.35 kU/L |
| ALLERGEN, BELL PEPPER/PAPRIKA, IGE | ICFBPP | ICFBPP | FEIA | Bell Pepper/Paprika, IgE LT 0.35 kU/L |
| ALLERGEN, BENTGRASS, IGE | ICGBG | ICGBG | FEIA | Bentgrass, IgE LT 0.35 kU/L |
| ALLERGEN, BERMUDA GRASS, IGE | ICGBM | ICGBM | FEIA | Bermuda Grass, IgE LT 0.35 kU/L |
| ALLERGEN, BIRD FANCIER'S PRECIPITIN PANEL 1 [IBT] | ICBFP | ICBFP | Gel Diffusion (Ouchterlony) | Canary Droppings Negative
Chicken Serum Negative
Cockatiel Droppings Negative
Finch Droppings Negative
Parakeet Droppings Negative
Parakeet Serum Negative
Parrot Droppings Negative
Parrot Serum Negative
Pigeon/Dove Droppings Negative
Pigeon/Dove Serum Negative
|
| ALLERGEN, BLACK PEPPER, IGE [ARUP] | ICPEBL | ICPEBL | Immunocap | Black Pepper, IgE LT 0.35 kU/L |
| ALLERGEN, BLUE MUSSEL, IGE | ICFBM | ICFBM | FEIA | Blue Mussel, IgE LT 0.35 kU/L |
| ALLERGEN, BLUEBERRY IGE [ARUP] | ICBLAR | ICBLAR | Immunocap | Blueberry, IgE LT 0.35 kU/L |
| ALLERGEN, BOX ELDER, IGE | ICTBE | ICTBE | FEIA | Box Elder, IgE LT 0.35 kU/L |
| ALLERGEN, BRAZIL NUT, IGE | ICFBZ | ICFBZ | FEIA | Brazil Nut, IgE LT 0.35 kU/L |
| ALLERGEN, BROCCOLI, IGE | ICFBR | ICFBR | FEIA | Broccoli, IgE LT 0.35 kU/L |
| ALLERGEN, BROME GRASS, IGE | ICGBR | ICGBR | FEIA | Brome Grass, IgE LT 0.35 kU/L |
| ALLERGEN, BUCKWHEAT IGE [IBT] | ICBWIB | ICBWIB | FEIA | Buckwheat, IgE LT 0.35 kU/L |
| ALLERGEN, CABBAGE [ARUP] | ICCAAR | ICCAAR | Immunocap | Cabbage, IgE LT 0.35 kU/L |
| ALLERGEN, CANDIDA ALBICANS, IGE | ICMCA | ICMCA | FEIA | Candida Albicans, IgE LT 0.35 kU/L |
| ALLERGEN, CARROT, IGE | ICFCA | ICFCA | FEIA | Carrot, IgE LT 0.35 kU/L |
| ALLERGEN, CASEIN, IGE | ICFCS | ICFCS | FEIA | Casein, IgE LT 0.35 kU/L |
| ALLERGEN, CASHEW NUT, IGE | ICFCW | ICFCW | FEIA | Cashew Nut, IgE LT 0.35 kU/L |
| ALLERGEN, CAT DANDER, IGE | ICECE | ICECE | FEIA | Cat Dander, IgE LT 0.35 kU/L |
| ALLERGEN, CELERY, IGE | ICFCEL | ICFCEL | FEIA | Celery, IgE LT 0.35 kU/L |
| ALLERGEN, CHEESE, CHEDDAR TYPE, IGE | ICFCC | ICFCC | FEIA | Cheese, Cheddar Type, IgE LT 0.35 kU/L |
| ALLERGEN, CHEESE, MOLD TYPE, IGE | ICFMC | ICFMC | FEIA | Cheese, Mold Type, IgE LT 0.35 kU/L |
| ALLERGEN, CHERRY, IGE | ICFCHE | ICFCHE | FEIA | Cherry, IgE LT 0.35 kU/L |
| ALLERGEN, CHICKEN MEAT, IGE | ICFCK | ICFCK | FEIA | Chicken Meat, IgE LT 0.35 kU/L |
| ALLERGEN, CHICKPEA [ARUP] | ICCPAR | ICCPAR | Immunocap | Chickpea, IgE LT 0.35 kU/L |
| ALLERGEN, CHOCOLATE, IGG4 [IBT] | ICCHG4 | ICCHG4 | ImmunoCAP FEIA | Chocolate, IgG4 LT 1 mcg/mL
|
| ALLERGEN, CHOCOLATE/CACAO, IGE | ICFCH | ICFCH | FEIA | Chocolate/Cacao, IgE LT 0.35 kU/L |
| ALLERGEN, CLADOSPORIUM HERBARUM, IGE | ICMCH | ICMCH | FEIA | Cladosporium Herbarum, IgE LT 0.35 kU/L |
| ALLERGEN, CLAM, IGE | ICFCL | ICFCL | FEIA | Clam, IgE LT 0.35 kU/L |
| ALLERGEN, COCKLEBUR, IGE | ICWCB | ICWCB | FEIA | Cocklebur, IgE LT 0.35 kU/L |
| ALLERGEN, COCKROACH, IGE | ICICR | ICICR | FEIA | Cockroach, IgE LT 0.35 kU/L |
| ALLERGEN, COCONUT IGE | ICFCOC | ICFCOC | FEIA | Coconut, IgE LT 0.35 kU/L |
| ALLERGEN, CODFISH (WHITEFISH), IGE | ICFCD | ICFCD | FEIA | Codfish (Whitefish), IgE LT 0.35 kU/L |
| ALLERGEN, COMMON SILVER BIRCH , IGE | ICTBR | ICTBR | FEIA | Common Silver Birch, IgE LT 0.35 kU/L |
| ALLERGEN, CORIANDER/CILANTRO, IGE [IBT] | ICCOCI | ICCOCI | FEIA | Coriander/Citantro, IgE LT 0.35 kU/L |
| ALLERGEN, CORN (MAIZE), IGE | ICFCN | ICFCN | FEIA | Corn (Maize), IgE LT 0.35 kU/L |
| ALLERGEN, CORN, IGG4 [IBT] | ICCNG4 | ICCNG4 | ImmunoCAP FEIA | Corn, IgG4 LT 1 mcg/mL
|
| ALLERGEN, COTTONWOOD TREE, IGE | ICTCW | ICTCW | FEIA | Cottonwood Tree, IgE LT 0.35 kU/L |
| ALLERGEN, COW DANDER, IGE | ICECD | ICECD | FEIA | Cow Dander, IgE LT 0.35 kU/L |
| ALLERGEN, COW'S MILK, IGE | ICFCM | ICFCM | FEIA | Cow's Milk, IgE LT 0.35 kU/L |
| ALLERGEN, COWS MILK, IGG4 [IBT] | ICMCG4 | ICMCG4 | ImmunoCAP FEIA | Cows Milk, IgG4 LT 30 mcg/mL
|
| ALLERGEN, CRAB, IGE | ICFCR | ICFCR | FEIA | Crab, IgE LT 0.35 kU/L |
| ALLERGEN, CULTIVATED OAT, IGE | ICGCO | ICGCO | FEIA | Cultivated Oat, IgE LT 0.35 kU/L |
| ALLERGEN, CUMIN, IGE [IBT] | ICCUMA | ICCUMA | RIA | Cumin, IgE LT 0.35 kU/L |
| ALLERGEN, CURRY (SANTA MARIA), IGE [IBT] | ICCURI | ICCURI | Immunocap FEIA | Curry (Santa Maria), IgE LT 0.35 kU/L |
| ALLERGEN, D. FARINAE (MITE), IGE | ICDM2 | ICDM2 | FEIA | D. farinae (Mite), IgE LT 0.35 kU/L |
| ALLERGEN, D. PTERONYSSINUS (MITE), IGE | ICDM1 | ICDM1 | FEIA | D. pteronyssinus (Mite), IgE LT 0.35 kU/L |
| ALLERGEN, DOG DANDER, IGE | ICEDD | ICEDD | FEIA | Dog Dander, IgE LT 0.35 kU/L |
| ALLERGEN, DOG EPITHELIUM, IGE | ICEDE | ICEDE | FEIA | Dog Epithelium, IgE LT 0.35 kU/L |
| ALLERGEN, EGG WHITE, IGE | ICFEW | ICFEW | FEIA | Egg White, IgE LT 0.35 kU/L |
| ALLERGEN, EGG WHOLE, IGE | ICFEG | ICFEG | FEIA | Egg Whole, IgE LT 0.35 kU/L |
| ALLERGEN, EGG YOLK, IGE | ICFEY | ICFEY | FEIA | Egg Yolk, IgE LT 0.35 kU/L |
| ALLERGEN, ELM TREE, IGE | ICTEL | ICTEL | FEIA | Elm Tree, IgE LT 0.35 kU/L |
| ALLERGEN, ENGLISH PLANTAIN (RIBWORT), IGE | ICWEP | ICWEP | FEIA | English Plantain (Ribwort), IgE LT 0.35 kU/L |
| ALLERGEN, EUCALYPTUS (GUM) TREE, IGE | ICTEU | ICTEU | FEIA | Eucalyptus (Gum) Tree, IgE LT 0.35 kU/L |
| ALLERGEN, FALSE RAGWEED, IGE | ICWFR | ICWFR | FEIA | False Ragweed, IgE LT 0.35 kU/L |
| ALLERGEN, FOOD PANEL 1, IGG4 [IBT] | FDPNG4 | FDPNG4 | ImmunoCAP FEIA | Banana, IgG4 LT 10 mcg/mL
Barley, IgG4 LT 1 mcg/mL
Green Bean, IgG4 LT 1 mcg/mL
Chocolate, IgG4 LT 1 mcg/mL
Corn, IgG4 LT 1 mcg/mL
Egg, Whole, IgG4 LT 5 mcg/mL
Milk, Cow, IgG4 LT 30 mcg/mL
Oat, IgG4 LT 1 mcg/mL
Orange, IgG4 LT 1 mcg/mL
Pea Green, IgG4 LT 1 mcg/mL
Peanut, IgG4 LT 1 mcg/mL
Pork, IgG4 LT 1 mcg/mL
Potato White, IgG4 LT 1 mcg/mL
Rice, IgG4 LT 1 mcg/mL
Rye Food, IgG4 LT 1 mcg/mL
Soybean, IgG4 LT 1 mcg/mL
Tomato, IgG4 LT 1 mcg/mL
Strawberry, IgG4 LT 0.8 mcg/mL
Wheat, IgG4 LT 5 mcg/mL
Baker's Yeast, IgG4 LT 1 mcg/mL
|
| ALLERGEN, GARLIC, IGE | ICFGA | ICFGA | FEIA | Garlic, IgE LT 0.35 kU/L |
| ALLERGEN, GIANT RAGWEED, IGE | ICWGR | ICWGR | FEIA | Giant Ragweed, IgE LT 0.35 kU/L |
| ALLERGEN, GINGER [IBT] | ICGINT | ICGINT | FEIA | Ginger, IgE LT 0.35 kU/L |
| ALLERGEN, GLUTEN, IGE | ICFGT | ICFGT | FEIA | Gluten, IgE LT 0.35 kU/L |
| ALLERGEN, GOLDENROD, IGE | ICWGD | ICWGD | FEIA | Goldenrod, IgE LT 0.35 kU/L |
| ALLERGEN, GOOSE FEATHERS, IGE | ICEGF | ICEGF | FEIA | Goose Feathers, IgE LT 0.35 kU/L |
| ALLERGEN, GRAPE (RAISIN), IGE | ICFGR | ICFGR | FEIA | Grape (Raisin), IgE LT 0.35 kU/L |
| ALLERGEN, GREEN BEAN IGE [ARUP] | ICGBAR | ICGBAR | Immunocap | Green Bean (String), IgE LT 0.35 kU/L |
| ALLERGEN, GREEN BEAN, IGG4 [IBT] | ICGBG4 | ICGBG4 | ImmunoCAP FEIA | Green Bean, IgG4 LT 1 mcg/mL
|
| ALLERGEN, GREEN PEA, IGG4 [IBT] | ICGPG4 | ICGPG4 | ImmunoCAP FEIA | Green Pea, IgG4 LT 1 mcg/mL
|
| ALLERGEN, GREY ALDER TREE, IGE | ICTAL | ICTAL | FEIA | Grey Alder Tree, IgE LT 0.35 kU/L |
| ALLERGEN, HADDOCK, IGE [ARUP] | ICHDAR | ICHDAR | Immunocap | Haddock, IgE LT 0.35 kU/L |
| ALLERGEN, HALIBUT [ARUP] | ICHBAR | ICHBAR | Immunocap | Halibut, IgE LT 0.35 kU/L |
| ALLERGEN, HAZEL NUT (FILBERT), IGE | ICFHZ | ICFHZ | FEIA | Hazel Nut (Filbert), IgE LT 0.35 kU/L |
| ALLERGEN, HAZEL NUT TREE, IGE | ICTHZ | ICTHZ | FEIA | Hazel Nut Tree, IgE LT 0.35 kU/L |
| ALLERGEN, HONEYBEE VENOM, IGE | ICIHB | ICIHB | FEIA | Honeybee Venom, IgE LT 0.35 kU/L |
| ALLERGEN, HORSE DANDER, IGE | ICEHH | ICEHH | FEIA | Horse Dander, IgE LT 0.35 kU/L |
| ALLERGEN, HOUSE DUST (GREER), IGE | ICHDG | ICHDG | FEIA | House Dust (Greer), IgE LT 0.35 kU/L |
| ALLERGEN, HOUSE DUST (HOLLISTER-STEIR), IGE | ICHDS | ICHDS | FEIA | House Dust (Hollister-Steir), IgE LT 0.35 kU/L |
| ALLERGEN, JAPANESE CEDAR, IGE | ICTRW | ICTRW | FEIA | Japanese Cedar, IgE LT 0.35 kU/L |
| ALLERGEN, JOHNSON GRASS, IGE | ICGJO | ICGJO | FEIA | Johnson Grass, IgE LT 0.35 kU/L |
| ALLERGEN, KIDNEY BEAN, IGE [ARUP] | IKDBNA | IKDBNA | Immunocap | Kidney Bean, IgE LT 0.35 kU/L |
| ALLERGEN, KIWI, IGE | ICFKIW | ICFKIW | FEIA | Kiwi, IgE LT 0.35 kU/L |
| ALLERGEN, KOCHIA (FIREBUSH), IGE | ICWKO | ICWKO | FEIA | Kochia (Firebush), IgE LT 0.35 kU/L |
| ALLERGEN, LAMB (MUTTON), IGE [ARUP] | ICLAAR | ICLAAR | Immunocap | Lamb, IgE LT 0.35 kU/L |
| ALLERGEN, LAMB'S QUARTERS (GOOSEFOOT), IGE | ICWLQ | ICWLQ | FEIA | Lamb's Quarters (Goosefoot), IgE LT 0.35 kU/L |
| ALLERGEN, LATEX (BRAZILIAN RUBBER TREE), IGE | ICOLT | ICOLT | FEIA | Latex (Brazilian Rubber Tree), IgE LT 0.35 kU/L |
| ALLERGEN, LEMON, IGE | ICFLEM | ICFLEM | FEIA | Lemon, IgE LT 0.35 kU/L |
| ALLERGEN, LENTIL [ARUP] | ICLTAR | ICLTAR | Immunocap | Lentil, IgE LT 0.35 kU/L |
| ALLERGEN, LETTUCE, IGE | ICFLE | ICFLE | FEIA | Lettuce, IgE LT 0.35 kU/L |
| ALLERGEN, LIMA BEAN/WHITE BEAN [ARUP] | ICLBAR | ICLBAR | Immunocap | Lima Bean/White Bean, IgE LT 0.35 kU/L |
| ALLERGEN, LOBSTER, IGE | ICFLB | ICFLB | FEIA | Lobster, IgE LT 0.35 kU/L |
| ALLERGEN, MALT, IGE | ICFML | ICFML | FEIA | Malt, IgE LT 0.35 kU/L |
| ALLERGEN, MANGO, IGE | ICFMAN | ICFMAN | FEIA | Mango, IgE LT 0.35 kU/L |
| ALLERGEN, MAPLE LEAF SYCAMORE TREE, IGE | ICTSY | ICTSY | FEIA | Maple Leaf Sycamore Tree, IgE LT 0.35 kU/L |
| ALLERGEN, MEADOW (KENTUCKY BLUE) GRASS, IGE | ICGKB | ICGKB | FEIA | Meadow (Kentucky Blue) Grass, IgE LT 0.35 kU/L |
| ALLERGEN, MEADOW FESCUE, IGE | ICGMF | ICGMF | FEIA | Meadow Fescue, IgE LT 0.35 kU/L |
| ALLERGEN, MELON, IGE | ICFWM | ICFWM | FEIA | Melon, IgE LT 0.35 kU/L |
| ALLERGEN, MOUNTAIN CEDAR (JUNIPER) TREE, IGE | ICTMC | ICTMC | FEIA | Mountain Cedar (Juniper) Tree, IgE LT 0.35 kU/L |
| ALLERGEN, MOZZARELLA CHEESE IGE [IBT] | ICMCI | ICMCI | RIA | Mozzarella Cheese, IgE LT 0.35 kU/L |
| ALLERGEN, MUCOR RACEMOSUS, IGE | ICMMR | ICMMR | FEIA | Mucor Racemosus, IgE LT 0.35 kU/L |
| ALLERGEN, MUGWORT, IGE | ICWMW | ICWMW | FEIA | Mugwort, IgE LT 0.35 kU/L |
| ALLERGEN, MULBERRY TREE, IGE | ICTML | ICTML | FEIA | Mulberry Tree, IgE LT 0.35 kU/L |
| ALLERGEN, MUSHROOM [ARUP] | ICMUAR | ICMUAR | Immunocap | Mushroom, IgE LT 0.35 kU/L |
| ALLERGEN, MUSTARD, IGE | ICFMS | ICFMS | FEIA | Mustard, IgE LT 0.35 kU/L |
| ALLERGEN, NETTLE, IGE | ICWNT | ICWNT | FEIA | Nettle, IgE LT 0.35 kU/L |
| ALLERGEN, OAK TREE, IGE | ICTOK | ICTOK | FEIA | Oak Tree, IgE LT 0.35 kU/L |
| ALLERGEN, OAT IGG4 [IBT] | ICOTG4 | ICOTG4 | ImmunoCAP FEIA | Oat, IgG4 LT 1 mcg/mL
|
| ALLERGEN, OAT, IGE | ICFOT | ICFOT | FEIA | Oat, IgE LT 0.35 kU/L |
| ALLERGEN, OIL PALM TREE IGE [IBT] | ICOPI | ICOPI | Immunocap FEIA | Oil Palm Tree, IgE LT 0.35 kU/L |
| ALLERGEN, OLIVE TREE, IGE | ICTOL | ICTOL | FEIA | Olive Tree, IgE LT 0.35 kU/L |
| ALLERGEN, ONION, IGE | ICFON | ICFON | FEIA | Onion, IgE LT 0.35 kU/L |
| ALLERGEN, ORANGE, IGE | ICFOG | ICFOG | FEIA | Orange, IgE LT 0.35 kU/L |
| ALLERGEN, ORANGE, IGG4 [IBT] | ICOGG4 | ICOGG4 | ImmunoCAP FEIA | Orange, IgG4 LT 30 mcg/mL
|
| ALLERGEN, ORCHARD GRASS (COCKSFOOT), IGE | ICGOG | ICGOG | FEIA | Orchard Grass (Cocksfoot), IgE LT 0.35 kU/L |
| ALLERGEN, OREGANO, IGE [IBT] | ICORGN | ICORGN | FEIA | Oregano, IgE LT 0.35 kU/L |
| ALLERGEN, OYSTER, IGE | ICFOY | ICFOY | FEIA | Oyster, IgE LT 0.35 kU/L |
| ALLERGEN, PAPAYA, IGE [ARUP] | IPAPR | IPAPR | Immunocap | Papaya, IgE LT 0.35 kU/L |
| ALLERGEN, PAPER WASP VENOM, IGE | ICIPW | ICIPW | FEIA | Paper Wasp Venom, IgE LT 0.35 kU/L |
| ALLERGEN, PARSLEY [ARUP] | ICPLAR | ICPLAR | Immunocap | Parsley, IgE LT 0.35 kU/L |
| ALLERGEN, PEA, GREEN, IGE | ICFGP | ICFGP | FEIA | Pea, Green, IgE LT 0.35 kU/L |
| ALLERGEN, PEACH, IGE | ICFPCH | ICFPCH | FEIA | Peach, IgE LT 0.35 kU/L |
| ALLERGEN, PEANUT IGG4 [IBT] | ICPNG4 | ICPNG4 | ImmunoCAP FEIA | Peanut, IgG4 LT 1 mcg/mL
|
| ALLERGEN, PEANUT, IGE | ICFPN | ICFPN | FEIA | Peanut, IgE LT 0.35 kU/L |
| ALLERGEN, PEAR, IGE | ICFPR | ICFPR | FEIA | Pear, IgE LT 0.35 kU/L |
| ALLERGEN, PECAN (WHITE HICKORY) TREE, IGE | ICTPE | ICTPE | FEIA | Pecan (White Hickory) Tree, IgE LT 0.35 kU/L |
| ALLERGEN, PECAN NUT, IGE | ICFPE | ICFPE | FEIA | Pecan Nut, IgE LT 0.35 kU/L |
| ALLERGEN, PENICILLIUM CHRYSOGENUM, IGE | ICMPN | ICMPN | FEIA | Penicillium Chrysogenum, IgE LT 0.35 kU/L |
| ALLERGEN, PENICILLOYL G, IGE | ICDRP | ICDRP | FEIA | Penicilloyl G, IgE LT 0.35 kU/L |
| ALLERGEN, PENICILLOYL V, IGE | ICDRPV | ICDRPV | FEIA | Penicilloyl V, IgE LT 0.35 kU/L |
| ALLERGEN, PEPPER CAYENNE, IGE [IBT] | ICPECY | ICPECY | RIA | Pepper, Cayenne, IgE LT 0.35 kU/L |
| ALLERGEN, PERCH [ARUP] | ICPRAR | ICPRAR | Immunocap | Perch, IgE LT 0.35 kU/L |
| ALLERGEN, PERENNIAL RYE GRASS, IGE | ICGPR | ICGPR | FEIA | Perennial Rye Grass, IgE LT 0.35 kU/L |
| ALLERGEN, PHOMA HERBARUM GEL DIFFUSION [IBT] | ICPHIB | ICPHIB | Gel Diffusion | Phoma herbarum by Gel Diffusion Negative |
| ALLERGEN, PIGWEED, IGE | ICWPG | ICWPG | FEIA | Pigweed, IgE LT 0.35 kU/L |
| ALLERGEN, PINE NUT [ARUP] | ICNAR | ICNAR | Immunocap | Pine Nut, IgE LT 0.35 kU/L |
| ALLERGEN, PINEAPPLE, IGE | ICFPA | ICFPA | FEIA | Pineapple, IgE LT 0.35 kU/L |
| ALLERGEN, PINTO BEAN, IGE [IBT] | ICPBEI | ICPBEI | Radioimmunoassay | Pinto Bean, IgE LT 0.35 kU/L |
| ALLERGEN, PISTACHIO, IGE | ICFPIS | ICFPIS | FEIA | Pistachio, IgE LT 0.35 kU/L |
| ALLERGEN, PLUM, IGE [ARUP] | ICPUAR | ICPUAR | Immunocap | Plum, IgE LT 0.35 kU/L |
| ALLERGEN, PORK IGG4 [IBT] | ICPKG4 | ICPKG4 | ImmunoCAP FEIA | Pork, IgG4 LT 1 mcg/mL
|
| ALLERGEN, PORK, IGE | ICFPK | ICFPK | FEIA | Pork, IgE LT 0.35 kU/L |
| ALLERGEN, POTATO (WHITE), IGE | ICFPT | ICFPT | FEIA | Potato (White), IgE LT 0.35 kU/L |
| ALLERGEN, POTATO WHITE IGG4 [IBT] | ICPTG4 | ICPTG4 | ImmunoCAP FEIA | Potato White, IgG4 LT 1 mcg/mL
|
| ALLERGEN, RASPBERRY, IGE [ARUP] | ICRAAR | ICRAAR | Immunocap | Raspberry, IgE LT 0.35 kU/L |
| ALLERGEN, RICE IGG4 [IBT] | ICRCG4 | ICRCG4 | ImmunoCAP FEIA | Rice, IgG4 LT 1 mcg/mL
|
| ALLERGEN, RICE, IGE | ICFRC | ICFRC | FEIA | Rice, IgE LT 0.35 kU/L |
| ALLERGEN, ROUGH MARSH ELDER, IGE | ICWME | ICWME | FEIA | Rough Marsh Elder, IgE LT 0.35 kU/L |
| ALLERGEN, RUSSIAN THISTLE (SALTWORT), IGE | ICWRT | ICWRT | FEIA | Russian Thistle (Saltwort), IgE LT 0.35 kU/L |
| ALLERGEN, RYE IGG4 [IBT] | ICRYG4 | ICRYG4 | ImmunoCAP FEIA | Rye, IgG4 LT 1 mcg/mL
|
| ALLERGEN, RYE, IGE | ICFRY | ICFRY | FEIA | Rye, IgE LT 0.35 kU/L |
| ALLERGEN, SALMON, IGE | ICFSA | ICFSA | FEIA | Salmon, IgE LT 0.35 kU/L |
| ALLERGEN, SCALE (LENSCALE), IGE | ICWSC | ICWSC | FEIA | Scale (Lenscale), IgE LT 0.35 kU/L |
| ALLERGEN, SCALLOP, IGE | ICFSC | ICFSC | FEIA | Scallop, IgE LT 0.35 kU/L |
| ALLERGEN, SCOTCH BROOM, IGE [IBT] | ICSCIB | ICSCIB | FEIA | Scotch Broom, IgE LT 0.35 kU/L |
| ALLERGEN, SESAME SEED, IGE | ICFSS | ICFSS | FEIA | Sesame Seed, IgE LT 0.35 kU/L |
| ALLERGEN, SETOMELANOMMA ROSTRATA / HELMINTHOSPORIUM HALODES IGE | ICMHL | ICMHL | FEIA | Setomelanomma rostrata, Helminthosporium halodes, IgE LT 0.35 kU/L |
| ALLERGEN, SHEEP SORREL (YELLOW DOCK), IGE | ICWSO | ICWSO | FEIA | Sheep Sorrel (Yellow Dock), IgE LT 0.35 kU/L |
| ALLERGEN, SHORT (COMMON) RAGWEED, IGE | ICWRG | ICWRG | FEIA | Short (Common) Ragweed, IgE LT 0.35 kU/L |
| ALLERGEN, SHRIMP, IGE | ICFSH | ICFSH | FEIA | Shrimp, IgE LT 0.35 kU/L |
| ALLERGEN, SOYBEAN IGG4 [IBT] | ICSBG4 | ICSBG4 | ImmunoCAP FEIA | Soybean, IgG4 LT 1 mcg/mL
|
| ALLERGEN, SOYBEAN, IGE | ICFSB | ICFSB | FEIA | Soybean, IgE LT 0.35 kU/L |
| ALLERGEN, SPINACH, IGE | ICFSP | ICFSP | FEIA | Spinach, IgE LT 0.35 kU/L |
| ALLERGEN, SQUASH SUMMER IGE [IBT] | ICSSI | ICSSI | FEIA | Squash Summer, IgE LT 0.35 kU/L |
| ALLERGEN, SQUID (PACIFIC) [ARUP] | ICSQAR | ICSQAR | Immunocap | Squid (Pacific), IgE LT 0.35 kU/L |
| ALLERGEN, STRAWBERRY IGG4 [IBT] | ICSTG4 | ICSTG4 | ImmunoCAP FEIA | Strawberry, IgG4 LT 0.8 mcg/mL
|
| ALLERGEN, STRAWBERRY, IGE | ICFST | ICFST | FEIA | Strawberry, IgE LT 0.35 kU/L |
| ALLERGEN, SUNFLOWER, IGE [ARUP] | ICSUAR | ICSUAR | Immunocap | Sunflower, IgE LT 0.35 kU/L |
| ALLERGEN, SWEET POTATO [IBT] | ICSPI | ICSPI | FEIA | Sweet Potato, IgE LT 0.35 kU/L |
| ALLERGEN, SWEET VERNAL GRASS, IGE | ICGSV | ICGSV | FEIA | Sweet Vernal Grass, IgE LT 0.35 kU/L |
| ALLERGEN, TIMOTHY GRASS, IGE | ICGTM | ICGTM | FEIA | Timothy Grass, IgE LT 0.35 kU/L |
| ALLERGEN, TOMATO, IGE | ICFTM | ICFTM | FEIA | Tomato, IgE LT 0.35 kU/L |
| ALLERGEN, TRICHOPHYTON RUBRUM, IGG [IBT] | ICTRGI | ICTRGI | ImmunoCAP FEIA | Trychophyton rubrum, IgG LT 5 ug/mL |
| ALLERGEN, TROUT [ARUP] | ICTRAR | ICTRAR | Immunocap | Trout, IgE LT 0.35 kU/L |
| ALLERGEN, TUNA, IGE | ICFTU | ICFTU | FEIA | Tuna, IgE LT 0.35 kU/L |
| ALLERGEN, TURKEY MEAT, IGE | ICFTR | ICFTR | FEIA | Turkey Meat, IgE LT 0.35 kU/L |
| ALLERGEN, WALNUT TREE, IGE | ICTWL | ICTWL | FEIA | Walnut Tree, IgE LT 0.35 kU/L |
| ALLERGEN, WALNUT, IGE | ICFWL | ICFWL | FEIA | Walnut, IgE LT 0.35 kU/L |
| ALLERGEN, WATERMELON [ARUP] | ICWTAR | ICWTAR | Immunocap | Watermelon, IgE LT 0.35 kU/L |
| ALLERGEN, WESTERN RAGWEED, IGE | ICWWR | ICWWR | FEIA | Western Ragweed, IgE LT 0.35 kU/L |
| ALLERGEN, WHEAT IGG4 [IBT] | ICWTG4 | ICWTG4 | ImmunoCAP FEIA | Wheat, IgG4 LT 5 mcg/mL
|
| ALLERGEN, WHEAT CULTIVATED (TRITICUM SATIVUM IGG [IBT] | ICWHE | ICWHE | ImmunoCAP FEIA | Wheat Cultivated (T. sativum) IgG LT 13 mcg/mL
|
| ALLERGEN, WHEAT, IGE | ICFWT | ICFWT | FEIA | Wheat, IgE LT 0.35 kU/L |
| ALLERGEN, WHITE ASH TREE, IGE | ICTWA | ICTWA | FEIA | White Ash Tree, IgE LT 0.35 kU/L |
| ALLERGEN, WHITE PINE TREE, IGE | ICTWP | ICTWP | FEIA | White Pine Tree, IgE LT 0.35 kU/L |
| ALLERGEN, WHITE-FACED HORNET VENOM, IGE | ICIWF | ICIWF | FEIA | White-faced Hornet Venom, IgE LT 0.35 kU/L |
| ALLERGEN, WHITE/NAVY BEAN, IGE | ICFWB | ICFWB | FEIA | White/Navy Bean, IgE LT 0.35 kU/L |
| ALLERGEN, WORM WOOD (SAGEBRUSH), IGE | ICWSG | ICWSG | FEIA | Worm Wood (Sagebrush), IgE LT 0.35 kU/L |
| ALLERGEN, YEAST (BAKERS OR BREWERS), IGE | ICFBY | ICFBY | FEIA | Yeast (Bakers or Brewers), IgE LT 0.35 kU/L |
| ALLERGEN, YELLOW JACKET VENOM, IGE | ICIYJ | ICIYJ | FEIA | Yellow Jacket Venom, IgE LT 0.35 kU/L |
| ALLERGEN, YELLOW-FACED HORNET VENOM, IGE | ICIYF | ICIYF | FEIA | Yellow-faced Hornet Venom, IgE LT 0.35 kU/L |
| ALLERGEN,EGG WHOLE IGG4 [IBT] | ICWEG4 | ICWEG4 | ImmunoCAP FEIA | Egg, Whole, IgG4 LT 5 mcg/mL
|
| ALLERGEN,TOMATO IGG4 [IBT] | ICTMG4 | ICTMG4 | ImmunoCAP FEIA | Tomato, IgG4 LT 1 mcg/mL
|
| ALLERGENS, 32 | SCRN32 | SCRN32 | FEIA | D. farinae (Mite), IgE LT 0.35 kU/L
D. pteronyssinus (Mite), LT 0.35 kU/L
IgE
Cat Epithelium, IgE LT 0.35 kU/L
Dog Dander, IgE LT 0.35 kU/L
Dog Epithelium, IgE LT 0.35 kU/L
Goose Feathers, IgE LT 0.35 kU/L
Horse Dander, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Johnson Grass, IgE LT 0.35 kU/L
Perennial Rye Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Acremonium kiliense, LT 0.35 kU/L
IgE
Setomelanomma rostrata, LT 0.35 kU/L
IgE
Penicillium chrysogenum, LT 0.35 kU/L
Acacia Tree, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Eucalyptus (Gum) Tree, IgE LT 0.35 kU/L
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Olive Tree, IgE LT 0.35 kU/L
Maple Leaf Sycamore Tree, LT 0.35 kU/L
IgE
Walnut Tree, IgE LT 0.35 kU/L
English Plantain(Ribwort), LT 0.35 kU/L
IgE
Lambs Quarters(Goosefoot), LT 0.35 kU/L
IgE
Mugwort, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
Russian Thistle(Saltwort), LT 0.35 kU/L
IgE
Sheep Sorrel(Yellow Duck), LT 0.35 kU/L
IgE
Western Ragweed, IgE LT 0.35 kU/L |
| ALLERGENS, 37 | SCRN37 | SCRN37 | FEIA | D. farinae (Mite), IgE LT 0.35 kU/L
Cat Dander, IgE LT 0.35 kU/L
Dog Dander, IgE LT 0.35 kU/L
Dog Epithelium, IgE LT 0.35 kU/L
Goose Feathers, IgE LT 0.35 kU/L
Horse Dander, IgE LT 0.35 kU/L
Yeast (Bakers/Brewer), IgE LT 0.35 kU/L
Cows Milk, IgE LT 0.35 kU/L
Corn (Maize), IgE LT 0.35 kU/L
Egg White, IgE LT 0.35 kU/L
Egg Yolk, IgE LT 0.35 kU/L
Malt, IgE LT 0.35 kU/L
Peanut, IgE LT 0.35 kU/L
Soybean, IgE LT 0.35 kU/L
Tomato, IgE LT 0.35 kU/L
Wheat, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Johnson Grass, IgE LT 0.35 kU/L
Perennial Rye Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Acremonium kiliense, LT 0.35 kU/L
IgE
Setomelanonna rostrata, LT 0.35 kU/L
IgE
Elm Tree, IgE LT 0.35 kU/L
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Olive Tree, IgE LT 0.35 kU/L
Maple Leaf Sycamore Tree, LT 0.35 kU/L
IgE
Walnut Tree, IgE LT 0.35 kU/L
English Plantain(Ribwort), LT 0.35 kU/L
IgE
Lambs Quarters(Goosefoot), LT 0.35 kU/L
IgE
Mugwort, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
Russian Thistle(Saltwort), LT 0.35 kU/L
IgE
Western Ragweed, IgE LT 0.35 kU/L |
| ALLERGENS, ADULT FOOD PROFILE 22 | ADFP22 | ADFP22 | FEIA | Beef, IgE LT 0.35 kU/L
Yeast (Bakers/Brewers), LT 0.35 kU/L
IgE
Codfish (Whitefish), IgE LT 0.35 kU/L
Chocolate/Cacao, IgE LT 0.35 kU/L
Clam, IgE LT 0.35 kU/L
Cows Milk, IgE LT 0.35 kU/L
Corn (Maize), IgE LT 0.35 kU/L
Egg White, IgE LT 0.35 kU/L
Garlic, IgE LT 0.35 kU/L
Pea, Green, IgE LT 0.35 kU/L
Mustard, IgE LT 0.35 kU/L
Orange, IgE LT 0.35 kU/L
Pork, IgE LT 0.35 kU/L
Peanut, IgE LT 0.35 kU/L
Potato (White), IgE LT 0.35 kU/L
Rice, IgE LT 0.35 kU/L
Soybean, IgE LT 0.35 kU/L
Shrimp, IgE LT 0.35 kU/L
Tomato, IgE LT 0.35 kU/L
Tuna, IgE LT 0.35 kU/L
Walnut, IgE Lt 0.35 kU/L
Wheat, IgE LT 0.35 kU/L |
| ALLERGENS, FOOD PROFILE 10 | FOOD10 | FOOD10 | FEIA | Egg White, IgE LT 0.35 kU/L
Cows Milk, IgE LT 0.35 kU/L
Codfish (Whitefish), IgE LT 0.35 kU/L
Wheat, IgE LT 0.35 kU/L
Corn (Maize), IgE LT 0.35 kU/L
Peanut, IgE LT 0.35 kU/L
Soybean, IgE LT 0.35 kU/L
Shrimp, IgE LT 0.35 kU/L
Walnut, IgE LT 0.35 kU/L
Clam, IgE LT 0.35 kU/L |
| ALLERGENS, GRASS PROFILE 9 | GRASS9 | GRASS9 | FEIA | Redtop Bentgrass, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Brome Grass, IgE LT 0.35 kU/L
Meadow Kentucky Blue Grass, LT 0.35 kU/L
IgE
Meadow Fescue, IgE LT 0.35 kU/L
Orchard Grass, IgE LT 0.35 kU/L
Perennial Rye Grass, IgE LT 0.35 kU/L
Sweet Vernal Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
English Plantain (Ribwort), LT 0.35 kU/L
IgE
Lamb's quaters (Goosefoot), LT 0.35 kU/L
IgE |
| ALLERGENS, HYMENOPTERA PANEL | VENOM5 | VENOM5 | FEIA | Honeybee Venom, IgE LT 0.35 kU/L
Paper Wasp Venom, IgE LT 0.35 kU/L
Whitefaced Hornet Venom, LT 0.35 kU/L
IgE
Yellowfaced Hornet Venom, LT 0.35 kU/L
IgE
Yellow Jacket Venom, IgE LT 0.35 kU/L |
| ALLERGENS, INHALANT 9 | INHAL9 | INHAL9 | FEIA | D. farinae (Mite), IgE LT 0.35 kU/L
Cat Dander, IgE LT 0.35 kU/L
Dog Epithelium, IgE LT 0.35 kU/L
Perennial Rye Grass, IgE LT 0.35 kU/L
Alternaria tenius, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Olive Tree, IgE LT 0.35 kU/L
English Plantain (Ribwort), LT 0.35 kU/L
IgE
Short (Common) Ragweed, IgE LT 0.35 kU/L
IgE |
| ALLERGENS, INLAND NORTHWEST 17 | INW17 | INW17 | FEIA | D. pteronyssinus (Mite), IgE LT 0.35 kU/L
D. farinae (Mite),IgE LT 0.35 kU/L
Cat Dander, IgE LT 0.35 kU/L
Dog Dander, IgE LT 0.35 kU/L
Redtop Bentgrass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Grey Alder Tree, IgE LT 0.35 kU/L
Box Elder, IgE LT 0.35 kU/L
Common Silver Birch Tree, LT 0.35 kU/L
IgE
Cottonwood Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Mugwort, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
Russian Thistle(Saltwort), LT 0.35 kU/L
IgE |
| ALLERGENS, INTERMOUNTAIN WEST 14 | IMW14 | IMW14 | FEIA | D. farinae (Mite),IgE LT 0.35 kU/L
Cat Dander, IgE LT 0.35 kU/L
Dog Dander, IgE LT 0.35 kU/L
Redtop Bentgrass, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Grey Alder Tree, IgE LT 0.35 kU/L
Box Elder, IgE LT 0.35 kU/L
Common Silver Birch Tree, LT 0.35 kU/L
IgE
Cottonwood Tree, IgE Lt 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
Mugwort, IgE LT 0.35 kU/L
Russian Thistle(Saltwort), LT 0.35 kU/L
IgE |
| ALLERGENS, MOLD PROFILE 5 | MOLD5 | MOLD5 | FEIA | Alternaria tenius, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Candida albicans, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Penicillium chrysogenum, IgE LT 0.35 kU/L |
| ALLERGENS, NUT PROFILE 6 | NUT6 | NUT6 | FEIA | Almond, IgE LT 0.35 kU/L
Cashew, IgE LT 0.35 kU/L
Hazelnut, IgE LT 0.35 kU/L
Pecan nut, IgE LT 0.35 kU/L
Peanut, IgE LT 0.35 kU/L
Walnut, IgE LT 0.35 kU/L |
| ALLERGENS, PACIFIC NORTHWEST 14 | PNW14 | PNW14 | FEIA | D. pteronyssinus (Mite), LT 0.35 kU/L
IgE
Cat Dander, IgE LT 0.35 kU/L
Dog Dander, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Grey Alder Tree, IgE LT 0.35 kU/L
Box Elder, IgE LT 0.35 kU/L
Common Silver Birch Tree, LT 0.35 kU/L
IgE
Oak Tree, IgE LT 0.35 kU/L
Walnut Tree, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
Russian Thistle(Saltwort), LT 0.35 kU/L
IgE
Western Ragweed, IgE LT 0.35 kU/L |
| ALLERGENS, PEDIATRIC FOOD PROFILE 21 | PDFP21 | PDFP21 | FEIA | Barley, IgE LT 0.35 kU/L
Banana, IgE LT 0.35 kU/L
Yeast (Bakers/Brewers), LT 0.35 kU/L
IgE
Codfish, IgE LT 0.35 kU/L
Chocolate/Cacao, IgE LT 0.35 kU/L
Cows Milk, IgE LT 0.35 kU/L
Corn (Maize), IgE LT 0.35 kU/L
Egg White, IgE LT 0.35 kU/L
Pea, Green, IgE LT 0.35 kU/L
Orange, IgE LT 0.35 kU/L
Oat, IgE LT 0.35 kU/L
Pork, IgE LT 0.35 kU/L
Peanut, IgE LT 0.35 kU/L
Potato (White), IgE LT 0.35 kU/L
Rice, IgE LT 0.35 kU/L
Rye, IgE LT 0.35 kU/L
Soybean, IgE LT 0.35 kU/L
Strawberry, IgE LT 0.35 kU/L
Tomato, IgE LT 0.35 kU/L
White/Navy Bean, IgE LT 0.35 kU/L
Wheat, IgE LT 0.35 kU/L |
| ALLERGENS, PEDIATRIC PROFILE 11 | PEDS11 | PEDS11 | FEIA | D. farinae (Mite),IgE LT 0.35 kU/L
Cat Dander, IgE LT 0.35 kU/L
Dog Dander, IgE LT 0.35 kU/L
Cows Milk, IgE LT 0.35 kU/L
Soybean, IgE LT 0.35 kU/L
Egg White, IgE LT 0.35 kU/L
Wheat, IgE LT 0.35 kU/L
Peanut, IgE LT 0.35 kU/L
Codfish (Whitefish), IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L |
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 1, NORTH ATLANTIC STATES (CT,MA,NJ,NY,PA,VT,ME,NH,RI) | RDPNA | RDPNA | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Box Elder Tree, IgE LT 0.35 kU/L
Common Silver Birch, IgE LT 0.35 kU/L
Cottonwood, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Maple Leaf Sycamore, IgE LT 0.35 kU/L
Mountain Cedar-Juniper Tree, IgE LT 0.35 kU/L
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Walnut Tree, IgE LT 0.35 kU/L
White Ash Tree, IgE LT 0.35 kU/L
Short (common) Ragweed, IgE LT 0.35 kU/L
Mugwort, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
Sheep Sorrel (Yellow Dock), IgE LT 0.35 kU/L |
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 10 SOUTHWESTERN GRASSLAND STATES (TX, OK) | RDPSWG | RDPSWG | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Box Elder Tree, IgE LT 0.35 kU/L
Common Silver Birch, IgE LT 0.35 kU/L
Cottonwood, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Mountain Cedar-Juniper Tree, IgE LT 0.35 kU/L
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Pecan (white hickory) Tree, IgE LT 0.35 kU/L
White Ash Tree, IgE LT 0.35 kU/L
Short (common) Ragweed, IgE LT 0.35 kU/L
Mugwort, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
Rough Marsh Elder, IgE LT 0.35 kU/L
Sheep Sorrel (Yellow Dock), IgE LT 0.35 kU/L
Nettle, IgE LT 0.35 kU/L
|
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 11, ROCKY MOUNTAIN STATES (AZ[MTN], ID[MTN],NM,WY,CO,UT[MTN]) | RDPRM | RDPRM | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Grey Alder, IgE LT 0.35 kU/L
Box Elder Tree, IgE LT 0.35 kU/L
Cottonwood, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Mountain Cedar-Juniper Tree, IgE LT 0.35 kU/L
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Olive Tree, IgE LT 0.35 kU/L
Short (common) Ragweed, IgE LT 0.35 kU/L
Mugwort, IgE LT 0.35 kU/L
Russian Thistle, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
Sheep Sorrel (Yellow Dock), IgE LT 0.35 kU/L |
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 12, ARID SOUTHWEST (S.AZ, SE CA DESERT) | RDPASW | RDPASW | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Johnson Grass, IgE LT 0.35 kU/L
Perennial Rye Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Acacia Tree, IgE LT 0.35 kU/L
Cottonwood, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Mountain Cedar-Juniper Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Olive Tree, IgE LT 0.35 kU/L
Short (common) Ragweed, IgE LT 0.35 kU/L
Mugwort, IgE LT 0.35 kU/L
Russioan Thistle, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L |
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 13 SOUTH COASTAL CALIFORNIA (CA) | RDPSCC | RDPSCC | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Johnson Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Grey Alder Tree, IgE LT 0.35 kU/L
Cottonwood, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Mountain Cedar-Juniper Tree, IgE LT 0.35 kU/L
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Olive Tree, IgE LT 0.35 kU/L
Walnut Tree, IgE LT 0.35 kU/L
Short (common) Ragweed, IgE LT 0.35 kU/L
Mugwort, IgE LT 0.35 kU/L
Russian Thistle, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
|
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 14, CENTRAL CALIFORNIA (CA) | RDPCC | RDPCC | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Grey Alder Tree, IgE LT 0.35 kU/L
Common Silver Birch, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Maple Leaf Sycamore Tree, IgE LT 0.35 kU/L
Mountain Cedar-Juniper Tree, IgE LT 0.35 kU/L
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Olive Tree, IgE LT 0.35 kU/L
Short (common) Ragweed, IgE LT 0.35 kU/L
Mugwort, IgE LT 0.35 kU/L
Russian Thistle, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L |
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 15, INTERMOUNTAIN WEST (SOUTH ID,NV) | RDPIMW | RDPIMW | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Box Elder Tree, IgE LT 0.35 kU/L
Cottonwood, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Mountain Cedar-Juniper Tree, IgE LT 0.35 kU/L
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Olive Tree, IgE LT 0.35 kU/L
Short (common) Ragweed, IgE LT 0.35 kU/L
Mugwort, IgE LT 0.35 kU/L
Russian Thistle, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L |
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 16, INLAND NORTHWEST(CENTRAL & EASTERN WA, OR) | RDPINW | RDPINW | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Grey Alder Tree, IgE LT 0.35 kU/L
Box Elder Tree, IgE LT 0.35 kU/L
Common Silver Birch, IgE LT 0.35 kU/L
Cottonwood, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Mountain Cedar-Juniper Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Mugwort, IgE LT 0.35 kU/L
Russian Thistle, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
Sheep Sorrel (Yellow Dock), IgE LT 0.35 kU/L |
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 17, CASCADE/PACIFIC NORTHWEST (NW CA, WESTERN WA & OR) | RDPCPN | RDPCPN | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Box Elder Tree, IgE LT 0.35 kU/L
Grey Alder Tree, IgE LT 0.35 kU/L
Common Silver Birch, IgE LT 0.35 kU/L
Cottonwood, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Mountain Cedar-Juniper Tree, IgE LT 0.35 kU/L
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Walnut Tree, IgE LT 0.35 kU/L
White Ash Tree, IgE LT 0.35 kU/L
Short (common) Ragweed, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
Sheep Sorrel (Yellow Dock), IgE, LT 0.35 kU/L
Nettle, IgE LT 0.35 kU/L |
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 18, ALASKA (AK) | RDPAK | RDPAK | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Grey Alder Tree, IgE LT 0.35 kU/L
Common Silver Birch, IgE LT 0.35 kU/L
Cottonwood, IgE LT 0.35 kU/L
Mugwort, IgE LT 0.35 kU/L
Sheep Sorrel (Yellow Dock), IgE LT 0.35 kU/L |
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 2, MID-ATLANTIC STATES (DE,MD,VA,DC,NC) | RDPMA | RDPMA | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Johnson Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Box Elder Tree, IgE LT 0.35 kU/L
Common Silver Birch, IgE LT 0.35 kU/L
Cottonwood, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Mountain Cedar-Juniper Tree, IgE LT 0.35 kU/L
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Pecan (white hickory) Tree, IgE LT 0.35 kU/L
Short (common) Ragweed, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
Sheep Sorrel (Yellow Dock), IgE LT 0.35 kU/L |
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 5, GREATER OHIO VALLEY (IN,OH,TN,WV,KY) | RDPGOV | RDPGOV | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Box Elder Tree, IgE LT 0.35 kU/L
Common Silver Birch, IgE LT 0.35 kU/L
Cottonwood, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Maple Leaf Sycamore Tree, IgE LT 0.35 kU/l
Mountain Cedar-Juniper Tree, IgE LT 0.35 kU/L
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Pecan (white hickory) Tree, IgE LT 0.35 kU/L
Walnut Tree, IgE LT 0.35 kU/L
White Ash Tree, IgE LT 0.35 kU/L
Short (common) Ragweed, IgE LT 0.35 kU/L
Russian Thistle, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
Sheep Sorrel (Yellow Dock), IgE, LT 0.35 kU/L
Nettle, IgE LT 0.35 kU/L |
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 6, SOUTH CENTRAL STATES (AL, AR, LA, MS) | RDPSC | RDPSC | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Box Elder Tree, IgE LT 0.35 kU/L
Common Silver Birch, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Mountain Cedar-Juniper Tree, IgE LT 0.35 kU/L
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Pecan (white hickory) Tree, IgE LT 0.35 kU/L
Walnut Tree, IgE LT 0.35 kU/L
Short (common) Ragweed, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
Rough Marsh Elder, IgE LT 0.35 kU/L |
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 7, NORTHERN ,MIDWEST STATES (MI,WE,MN) | RDPNMW | RDPNMW | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Box Elder Tree, IgE LT 0.35 kU/L
Common Silver Birch, IgE LT 0.35 kU/L
Cottonwood, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Mountain Cedar-Juniper Tree, IgE LT 0.35 kU/L
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
White Ash Tree, IgE LT 0.35 kU/L
Short (common) Ragweed, IgE LT 0.35 kU/L
Russian Thistle, IgE LT 0.35 kU/L
Rough Marsh Elder, IgE LT 0.35 kU/L
Nettle, IgE LT 0.35 kU/L |
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 8, CENTRAL MIDWEST STATES (IL, MO, IA) | RDPCMW | RDPCMW | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Box Elder Tree, IgE LT 0.35 kU/L
Cottonwood, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Maple Leaf Sycamore Tree, IgE LT 0.35 kU/L
Mountain Cedar-Juniper Tree, IgE LT 0.35 kU/L
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Pecan (white hickory) Tree, IgE LT 0.35 kU/L
Walnut Tree, IgE LT 0.35 kU/L
Short (common) Ragweed, IgE LT 0.35 kU/L
Russian Thistle, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
Rough Marsh Elder, IgE LT 0.35 kU/L |
| ALLERGENS, RESPIRATORY DISEASE PROFILE, REGION 9, GREAT PLAINS STATES (KS,NE,ND,SD) | RDPGP | RDPGP | FEIA | D. pteronyssinus (mite), IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Penicillium chrysogenum/notatum, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Box Elder Tree, IgE LT 0.35 kU/L
Cottonwood, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Mountain Cedar-Juniper Tree, IgE LT 0.35 kU/L
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Pecan (white hickory) Tree, IgE LT 0.35 kU/L
Walnut Tree, IgE LT 0.35 kU/L
White Ash Tree, IgE LT 0.35 kU/L
Short (common) Ragweed, IgE LT 0.35 kU/L
Russian Thistle, IgE LT 0.35 kU/L
Sheep Sorrel (Yellow Dock), IgE, LT 0.35 kU/L
Nettle, IgE LT 0.35 kU/L |
| ALLERGENS, ROCKY MOUNTAIN 15 | RMS15 | RMS15 | FEIA | D. farinae (Mite),IgE LT 0.35 kU/L
Cat Dander, IgE LT 0.35 kU/L
Dog Dander, IgE LT 0.35 kU/L
Redtop Bentgrass, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Grey Alder Tree, IgE LT 0.35 kU/L
Box Elder, IgE LT 0.35 kU/L
Cottonwood Tree, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Mountain Cedar(Juniper) LT 0.35 kU/L
IgE
Oak Tree, IgE LT 0.35 kU/L
Kochia (Firebush), IgE LT 0.35 kU/L
Russian Thistle(Saltwort), LT 0.35 kU/L
IgE |
| ALLERGENS, SEAFOOD PROFILE 7 | SEAFD7 | SEAFD7 | FEIA | Codfish (whitefish), IgE LT 0.35 kU/L
Clam, IgE LT 0.35 kU/L
Crab, IgE LT 0.35 kU/L
Lobster, IgE LT 0.35 kU/L
Salmon, IgE LT 0.35 kU/L
Shrimp, IgE LT 0.35 kU/L
Tuna, IgE LT 0.35 kU/L |
| ALLERGENS, SOUTH CENTRAL STATES 18 | SOCN18 | SOCN18 | FEIA | Alternaria tenuis, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Cat dander, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Short (common Ragweed),IgE LT 0.35 kU/L
D. farinae (mite), IgE LT 0.35 kU/L
D. pteronyssinus(mite),IgE LT 0.35 kU/L
Dog dander, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Cladosporium herbarum,IgE LT 0.35 kU/L
Johnson Grass, IgE LT 0.35 kU/L
Meadow (Ktky Blue Grass) LT 0.35 kU/L
IgE
Oak Tree, IgE LT 0.35 kU/L
Pecan (White hickory) LT 0.35 kU/L
Tree, IgE
Penicillium chrysogenum/ LT 0.35 kU/L
notatum, IgE
Rough Marsh Elder, IgE LT 0.35 kU/L
Walnut Tree, IgE LT 0.35 kU/L
|
| ALLERGENS, SOUTHERN CALIFORNIA 21 | SCAL21 | SCAL21 | FEIA | D. pteronyssinus (Mite), LT 0.35 kU/L
IgE
D. farinae (Mite), IgE LT 0.35 kU/L
Cat Dander, IgE LT 0.35 kU/L
Dog Dander, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Brome Grass, IgE LT 0.35 kU/L
Cultivated Oat, IgE LT 0.35 kU/L
Cockroach, IgE LT 0.35 kU/L
Alternaria tenuis, IgE LT 0.35 kU/L
Aspergillus fumigatus, IgE LT 0.35 kU/L
Cladosporium herbarum, IgE LT 0.35 kU/L
Box Elder, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Olive Tree, IgE LT 0.35 kU/L
Walnut Tree, IgE LT 0.35 kU/L
Maple Leaf Sycamore Tree, LT 0.35 kU/L
IgE
Japanese Cedar, IgE LT 0.35 kU/L
False Ragweed, IgE LT 0.35 kU/L
Russian Thistle(Saltwort), LT 0.35 kU/L
IgE
Pigweed, IgE LT 0.35 kU/L
Scale (Lenscale), IgE LT 0.35 kU/L |
| ALLERGENS, SOUTHWEST INHALENTS COMPREHENSIVE 2 [ARUP] | ICSWAR | ICSWAR | Immunocap | Cat Epi/Dander, IgE LT 0.35 kU/L
Dog Dander, IgE LT 0.35 kU/L
A. alternata, IgE LT 0.35 kU/L
A. fumigatus, IgE LT 0.35 kU/L
Helminthospirium, IgE LT 0.35 kU/L
Hormodendrum, IgE LT 0.35 kU/L
Bahia, IgE LT 0.35 kU/L
Bermuda Grass, IgE LT 0.35 kU/L
Johnson Grass, IgE LT 0.35 kU/L
Timothy Grass, IgE LT 0.35 kU/L
D. farinae, IgE LT 0.35 kU/L
D. pteronyssinus, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Mountain Cedar Tree, LT 0.35 kU/L
IgE
Pecan Tree, IgE LT 0.35 kU/L
Privet Tree, IgE LT 0.35 kU/L
Sycamore Tree, IgE LT 0.35 kU/L
Virginia Live Oak, IgE LT 0.35 kU/L
White ASh Tree, IgE LT 0.35 kU/L
Common Short Ragweed, LT 0.35 kU/L
IgE
English Plantain, IgE LT 0.35 kU/L
Marsh Elder, IgE LT 0.35 kU/L
Pigweed, IgE LT 0.35 kU/L
Russian Thistle, IgE LT 0.35 kU/L
Interp, Immunocap
Score
|
| ALLERGENS, TREE PROFILE 11 | TREE11 | TREE11 | FEIA | Box Elder Tree, IgE LT 0.35 kU/L
Grey Alder Tree, , IgE LT 0.35 kU/L
Common Silver Birch Tree, LT 0.35 kU/L
IgE
Cottonwood Tree, IgE LT 0.35 kU/L
Elm Tree, IgE LT 0.35 kU/L
Hazelnut Tree, IgE LT 0.35 kU/L
Mountain Cedar (Juniper), LT 0.35 kU/L
Tree, IgE
Mulberry Tree, IgE LT 0.35 kU/L
Oak Tree, IgE LT 0.35 kU/L
Olive Tree, IgE LT 0.35 kU/L
Walnut Tree, IgE LT 0.35 kU/L |
| ALLERGENS, WEED PROFILE 12 | WEED12 | WEED12 | FEIA | Cocklebur, IgE LT 0.35 kU/L
English Plantain (Ribwort), LT 0.35 kU/L
IgE
Kochia (Firebush), IgE LT 0.35 kU/L
Lamb's Quarters (Goosefoot),LT 0.35 kU/L
IgE
Rough Marsh Elder, IgE LT 0.35 kU/L
Mugwort, IgE LT 0.35 kU/L
Nettle, IgE LT 0.35 kU/L
Short (Common) Ragweed, LT 0.35 kU/L
IgE
Russian Thistle (Saltwort), LT 0.35 kU/L
IgE
Scale (Lenscale), IgE LT 0.35 kU/L
Sheep Sorrel (Yellow Dock), LT 0.35 kU/L
IgE
Pigweed,IgE LT 0.35 kU/L |
| ALPHA ANTIPLASMIN ACTIVITY | ALP2A | ALP2A | Chromogenic Assay | Alpha 2 Antiplasmin Activity %
1-4 days 55-115
5-29 days 70-130
30-89 days 76-124
90-179 days 76-140
180-364 days 83-139
1-5 yrs 93-117
6 yrs 89-110
7-9 yrs 88-147
10-11 yrs 90-144
12-13 yrs 87-142
14-15 yrs 83-136
16-17 yrs 77-134
18 yrs + 82-133 |
| ALPHA FETOPROTEIN (MATERNAL) | AFP | AFPMS | Immunometric | AFP ng/mL
Gestational age wk
Maternal Weight lbs
MOM
Weight corrected MOM
30 yrs and under 0.40-2.50 MOM
Over 30 yrs old 0.50-2.50 MOM
2.50 MOM equals OSB Risk of 1/605
Diabetic Corrected MOM
Comment |
| ALPHA FETOPROTEIN (NON-MATERNAL) | AFP-NM | AFPTM | Immunometric | Alpha Fetoprotein
Males & non-pregnant females 0.6-6.6 ng/mL |
| ALPHA FETOPROTEIN, AMNIOTIC FLUID (REFLEXIVE) | AFAFP | AFAFP | Immunometric | Blood Present
Alpha Fetoprotein, ug/mL
Amniotic Fluid
MoM LT 2.0 MoM
Interpretation Negative Screen
Fetal Hemoglobin F Negative |
| ALPHA FETOPROTEIN, TOTAL AND L3 PERCENT | AFPL3 | AFPL3 | Liquid-phase Binding Immunoassay | Alpha Feto Protein, Total 0-15 ng/mL
Alpha Feto Protein, L3% 10% or less %
The Wako LiBASSys method is used. Results obtained
with different assay methods or kits cannot be used
interchangeably. The Wako AFP-L3% assay is intended as
a risk assessment test for the development of
hepatocellular carcinoma in patients with chronic liver
diseases. Elevated AFP-L3% values have been shown to be
associated with a seven-fold increase in the risk of
developing hepatocellular carcinoma within the next 21
months. Patients with elevated serum AFP-L3% should be
more intensely evaluated for evidence of hepatocellular
carcinoma. The result is not interpretable as a tumor
marker in pregnant females. |
| ALPHA SUBUNIT PITUITARY TUMOR MARKER | ALPHA.PGH | ASUB | ICMA | Alpha Subunit Pituitary Tumor Marker ng/mL
5 days or less 50 or less
5 days -Lt 3 mo 10 or less
3 mo-LT 2 yrs 1.2 or less
2 yrs-puberty 1.2 or less
Tanner II-IV 1.2 or less
M Adult 0.5 or less
F Premenopausal 1.2 or less
F Postmenopausal 1.8 or less
|
| ALPHA-1 ANTITRYPSIN, FECES | A1AF | A1AF | Radial Immunodiffusion | Alpha-1 Antitrypsin 0.00-0.62 mg/g |
| ALPHA-1-ANTITRYPSIN | AAT | AAT | Turbidimetric | Alpha-1-Antitrypsin 100-200 mg/dL |
| ALPHA-1-ANTITRYPSIN PHENOTYPE | AAT-PHENO | AATPH | Isoelectric Focusing/ Immunoturbidimetric | AAT-Phenotype
Alpha-1-Antitrypsin 100-200 mg/dL
Interpret with caution if the
patient has been transfused
previous 21 days. |
| ALPHA-GLOBIN GENE ANALYSIS | ALGGA | ALGGA | PCR. MLPA and Luminex | Specimen
Specimen ID
Source
Order date
Method
Result
Interpretation
Amendment
Reviewed by
Release date |
| ALPRAZOLAM | XANAX | ALPRAZ | Liquid Chromatography/Tandem Mass Spectrometry | Alprazolam ng/mL
Anxiety 10-40 (Dose 1-4 mg/d)
Phobia & Panic 50-100 (Dose 6-9 mg/d)
The lowest possible effective dose should
be used, as side effected increase & anti-
anxiety efficiency decrease as dosage
increases. |
| ALT | SGPT | ALT | Enzymatic | ALT 5-50 U/L |
| ALUMINUM, PLASMA | ALUMINUM | AL | Electrothermal (Flameless) AAS | Aluminum ug/L
0-10 Normal
0-40 Normal for dialysis patients
10-60 Increased aluminum uptake
60-100 Potential clinical problems
GT 100 Generally leads to clinical symptoms |
| ALUMINUM, URINE | ALU-U | ALUUQ | ICP/MS | Collection Period hr
Volume mL
Creatinine, Urine mg/dL
Creatinine, Urine mg/d
M 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81+ yrs 600-2000
F 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
81+ yrs 400-1300
Aluminum, Urine 0-7 ug/L
Aluminum, Urine 0-10 ug/d
Aluminum, Urine No reference ug/gCr
range established.
Urine aluminum values
do not correlate well
with exposure. Elevated
levels should be
confirmed with a second
specimen due to a high
susceptibility of the
specimen to collection-
related environmental
contamination. |
| AMENORRHEA PROFILE | AMEN | AMEN | ICMA | LH mIU/mL
M 7-9 yrs 0.0-0.7
10-12 yrs 0.0-3.4
13-15 yrs 0.3-5.6
16-17 yrs 1.1-9.0
18 yrs+ 1.7-8.6
Tanner Stage I 0.0-1.0
Tanner Stage II 0.0-3.6
Tanner Stage III 0.2-6.4
Tanner Stage IV-V 0.9-8.3
F 7-9 yrs 0.0-0.7
10-12 yrs 0.0-6.8
13-15 yrs 0.3-23.0
16-17 yrs 0.0-26.4
18 yrs+
Follicular 2.4-12.6
Mid-cycle 14.00-95.6
Luteal phase 1.0-11.4
Post menopausal 7.7-58.5
Tanner Stage I 0.0-9.3
Tanner Stage II 0.0-16.0
Tanner Stage III 0.0-23.0
Tanner Stage IV-V 0.0-19.1
FSH mIU/mL
M 7-9 yrs 0.3-2.3
10-12 yrs 0.5-4.4
13-15 yrs 1.0-6.7
16-17 yrs 0.8-7.0
18 yrs + 1.4-11.2
Tanner Stage I 0.3-2.6
Tanner Stage II 0.5-4.3
Tanner Stage III 0.9-5.8
Tanner Stage IV-V 0.9-7.3
F 7-9 yrs 0.4-4.0
10-12 yrs 0.6-7.5
13-15 yrs 0.9-8.2
16-17 yrs 0.4-8.9
18 yrs+
Follicular 3.2-11.3
Midcycle peak 4.2-19.4
Luteal phase 1.5-6.9
Postmenopausal 23.2-121.3
Tanner Stage I 0.5-7.6
Tanner Stage II 0.5-8.0
Tanner Stage III 0.5-8.0
Tanner Stage IV-V 0.6-8.4
Prolactin ng/mL
M 1.6-18.8
Non-Pregnant
Females 1.4-24.2 |
| AMIKACIN (SINGLE) | AMIK | AMIKR | FPIA | Amikacin ug/mL
Trough 4.0-8.0 Toxic GT 8.0
Peak 10.0-30.0 Toxic GT 35.0
|
| AMIKACIN, PEAK | AMIK.PK | AMIKPK | FPIA | Amikacin, ug/mL
Peak 10.0-30.0
Toxic GT 35.0
|
| AMIKACIN, TROUGH | AMIK.TR | AMIKTR | FPIA | Amikacin, ug/mL
Trough 4.0-8.0
Toxic GT 8.0
|
| AMINO ACIDS, PLASMA (QUANTITATIVE) | AA.QUANT | AAQ | HPLC | Taurine umol/L
Newborn 19-265
1 mo-5 yrs 11-93
6+ yrs 0-240
Aspartic Acid umol/L
Newborn 0-8
1 mo-5 yrs 3-12
6+ yrs 0-14
OH-Proline umol/L
Newborn 18-72
1 mo-5 yrs 0-50
6+ yrs 0-50
Threonine umol/L
Newborn 65-147
1 mo-5 yrs 40-225
6+ yrs 74-202
Serine umol/L
Newborn 62-161
1 mo-5 yrs 93-176
6+ yrs 71-181
Asparagine umol/L
Newborn 6-33
1 mo-5 yrs 23-79
6+ yrs 32-62
Glutamic Acid umol/L
Newborn 30-103
1 mo-5 yrs 11-79
6+ yrs 7-65
Glutamine umol/L
Newborn 243-822
1 mo-5 yrs 475-746
6+ yrs 360-740
Proline umol/L
Newborn 144-329
1 mo-5 yrs 40-332
6+ yrs 58-324
Glycine umol/L
Newborn 106-318
1 mo-5 yrs 105-318
6+ yrs 158-302
Alanine umol/L
Newborn 132-455
1 mo-5 yrs 148-475
6+ yrs 193-545
Citrulline umol/L
Newborn 3-36
1 mo-5 yrs 8-47
6+ yrs 19-52
Valine umol/L
Newborn 78-264
1 mo-5 yrs 85-334
6+ yrs 156-288
Cystine umol/L
Newborn 26-71
1 mo-5 yrs 23-68
6+ yrs 36-58
Methionine umol/L
Newborn 6-36
1 mo-5 yrs 5-34
6+ yrs 16-37
Isoleucine umol/L
Newborn 27-80
1 mo-5 yrs 13-81
6+ yrs 38-95
Leucine umol/L
Newborn 61-183
1 mo-5 yrs 40-158
6+ yrs 79-174
Tyrosine umol/L
Newborn 32-124
1 mo-5 yrs 24-110
6+ yrs 43-88
Phenylalanine umol/L
Newborn 16-71
1 mo-5 yrs 24-101
6+ yrs 39-76
Ornithine umol/L
Newborn 38-207
1 mo-5 yrs 27-117
6+ yrs 19-81
Lysine umol/L
Newborn 71-272
1 mo-5 yrs 85-218
6+ yrs 108-233
Histidine umol/L
Newborn 32-107
1 mo-5 yrs 22-108
6+ yrs 64-106
Arginine umol/L
Newborn 17-119
1 mo-5 yrs 32-142
6+ yrs 44-130
Amino Acids Interpretation |
| AMINO ACIDS, URINE (QUANTITATIVE) | AAU.QUANT | AAURQ | Anion Exchange Chromatography | Amino Acids, Urine (Quantitative)
Separate Report to Follow |
| AMINOLEVULINIC ACID, URINE | ALA-U | ALAUQ | Chromatography/Spectrophotometry | Collection Period h
Volume mL
Creatinine Urine mg/dL
Creatinine Urine mg/d
M 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81+ yrs 600-2000
F 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-60 yrs 500-1400
81+ yrs 400-1300
Aminolevulinic Acid, Urine umol/L
0-35
Aminolevulinic Acid, Urine umol/d
0-60 |
| AMIODARONE | AMIO | AMIO | HPLC | Amiodarone ug/mL
1.0-3.0
GT 3.0 Potentially Toxic
Desethlyamiodarone ug/mL
No Normals Established |
| AMITRIPTYLINE & METABOLITE | AMI | AMITR | HPLC | Amitriptyline ng/mL
No reference range established
for parent drug. See Total for reference
range, which takes into account all
metabolites.
Nortriptyline ng/mL
Therapeutic 50-150 Toxic GT 499
Total Drug ng/mL
Therapeutic 80-220 Toxic GT 499
Studies have determined that Norpace
will interfere with the measurement of
the Amitriptyline metabolite, Nortrip-
tyline. Nortriptyline results & total
tricyclic results are not valid for
patients on Norpace. |
| AMMONIA | AMM | AMM | Thin Layer Colorimetric | Ammonia 9-33 umol/L |
| AMNIOTIC FLUID SCAN | DOD | AMNFS | Spectrophotometry | Amniotic Fluid Scan
Appearance
Color
RBCS
Gestational Age wk
Abs at 450 Abs
Interpretation |
| AMOXAPINE | AMOX | AMOX | HPLC | Amoxapine ng/mL
8-Hydroxyamoxapine ng/mL
Optimal therapeutic range
(Amoxapine + Active Metabolite)
200-400 ng/mL |
| AMYLASE | AMY | AMY | Enzymatic | Amylase 16-108 U/L |
| AMYLASE ISOENZYMES | AMY.ISO | AMYISO | Enzymatic | Amylase Pancreatic U/L
6-35 mo 2-28
3-6 yrs 8-34
7-17 yrs 9-39
18 yrs & more 12-52
Amylase Salivary
18 mo & more 9-86 U/L
Amylase Total U/L
3-90 days 0-30
3-6 mo 7-40
7-8 mo 5-57
9-11 mo 11-70
12-17 mo 11-79
13-35 mo 19-92
3-4 yrs 26-106
5-12 yrs 30-119
13 yrs & more 30-110 |
| AMYLASE, FLUID | AMY.FLD | AMYFL | Enzymatic | Amylase, Fluid U/L
No normals established |
| AMYLASE, URINE (2HR) | AMYLASE-URINE | AMYU2H | Enzymatic | Collection Period h
Volume mL
Amylase, Urine 0-28 U/2h |
| AMYLASE, URINE (PANCREATIC TRANSPLANT) | AMY.PANCR | AMYU12 | Enzymatic | Collection Period h
Volume mL
Amylase, Urine 0-500 U/L
Amylase, Urine 0-14 U/h |
| AMYLASE, URINE (QUANTITATIVE) | AMYUQ | AMYUQ | Enzymatic | Collection Period h
Volume mL
Amylase, Urine 0-14 U/h |
| AMYLASE, URINE (RANDOM) | AMY.R | AMYUR | Enzymatic | Amylase, Urine (Random) 0-500 U/L |
| AMYLASE/CREATININE CLEARANCE | AMY-CL | AMYCL | Enzymatic, Enzymatic (IDMS Traceable), Calculation | Creatinine
F 0.40-1.00 mg/dL
M 0.50-1.30 mg/dL
Creatinine, Urine
No normals established mg/dL
Amylase 16-108 U/L
Amylase, Urine 0-500 U/L
Amylase/Creatinine 0.2-3.2
Amylase/Creatinine Ratio
Clearance Ratio LT 5 |
| AMYLASE/CREATININE, URINE (RANDOM) | AMY-U | AMYCUR | Enzymatic, Enzymatic (IDMS Traceable), Calculation | Amylase, Urine 0-500 U/L
Creatinine, Urine
No normals established mg/dL
Amylase/Creatinine 0.2-3.2 Ratio |
| ANA SCREEN (REFLEXIVE) | ANAMP | ANAMP | Multiplex luminex | ANA Negative
A multiplex screen for 11 autoantibodies
(dsDNA, Smith, Ribosomal P, Chromatin, RNP,
SmRNP, Scl-70, Centromere B, SSA, SSB and
J0-1) was performed and no autoantibodies
were detected. A negative multiplex ANA
does not rule out all possibility of a
connective tissue or autoimmune disease,
and further studies should be considered
if clinical suspicion is high.
DSDNA Autoantibody Negative LT 5 IU/mL
Indeterminate 5-9
Positive 10 or more
Smith Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
Ribosomal P Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
Chromatin Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
RNP Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
SMRNP Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
SCL-70 Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
Centromere B Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
SSA (RO) Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
SSB (LA) Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
JO-1 Autoantibody Negative LT 1.0 AI
antibody Positive 1.0 or more |
| ANALYZER | ANALZ4 | ANALZ4 | EIA/LIA | ANA LT 7.5 IU/mL
ANA Pattern
dsDNA AutoAbs LT 5.0
RNP/Sm Negative LT 5.0
Borderline 5.0-10.0
Positive GT 10.0
Sm(Smith) Negative LT 5.0
IgG Borderline 5.0-10.0
AutoAbs Positive GT 10.0
SS-A IgG Negative LT 5.0
AutoAbs Borderline 5.0-10.0
Positive GT 10.0
SS-B IgG Negative LT 5.0
AutoAbs Borderline 5.0-10.0
Positive GT 10.0
Scl-70 Negative LT 5.0
IgG Borderline 5.0-10.0
AutoAbs Positve GT 10.0
Thyroid LT 60 U/mL
Peroxidase
AutoAbs
C3 Complement 90-180 mg/dL
C4 Complement 16-47 mg/dL
Rheumatoid Factor LT 14 IU/mL
Ribosmal Negative LT 5.0 Units
P Borderline 5.0-10.0
AutoAbs Positive GT 10.0 |
| ANCA PANEL (REFLEXIVE) | ANCAME | ANCAME | Multiplex luminex, IFA, ELISA | ANA Negative
A multiplex screen for 11 autoantibodies
(dsDNA, Smith, Ribosomal P, Chromatin, RNP,
SmRNP, Scl-70, Centromere B, SSA, SSB and
J0-1) was performed and no autoantibodies
were detected. A negative multiplex ANA
does not rule out all possibility of a
connective tissue or autoimmune disease,
and further studies should be considered
if clinical suspicion is high.
DSDNA Autoantibody Negative LT 5 IU/mL
Indeterminate 5-9
Positive 10 or more
Smith Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
Ribosomal P Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
Chromatin Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
RNP Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
SMRNP Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
SCL-70 Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
Centromere B Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
SSA (RO) Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
SSB (LA) Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
JO-1 Autoantibody Negative LT 1.0 AI
antibody Positive 1.0 or more
ANCA Titer, IFA
ANCA Pattern
Proteinase 3 LT 3.5 U/mL
Antibody
Myeloperoxidase LT 9.0 U/mL
Antibody |
| ANCA PANEL-NO ANA | ANCAPR | ANCAPR | IFA, EIA | ANCA Titer, IFA LT 1:20 Negative
ANCA Pattern
Myeloperoxidase Antibody LT 9.0 U/mL
Proteinase 3 Antibody LT 3.5 U/mL |
| ANDROSTENEDIONE | ANDSDE | ANDSDE | HPLC/TMS | Androstenedione ng/mL
F Premature 26-28 weeks-day 4 0.920-2.820
Premature 31-35 weeks-day 4 0.800-4.460
Full-term 1-7 days 0.200-2.900
8-30 days 0.180-0.800
1 mo-11 mo 0.060-0.680
1-6 yrs 0.080-0.500
7-9 yrs 0.038-0.490
10-11 yrs 0.094-1.270
12-13 yrs 0.190-2.090
14-15 yrs 0.430-2.090
16-17 yrs 0.390-2.150
18-40 yrs Pre-menopausal 0.260-2.140
41 yrs+ Post-menopausal 0.130-0.820
Tanner Stage I 0.039-0.760
Tanner Stage II 0.170-1.530
Tanner Stage III 0.400-2.350
Tanner Stage IV-V 0.390-2.090
M Premature 26-28 weeks-day 4 0.920-2.820
Premature 31-35 weeks-day 4 0.800-4.460
Full-term 1-7 days 0.200-2.900
8-30 days 0.180-0.800
1 mo-11 mo 0.600-0.680
1-6 yrs 0.080-0.500
7-9 yrs 0.031-0.310
10-11 yrs 0.072-0.410
12-13 yrs 0.110-0.640
14-15 yrs 0.180-1.010
16-17 yrs 0.310-1.140
18-40 yrs 0.330-1.340
41 yrs+ 0.230-0.890
Tanner Stage I 0.037-0.330
Tanner Stage II 0.078-0.480
Tanner Stage III 0.160-1.000
Tanner Stage IV-V 0.280-1.070
|
| ANDROSTERONE, URINE | ANDR-U | ANDRUQ | GC/MS | Collection Period Hrs
Volume mL
Androsterone (Urine) ug/24h
M 12 yrs or less 6.0-725
More than 12 yrs 234-2,703
F 12 yrs or less 6.0-725
More than 12 yrs 55-1,589 |
| ANEMIA PROFILE | ANEMPR | ANEMPR | Automated/Hemagglutination/Colorimetric | Anemia Profile
Autoheme
Retic Count %
0-2 days 3.0-7.0
3-6 days 1.0-3.0
7 days-1 mo 0.0-1.0
2 mo-4 yr 1.0-2.0
5+ yrs 0.4-2.7
Retic Abs K/uL
5+ yrs 16-123
Immature Retic Fraction %
1+ yrs 0.17-0.43
Direct Coombs Negative
Iron
M 35-190 ug/dL
F 30-150
Iron Binding Capacity
M 230-430 ug/dL
F 250-450
% Saturation
M 20-55 %
F 15-50
Interpretation No longer reported
Reviewed by No longer reported |
| ANGIOTENSIN CONVERTING ENZYME | ANGIO | ACE | Enzymatic | Angiotensin Converting Enzyme 4-60 U/L |
| ANGIOTENSIN CONVERTING ENZYME (ACE) POLYMORPHINSM | ACEP | ACEP | FPCR & Capillary Electrophoresis | Angiotensin Converting Enzyme Polymorphism Result. |
| ANGIOTENSIN CONVERTING ENZYME, CSF | ACECF | ACECF | Spectrophotometry | Angiotensin Converting Enzyme, CSF U/L
0.0-2.5 |
| ANNA, TITER & WB CONFIRMATION, SF | ASFCON | ASFCON | IFA and Western Blot | ANNA Titer, SF LT 1:1
ANNA Wester Blot Negative |
| ANTABUSE | ANTABUSE | ABUSE | GC | Antabuse ug/mL
None detected
Therapeutic 0.3-1.5 |
| ANTI-CONVULSANT PROFILE | CONV-PAN | CONV | ICMA | Dilantin ug/mL
Therapeutic 10.0-20.0 Toxic GT 25.0
Phenobarbital ug/mL
Therapeutic 15.0-40.0 Toxic GT 50.0 |
| ANTI-DNA (FARR TECHNIQUE) | DNA.FARR | DNAFA | RIA | Anti-DNA (Farr Technique) LT 7.0 IU/mL |
| ANTI-GLIADIN ANTIBODIES, IGA & IGG | GLIGA | GLIGA | ELISA | Anti-Gliadin Ab, IgA U/mL
Negative LT 10.0
Positive 10.0 or greater
Anti-Gliadin Ab, IgG U/mL
Negative LT 10.0
Positive 10.0 or greater |
| ANTI-ISLET CELL ANTIBODY | ISLET | ISLET | IFA | Anti-Islet Cell Ab Titer
LT 1:4 No antibody detected
Islet cell antibodies have been associated
with "autoimmune" endocrine disorders and
insulin-dependent diabetes. This disorder
is characterized by the presence of
antibodies in patients that may be
detected years before the onset of the
clinical symptoms. To calculate Juvenile
Diabetes Foundation (JDF) units; multiply
the titer x 5 (1.8 8x5=40 JDF Units). |
| ANTI-MYOCARDIAL ANTIBODY (REFLEXIVE) | ABMYO | ABMYO | Indirect Fluorescent Ab | Myocardial Ab, IgG Screen LT 1:20
Myocardial Ab, IgG Titer LT 1:20 |
| ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY SCREEN (REFLEXIVE) | ANCASR | ANCASR | IFA | ANCA Titer, IFA LT 1:20 Negative
ANCA Pattern |
| ANTI-PARIETAL CELL ANTIBODY, TOTAL, IGA, IGG & IGM | PARIETAL CELL AB | APCA | IFA | Parietal Cell Ab, Total(IgA, IgG, IgM)
Negative LT 1:20 |
| ANTI-SMOOTH MUSCLE ANTIBODY | ASM | ASM | IFA | Smooth Muscle Ab Negative LT 1:40 |
| ANTI-THYROID ANTIBODIES | TAB | TAB | ICMA | Thyroglobulin Autoantibodies IU/mL
0.0-40.0
Thyroid Peroxidase Autoantibodies IU/mL
0.0-35.0 |
| ANTIBODY IDENTIFICATION | AB ID | MABID | Hemagglutination | Antibody Screen
Antibody ID
Antibody Titer |
| ANTICARDIOLIPIN ANTIBODY, IGG, IGM & IGA | CARDS | CARDS | EIA | Cardiolipin Ab, IgG GPL U/mL
Negative LT 10
Indeterminate 10-19
Low-Med Positive 20-80
Strong Positive GT 80
Cardiolipin Ab, IgM MPL U/mL
Negative LT 10
Indeterminate 10-19
Low-Med Positive 20-80
Strong Positive GT 80
Cardiolipin Ab, IgA APL U/mL
Negative LT 13
Positive 13 or more |
| ANTICARDIOLIPIN ANTIBODY, IGA | CARDA | CARDA | ELISA | Cardiolipin Antibody, IgA Negative LT 13 APL U/mL
Positive 13 or more |
| ANTICARDIOLIPIN ANTIBODY, IGG | CARDG | CARDG | ELISA | Cardiolipin Antibody, IgG Negative LT 10 GPL U/mL
Indeterminate 10-19
Low-Med Positive 20-80
Strong Positive GT 80 |
| ANTICARDIOLIPIN ANTIBODY, IGM | CARDM | CARDM | ELISA | Cardiolipin Antibody, IgM Negative LT 10 MPL U/mL
Indeterminate 10-19
Low-Med Positive 20-80
Strong Positive GT 80 |
| ANTINEURONAL ANTIBODIES IGG BY IMMUNOBLOT (HU, RI, YO, AMPHIPHYSIN) | NEUIGG | NEUIGG | Immunoblot | Neuronal Ab (Hu) Negative
Neuronal Ab (Ri) Negative
Neruonal Ab (Yo) Negative
Neuronal Ab Negative
(Amphiphysin) |
| ANTINEURONAL CELL ANTIBODY | NCABUW | NCABUW | Enzyme Linked Immunosorbent Assay | Anti-Neuronal Units
Cell Ab
Interpretation |
| ANTINEURONAL NUCLEAR ANTIBODY (REFLEXIVE) | ANEU | ANEU | IFA | Anti-Neuronal Nuclear Ab Negative
|
| ANTINEURONAL NUCLEAR ANTIBODY, SF (REFLEXIVE) | ANEUSF | ANEUSF | IFA | Anti Neuronal Nuclear Ab, SF Negative |
| ANTINUCLEAR ANTIBODY TITER BY IFA | IFANA | IFANA | IFA | ANA by IFA Titer LT 1:40 Titer
ANA by IFA Pattern |
| ANTIPHOSPHATIDYLSERINE, IGA | APSA | APSA | ELISA | Antiphosphatidylserine, Negative LT 20 APS U/mL
IgA Positive 20 or more
The presence of phosphatidylserine Abs maybe
associated with anti-phospholipid
syndrome characterized by recurrent
fetal loss, thrombosis and
thrombocytopenia. |
| ANTIPHOSPHATIDYLSERINE, IGG | APSG | APSG | ELISA | Antiphosphatidylserine, Negative LT 11 GPS U/mL
IgG Positive 11 or more
The presence of phosphatidylserine Abs maybe
associated with anti-phospholipid
syndrome characterized by recurrent
fetal loss, thrombosis and
thrombocytopenia. |
| ANTIPHOSPHATIDYLSERINE, IGM | APSM | APSM | ELISA | Antiphosphatidylserine, Negative LT 25 MPS U/mL
IgM Positive 25 or more
The presence of phosphatidylserine Abs maybe
associated with anti-phospholipid
syndrome characterized by recurrent
fetal loss, thrombosis and
thrombocytopenia. |
| ANTIPHOSPHOLIPID PANEL 1, (REFLEXIVE) | APP1 | AP1 | ELISA and Electromechanical | Cardiolipin Ab IgG Negative LT 10 GPL U/mL
Indeterminate 10-19
Low-Med Positive 20-80
Strong Positive GT 80
Cardiolipin Ab IgM Negative LT 10 MPL U/mL
Indeterminate 10-19
Low-Med Positive 20-80
Strong Positive GT 80
Beta-2 Glycoprotein Negative LT 20 U/mL
1 Ab, IgG Positive 20 or more
Beta-2 Glycoprotein Negative LT 10 U/mL
1 Ab, IgM Positive 10 or more
PT, Patient 0-1 month 13.0-20.0 sec
2+ months 11.9-15.0
PT, PT/NT Mix sec
Thrombin Time, Patient 15.6-20.0 sec
TT, PT/PS Mix sec
APTT, Patient 0-1 month 40-50 sec
2 mon-4 yrs 25-40
5+ years 26-36
APTT Control
APTT, PT/CT Mix
PNP 0.0-7.0
dRVVT 31.8-45.7 sec
dRVVT Mix Ratio LT 1.2
dRVVT Confirm Ratio LT 1.2
dRVVT Confirm Mix Ratio LT 1.2 |
| ANTIPHOSPHOLIPID PANEL 2, (REFLEXIVE) | APP2 | APP2 | ELISA and Electromechanical | Antiphosphatidylserine, Negative LT 20 APS U/mL
IgA Positive 20 or more
The presence of phosphatidylserine Abs maybe
associated with anti-phospholipid
syndrome characterized by recurrent
fetal loss, thrombosis and
thrombocytopenia.
Antiphosphatidylserine, Negative LT 11 GPS U/mL
IgG Positive 11 or more
The presence of phosphatidylserine Abs maybe
associated with anti-phospholipid
syndrome characterized by recurrent
fetal loss, thrombosis and
thrombocytopenia.
Antiphosphatidylserine, Negative LT 25 MPS U/mL
IgM Positive 25 or more
The presence of phosphatidylserine Abs maybe
associated with anti-phospholipid
syndrome characterized by recurrent
fetal loss, thrombosis and
thrombocytopenia.
Cardiolipin Ab IgA Negative LT 13 APL U/mL
Positive 13 or more
Cardiolipin Ab IgG Negative LT 10 GPL U/mL
Indeterminate 10-19
Low-Med Positive 20-80
Strong Positive GT 80
Cardiolipin Ab IgM Negative LT 10 MPL U/mL
Indeterminate 10-19
Low-Med Positive 20-80
Strong Positive GT 80
dRVVT 31.8-45.7 sec
dRVVT Mix Ratio LT 1.2
Negative for Lupus Inhibitor screen.
dRVVT Confirm Ratio LT 1.2
Negative for Lupus Inhibitor screen.
dRVVT Confirm Mix Ratio LT 1.2
Negative for Lupus Inhibitor screen. |
| ANTIPHOSPHOLIPID PANEL 3, (REFLEXIVE) | APP3 | APP3 | ELISA and Electromechanical | Antiphosphatidylserine, Negative LT 20 APS U/mL
IgA Positive 20 or more
The presence of phosphatidylserine Abs maybe
associated with anti-phospholipid
syndrome characterized by recurrent
fetal loss, thrombosis and
thrombocytopenia.
Antiphosphatidylserine, Negative LT 11 GPS U/mL
IgG Positive 11 or more
The presence of phosphatidylserine Abs maybe
associated with anti-phospholipid
syndrome characterized by recurrent
fetal loss, thrombosis and
thrombocytopenia.
Antiphosphatidylserine, Negative LT 25 MPS U/mL
IgM Positive 25 or more
The presence of phosphatidylserine Abs maybe
associated with anti-phospholipid
syndrome characterized by recurrent
fetal loss, thrombosis and
thrombocytopenia.
Cardiolipin Ab IgA Negative LT 13 APL U/mL
Positive 13 or more
Cardiolipin Ab IgG Negative LT 10 GPL U/mL
Indeterminate 10-19
Low-Med Positive 20-80
Strong Positive GT 80
Cardiolipin Ab IgM Negative LT 10 MPL U/mL
Indeterminate 10-19
Low-Med Positive 20-80
Strong Positive GT 80
Beta-2 Glycoprotein Negative LT 10 U/mL
1 Ab, IgA Positive 10 or more
Beta-2 Glycoprotein Negative LT 20 U/mL
1 Ab, IgG Positive 20 or more
Beta-2 Glycoprotein Negative LT 10 U/mL
1 Ab, IgM Positive 10 or more
dRVVT 31.8-45.7 sec
dRVVT Mix Ratio LT 1.2
Negative for Lupus Inhibitor screen.
dRVVT Confirm Ratio LT 1.2
Negative for Lupus Inhibitor screen.
dRVVT Confirm Mix Ratio LT 1.2
Negative for Lupus Inhibitor screen. |
| ANTIPHOSPHOLIPID SYNDROME EVALUATION (REFLEXIVE) | APSEEX | APSEEX | EIA, Clot detection | Antiphospholipid Syndrome Evaluation
See separate report |
| ANTITHROMBIN III ACTIVITY | THROMBIN III.ACT | AT3 | Chromogenic | Antithrombin III Activity 85-126 % |
| ANTITHROMBIN III ANTIGEN | THROMBIN.III.AG | AT3AG | Immuno-turbidimetric | Antithrombin III Antigen 21-33 mg/dL |
| APO E MUTATION DETECTION FOR CARDIOVASCULAR RISK | APOEC | APOEC | PCR/FM | APO E Specimen blood
APO E for Cardiovascular Risk
Homozygous apo e3 (e3/e3): This is
the most common (normal) genotype. |
| APOLIPOPROTEIN A-1 | APO A | APOA | Nephelometry | Apolipoprotein A-1 mg/dL
M 94-178
F 101-199 |
| APOLIPOPROTEIN B-100 | APO B | APOB | Nephelometry | Apolipoprotein B-100 mg/dL
M 55-140
F 55-125 |
| APT | APT | APT | Visual Hemolysis | Source
APT |
| ARBOVIRUS ANTIBODY PANEL, IGG & IGM | ARBO | ARBO | IFA | Eastern Equine Encephalitis Ab, IgG LT 1:16
Eastern Equine Encephalitis Ab, IgM LT 1:20
Eastern Equine Encephalitis Ab, Interp
California Encephalitis Ab, IgG LT 1:16
California Encephalitis Ab, IgM LT 1:20
California Encephalitis Ab, Interp
St. Louis Encephalitis Ab, IgG LT 1:16
St. Louis Encephalitis Ab, IgM LT 1:20
St. Louis Encephalitis Ab, Interp
Western Equine Encephalitis Ab, IgG LT 1:16
Western Equine Encephalitis Ab, IgM LT 1:20
Western Equine Encephalitis Ab, Interp
Specimens positive for arbovirus antibody
are CDC reportable. Please contact your
local public health agency.
Human infections caused by aroboviruses
are seasonal, from mid-summer to late-
summer. Typical geographic distributions
are: Eastern equine encephalitis virus
from New England to Texas, California
encephalitis virus in the north-central
states, St. Louis encephalitis virus
throughout the southern, south-western,
and west-central states and Western
encephalitis virus throughout the
western states. |
| ARBOVIRUS ANTIBODY PANEL, IGG & IGM, CSF | ARBOSF | ARBOSF | IFA | Eastern Equine Encephalitis Ab, IgG, CSF LT 1:4
Eastern Equine Encephalitis Ab, IgM, CSF LT 1:4
Eastern Equine Encephalitis Ab, Interp, CSF
California Encephalitis Ab, IgG, CSF LT 1:4
California Encephalitis Ab, IgM, CSF LT 1:4
California Encephalitis Ab, Interp, CSF
St. Louis Encephalitis Ab, IgG, CSF LT 1:4
St. Louis Encephalitis Ab, IgM, CSF LT 1:4
St. Louis Encephalitis Ab, Interp, CSF
Western Equine Encephalitis Ab, IgG, CSF LT 1:4
Western Equine Encephalitis Ab, IgM, CSF LT 1:4
Western Equine Encephalitis Ab, Interp, CSF
Interpretive Criteria:
LT 1:4 Antibody not detected
1:4 or more Antibody detected
Specimens positive for arbovirus antibody
are CDC reportable. Please contact your
local public health agency.
Diagnosis of infections of the central
nervous system can be accomplished by
demonstrating the presence of intrathecally-
produced specific antibody. However,
interpreting results is complicated by
low antibody levels fround in CSF,
passive transfer of antibody from blood,
and contamination via bloody taps. The
interpretation of CSF results must
consider CSF-serum ratios of the
infectious agent. |
| ARBOVIRUS ANTIBODY PANEL, IGM | ARBVM | ARBVM | IFA | California Encephalitis Ab, IgM LT 1:20
Eastern Equine Encephalitis Ab, IgM LT 1:20
St. Louis Encephalitis Ab, IgM LT 1:20
Western Equine Encephalitis Ab, IgM LT 1:20
Interpretive Criteria:
LT 1:20 Antibody not detected
1:20 or more Antibody detected
Specimens positive for arbovirus antibody
are CDC reportable. Please contact your
local public health agency.
Human infections caused by aroboviruses
are seasonal, from mid-summer to late-
summer. Typical geographic distributions
are: Eastern equine encephalitis virus
from New England to Texas, California
encephalitis virus in the north-central
states, St. Louis encephalitis virus
throughout the southern, south-western,
and west-central states and Western
encephalitis virus throughout the
western states. |
| ARBOVIRUS ANTIBODY PANEL, IGM, CSF | ARBMSF | ARBMSF | IFA | California Encephalitis Ab, IgM, CSF LT 1:4
Eastern Equine Encephalitis Ab, IgM, CSF LT 1:4
St. Louis Encephalitis Ab, IgM, CSF LT 1:4
Western Equine Encephalitis Ab, IgM, CSF LT 1:4
Interpretive Criteria:
LT 1:4 Antibody not detected
1:4 or more Antibody detected
Specimens positive for arbovirus antibody
are CDC reportable. Please contact your
local public health agency.
Diagnosis of infections of the central
nervous system can be accomplished by
demonstrating the presence of intrathecally-
produced specific antibody. However,
interpreting results is complicated by
low antibody levels fround in CSF,
passive transfer of antibody from blood,
and contamination via bloody taps. The
interpretation of CSF results must
consider CSF-serum ratios of the
infectious agent. |
| ARBOVIRUS IGM ANTIBODY PANEL, CSF | ARBMSF | ARBMSF | IFA | California Encephalitis Ab, IgM, CSF LT 1:4
Eastern Equine Encephalitis Ab, IgM, CSF LT 1:4
St. Louis Encephalitis Ab, IgM, CSF LT 1:4
Western Equine Encephalitis Ab, IgM, CSF LT 1:4
Interpretive Criteria:
LT 1:4 Antibody not detected
1:4 or more Antibody detected
Specimens positive for arbovirus antibody
are CDC reportable. Please contact your
local public health agency.
Diagnosis of infections of the central
nervous system can be accomplished by
demonstrating the presence of intrathecally-
produced specific antibody. However,
interpreting results is complicated by
low antibody levels fround in CSF,
passive transfer of antibody from blood,
and contamination via bloody taps. The
interpretation of CSF results must
consider CSF-serum ratios of the
infectious agent. |
| ARGININE VASOPRESSIN HORMONE | ADH | AVH | RIA | Arginine Vasopressin Hormone pg/mL
0.0-4.7 |
| ARIPIPRAZOLE | ARI | ARI | HPLC/MS/MS | Aripiprazole Steady state plasma levels in ng/mL
adults following a daily regimen
have been reported as:
5 mg 70-126
10 mg 109-216
15 mg 206-278
20 mg 212-574
30 mg 320-585 |
| ARSENIC | ARS | ARS | ICP/MS | Arsenic 0.0-13.0 ug/L
|
| ARSENIC CREATININE RATIO, RANDOM URINE | ARCR | ARCR | Atomic Absorption & Enzymatic (IDMS Traceable) | Arsenic, Urine Random No reference range established ug/L
Creatinine, Urine Random No reference range established mg/dL
Arsenic Creatinine No reference range established ug/gCR |
| ARSENIC TOTAL INORGANIC, URINE (SPECIATED) | ARTISU | ARTISU | ICP/MS, Colorimetric | Creatinine, Ur ACGIH Normal mg/L
adult range
300-3400
Arsenic, Total 35 ug/L ug/L
Inorganic, Ur meausred in the end
of work week specimen-
ACGIH
Arsenic, Total ug/gCr
Inorganic, Ur (Creatinine corrected)
Various states require that levels
above certain cutoffs must be reported
to the state in which the patient resides. |
| ARSENIC, URINE (QUANTITATIVE) | ARS-U | ARSUQ | Electrothermal (Flameless) AAS | Collection Period h
Volume mL
Arsenic, Urine ug/L
No reference range established
Arsenic, Urine 5-50 ug/24h |
| ARSENIC, URINE (RANDOM) | ARS-RU | ARSUR | Electrothermal (Flameless) AAS | Arsenic, Urine (Random) ug/L
No normals established |
| ARSENIC, URINE REFLEX TO FRACTIONS | ARSURF | ARSURF | ICP/MS/HPLC | Collection Period h
Volume mL
Creatinine, Urine mg/dL
Creatinine, Urine mg/d
Creatinine, 24hr Urine mg/d
Male 3-8 yrs: 140-700 mg/d
Male 9-12 yrs: 300-1300 mg/d
Male 13-17 yrs: 500-2300 mg/d
Male 18-50 yrs: 1000-2500 mg/d
Male 51-80 yrs: 800-2100 mg/d
Male 81+ yrs: 600-2000 mg/d
Female 3-8 yrs: 140-700 mg/d
Female 9-12 yrs: 300-1300 mg/d
Female 13-17 yrs: 400-1600 mg/d
Female 18-50 yrs: 700-1600 mg/d
Female 51-80 yrs: 500-1400 mg/d
Female 81+ yrs: 400-1300 mg/d
Arsenic, Urine 0-35.0 ug/L
Arsenic, Urine 0-50.0 ug/d
Arsenic, Urine No reference interval ug/gCR
Arsenic, Organic ug/L
Arsenic, Inorganic ug/L
Arsenic, Methylated ug/L |
| ARTERIAL BLOOD GASES BATTERY | ABG | ABG | Ion Transfer Electrode/Potentiometry/Co-oximeter | pH 7.37-7.47
PCO2 32-43 mm Hg
PO2 65-80 mm Hg
O2 Content 15-23 Vol %
O2 SAT 92-99.9 %
HCO3 23-28 mmol/L
BE -2.5 to +2.5 mmol/L
Base Deficit 0.0-2.5 mmol/L
Hemoglobin g/dL
0-3 days 14.5-22.5
3-7 days 13.5-21.5
7-14 days 12.5-20.5
14-30 days 10.0-18.0
30-60 days 9.0-14.0
2-6 mo 10.5-13.5
6-24 mo 11.5-13.5
2-6 yrs 11.5-13.5
6-12 yrs 11.5-15.5
12-18 yrs M 13.0-16.0
18 yrs+ M 13.7-16.7
12-18 yrs F 12.0-16.0
18 yrs+ F 11.6-15.5
Co Hgb 1-3 %
Met Hgb 0.4-1.5 %
O2 %
Additional Data |
| ARTHRITIS PROFILE | AR | ARPF | Enzymatic/Nephelometry | Uric Acid mg/dL
M 0-16 yrs 2.0-5.5
17+ yrs 3.1-8.1
F 0-16 yrs 2.0-5.5
17+ yrs 2.0-6.7
Sed Rate mm/h
M 0-10
F 0-20
RA LT 20 IU/mL |
| ARTHROPOD IDENTIFICATION, MACROSCOPIC | ARTHID | ARTHID | Macroscopic Inspection | Source
Arthropod Identification
Arthropod Identification, Status |
| ARYLSULFATASE A, URINE | ARYSUQ | ARYSUQ | Colorimetric/Kinetic | Time h
Volume mL
Arylsulfatase A, Ur 1.1 or more U/L |
| ASO | ASO | ASO | Nephelometry | ASO 250 or less IU/mL |
| ASPERGILLUS ANTIBODIES PANEL | ASPABP | ASPABP | CF/ID | Aspergillus Ab, CF
LT 1:8 No antibody detected.
A serum titer of LT 1:8 is expected.
Higher titers tend to be a stronger
indication of diseaSe and its severity.
Cross reactions with dimorphic fungi
are uncommon, but not unusual within
the genus Aspergillus. Negative test
does not exclude infection, especially
in immunocompromised patients. Best
use of test is with paried sera taken
three weeks apart to detect a rise in
titer against a single antigen.
Aspergillus Ab, ID
None detected.
In general immunodiffusion measures
IgG and a positive result may suggest
active or recent infection. The test
is positive in about 90% of sera from
patients with aspergilloma and 50-70%
of patients with allergic bronchopul-
monary aspergillosis. A negative test
(none detected) does not exclude
aspergillosis. |
| ASPERGILLUS ANTIBODY | ASPER | ASPAB | ID | Aspergillus Antibody
by Immunodiffusion None detected |
| ASPERGILLUS GALACTOMANNAN ANTIGEN BY EIA | ASGAG | ASGAG | EIA | Aspergillus Galactomannan Antigen Negative |
| ASPIRIN WORKS | ASAWK | ASAWK | ELISA | 11-Dehydro Thromboxane B2 1500 or less Normalized levels of 11-Dehydro Thromboxane B2 pg/mg
indicates an aspirin effect.
GT 1500 Normalized levels of 11-Dehydro Thromobxane B2
indicates a lack of an aspirin effect. |
| AST | GOT | AST | Enzymatic | AST U/L
0-6 yrs 20-60
6-10 yrs 20-40
10-18 yrs 14-40
18 yrs+ 5-40 |
| AUTOIMMUNE PROFILE (REFLEXIVE) | AIP | AIP | Multiplex luminex, Nephelometry | ANA Negative
A multiplex screen for 11 autoantibodies
(dsDNA, Smith, Ribosomal P, Chromatin, RNP,
SmRNP, Scl-70, Centromere B, SSA, SSB and
J0-1) was performed and no autoantibodies
were detected. A negative multiplex ANA
does not rule out all possibility of a
connective tissue or autoimmune disease,
and further studies should be considered
if clinical suspicion is high.
DSDNA Autoantibody Negative LT 5 IU/mL
Indeterminate 5-9
Positive 10 or more
Smith Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
Ribosomal P Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
Chromatin Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
RNP Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
SMRNP Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
SCL-70 Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
Centromere B Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
SSA (RO) Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
SSB (LA) Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
JO-1 Autoantibody Negative LT 1.0 AI
antibody Positive 1.0 or more
Complement, C3 0-1 days 50-168 mg/dL
2-60 days 55-170
2-5 months 59-176
6-24 months 66-180
25-60 months 74-184
5-9 years 74-190
10-14 years 77-198
15+ years 90-200
CRP 1.5 or less mg/dL
RA LT 20 IU/mL |
| B-TYPE NATRIURETIC PEPTIDE | BTNP | BNPEPR | CMIA | B-Type Natriuretic Peptide LT 100 pg/mL |
| BABESIA MICROTI ANTIBODY, IGG & IGM | BABMIC | BABMIC | IFA | Babesia microti, IgG LT 1:16 Negative
Negative LT 1:16 No significant
level of detectable Babesia IgG antibodies.
Equivocal 1:16 Repeat testing in
10-14 days may be helpful.
Positive GT 1:16 IgG Ab to Babesia
detected, which may indicate a current
or previous infection.
Babesia microti IgM LT 1:20 Negative
Negative LT 1:20 No significant
level of detectable Babesia IgM antibodies.
Equivocal 1:20 Repeat testing in
10-14 days may be helpful.
Positive GT 1:20 IgM Ab to Babesia
detected, which may indicate a current
or recent infection.
Babesia Interpretation |
| BACLOFEN, SERUM | BACLQT | BACLQT | LC/MS/MS | Baclofen, Serum 0.08-0.40 mcg/mL |
| BAL PROFILE (REFLEXIVE) | BALPR | BALPR | Microscopic | BAL-Volume
BAL-Color
BAL-Clarity
BAL-Neut Smoker 1 % or less
Nonsmoker up to 3 %
BAL-Lymph 6-8 %
BAL-Atypical Lymphs
BAL-Macro/Mono
BAL-Phag/Mono
BAL-Eos 0-1 %
BAL-Baso 0-1 %
BAL-Squam.Epis
BAL-Column.Epis
BAL-Others
BAL-Fungus
BAL-Bacteria
BAL-Note
BAL-Oil Red O Normal 0-50
Equivocal 51-100
GT 100 indicates aspiration
BAL-Iron Low 0-20
Moderate 21-100
Elevated GT 100
BAL-Interp
BAL-Reviewed By |
| BAL, BODY FLUID CONSULT REVIEW | BAL.REV | BALVWI | | BAL-Source
BAL-Interpretation |
| BAL, DIFFERENTIAL (REFLEXIVE) | BALDIF | BALDIF | Microscopic | Neutrophils smoker 0-1 %
non-smoker up to 3
Lymphocytes 6-8 %
Variant Lymphs %
Macrophages/Monos %
Phagocytic Monos %
Eosinophils 0-1 %
Basophils 0-1 %
Squamous Epi Cells %
Columnar Epi Cells %
Others %
Fungus
Bacteria
Bal Note |
| BAL, IRON STAIN | BAL.IRN | BALFE | Cytochemical Stain | BAL-Iron Low 0-20
Moderate 21-100
Elevated GT 100 |
| BAL, LYMPH SUBSETS (REFLEXIVE) | BAL.LYMPH | BALSUB | Immunocytochemical | BAL-CD3 %
BAL-CD4 %
BAL-CD8 %
BAL-CD19 %
BAL-CD4/CD8 Ratio |
| BAL, OIL RED O STAIN | BAL.ORO | BALORO | Cytochemical Stain | BAL, Oil Red O
Normal 0-50
Equivocal 51-100
Indicates aspiration GT 100 |
| BARTONELLA DNA BY PCR | BARPCR | BARPCR | PCR | Bartonella henselae DNA by PCR
Not detected
Bartonella quintana DNA by PCR
Not detected
The detection of Bartonella henselae
& Bartonella quintana DNA is based
upon the amplification of specific
Bartonella genomic DNA sequences by
PCR form total DNA extracted from
the specimen. Probes specific for
B. henselae & B. quintana are used to
identify & differentiate the products
of the PCR amplification. The diagnosis
of B. henselae or B. quintana infection
should not rely solely upon the result
of a PCR assay. A positive PCR result
should be considered in conjunction
with the clinical presentation &
additional established diagnostic
tests prior to establishing diagnosis.
A negative PCR result indicates only
the absence of B. henselae or B.
quintana DNA in the sample tested &
does not exclude the diagnosis of
disease. |
| BARTONELLA HENSELAE ANTIBODY | ROCHAL | ROCHAL | IFA | Bartonella henselae, IgG Ab
LT 1:64 Negative-No significant level
of Bartonella henselae IgG Ab detected.
1:64-1:128 Equivocal-Questionable
presence of Bartonella henselae IgG Ab
detected. Repeat testing in 10-14 days
may be helpful.
1:256 or greater Positive-Presence of IgG Ab to
Bartonella henselae detected, suggest-
ive of current or past infection.
Bartonella henselae, IgM
LT 1:16 Negative-No significant level
of Bartonella henselae IgM Ab detected.
1:16 or greater Equivocal-Questionable pre-
sence of Bartonella henselae IgM Ab
detected. Repeat testing in 10-14 days
may be helpful. |
| BARTONELLA SPECIES ANTIBODY, IGG/IGM (REFLEXIVE) | BARGM | BARGM | IFA | Bartonella henselae IgG Screen Negative
Bartonella henselae IgG Titer LT 1:64
Bartonella quintana IgG Screen Negative
Bartonella quintana IgG Titer LT 1:64
Bartonella henselae IgM Screen Negative
Bartonella henselae IgM Titer LT 1:20
Bartonella quintana IgM Screen Negative
Bartonella quintana IgM Titer LT 1:20 |
| BASIC METABOLIC PANEL | BMPA | BMPA | Colorimetric, Enzymatic, ISE, Hexokinase, Enzymatic (IDMS Traceable) | Ranges as they appear on report:
Glucose mg/dL
0-2 days premature 30-80
0-2 days full term 40-90
2 days to 1 month 60-105
Adults 65-99
ADA diagnostic comments:
Glucose mg/dL
0-2 days premature 30-80
0-2 days fullterm 40-90
2 days-1 month 60-105
Adult 65-99
Pregnant 65-94
ADA Diagnostic Categories for nonpregnant
adults:
Impaired fasting glucose 100-125 mg/dL
A fasting glucose result of 126 mg/dL or
greater indicates diabetes if the
abnormality is confirmed on a subsequent
day.
A random glucose result of GT 200 mg/dL
indicates diabetes if the abnormality
is confirmed on a subsequent day.
BUN 7-23 mg/dL
Creatinine M 0.50-1.30 mg/dL
F 0.40-1.00
BUN/Creatinine Ratio 11.0-35.0 Ratio
Calcium 8.5-10.5 mg/dL
Sodium 135-145 mmol/L
Potassium 0-30 days 3.9-6.9 mmol/L
1-12 mo 3.6-6.8
1-5 yrs 3.2-5.7
5-10 yrs 3.4-5.4
10 yrs+ 3.5-5.3
Chloride 98-109 mmol/L
CO2 0-10 days 13-22 mmol/L
11 days-4 yrs 20-28
5+ yrs 22-31
Anion Gap 5-16 mmol/L |
| BCL-1/JH, T (11;14) TRANSLOCATION, FLUID | BCL1F | BCL1F | PCR | bcl-1/JH, t(11;14) by PCR, Fluid Negative: bcl-1/JH gene rearrangement is not detected.
Positive: blc-1/JH gene rearrangement is detected.
A positive result indicates the presence of a bcl-1/JH
(11;14) chromosomal translocation. A negative result does
not entirely exclude the presence of a bcl-1/JH chromosomal
t(11;14) translocation. |
| BCL-2/JH, T(14;18) BY PCR, FLUID | BCLJHT | BCLJHT | PCR | bcl-2/JH, t(14;18) mbr, Fluid
Negative bcl-2/JH major breakpoint region
gene rearrangement is
not detected.
Positive bcl-2/JH major breakpoint region
gene rearrangement is
detected.
bcl-2/JH, t(14;18) mcr, Fluid
Negative bcl-2/JH minor cluster region
gene rearrangement is not
detected.
Positive: bcl-2/JH minor cluster region
gene rearrangement is detected.
This test is performed pursuant to an agree-
ment with Roche Molecular Systems, Inc. |
| BCR-ABL GENE REARRANGEMENT | BCRAB | BCRAB | Real-time qRT-PCR | Source
BCR/ABL Translocation Not detected
A bcr/abl t(9;22) translocation was not detected.
Major fusion transcript (p210 fusion gene product): Not detected
Minor fusion transcript (p190 fusion gene product): Not detected
The bcr/abl fusion gene transcript is found in GT 99% of patients
with chronic myelogenous leukemia (CML) & 25-40% of adult patients
with ALL. A negative result does not absolutely rule out the
presence of the fusion transcript in this patient's sample.
This test is performed by real-time quantitative reverse transcription PCR using fluorescence detection.
Analytical specificity: detects the three major fusion transcripts, b3a2, b2a2, and e1a2. Limit of detection and limit of quantification p210: 0.0005% and 0.005%. Limit of detection and limit of quantification for p190: 0.01% and 0.1%. |
| BENCE JONES PROTEIN, QUANTITATIVE FREE KAPPA & LAMBDA LIGHT CHAINS,URINE | BJKLQ | BJKLQ | Immunofixation/Electrophoresis/Nephelometry | Collection time hr
Total Volume mL
Total Protein 10-140 mg/d
Albumin, Urine None detected
Alpha-1, Urine None detected
Alpha-2, Urine None detected
Urine Beta Globulin None detected
Gamma, Urine None detected
Free Urinary Kappa 0.14-2.42 mg/dL
Light Chains
Free Uinary Kappa mg/d
Excretion/day
Free Urinary Lambda mg/dL
Light Chains
Free Urinary Lambda 0.02-0.67 mg/dL
Excretion/day mg/d
Free Urinary Kappa/ 2.04-10.37 ratio
Lambda Ratio
IFE Interpretation Total urinary protein is determined
nephelometrically by adding the albumin
and kappa and/or lambda light chains.
This value may not agree with the total
protein as determined by chemical methods,
which characteristically underestimate urinary
light chains.
|
| BENZENE, WHOLE BLOOD | BENZENE | BENZWB | GC | Benzene mcg/mL
Following exposure to 25 ppm in air
for 2 hours Approximately 0.2 |
| BENZODIAZEPINES, (QUANTITATIVE) | BENUQ | BENUQ | LC-MS/MS | Diazepam ng/mL
Nordiazepam ng/mL
Oxazepam ng/mL
Temazepam ng/mL
Clobazam ng/mL
Chlordiazepoxide ng/mL
Lorazepam ng/mL
7-Amino Clonazepam ng/mL
Alprazolam ng/mL
Alpha-Hydroxyalprazolam ng/mL
1-Hydroxymidazolam ng/mL
Hydroxytriazolam ng/mL
Hydroxyethylflurazepam ng/mL
Desalkylflurazepam ng/mL
Estazolam ng/mL |
| BERYLLIUM | BERY | BERY | ICP/MS | Beryllium LT 1.0 ug/L |
| BETA 2 TRANSFERRIN | B2TRAN | B2TRAN | Immunofixation Electrophoresis | Beta 2 Transferrin None Detected
Detection of a beta-2 transferrin band by IFE is
diagnostic for the presence of CSF. This test is a
consideration in the differential diagnosis for CSF
otorrhea or CSF rhinorrhea. Beta-2 transferrin is not
detected in normal serum, tears, saliva, sputum, nasal,
aural fluid, or endolymph by this method. |
| BETA STREP GROUP B PCR | BSBPCR | BSBPCR | PCR | Source
Beta Strep Group B PCR Result
Beta Strep Group B PCR Status |
| BETA-2 GLYCOPROTEIN 1, IGA | B2GP1A | B2GP1A | ELISA | Beta-2 Glycoprotein 1 Ab, Negative LT 10 U/mL
IgA Positive 10 or more |
| BETA-2 GLYCOPROTEIN 1, IGG | B2GP1G | B2GP1G | ELISA | Beta-2 Glycoprotein 1 Ab, Negative LT 20 U/mL
IgG Positive 20 or more |
| BETA-2 GLYCOPROTEIN 1, IGG & IGM | B2GPGM | B2GPGM | ELISA | Beta-2 Glycoprotein 1 Ab, Negative LT 20 U/mL
IgG Positive 20 or more
Beta-2 Glycoprotein 1 Ab, Negative LT 10 U/mL
IgM Positive 10 or more |
| BETA-2 GLYCOPROTEIN 1, IGM | B2GP1M | B2GP1M | ELISA | Beta-2 Glycoprotein 1 Ab, Negative LT 10 U/mL
IgM Positive 10 or more |
| BETA-2-MICROGLOBULIN, CSF | B2M.CSF | B2MSF | Immunoturbidimetric | Beta-2-Microglobulin, CSF 0.0-2.4 mg/L |
| BETA-2-MICROGLOBULIN, SERUM | BETA.2.MIC | B2MIC | CLIA | Beta-2-Microglobulin 1010-1730 ug/L |
| BETA-2-MICROGLOBULIN, URINE | B2M-U | B2MU | CLIA | Beta-2-Microglobulin Urine 0-160 ug/L |
| BETA-HYDROXYBUTYRIC ACID | BOHA | BOHA | Enzymatic | Beta-Hydroxybutyric Acid 0.0-3.0 mg/dL |
| BICARBONATE, URINE | BICARU | BICARU | Enzymatic | Bicarbonate, Urine mmol/L
No reference range established |
| BILE ACIDS, FRACTIONATED | BILEAF | BILEAF | LCTMS | Cholic Acid umol/L
3.1 or less
Deoxycholic Acid umol/L
7.3 or less
Chenodeoxycholic Acid umol/L
9.9 or less
Total Bile Acids umol/L
4.5-19.2 |
| BILE ACIDS, TOTAL (CONJUGATED) | BILE ACIDS | BILEA | Enzymatic | Bile Acids Fasting 0-10 umol/L |
| BILIRUBIN, DIRECT | DBIL | DBIL | Colorimetric | Bilirubin, Direct 0.0-0.4 mg/dL |
| BILIRUBIN, FLUID | BILFL | BILFL | Colorimetric | Bilirubin, Fluid mg/dL
No reference range established.
Method not validated for body fluid.
Clinical correlation necessary. |
| BILIRUBIN, FRACTIONATED | FRBIL | BILFR | Colorimetric, Calculation | Bilirubin, Total mg/dL
0-30 days LT 11.7
1 mo-18 yrs LT 2.0
18-60 yrs 0.1-1.5
60-90 yrs 0.2-1.1
90 yrs+ 0.2-0.9
Direct 0.0-0.4 mg/dL
Indirect 0.3-1.0 mg/dL |
| BILIRUBIN, TOTAL | BIL | TBIL | Colorimetric | Bilirubin, Total mg/dL
0-30 days LT 11.7
1 mo-18 yrs LT 2.0
18-60 yrs 0.1-1.5
60-90 yrs 0.2-1.1
90 yrs+ 0.2-0.9 |
| BILIRUBIN, URINE | BILE | BILUD | Colorimetric | Bilirubin, Urine Negative |
| BIOTINIDASE, WITH PARIED NORMAL CONTROL | BIOTAS | BIOTAS | Spectrophotometry | Biotinidase, Patient 3.5-13.8 U/L
Biotinidase, Normal Control U/L |
| BK VIRUS DNA QUANTITATIVE BY PCR (VIRACOR) | BKVCOR | BKVCOR | RT qPCR | BK Source
BK Virus Quant by PCR Not detected
Assay Range: 500 copies/mL
to 1x10e10 copies/mL.
Results should be used in conjunction
with clinical findings & should not form
the sole basis for a diagnosis or treatment
decision. PCR tests are performed pursuant
to a license with Roche Molecular Systems. |
| BK VIRUS DNA, QUANTITATIVE REAL TIME PCR | BKPCR | BKPCR | Real Time PCR | Source
BKV DNA Quantitative LT 500 copies/mL
PCR |
| BKV PCR, URINE (VIRACOR) | BKPCRU | BKPCRU | RT qPCR | BK Virus, Urine Not detected
Assay Range: 500 copies/mL to 1x10e10 copies/mL.
Results should be used in conjunction with clinical
findings, and should not form the sole bases for a
diagnosis or treatment.
PCR tests are performed pursuant to a license agreement
with Roche Molecular Systems.
|
| BLADDER TUMOR ASSOCIATED ANTIGEN | BLTA | BLTA | Qualitative Immunoassay | Bladder Tumor Associated Antigen
Negative Bladder tumor associated
antigen not detected.
Interpretation
Negative Bladder tumor associated
antigen not detected.
Positive Bladder tumor associated
antigen detected.
Results of BTA stat test should not
be interpreted as absolute evidence for
the presence or absence of bladder
cancer. Any disease that would cause
endogenous hCFH to leak into the bladder
can cause a positive test result,
including renal stones, nephritis, renal
cancer, urinary tract infections, cystitis,
or recent trauma to the bladder or
urinary tract. |
| BLASTOMYCES ANTIBODIES PANEL | BLABP | BLABP | CF/ID | Blastomyces Ab, CF
LT 1:8 No antibody detected
Blastomyces Ab, ID
None detected.
In general, immunodiffusion measures
IgG, and a positive result may suggest
active or recent infection. The test
is positive in about 80% of cases.
Cross reactions occur, especially with
histoplasmosis. A negative test (none
detected) does not exclude blasto-
mycosis. |
| BLASTOMYCES ANTIBODY BY CF | BLASTO.CF | BLASCF | CF | Blastomyces Ab (by CF) Titer
LT 1:8 No antibody detected |
| BLASTOMYCES ANTIBODY BY ID | BLASTO | BLASTO | ID | Blastomyces Precipitin Ab by ID None detected |
| BLEEDING DIATHESIS PANEL (REFLEXIVE) | BLDPAN | BLDPAN | Electromechanical Clot Detection, Urea Solubility, Latex Immunoassay, Ristocetin Induced Platelet Aggregation | PT, Pt 0-1 mo 13.0-20.0 sec
2+ mo 10.9-14.8
PT, Pt/Clt Mix A protime that is not within 3 sec
sec of the control plasma may
suggest an inhibitor.
PT, Ctl Plasma sec
APTT, Patient
0-1 mo 40-50 sec
2 mo-4 yr 25-60
5+ yr 26-36
APTT, Pt/Ctl Mix A PTT mix is not within 5
seconds of the control
plasma ususally suggests
an inhibitor.
APTT Ctl Plasma sec
APTT, Pt Post sec
Incubation
Heparinase APTT 26-38 sec
Neutralization suggests heparin
effect.
TT, Pt 15.6-20.0 sec
TT, Control 15.6-20.0 sec
TT, Pt/Ctl Mix sec
TT, Pt/PSO4 Mix sec
Fibrinogen 211-419 mg/dL
Reptilase, Pt 14.8-21.2 sec
Reptilase, Ctl 14.8-21.2 sec
Reptilase, Pt/ sec
Ctl Mix
Factor XIII No clot dissolution
D-Dimer, Quant LT 0.50 ug/mL FEU
Factor VIII 55-150 %
von Willebrand GT 40 %
Factor Activity
von Willebrand 50-165 %
Factor Antigen
Factor II 80-117 %
Factor V 50-150 %
Factor X 45-155 %
Factor VII 65-135 %
Factor IX 60-140 %
Factor XI 65-135 %
PNP 0-7 sec
dRVVT 31.8-45.7 sec
dRVVT Mix 0.0-1.2
Ratio
dRVVT Confirm LT 1.2
Ratio
dRVVT Confirm LT 1.2
Mix Ratio
Factor VIII Negative Bethesda Units
Inhibitor, Qnt
Factor II Negative Bethesda Units
Inhibitor
Factor V Negative Bethesda Units
Inhibitor
Factor X Negative Bethesda Units
Inhibitor
Factor VII Negative Bethesda Units
Inhibitor
Factor IX Negative Bethesda Units
Inhibitor
Factor XI Negative Bethesda Units
Inhibitor
Interpretation
Reviewed by |
| BLEEDING TIME | BLEED | BTIVY | Template | Bleeding Time 2.0-9.5 min |
| BORDETELLA PERTUSSIS IGA, IGG, IGM ANTIBODIES | BPAGM | BPAGM | ELISA | Bordetella pertussis Ab, IgA U/mL
0.9 or less Negative-No significant
level of detectable Bordetella pertussis
IgA antibody.
1.0-1.1 Equivocal-Repeat testing
in 10-14 days may be helpful.
1.2 or more Positive-IgA Ab to
Bordetella pertussis detected which may
indicate a current or past exposure/
immunization to B. pertussis.
Bordetella pertussis Ab, IgG U/mL
0.9 or less Negative-No siginficant
level of Bordetella perutssis IgG Ab.
1.0-2.4 Equivocal-Repeat testing
in 10-14 days may be helpful.
2.5 or more Positive-IgG Ab to
Bordetella pertussis detected, which may
indicate a current or past exposure/
immunization to B. pertussis.
Bordetella pertussis Ab, IgM U/mL
0.9 or less Negative-No significant
level of detectable Bordetella pertussis
IgM Ab.
1.0-1.1 Equivocal-Repeat testing in
10-14 days may be helpful.
1.2 or more Positive-IgM ab to Bordetella
pertussis detected, which may indicate a
current or recent exposure/immunization
to B. pertussis.
|
| BORDETELLA PERTUSSIS SCREEN | PERT | PERTSM | FA | Source
Bordetella pertussis Screen Negative
Bordetella pertussis Status |
| BORDETELLA PERTUSSIS/PARAPERTUSSIS BY PCR | BORPCR | BORPCR | RT-PCR | Bordetella pertussis/parapertussis
by PCR Result
Negative for Bordetella pertussis DNA.
Negative for Bordetella parapertussis DNA.
Comment The analytic sensitivity of this assay is 1 organism per 3 microliters of processed specimen.
A false positive result for Bordetella pertussis may occur in samples containing Bordetella
holmesii or Bordetella bronchiseptica.
Method This test was performed by PCR and fluorescent hydrolysis probe detection.
Comment |
| BORON, SERUM/PLASMA | BORONS | BORONS | ICP/MS | Boron None Detected mcg/L
Normally: LT 100 |
| BORRELIA BURGDORFERI ANTIBODY, IGG/IGM BY WESTERN BLOT | LYWBCF | LYWBCF | Western Blot | Borrelia burgdorferi Ab, IgG-CSF Positive Any five of the following 10 bands: 18, 23,
28, 30, 39, 41, 45, 58, 66 or 93 kDa
Negative Any pattern that does not meet the IgG-positive
criteria.
Borrelia burgdorferi Ab, IgM-CSF Positive Any two of the following 3 bands: 23, 39, or 41 kDa.
Negative Any pattern that does not meet the IgM-positive
criteria.
The detection of Abs to Borrelia burgdorferi in CSF may indicate
central nervous system infection. However, consideration must be
given to possible contamination by blood or transfer of serum
Abs across the blood-brain barrier. |
| BORRELIA BURGDORFERI ANTIBODY, IGM | LYME.IGM | LYMEM | EIA | Borrelia burgdorferi, IgM LT 0.8 Index
LT 0.8 Not detected
0.8-1.2 Indeterminate
GT 1.2 Positive |
| BORRELIA HERMSII ANTIBODY PANEL | BHERAB | BHERAB | IFA | Borrelia hermsii, IgG LT 1:64
Borrelia hermsii, IgM LT 1:16
Interpretation |
| BORRELIA HERMSII, SMEAR (BLOOD PARASITES) | BLD-PARA BOR | BORR | Microscopic | Borrelia (Bld) None Seen
(If present reported as "Parasites seen" with
the number of parasites/1000 RBC) |
| BORRELIA SPECIES DNA DETECTION BY PCR | LYMPCR | LYMPCR | PCR | Source
Borrelia Species by PCR
Negative-Borrelia species DNA not detected
by PCR.
This test is performed pursuant
to an agreement with Roche Molecular Systems,
Inc. |
| BRETYLIUM TOSYLATE | BRET | BRET | HPLC | Bretylium tosylate mcg/mL
Following a 300 mg IM dose the average
plasma concentration is 1.3 mcg/mL at
approximately 30 minutes. |
| BRILLIANT CRESYL BLUE | BCB | BCB | Visual Microscopic | Brilliant Cresyl Blue Negative |
| BROMIDES | BROMIDE | BROMID | Spectrophotometric | Bromide mg/dL
Sedation 10-50
Seizure control 75-150
Toxic for many patients 75-150
Possibly debilitatingly toxic GT 150
Possibly fatal GT 300 |
| BRUCELLA AB, IGG & IGM | BRABGM | BRABGM | ELISA | Brucella Ab, IgG LT 0.80 U
LT 0.80 Antibody not detected
0.80-1.09 Equivocal
1.10 or greater Antibody detected
Brucella Ab, IgM LT 0.80 U
LT 0.80 Antibody not detected
0.80-1.09 Equivocal
1.10 or greater Antibody detected
|
| BUN | BUN | BUN | Enzymatic | BUN (UREA) 7-23 mg/dL |
| BUN/CREATININE RATIO | BUN/CRE | BUNCRE | Enzymatic, Enzymatic (IDMS Traceable), Calculation | BUN (UREA) 7-23 mg/dL
Creatinine M 0.50-1.30 mg/dL
F 0.40-1.00
BUN/Cre 11.0-35.0 Ratio |
| BUPROPION | BUPROPION | BUPRO | HPLC | Bupropion 50-100 ng/mL
The therapeutic range is not well established.
Patient response appears to improve with
concentrations between 50-100 ng/mL. Levels
below 25 ng/mL may have no effect. Poor
response and increased toxicity have been
reported at concentrations above 100 ng/mL. |
| BUTALBITAL | BUT | BUTALB | GC | Butalbital ug/mL
Therapeutic 1-10
Toxic GT 30 |
| C-PEPTIDE | CPEPS | CPEPS | ICMA | C-Peptide Fasting 1.0-5.5 ng/mL |
| C-TELOPEPTIDE, BETA-CROSS LINKED | CTXAR | CTXAR | Electrochemiluminescent Immunoassay | C-Telopeptide, Beta-Cross Linked pg/mL
F 18-29 yrs 64-640
30-39 yrs 60-650
40-49 yrs 40-465
Postmenopausal 104-1008
M 18-29 yrs 87-1200
30-39 yrs 70-780
40-49 yrs 60-700
50-69 yrs 87-345
70 yrs + 80-1050 |
| C1 ESTERASE INHIBITOR (FUNCTIONAL) | C-1 FUNC | C1FUNC | ELISA | C1 Esterase Inhibitor, Functional %
Normal GT 67
Indeterminate 41-67
Abnormal 40 or less |
| C1 ESTERASE INHIBITOR (TOTAL) | C-1 EST | C1EST | Nephelometric | C1 Esterase Inhibitor, Total 21-39 mg/dL |
| C1Q BINDING ASSAY | C1Q | C1Q | ELISA | C1Q Binding ugE/mL
LT 4 is considered negative for
circulating complement binding immune
complexes. |
| C2 COMPLEMENT COMPONENT | C2 | C2 | RID | Complement, C2 1.0-4.0 mg/dL |
| C3 & C4 COMPLEMENT COMPONENTS | C3/C4 | C3C4 | Nephelometry | C3C 0-1 days 50-168 mg/dL
2-60 days 55-170
2-5 mo 59-176
6-24 mo 66-180
25-60 mo 74-184
5-9 yrs 74-190
10-14 yrs 77-198
15+ yrs 90-200
C4 0-7 days 0.0-45.7 mg/dL
8-60 days 1.5-47.9
2-5 mo 1.5-47.9
6-24 mo 3.0-47.9
25-60 mo 4.5-48.4
5-9 yrs 5.3-50.6
10-14 yrs 6.0-52.8
15+ yrs 15.0-55.0 |
| C3 COMPLEMENT COMPONENT | C3 | C3 | Nephelometry | C3C 0-1 days 50-168 mg/dL
2-60 days 55-170
2-5 mo 59-176
6-24 mo 66-180
25-60 mo 74-184
5-9 yrs 74-190
10-14 yrs 77-198
15+ yrs 90-200 |
| C4 COMPLEMENT COMPONENT | C4 | C4 | Nephelometry | C4 0-7 days 0.0-45.7 mg/dL
8-60 days 1.5-47.9
2-5 mo 1.5-47.9
6-24 mo 3.0-47.9
25-60 mo 4.5-48.4
5-9 yrs 5.3-50.6
10-14 yrs 6.0-52.8
15+ yrs 15.0-55.0 |
| CA 125 | CA125 | CA125 | ICMA | CA 125 0-35 U/mL
The Bayer Advia Centaur immunoassay
method is used. Results obtained with
different assay methods or kits cannot
be used interchangeably. |
| CA 15-3 | CA15-3 | CA153 | ICMA-Bayer Centaur | Ca 15-3 32 or less U/mL |
| CA 27.29 | CA27.29 | C2729 | ICMA | CA27.29 0-40 U/mL
Based on a prospective study of 166
stage II and III breast cancer
patients who were clinically free of
the disease at the time of enroll-
ment, the sensitivity and specificity
of CA 27.29 for breast cancer re-
currence are 58% and 98% respectivly.
The usefulness of this test in stage
I patients or in therapeutic monitor-
ing has not been established.
CA 27.29 can be elevated by non-
malignant conditions and by malig-
nancies other than breast cancer. |
| CA 72-4 | C724 | C724 | Immunoradiometric Assay | CA 72-4 0-6 IU/mL
CA72-4 is for research use only. The
performance characteristics of this test
have not been established. CA72-4 is not
to be used as a diagnostic procedure without
confirmation of the diagnosis by another
established product or procedure. |
| CA19-9 | CA19-9 | CA199 | ICMA | CA 19-9 0-37 U/mL |
| CADMIUM EXPOSURE PANEL (OSHA) | CADOSH | CADOSH | Flameless AAS, ICMA, Colorimetric | Cadmium, Urine 0.0-2.6 ug/L
Cadmium, Urine 0.0-3.0 ug/gCr
Cadmium, Whole Blood 0.0-5.0 ug/L
Creatinine, Urine mg/dL
Beta-2-Microglobulin, Urine 0-160 ug/L
Beta-2-Microglobulin, Urine 0-300 ug/gCr |
| CADMIUM, URINE (QUANTITATIVE) | CAD | CADUQ | Electrothermal (Flameless) AAS | Cadmium, Urine 0.0-2.6 ug/L
Cadmium, Urine 0.0-3.3 ug/24h
Cadmium, Urine 0.0-3.0 ug/gCr |
| CADMIUM, URINE (RANDOM) | CADUUR | CADUUR | Flameless AAS | Cadmium, Urine 0.0-2.6 ug/L
Cadmium, Urine 0.0-3/0 ug/gCr |
| CADMIUM, WHOLE BLOOD | CADWB | CADWB | Flameless AAS | Cadmium, Blood 0.0-5.0 ug/L |
| CAFFEINE | CAFN | CAFN | EIA | Caffeine ug/mL
Therapeutic 6-20
Toxic GT 40 |
| CAH PEDIATRIC PROFILE 6 | CAHPP6 | CAHPP6 | | Androstenedione ng/dL
Premature (26-28 w) Day 4 92-892
Premature (31-35 w) Day 4 80-446
Full-term (1 week) 20-290
Levels decrease rapidly after one week
(18-80
1 month-11 months 6-68
Androstenedione gradually decreases
during the first six months to pre-
pubertal levels.
Prepubertal Children 8-50
Adult Males (18-40 yr) 75-250
Adult Females (18-40 yr) 60-245
Females Postmenopausal 30-120
Cortisol ug/dL
Premature (26-28 W) Day 3 1.0-11
Premature (31-35 w) Day 4 2.5-9.1
Full-term Day 3 1.7-14
Full-term Day 7 2.0-11
31 days-11 months 2.8-23
12 months-15 yrs (8:00 am) 3.0-21
Adults 8:00 am 8.0-19
4:00 pm 4.0-11
Dehydroepiandrosterone (DHEA) ng/dL
Premature (26-28 w) Day 4 236-3640
Premature (31-35 w) Day 4 80-3150
Full-term Day 3 65-1250
8-30 days 50-760
31 days-5 months 26-385
6-11 months 20-100
12 months-5 years 20-130
6-7 years 20-275
Prepubertal 31-345
Adults 160-800
Values begin to increase progressively
at about six years of age, prior to
any physical evidence of puberty.
Deoxycorticosterone (DOC) ng/dL
Premature (26-28 w) Day 4 20-105
Premature (34-36 w) Day 4 28-78
Newborn: levels are markedly elevated
at birth and decrease rapidly during
the first week to the range of 7-49
as found in older infants.
1-11 months 7-49
Prepubertal Children 2-34
Pubertal Children & Adults
8:00 am 2-19
11-Desoxycortisol (Specific ng/dL
Compound S)
Premature (26-28 w) Day 4 110-1376
Premature (31-35 w) Day 4 48-579
Newborn Day 3 13-147
31 days-11 months LT 10-156
Prepubertal (8:00 am) 20-155
Pubertal Children & Adults 12-158
(8:00 am)
17-OH Pregnenolone ng/dL
Premature (26-28 w) Day 4 375-3559
Premature (31-35 w) Day 4 64-2380
3 days 10-829
1- 5 months 36-763
6-11 months 42-540
12-23 months 14-207
24 months-5 years 10-103
6-9 years 10-186
Pubertal 44-357
Adults 53-357
Progesterone ng/dL
Premature (26-28 w) Day 4 18-640
Premature (31-35 w) Day 4 84-1360
Prepubertal 7-52
Adult Males 13-97
Adult Females
Follicular 15-70
Luteal 200-2500
Full-term infants: Progesterone levels
are markedly elevated in the neonate
but fall rapidly to reach prepubertal
levels of 7-52 by seven days where they
remain until puberty.
17-Alpha-hydroxyprogesterone ng/dL
Premature (26-28 w) Day 4 124-841
Premature (31-35 w) Day 4 26-568
Full-term Day 3 7-77
Males: Levels increase after the first
week to peak values ranging from
40-200 between 30 and 60 days. Values
then decline to the prepubertal range
of 3-90 before one year.
Prepubertal 3-90
Adult Males 27-199
Females
1-11 months 13-106
Prepubertal 3-90
Adult Females
Follicular 15-70
Luteal 35-290
Testosterone, Total ng/dL
Males
Premature (26-28 w) Day 4 59-125
Premature (31-35 w) Day 4 37-198
Newborns 1-7 months: Levels decrease
rapidly the first week to 20-50, then
increase to 60-400 between 20-60
days. Levels then decline to prepubertal
range levels of LT 3-10 by seven
months.
Females
Premature (26-28 w) Day 4 5-16
Premature (31-35 w) Day 4 5-22
Newborns 1-7 months: Levels decrease
during the first month to less than
10 and remain there until puberty.
Prepubertal Male & Female LT 3-10
Males (20-50 years) 350-1030
Females (20-50 years)
Premenopausal 10-55
Postmenopausal 7-40 |
| CALCITONIN | CALCI | CALCI | ICMA | Calcitonin LT 13.0 pg/mL |
| CALCIUM | CAL | CA | Colorimetric | Calcium 8.5-10.5 mg/dL |
| CALCIUM, IONIZED | CAL-ION | ICAL | ISE | Calcium, Ionized mg/dL
0-18 yrs 4.90-5.50
19+ yrs 4.75-5.30
Calcium, Normalized mg/dL
0-18 yrs 4.90-5.50
19+ yrs 4.75-5.30 |
| CALCIUM, URINE (QUANTITATIVE) | CAL-U | CAUQ | Spectrophotometry | Collection Period h
Volume mL
Calcium, Urine mg/dL
Calcium, Urine 100-300 mg/24h |
| CALCIUM, URINE (RANDOM) | CAL-R | CAUR | Spectrophotometry | Calcium, Urine No normals established mg/dL |
| CALCIUM/CREATININE RATIO | CAL/CRE | CACRER | ISE/Modified Jaffe Reaction | Calcium, Urine, Random No normals established mg/dL
Creatinine, Urine, Random No normals established mg/dL
Calcium/Creatinine Ratio No normals established |
| CALCULI (STONE) ANALYSIS | STONEC | STONEC | FTIR/Polar & Infrared Mircroscopy/Total Reflectance | Stone Mass mg
Calculi Number
Calculi Size mm
Calculi Description
Composition
Stone Compostition |
| CALPROTECTIN, FECAL | CALPFC | CALPFC | ELISA | Calprotectin, Fecal 50 ug/g or less Normal ug/g
51-120 Borderline elevated
121 ug/g or more Abnormal Suggestive
of inflammatory bowel
disease (IBD). |
| CAMPYLOBACTER JEJUNI ANTIBODY IGG | CAMPAB | CAMPAB | Indirect Fluorescent Antibody | Campylobacter LT 1:320 Negative-no significant level of
C. jejuni IgG Ab detected.
1:320 or higher Positive-IgG Ab to C. jejuni
detected, suggestive of current or past
infection.
The best evidence for current infection is
a significant change on two appropriately
timed specimens, where both tests are done
in the same laboratory at the same time. |
| CANDIDA ANTIBODY & ANTIGEN PANEL | CAAGAB | CAAGAB | ELISA & LA | Candida albicans Antigen Detection LT 1:2
Interpretive Criteria
LT 1:2 Antigen not detected
1:2 or more Antigen detected
Detection of Candida albicans antigen
in serum is highly suggestive of
systemic or disseminated candidiasis.
Candida albicans IgG Antibody LT 1.00
Candida albicans IgA Antibody LT 1.00
Candida albicans IgM Antibody LT 1.00
Interpretative Criteria:
LT 1.00 Antibody not detected
1.00 or more Antibody detected
Systemic candidiasis is often
characterized by markedly elevated
levels of IgG, IgA, and IgM antibodies
recognizing Candida. However, inter-
pretation of Candida antibody levels
is complicated by detection of
antibodies in 20-30% of healthy individuals,
and blunted antibody responses in
immunocompromised patients at risk
for candidiasis.
Candida antibody results should be
considered within the context of
clinical findings and results from
other relevant laboratory tests, such
as Candida antigen detection and/or
culture. |
| CANDIDA ANTIGEN | CANAG | CANAG | Latex Agglutination | Candida Antigen Negative
A negative reaction does not exlude
the possibility of systemic Candida
infection. |
| CANDIDA IGG, IGA & IGM ANTIBODY PANEL | CANAGM | CANAGM | ELISA | Candida IgG Antibody LT 1.0
Candida IgA Antibody LT 1.0
Candida IgM Antibody LT 1.0
Interpretative Criteria:
LT 1.0 Antibody not detected
1.0 or more Antibody detected
Systemic candidiasis is often
characterized by markedly elevated
levels of IgG, IgA, and IgM antibodies
recognizing Candida. However, inter-
pretation of Candida antibody levels
is complicated by detection of
antibodies in healthy individuals,
and blunted antibody responses in
immunocompromised patients at risk
for candidiasis. |
| CANDIDA PRECIPITINS | CAN AB | CANDID | Immunodiffusion | Candida Precipitins None detected |
| CANNABINOIDS (QUANTITATIVE) | CANNQS | CANNQS | GC/MS | Delta-9 THC ng/mL
Usual peak levels in serum for 1.75%
or 3.55% THC marijuana cigarettes:
50-270 ng/mL at 6-9 minutes after
beginning smoking, decreasing to
LT 5 ng/mL by 2 hours. Passive
inhalation: up to 2 ng/mL.
Delta-9 Carboxy THC ng/mL
Usual peak levels in serum for 1.75%
or 3.55% THC marijuana cigarettes:
10-101 ng/mL about 32 to 240 minutes
after beginning smoking, with a slow
decline. Usually not detectable after
passive inhalation.
11-Hydroxy THC ng/mL
Usual peak levels: LT 10% of the THC
levels after smoking. |
| CARBAMAZEPINE | CARB | CARB | ICMA | Carbamazepine ug/mL
Therapeutic 4-12
Toxic GT 15
Toxicity can also be seen at lower
levels with combined therapy. |
| CARBAMAZEPINE EPOXIDE & TOTAL | CAREPO | CAREPO | HPLC | Carbamazepine-10,11 Epoxide 0.5-2.0 ug/mL
Carbamazepine, Total 4.0-12.0 ug/mL
The 10,11 epoxide metabolite has
anticonvulsant activity similar to
the parent drug. The expected range
following chronic therapeutic dose
(5.2-20.0 mg/kg) of carbamazepine
is 0.5-2.0 ug/mL. No critical value
has been established. |
| CARBAMAZEPINE, FREE & TOTAL | CARB.FREE | CARBFR | Immunoassay | Free Carbamazepine 1.0-3.0 ug/mL
Toxic range GT 3.8
Total Carbamazepine 4.0-12.0 ug/mL
Toxic range GT 20
% Free Carbamazepine 8.0-35.0 % |
| CARBOXYHEMOGLOBIN | CO HGB | CXHGB | Colorimetric/Co-oximeter | Hemoglobin g/dL
0-3 days 14.5-22.5
3-7 days 13.5-21.5
7-14 days 12.5-20.5
14-30 days 10.0-18.0
30-60 days 9.0-14.0
2-6 mo 10.5-13.5
6-24 mo 11.5-13.5
2-6 yrs 11.5-13.5
6-12 yrs 11.5-15.5
12-18 yrs M 13.0-16.0
18 yrs+ M 13.7-16.7
12-18 yrs F 12.0-16.0
18 yrs+ F 11.6-15.5
Carboxyhemoglobin 1.0-3.0 % |
| CARCINOEMBRYONIC ANTIGEN | CEA | CEA | ICMA-Bayer Centaur | CEA (ICMA) Non-Smokers 0.0-3.0 ng/mL
Smokers 0.0-5.0 |
| CARCINOEMBRYONIC ANTIGEN (CEA), FLUID | CEAFL | CEAFL | Electrochemiluminescent Immunoassay | Source, Fluid
CEA, Fluid ng/mL
The Roche Modular E170 CEA
electrochmiluminescent immuno-
assay is used. Results obtained
with different assay methods or
kits cannot be used inter-
changeable. Measurements of CEA
have been shown to be clinically
relevant in the management of
patients with colorectal, breast,
lung, prostatic, pancreatic, &
ovarian carcinomas. Smokers may
have slightly eleveated levels of
CEA. The CEA assay value, regardless
of level, should not be interpreted
as absence of malignant disease and is
not recommended for use as a screening
procedure to detect the presence of cancer
in the general population. |
| CARCINOEMBRYONIC ANTIGEN, CSF | CEA.CSF | CEASF | Chemiluminometric immunoassay | CEA, CSF LT 0.6 ng/mL
Tumor markers are not specific for
malignancy, and values may vary by
method. |
| CARDIAC RISK ASSESSMENT BATTERY | CRABAT | CRABAT | Enzymatic, Hexokinase, FPIA, Neph | Cholesterol mg/dL
LT 200 Desirable
200-239 Borderline high
240 or more High
Triglycerides mg/dL
LT 150 Normal
150-199 Borderline high
200-499 High
500 or more Very high
HDL mg/dL
LT 40 Low
40-59 Within normal limits
60 or more High
HDL Cholesterol greater than or equal
to 60 mg/dL is considered to be a
'negative' risk factor, serving to
remove one risk factor from the total
count.
LDL (calculated) mg/dL
LT 100 Optimal
100-129 Near or above normal
130-159 Borderline high
160-189 High
190 or more Very high
To calculate 10-year cardiac risk for
the patient, go to http://www.paml.com,
click on testing, then on ranges/
algorithms, and then on lipid results.
LDL/HDL Ratio
No longer applicable or reported.
CHO/HDL Ratio
No longer applicable or reported.
High Sensitivity CRP mg/L
Low risk LT 1.0
Average risk 1.0-3.0
High risk GT 3.0
Relative risk categories follow the
recommendations of the American Heart
Association and the CDC. Measurement
of hsCRP should be done twice (averaging
results), optimally two weeks apart,
in metabolically stable patients. If
the hsCRP level is GT 10 mg/L, the test
should be repeated and the patient
examined for non-cardiovascular sources
of inflammation, such as infection.
Homocysteine 4.0-12.0 umol/L
Glucose mg/dL
0-2 days premature 30-80
0-2 days fullterm 40-90
2 days-1 month 60-105
Adult 65-99
Pregnant 65-94
ADA Diagnostic Categories for nonpregnant
adults:
Impaired fasting glucose 100-125 mg/dL
A fasting glucose result of 126 mg/dL or
greater indicates diabetes if the
abnormality is confirmed on a subsequent
day.
A random glucose result of GT 200 mg/dL
indicates diabetes if the abnormality
is confirmed on a subsequent day. |
| CARDIOLIPIN ANTIBODY , IGG & IGM | CARD.AB | CARD | ELISA | Cardiolipin Ab, IgG GPL U/mL
Negative LT 10
Indeterminate 10-19
Low-Med Positive 20-80
Strong Positive GT 80
Cardiolipin Ab, IgM MPL U/mL
Negative LT 10
Indeterminate 10-19
Low-Med Positive 20-80
Strong Positive GT 80 |
| CARNITINE, FREE & TOTAL | CARFTR | CARFTR | Tandem Mass Spectrophotometry | Carnitine, Free umol/L
0-31 days 15-55
1-12 mo 29-61
13 mon-6 yrs 25-55
7-20 yrs 22-63
21 yrs + 25-60
Carnitine, Total umol/L
0-31 days 21-83
1-12 mo 38-73
13 mon-6 yrs 35-90
7-20 yrs 31-78
21 yrs + 34-86
Carnitine, Esterified umol/L
0-31 days 4-29
1-12 mo 7-24
13 mon-6 yrs 4-36
7-20 yrs 3-38
21 yrs + 5-29
Carnitine, Esterified/Free Ratio
0-31 days 0.2-0.8
1-12 mo 0.1-0.8
13 mon-6 yrs 0.1-0.8
7-20 yrs 0.1-0.9
21 yrs + 0.1-1.0 |
| CAROTENE | CAROT | CAR | Extraction/Spectrophotometric | Carotene 50-200 ug/dL |
| CATECHOLAMINES, PLASMA FRACTIONATED | PCAT | PCAT | HPLC | Catecholamines
Dopamine 2 days-150 yrs 0-20 pg/mL
Epinephrine 2-10 days 36-400 pg/mL
11 days-3 mo 55-200
4-11 mo 55-440
12-23 mo 36-640
24-35 mo 18-440
3-17 yrs 18-460
18+ yrs 10-200
Norepinephrine 2-10 days 170-1180 pg/mL
11 days-3 mo 370-2080
4-11 mo 270-1120
12-23 mo 68-1810
24-35 mo 170-1470
3-17 yrs 85-1250
18+ yrs 80-520
All reference rnges assume patient is in
a supine pisition. |
| CATECHOLAMINES, URINE (FRACTIONATED) | CAT.UF | CATUQ | HPLC/Electrochemical Detection | Collection Period h
Volume mL
Epinephrine 2-24 ug/24h
Norepinephrine 12-86 ug/24h
Dopamine 88-420 ug/24h
Catecholamines, Total 14-110 ug/24h |
| CATECHOLAMINES, URINE (RANDOM) | CATEUR | CATEUR | HPLC/Enzymatic (IDMS Traceable) | Creatinine, Urine Random No reference range established mg/dL
Epinephrine, Urine Random No reference range established ug/L
Epinephrine (Calculation) ug/gCr
0-1 yrs 0-375
2-4 yrs 0-82
5-10 yrs 0-93
11-Adults 9-58
Norepinephrine, Urine Random No reference range established ug/L
Norepinephrine (Calculation) ug/gCr
0-1 yr 25-310
2-4 yrs 25-390
5-10 yrs 27-108
11-Adults 4-105
Dopamine, Urine Random No reference range established ug/L
Dopamine (Calculation) ug/gCr
0-1 yr 240-1290
2-4 yrs 80-1220
5-10 yrs 220-720
11-Adults 120-450
Please note: A 24-hr urine collection is the preferred specimen.
These reference ranges for random urine collections are based
on literature review.
|
| CATHARTIC LAXATIVES PROFILE, URINE | LAXPUR | LAXPUR | FAAS/ ICP/MS/TLC | Anthraquinones mcg/mL
Following 150 mg dose:
Detectable up to approximately
32 hours post dose.
Bisacodyl mcg/mL
Following 5 mg dose:
Detectable up to approximately
32 hours post dose.
Oxphenisatin mcg/mL
Following 10 mg dose:
Detectable in urine up to
approximately 18 hours
post dose.
Phenolphthalein mcg/mL
Following 150 mg dose:
Detectable up to approximately
32 hours post dose.
Magnesium mg/L
Based on 24-hour urine:
72-120 mg/L
Phosphorus g/L
Calculated normal:
0.3-1.1 g/L
Based on the reported
excretion rate for
phosphorus of 0.4-1.3 g/24
hours and an average urine
rate of 1200 ml/day |
| CBC WITH PLATELET | CBC | CBCP2 | Automated | WBC K/uL
0 days 9.0-30.0
1-7 days 5.0-21.0
7-30 days 5.0-19.5
1-12 mo 6.0-17.5
1-2 yrs 5.0-15.5
2-4 yrs 6.0-15.5
4-6 yrs 5.0-13.5
6-10 yrs 4.5-13.5
10-14 yrs 5.0-11.0
14-18 yrs 4.5-11.0
18 yrs+ 4.0-11.0
RBC M/uL
0-3 days 4.00-6.60
3-7 days 3.90-6.30
7-14 days 3.60-6.20
14-30 days 3.00-5.40
30-60 days 2.70-4.90
2-6 mo 3.10-4.50
6-24 mo 3.70-5.30
2-6 yrs 3.90-5.30
6-12 yrs 4.00-5.20
12-18 yrs M 4.50-5.30
18 yrs+ M 4.30-5.70
12-18 yrs F 4.10-5.10
18 yrs+ F 3.80-5.20
Hemoglobin g/dL
0-3 days 14.5-22.5
3-7 days 13.5-21.5
7-14 days 12.5-20.5
14-30 days 10.0-18.0
30-60 days 9.0-14.0
2-6 mo 10.5-13.5
6-24 mo 11.5-13.5
2-6 yrs 11.5-13.5
6-12 yrs 11.5-15.5
12-18 yrs M 13.0-16.0
18 yrs+ M 13.7-16.7
12-18 yrs F 12.0-16.0
18 yrs+ F 11.6-15.5
Hematocrit %
0-3 days 45.0-67.0
3-7 days 42.0-66.0
7-14 days 39.0-63.0
14-30 days 31.0-55.0
30-60 days 28.0-42.0
2-6 mo 29.0-41.0
6-24 mo 33.0-39.0
2-6 yrs 34.0-40.0
6-12 yrs 35.0-45.0
12-18 yrs M 37.0-49.0
18 yrs+ M 40.0-50.0
12-18 yrs F 36.0-46.0
18 yrs+ F 35.0-46.0
MCV fL
0-3 days 95.0-121.0
3-7 days 88.0-126.0
7-14 days 86.0-124.0
14-30 days 85.0-123.0
30-60 days 77.0-115.0
2-6 mo 74.0-108.0
6-24 mo 70.0-86.0
2-6 yrs 75.0-87.0
6-12 yrs 77.0-95.0
12-18 yrs M 78.0-98.0
12-18 yrs F 78.0-102.0
18 yrs+ 80.0-100.0
MCH pg
0-3 days 31.0-37.0
3-30 days 28.0-37.0
30-60 days 26.0-34.0
2-6 mo 25.0-35.0
6-24 mo 23.0-31.0
2-6 yrs 24.0-30.0
6-12 yrs 25.0-33.0
12-18 yrs 25.0-35.0
18 yrs+ 27.0-34.0
MCHC g/dL
0-3 days 29.0-37.0
3-14 days 28.0-37.0
14-60 days 29.0-37.0
2-24 mo 30.0-36.0
2-18 yrs 31.0-37.0
18 yrs+ 32.0-35.5
RDW %
0-7 days 11.0-18.0
7-60 days 11.0-17.0
2-6 mo 11.0-16.5
6-24 mo 11.0-16.0
2-6 yrs 11.0-15.0
6-18 yrs 11.0-14.5
18 yrs+ 11.0-15.0
Platelet Count K/uL
0-3 days 250-450
3-9 days 200-400
9-30 days 250-450
1-6 mo 300-750
6 mo-2 yrs 250-600
2-8 yrs 250-550
8-12 yrs 200-450
12-18 yrs 150-450
18 yrs+ 150-400
Neutrophils Newborn 44.0-85.0 %
(Automated) 1-7 days 28.0-62.0
8-14 days 23.0-57.0
15-60 days 18.0-52.0
2-11 mon 15.0-49.0
1-4 yrs 14.0-59.0
5-12 yrs 34.0-71.0
13-18 yrs 40.0-74.0
19+ yrs 40.0-80.0
Segs (Manual) 0-1 day 33-70 %
1-7 days 15-50
7-30 days 15-45
1-12 mo 15-70
1-4 yrs 25-70
4-10 yrs 30-70
10-14 yrs 25-70
14-18 yrs 30-70
18 yrs+ 38-70
Bands 0-2 days 10-18 %
(Automated) 3 days - 36 mon 7-19
37 mon - 4 yrs 5-12
5-16 yrs 5-11
17+ yrs 0-8
Metamyelocytes %
Myelocytes %
Promyelocytes %
Blasts %
Lymphocytes Newborn 9.0-46.0 %
(Automated) 1-3 days 16.0-46.0
4-7 days 26.0-56.0
8-14 days 33.0-63.0
15-60 days 41.0-71.0
2-11 mon 46.0-76.0
1-4 yrs 35.0-76.0
5-12 yrs 23.0-57.0
13-18 yrs 20.0-50.0
19+ yrs 15.0-45.0
Variant Lymphs 0-6 %
Monocytes Newborn 1.0-10.0 %
(Automated) 1-3 days 2.0-10.0
4-14 days 5.0-13.0
15-60 days 3.0-11.0
2 mon-4 yrs 1.0-9.0
5-12 yrs 0.0-9.0
13-18 yrs 1.0-9.0
19+ yrs 0.0-12.0
Eosinophils 0.0-7.0 %
(Automated)
Basophils 0.0-2.0 %
(Automated)
Others %
Nucleated RBCs /100WB
Megakaryocyte /100WB
fragments
Neutrophils, Newborn 6.00-28.00 K/uL
Absolute 1-7 days 1.50-10.00
(Automated) 8-60 days 1.00-9.50
2-11 mon 1.00-8.50
1-4 yrs 1.50-8.50
5-12 yrs 1.50-8.00
13-18 yrs 1.80-8.00
19+ yrs 2.00-7.30
Segs, Absolute 0-1 day 3.00-12.00 K/uL
(Manual) 1-7 days 2.00-6.00
1 wk-1 yr 1.50-5.00
1-4 yrs 1.50-7.50
4-10 yrs 1.80-7.00
10-18 yrs 1.50-7.00
18 yrs+ 1.80-7.70
Bands, Abs K/uL
(Automated)
Lymphs, Abs Newborn 2.00-11.00 K/uL
(Automated) 1-3 days 2.00-11.50
4-14 days 2.00-17.00
15-60 days 2.50-16.50
2-11 mon 4.00-13.50
1-4 yrs 2.00-10.50
5-12 yrs 1.50-7.00
13-18 yrs 1.20-5.20
19+ yrs 1.00-3.40
Var Lymph, Abs K/uL
Monocytes, Abs Newborn 0.90-1.40 K/uL
(Automated) 1-7 days 0.90-1.30
8-14 days 0.80-1.20
15-60 days 0.50-0.90
2-11 mon 0.40-0.80
1-4 yrs 0.30-0.80
5-18 yrs 0.20-0.60
19+ yrs 0.00-0.80
Eos, Abs 0.00-0.50 K/uL
(Automated)
Baso, Abs 0.00-0.10 K/uL
(Automated)
RBC Morphology Normal
WBC Morphology Normal
Platelet Morph Normal
No. of Cells
in Diff |
| CBC WITH PLATELET + MANUAL DIFFERENTIAL | CBCMDI | CBCPM2 | Automated/Microscopic | WBC K/uL
0 days 9.0-30.0
1-7 days 5.0-21.0
7-30 days 5.0-19.5
1-12 mo 6.0-17.5
1-2 yrs 5.0-15.5
2-4 yrs 6.0-15.5
4-6 yrs 5.0-13.5
6-10 yrs 4.5-13.5
10-14 yrs 5.0-11.0
14-18 yrs 4.5-11.0
18 yrs+ 4.0-11.0
RBC M/uL
0-3 days 4.00-6.60
3-7 days 3.90-6.30
7-14 days 3.60-6.20
14-30 days 3.00-5.40
30-60 days 2.70-4.90
2-6 mo 3.10-4.50
6-24 mo 3.70-5.30
2-6 yrs 3.90-5.30
6-12 yrs 4.00-5.20
12-18 yrs M 4.50-5.30
18 yrs+ M 4.30-5.70
12-18 yrs F 4.10-5.10
18 yrs+ F 3.80-5.20
Hemoglobin g/dL
0-3 days 14.5-22.5
3-7 days 13.5-21.5
7-14 days 12.5-20.5
14-30 days 10.0-18.0
30-60 days 9.0-14.0
2-6 mo 10.5-13.5
6-24 mo 11.5-13.5
2-6 yrs 11.5-13.5
6-12 yrs 11.5-15.5
12-18 yrs M 13.0-16.0
18 yrs+ M 13.7-16.7
12-18 yrs F 12.0-16.0
18 yrs+ F 11.6-15.5
Hematocrit %
0-3 days 45.0-67.0
3-7 days 42.0-66.0
7-14 days 39.0-63.0
14-30 days 31.0-55.0
30-60 days 28.0-42.0
2-6 mo 29.0-41.0
6-24 mo 33.0-39.0
2-6 yrs 34.0-40.0
6-12 yrs 35.0-45.0
12-18 yrs M 37.0-49.0
18 yrs+ M 40.0-50.0
12-18 yrs F 36.0-46.0
18 yrs+ F 35.0-46.0
MCV fL
0-3 days 95.0-121.0
3-7 days 88.0-126.0
7-14 days 86.0-124.0
14-30 days 85.0-123.0
30-60 days 77.0-115.0
2-6 mo 74.0-108.0
6-24 mo 70.0-86.0
2-6 yrs 75.0-87.0
6-12 yrs 77.0-95.0
12-18 yrs M 78.0-98.0
12-18 yrs F 78.0-102.0
18 yrs+ 80.0-100.0
MCH pg
0-3 days 31.0-37.0
3-30 days 28.0-37.0
30-60 days 26.0-34.0
2-6 mo 25.0-35.0
6-24 mo 23.0-31.0
2-6 yrs 24.0-30.0
6-12 yrs 25.0-33.0
12-18 yrs 25.0-35.0
18 yrs+ 27.0-34.0
MCHC g/dL
0-3 days 29.0-37.0
3-14 days 28.0-37.0
14-60 days 29.0-37.0
2-24 mo 30.0-36.0
2-18 yrs 31.0-37.0
18 yrs+ 32.0-35.5
RDW %
0-7 days 11.0-18.0
7-60 days 11.0-17.0
2-6 mo 11.0-16.5
6-24 mo 11.0-16.0
2-6 yrs 11.0-15.0
6-18 yrs 11.0-14.5
18 yrs+ 11.0-15.0
Platelet Count K/uL
0-3 days 250-450
3-9 days 200-400
9-30 days 250-450
1-6 mo 300-750
6 mo-2 yrs 250-600
2-8 yrs 250-550
8-12 yrs 200-450
12-18 yrs 150-450
18 yrs+ 150-400
Differential (Manual)
Segs %
0-1 day 33-70
1-7 days 15-50
7-30 days 15-45
1-12 mo 15-70
1-4 yrs 25-70
4-10 yrs 30-70
10-14 yrs 25-70
14-18 yrs 30-70
18 yrs+ 38-70
Segs, Abs K/uL
0-1 day 3.00-12.00
1-7 days 2.00-6.00
1 wk-1 yr 1.50-5.00
1-4 yrs 1.50-7.50
4-10 yrs 1.80-7.00
10-18 yrs 1.50-7.00
18 yrs+ 1.80-7.70
Bands %
0-18 yrs 0-9
18 yrs+ 0-8
Bands, Abs K/uL
0-1 day 0.00-1.50
1-7 days 0.00-1.20
7-30 days 0.00-0.50
1-12 mo 0.00-0.40
1-4 yrs 0.00-0.30
4-10 yrs 0.00-0.20
10-18 yrs 0.00-0.20
Lymphocytes %
0-1 day 10-35
1-7 days 15-70
1 wk-4 yrs 30-70
4-6 yrs 20-70
6-10 yrs 20-50
10-18 yrs 20-40
18 yrs+ 21-49
Lymphocytes, Abs K/uL
0-1 day 2.00-11.00
1-7 days 2.00-7.00
7-30 days 3.00-7.00
1-12 mo 1.50-8.50
1-4 yrs 1.50-5.00
4-10 yrs 1.20-5.00
10-18 yrs 1.10-4.50
18 yrs+ 1.00-5.00
Variant Lymph 0-6 %
Variant Lymphs, Abs K/uL
Monocytes %
0-18 yrs 0-10
18 yrs+ 3-11
Monocytes, Abs K/uL
0-1 day 0.00-1.10
1-7 days 0.00-0.90
7-30 days 0.00-0.60
1-12 mo 0.00-0.50
1-4 yrs 0.00-0.50
4-10 yrs 0.00-0.40
10-18 yrs 0.00-0.90
18 yrs+ 0.00-0.80
Eosinophils %
0-18 yrs 0-4
18 yrs+ 0-7
Eosinophils, Abs K/uL
0-1 day 0.00-0.40
1-7 days 0.00-0.50
7 days-1 yr 0.00-0.30
1-10 yrs 0.00-0.30
10-18 yrs 0.00-0.20
18 yrs+ 0.00-0.50
Basophils %
1-18 yrs 0-1
18 yrs+ 0-2
Basophils, Abs K/uL
0-7 days 0.00-0.10
1 wk-4 yrs 0.00-0.01
4-18 yrs 0.00-0.01
18 yrs+ 0.00-0.20
Metamyelocytes %
Myelocytes %
Promyelocytes %
Blast Cells %
Other %
NRBC /100WBC
Meg Frag /100WBC
RBC Morph
WBC Morph
Platelet Morph
Cells Counted |
| CD19 | CD19S | CD19S | Flow Cytometry | Source
WBC K/uL
0 days 9.0-30.0
1-7 days 5.0-21.0
7-30 days 5.0-19.5
1-12 mo 6.0-17.5
1-2 yrs 5.0-15.0
2-4 yrs 6.0-15.5
4-6 yrs 5.0-13.5
6-10 yrs 4.5-13.5
10-14 yrs 5.0-11.0
14-18 yrs 4.5-11.0
18 yrs+ 4.0-11.0
Lymphocytes Newborn 9.0-46.0 %
1-3 days 16.0-46.0
4-7 days 26.0-56.0
8-14 days 33.0-63.0
15-60 days 41.0-71.0
2-11 mo 46.0-76.0
1-4 yrs 35.0-76.0
5-12 yrs 23.0-57.0
13-18 yrs 20.0-50.0
19+ yrs 15.0-45.0
Lymphs, Abs Newborn 2.00-11.00 K/uL
1-3 days 2.00-11.50
4-7 days 2.00-17.00
8-14 days 2.00-17.00
15-60 days 2.50-16.50
2-11 mo 4.00-13.50
1-4 yrs 2.00-10.50
5-12 yrs 1.50-7.00
13-18 yrs 1.20-5.20
19+ yrs 1.00-3.40
CD19 0-2 yrs 11.0-45.0 %
3 yrs 9.0-29.0
4+ yrs 3.0-21,0
CD19 Abs 0-2 yrs 430-3300 /uL
3 yrs 200-1300
4+ yrs 80-450
Note
Note |
| CD3 | CD3 | CD3 | Flow Cytometry | Source
WBC K/uL
0 days 9.0-30.0
1-7 days 5.0-21.0
7-30 days 5.0-19.5
1-12 mo 6.0-17.5
1-2 yrs 5.0-15.5
2-4 yrs 6.0-15.5
4-6 yrs 5.0-13.5
6-10 yrs 4.5-13.5
10-14 yrs 5.0-11.0
14-18 yrs 4.5-11.0
18 yrs+ 4.0-11.0
Lymphocytes Newborn 9.0-46.0 %
1-3 days 16.0-46.0
4-7 days 26.0-56.0
8-14 days 33.0-63.0
15-60 days 41.0-71.0
2-11 mo 46.0-76.0
1-4 yrs 35.0-76.0
5-12 yrs 23.0-57.0
13-18 yrs 20.0-50.0
19+ yrs 15.0-45.0
Lymphs, Abs Newborn 2.00-11.00 K/uL
1-3 days 2.00-11.50
4-7 days 2.00-17.00
8-14 days 2.00-17.00
15-60 days 2.50-16.50
2-11 mo 4.00-13.50
1-4 yrs 2.00-10.50
5-12 yrs 1.50-7.00
13-18 yrs 1.20-5.20
19+ yrs 1.00-3.40
CD3 0-3 yrs 55.0-82.0 %
4+ yrs 53.0-91.0
CD3 Abs 0-5 mo 3500-5000 /uL
6-11 mo 3400-4600
12-17 mo 3200-3900
18-29 mo 2800-3500
30-35 mo 1900-3100
3 yrs 1000-3900
4+ yrs 560-3000
Note
Note |
| CD4 | CD4 | CD4 | Flow Cytometry | Source
WBC K/uL
0 days 9.0-30.0
1-7 days 5.0-21.0
7-30 days 5.0-19.5
1-12 mo 6.0-17.5
1-2 yrs 5.0-15.5
2-4 yrs 6.0-15.5
4-6 yrs 5.0-13.5
6-10 yrs 4.5-13.5
10-14 yrs 5.0-11.0
14-18 yrs 4.5-11.0
18 yrs+ 4.0-11.0
Lymphocytes Newborn 9.0-46.0 %
1-3 days 16.0-46.0
4-7 days 26.0-56.0
8-14 days 33.0-63.0
15-60 days 41.0-71.0
2-11 mo 46.0-76.0
1-4 yrs 35.0-76.0
5-12 yrs 23.0-57.0
13-18 yrs 20.0-50.0
19+ yrs 15.0-45.0
Lymphs, Abs Newborn 2.00-11.00 K/uL
1-3 days 2.00-11.50
4-7 days 2.00-17.00
8-14 days 2.00-17.00
15-60 days 2.50-16.50
2-11 mo 4.00-13.50
1-4 yrs 2.00-10.50
5-12 yrs 1.50-7.00
13-18 yrs 1.20-5.20
19+ yrs 1.00-3.40
CD4 0-5 mo 50.0-57.0 %
6-11 mo 49.0-55.0
12-17 mo 46.0-51.0
24-29 mo 38.0-46.0
30-35 mo 33.0-44.0
3 yrs 27.0-57.0
CD4 Abs 0-5 mo 2800-3900 /uL
6-11 mo 2600-3500
12-17 mo 2300-2900
18-23 mo 1900-2500
24-29 mo 1500-2200
30-35 mo 1200-2000
3 yrs 560-2700
4+ yrs 490-1400
Note
Note |
| CD57 Antibody | CD57AB | CD57AB | Flow Cytometry | Source
Result
Note |
| CELIAC PANEL, BASIC | CELPAN | CELPAN | ELISA | Tissue Transglutaminase Ab, IgA U/mL
Negative LT 4.0
Equivocal 4.0-10.0
Positive GT 10.0
Tissue Transglutaminase Ab, IgG U/mL
Negative LT 6.0
Equivocal 6.0-9.0
Positive GT 9.0
tTG antibody, especially IgA, is
sensitive and specific for untreated
celiac disease. Levels can decrease
significantly in response to a gluten-
free diet. The IgG assay is used
mainly to detect celiac patients who
are IgA-deficient. |
| CELIAC PANEL, EXTENDED | CELPEX | CELPEX | ELISA/Nephelometry | Tissue Transglutaminase Ab, IgA U/mL
Negative LT 4.0
Equivocal 4.0-10.0
Positive GT 10.0
Tissue Transglutaminase Ab, IgG U/mL
Negative LT 6.0
Equivocal 6.0-9.0
Positive GT 9.0
tTG antibody, especially IgA, is
sensitive and specific for untreated
celiac disease. Levels can decrease
significantly in response to a gluten-
free diet. The IgG assay is used
mainly to detect celiac patients who
are IgA-deficient.
Anti-gliadin Ab, IgA U/mL
Negative LT 10.0
Positive 10.0 or greater
Anti-gliadin Ab, IgG U/mL
Negative LT 10.0
Positive 10.0 or greater
IgA mg/dL
0-4 months No normals established
5-9 months 14-77
10-11 months 16-90
1 year 21-113
2 years 27-153
3 years 31-176
4 years 34-194
5 years 40-225
6 years 54-297
7 years 66-374
8 years 68-387
9 years 71-387
10+ years 80-450 |
| CELIAC PROFILE, PEDIATRIC BASIC | CELPED | CELPED | ELISA/Nephelometry | IgA mg/dL
0-4 months No normals established
5-9 months 14-77
10-11 months 16-90
1 year 21-113
2 years 27-153
3 years 31-176
4 years 34-194
5 years 40-225
6 years 54-297
7 years 66-374
8 years 68-387
9 years 71-387
10+ years 80-450
Tissue Transglutaminase Ab, IgA U/mL
Negative LT 4.0
Equivocal 4.0-10.0
Positive GT 10.0
tTG antibody, especially IgA, is
sensitive and specific for untreated
celiac disease. Levels can decrease
significantly in response to a gluten-
free diet. The IgG assay is used
mainly to detect celiac patients who
are IgA-deficient. |
| CELIAC PROFILE, PEDIATRIC EXTENDED | CELPRO | CELPRO | ELISA/Nephelometry | IgA mg/dL
0-4 months No normals established
5-9 months 14-77
10-11 months 16-90
1 year 21-113
2 years 27-153
3 years 31-176
4 years 34-194
5 years 40-225
6 years 54-297
7 years 66-374
8 years 68-387
9 years 71-387
10+ years 80-450
Tissue Transglutaminase Ab, IgA U/mL
Negative LT 4.0
Equivocal 4.0-10.0
Positive GT 10.0
Anti-gliadin Ab, IgA U/mL
Negative LT 10.0
Positive 10.0 or greater
Anti-gliadin Ab, IgG U/mL
Negative LT 10.0
Positive 10.0 or greater
tTG antibody, especially IgA, is
sensitive and specific for untreated
celiac disease. Levels can decrease
significantly in response to a gluten-
free diet. The IgG assay is used
mainly to detect celiac patients who
are IgA-deficient. |
| CELL COUNT, DIFFERENTIAL, BODY FLUID | CBC.FLD | CTDFFL | Manual Microscopy | Color
Clarity
RBC M/L
Nucleated Cells M/L
Number of Cells Seen
Segs %
Bands %
Lymphocytes %
Variant Lymphocytes %
Mononuclear Phagocytes %
Eosinophils %
Basophils %
Others %
Non-Heme Cells %
Nucleated RBC /100 WBCs
Mesothelial Cells /100 WBCs
Note
Reviewed by |
| CELL COUNT, DIFFERENTIAL, CSF | CBCCSF | CTDFSF | Manual Microscopy | Tube
Xanthochromia
Color
Clarity
RBC M/L
Nucleated Cells 0-5 M/L
Number of Cells Seen
Segs %
Bands %
Lymphocytes %
Variant Lymphocytes %
Monocytes %
Histiocytes %
Eosinophils %
Basophils %
Others %
Non-Heme Cells
Nucleated RBC /100wbc |
| CENTROMERE B AUTOANTIBODY | CENTMP | CENTMP | Multiplex luminex | Centromere B Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more |
| CERULOPLASMIN | CER | CER | Nephelometry | Ceruloplasmin 21-53 mg/dL |
| CH50 COMPLEMENT, TOTAL | CH50 | CH50 | EIA | CH50 Complement, Total 60-185 CAE Units |
| CHEMISTRY REFLEX PANEL | CHEMRA | CHEMRA | | Comprehensive Metabolic Panel
Lipid Profile
TSH (Reflex) |
| CHLAMYDIA ANTIBODY PANEL. IGG/IGM | CHLGM | CHLGM | IFA | C. pneumoniae, IgM
C. trachomatis, IgM
C. psittaci, IgM
C. pneumoniae, IgG
C. trachomatis, IgG
C. psittaci, IgG |
| CHLAMYDIA & CHLAMYDOPHILIC ANTIBODY PANEL 3 | CHLGAM | CHLGAM | IFA | C. trachomatis, IgG LT 1:64
C. trachomatis, IgA LT 1:16
C. trachomatis, IgM LT 1:10
Interpretation
C. pneumoniae, IgG LT 1:64
C. pneumoniae, IgA LT 1:16
C. pneumoniae, IgM LT 1:10
Interpretation
C. psittaci, IgG LT 1:64
C. psittaci, IgA LT 1:16
C. psittaci, IgM LT 1:10
Interpretation
|
| CHLAMYDIA (LGV) ANTIBODIES | CHLGV | CHLGV | Micro-immunofluorescent (MIF) | Chlamydia pneumoniae, IgG LT 1:64
Chlamydia pneumoniae, IgM LT 1:10
Chlamydia trachomatis, IgG LT 1:64
Chlamydia trachomatis, IgM LT 1:10
Chlamydia psittaci, IgG LT 1:64
Chlamydia psittaci, IgM LT 1:10 |
| CHLAMYDIA ANTIBODY PANEL, IGM | CHLABM | CHLABM | IFA | C. Pneumoniae IgM LT 1:20
C. Trachomatis IgM LT 1:20
C. Psittaci IgM LT 1:20
Chlamydia IGM Panel Interpretation |
| CHLAMYDIA PNEUMONIAE CULTURE | CHLPC | CHLPC | Culture | Chlamydia pneumoniae Culture
No Chlamydia pneumoniae isolated |
| CHLAMYDIA TRACHOMATIS DFA | CHDFA | CHDFA | DFA | C. Trachomatis By DFA, Preliminary
C. Trachomatis By DFA
Negative-no Chlamydia trachomatis
detected. |
| CHLAMYDIA TRACHOMATIS BY AMPLIFIED DETECTION (APTIMA) | APTCT | APTCT | TMA | Source
Chlamydia trachomatis by APTIMA
Not detected |
| CHLAMYDIA TRACHOMATIS CULTURE | CHLAM | CHLAM | Isolation in Tissue Culture | Source
C Trachomatis Culture Negative
C Trachomatis Culture, Status |
| CHLAMYDIA TRACHOMATIS IGG & IGM ANTIBODIES | CHLAB | CHLAB | Micro-IF | Chlamydia trachomatis IgG Abs LT 1:16 Titer
Chlamydia trachomatis IgM Abs LT 1:10 Titer
A positive result for Chlamydia IgM and/or IgG does
not always indicate current acute infection. Anti-
Chlamydia antibodies can persist in some patients for
several months or more. Cross-reactivity may also occur
with multiple Chlamydia species in primary Chlamydia infection.
Some patients may show cross-reactivity due to exposure to
more than on Chlamydia species. |
| CHLAMYDIA TRACHOMATIS/NEISSERIA GONORRHOEAE BY AMPLIFIED DETECTION (APTIMA) | APTCG | APTCG | TMA | Source
Chlamydia trachomatis by APTIMA
Not detected
Neisseria gonorrhoeae by APTIMA
Not detected |
| CHLORALHYDRATE | CHLORAL | CHLORS | GC | Chloralhydrate mcg/mL
Therapeutic 2-12
(Post 1 gram dose) |
| CHLORALHYDRATE, URINE | CHLORAL-U | CHLUR | GC | Chloralhydrate, Urine ug/mL
No normals established |
| CHLORAMPHENICOL | CHLOR | CHLOR | HPLC | Chloramphenicol ug/mL
Therapeutic Peak 10-20
Toxic GT 25 |
| CHLORIDE | CL | CL | ISE | Chloride 98-109 mmol/L |
| CHLORIDE, CSF | CL-CSF | CLSF | Ion Selective Electrode | Chloride, CSF 118-132 mmol/L |
| CHLORIDE, FLUID | CHFLD | CHFLD | ISE | Chloride, Fluid mmol/L
No reference range established.
Method not validated for body fluid.
Clinical correlation necessary. |
| CHLORIDE, URINE (QUANTITATIVE) | CL-U | CLUQ | Colorimetric | Collection Period h
Volume mL
Chloride, Urine 110-250 mmol/24h |
| CHLORIDE, URINE (RANDOM) | CL-R | CLUR | Colorimetric | Chloride, Urine, Random mmol/L
No normals established |
| CHLORPROMAZINE | THOR | CHLORP | HPLC | Chlorpromazine (Thorazine) ng/mL
0-11 yrs Therapeutic 30-80
Toxic GT 200
12+ yrs Therapeutic 50-300
Toxic GT 500 |
| CHOLESTEROL | CHO | CHOL | Enzymatic | Cholesterol mg/dL
LT 200 Desirable
200-239 Borderline high
240 or more High |
| CHOLINESTERASE, PLASMA & RBC | CHESCR | CHESCR | Enzymatic | Cholinesterase, Plasma 2.9-7.1 U/mL
Cholinesterase, RBC 7.9-17.1 U/mL
Cholinesterase, RBC Hgb 25-52 U/gHgb
Ratio
Cholinesterase, Plasma 1.0-2.4 U/mL
Ellman Standard
Cholinesterase, RBC Ellman 4.0-9.0 U/mL
Standard |
| CHROMATIN AUTOANTIBODIES | CHROMP | CHROMP | Multiplex luminex | Chromatin Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more |
| CHROMIUM | CHROM.S | CHRM | ICP/MS | Chromium 5.0 or less ug/L |
| CHROMIUM, URINE (QUANTITATIVE) | CHROM-U | CHRMUQ | ICP/MS(DRC) | Collection Period h
Volume mL
Chromium, Ur 0.0-5.0 ug/L
Chromium, Ur 0.0-6.0 ug/d
Creatinine, Ur mg/dL
Creatinine, Ur mg/d
M 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81+ yrs 600-2000
F 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
81+ yrs 400-1300
Chromium, Ur No reference range ug/gCr |
| CHROMIUM, WHOLE BLOOD | CHROM | CHROM | GFAAS | Chromium, Blood 0.5-5.0 ug/L |
| CHROMOGRANIN A | CHROMA | CHROMA | EIA | Chromogranin A 0-50 ng/mL
This assay is performed using ALPCO
Diagnostics chromogranin A EIA.
Results obtained with different assay
methods or kits cannot be used
interchangeably. |
| CHRONIC URTICARIA INDEX PANEL [IBT] | CUPIBT | CUPIBT | Ex Vivo Challenge, Cell Culture and Histamine Analysis | Anti-Thyroid Peroxidase IgG LT 35 IU/mL
Anti-Thyroglobulin LT 40 IU/mL
TSH (Thyrotropin) 0.4-4.0 uIU/mL
CU Index LT 10.0
|
| CHRONIC URTICARIA INDEX [IBT] | CUIIBT | CUIIBT | Ex Vivo Challenge, Cell Culture and Histamine Analysis | CU Index LT 10.0
|
| CIMETIDINE | TAG | TAG | HPLC | Cimetidine (Tagamet) mcg/mL
Therapeutic 0.5-1.5 |
| CITALOPRAM | CELEX | CELEX | GC | Citalopram ng/mL
Steady-state serum levels from
patients on a dialy regimen of
30-60 mg citalopram: 9-200. |
| CITRIC ACID, URINE | CITQU | CITQU | Enzymatic | Collection Period hr
Volume mL
Citric Acid, Urine mg/L
Citric Acid, Urine mg/d
18 yrs and older 320-1240
Creatinine, Ur mg/dL
Creatinine, Ur mg/d
M 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81+ yrs 600-2000
F 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
81+ yrs 400-1300
Citric Acid/ mg/g
CRT Ratio Urine
1 yr or older 150 or more |
| CLINICAL HEMATOLOGY INTERPRETATION, COMPREHENSIVE | CHICOM | CHICOM | | Reviewed material
Interpretation
Reviewed by
Comment |
| CLINICAL HEMATOLOGY INTERPRETATION, LIMITED | CHILIM | CHILIM | | Reviewed material
Interpretation
Reviewed by
Comment |
| CLOMIPRAMINE & METABOLITE | CLOMIP | CLOMIP | HPLC | Clomipramine ng/mL
Desmethylclomipramine ng/mL
Total 220-500 ng/mL
Plasma concentrations vary widely
among patients. The therapeutic
range listed relates to the
antidepressant characteristics of
the drug. A therapeutic range for
treating obsessive compulsive
disorder is not well defined. |
| CLONAZEPAM | CLON | CLON | Liquid Chromatography/Tandem Mass Spectrometry | Clonazepam ng/mL
Therapeutic range 10-75
based on dosages up to 6 mg/d |
| CLONIDINE | CLONIDINE | CLONID | LC-MS/MS | Clonidine (Catapres) ng/mL
Therapeutic 0.5-4.5 |
| CLORAZEPATE | TRAN | CLORAZ | GC | Tranxene (Clorazepate) 0.10-2.20 ug/mL
Clorazepate dose related range
0.10-2.20 ug/mL based on common dosage
amounts.
Minor adverse effects may occur within
this range. Clorazepate is assayed as
Nordiazepam. |
| CLOSTRIDIUM DIFFICILE BY PCR | CDTPCR | CDTPCR | RT-PCR | Source
C. difficile Toxin B gene Result Negative for Clostridium difficile
Toxin B gene by PCR
C. difficile Toxin B gene Status |
| CLOSTRIDIUM DIFFICILE CYTOTOXIN ANTIBODY | CDIFAB | CDIFAB | Neutralization | Clostridium Difficile Cytotoxin Antibody
LT 1:2
Clostridium difficile cytotoxin is
measured by an in vitro neutralization
assay. The level of antibody is reported
as the final serial dilutuion showing
neutralization of cytotoxins. Patients
with C. difficile-associated diarrhea
usually produce secretory and serum
antibodies to both toxins. Therefore,
the presence of antibodies indicates
past or current exposure to C. difficile
toxins, but the associations between
antibody levels and disease protection
is undefined. Evidence suggesting a
protective role for antibodies can be
found in a recent report where it was
shown that children with chronic
relapsing C. difficile-associated colitis
do not produce antibodies and can be
successfully treated with hyperimmune
gamma gobulin. |
| CLOSTRIDIUM DIFFICILE CYTOTOXIN ASSAY | CL-TOX | CLTOX | Tissue culture cytotoxin assay | Source
C Difficile Toxin Negative
C Difficile Toxin, Status |
| CLOZAPINE | CLOZAP | CLOZAP | HPLC | Clozapine ng/mL
Suggested minimum threshold 100 ng/mL.
Concentrations between 200-700 correlate
more with response. However, non-response
does occur within this range.
For schizophrenia, at least 350 mg/d is
suggested for therapeutic repsonse. After
initial therapeutic response occurs, the
dose should be progressively reduced to the
minimum level to maintain clinical
remission. The likelihood of seizures
and other side effects increase with
clozapine levels GT 1200 ng/mL
and/or dosages GT 600 mg/d. |
| CO2 | CO2 | CO2 | Enzymatic | CO2 mmol/L
0-10 days 13-22
11 days-4 yrs 20-28
5+ yrs 22-31 |
| COAGULATION CONSULT FOR VON WILLEBRAND | VONPCC | VONPCC | Electromechanical | Factor VIII 55-150 %
Von Willebrand Factor Antigen 50-165 %
Von Willebrand Factor Activity GT 40 %
Interpretation
Reviewed by |
| COAGULATION PROFILE | COAG-BAT | COAGB | | Bleeding Time 2.0-9.5 min
PT 0-1 mo 13.0-20.0 sec
2+ mo 10.9-14.8
PT, Pop Mean 13.4 sec
PT, INR 0.9-1.2
2.0-3.0 Usual oral anticoagulation range.
2.5-3.5 High level oral anticoagulation range.
PTT 0-1 mo 40-50 sec
2 mo-4 yrs 25-40
5+ yrs 26-36
Deep venous thrombosis or pulmonary
embolism therapeutic heparin levels
of 0.3 to 0.7 Units/mL anti-factor
Xa levels usually correspond to an
aPTT of 60-85 seconds. Acute cardiac
syndrome therapeutic range based on
heparin levels of 0.2 to 0.5
usually correspond to an aPTT of
55 to 75 seconds.
PTT, Pop Mean 31 sec
Platelet Count K/uL
0-3 days 250-450
3-9 days 200-400
9-30 days 250-450
1-6 mo 300-750
6 mo-2 yrs 250-600
2-8 yrs 250-550
8-12 yrs 200-450
12-18 yrs 150-450
18 yrs+ 150-400
Interpretation
Reviewed by |
| COCAINE & METABOLITES | COCQTS | COCQTS | GC/MS | Cocaine ng/mL
Up to 200 ng/mL following oral dose or
nasal intake of 2 mg/kg.
Cocaethylene ng/mL
Benzoylecgonine ng/mL |
| COCCIDIOIDES ANTIBODIES, IGG & IGM BY ELISA | COCAB | COCAB | ELISA | Coccidioides Ab, IgG 0.9 or less Negative-no significant level of IV
Coccidioides IgG Ab detected.
1.0-1.4 Equivocal-Questionable presence
of Coccidioides IgG Ab detected.
Repeat tsting in 10-14 days may be
helpful.
1.5 or greater Positive-Presence of IgG Ab
Coccidiodes detected, suggestive
of current or past infection.
IgG Abs usually appear by the third
week of infection and may persist for
years. Both tube precipitin (TP) and
CF antigens are represented by the
ELISA tests.
Coccidioides Ab, IgM 0.9 or less Negative-No significant level of IV
Coccidioides IgM Ab detected.
1.0-1.4 Equivocal-Questionable presence of
Coccidioides IgM Ab detected. Repeat
testing in 10-14 days may be helpful.
1.5 or greater Positive-Presence of IgM Ab to
Coccidioides detected, suggestive of
current or past infection.
In most symptomatic patients, IgM Abs
usually appear by the second week of
infection and disappear by the fourth
month. Both tube precipitin (TP) and CF
antigens are represented in the ELISA
tests.
Note: Negative fungal serology does not
rule our the possibility of current
infection. |
| COCCIDIOIDES ANTIBODY BY CF | COCC.CF | COCCAB | CF | Coccidioides Ab by CF Titer
LT 1:2 No antibody detected |
| COCCIDIOIDES ANTIBODY PANEL, CSF | COC.AB-CSF | COCPSF | CF, ELISA, ID | Coccidioides Ab LT 1:2 No Antibody Detected
CSF by CF
Coccidioides Ab, CSF IV
IgG Negative 0.9 or less No significant level
of Coccidioides IgG
Ab detected.
Equivocal 1.0-1.4 Questionable presence
of Coccidioides IgG
Ab detected. Repeat
testing in 10-14 days
may be helpful.
Positive 1.5 or more Presence of IgG Ab to
Coccidioides detected,
suggestive of current or
past infection.
Coccidioides Ab, CSF IV
IgM Negative 0.9 or less No significant level
of Coccidioides IgM
Ab detected.
Equivocal 1.0-1.4 Questionable presence
of Coccidioides IgM
Ab detected. Repeat
testing in 10-14 days
may be helpful.
Positive 1.5 or more Presence of IgM Ab to
Coccidioides detected,
suggestive of current or
past infection.
Coccidioides Ab None detected
CSF by ID |
| COCCIDIOIDES ANTIBODY PROFILE | COCCIDIO.CF | COCPAN | CF, ID and ELISA | Coccidioides Ab LT 1:2 No Antibody Detected
by CF
Coccidioides Ab IV
IgG Negative 0.9 or less No significant level
of Coccidioides IgG
Ab detected.
Equivocal 1.0-1.4 Questionable presence
of Coccidioides IgG
Ab detected. Repeat
testing in 10-14 days
may be helpful.
Positive 1.5 or more Presence of IgG Ab to
Coccidioides detected,
suggestive of current or
past infection.
Coccidioides Ab IV
IgM Negative 0.9 or less No significant level
of Coccidioides IgM
Ab detected.
Equivocal 1.0-1.4 Questionable presence
of Coccidioides IgM
Ab detected. Repeat
testing in 10-14 days
may be helpful.
Positive 1.5 or more Presence of IgM Ab to
Coccidioides detected,
suggestive of current or
recent infection.
Coccidioides Ab None detected
by ID |
| COCCIDIOIDES IMMITIS ID BY DNA
| COCIPR | COCIPR | Nucleic Acid Probe | Source
Coccidioides Immitis ID by DNA Probe |
| CODEINE | COD | COD | GC | Codeine ng/mL
Therapeutic range 30-120 |
| COENZYME Q10A, TOTAL | CQ10A | CQ10A | HPLC | Coenzyme Q10A, Serum 0.4-1.6 mg/L |
| COLD AGGLUTININS | COLD | COLD | Agglutination | Cold Agglutinins LT 1:32 |
| COLONY COUNT DIALYSATE | CCDI | CCDI | Organism Isolation | Source
Culture, Fluid
Report Status |
| COLONY COUNT DIALYSIS WATER | CCDW | CCDW | Organism Isolation | Source
Culture, Fluid
Report Status |
| COLORADO TICK FEVER IGG ANTIBODY | COL.TICK | COTICK | IFA | Colorado Tick Fever IgG Antibody LT 1:16
Interpretive criteria
LT 1:16 Antibody not detected
1:16 or greater Antibody detected
A four-fold or greater change in IgG titer
between acute and convalescent sera is
indicative of recent or current infection. |
| COMPLEMENT COMPONENT 1, FUNCTIONAL | COM1 | COM1 | Hemolytic Assay | Complement Component 1, Functional
75672-190932 C1H50 Units/mL |
| COMPLEMENT COMPONENT C5 | C5SP | C5SP | RID | C5 6-20 mg/dL
Low levels of C5 indicate either increased catabolism or decreased synthesis. |
| COMPLEMENT COMPONENT C7 | C7SP | C7SP | RID | C7 4-11 mg/dL
Low levels of C7 indicate either increased catabolism or decreased synthesis. |
| COMPLEMENT COMPONENT C8 | C8SP | C8SP | RID | C8 10.7-24.9 mg/dL
Low levels of C8 indicates either increased catbolism or decreased synthesis. |
| COMPLEMENT COMPONENT C9 | C9CSP | C9CSP | RID | C9 6-20 mg/dL
Low levels of C9 indicate either catabolism or decreased synthesis. |
| COMPLEMENT SPLIT PRODUCT C3AL | C3AL | C3AL | RIA | Complement Split Product C3AL 100-400 ng/mL
For Research Use Only |
| COMPREHENSIVE METABOLIC PANEL | CMPA | CMPA | Colorimetric, Enzymatic, ISE, Hexokinase, Enzymatic (IDMS Traceable) | Ranges as they appear on report:
Glucose mg/dL
0-2 days premature 30-80
0-2 days full term 40-90
2 days to 1 month 60-105
Adults 65-99
ADA diagnostic comments:
Glucose mg/dL
0-2 days premature 30-80
0-2 days fullterm 40-90
2 days-1 month 60-105
Adult 65-99
Pregnant 65-94
ADA Diagnostic Categories for nonpregnant
adults:
Impaired fasting glucose 100-125 mg/dL
A fasting glucose result of 126 mg/dL or
greater indicates diabetes if the
abnormality is confirmed on a subsequent
day.
A random glucose result of GT 200 mg/dL
indicates diabetes if the abnormality
is confirmed on a subsequent day.
BUN 7-23 mg/dL
Creatinine M 0.50-1.30 mg/dL
F 0.40-1.00
BUN/Creatinine ratio 11.0-35.0
Calcium 8.5-10.5 mg/dL
Total Protein 0-12 mo 4.3-6.9 g/dL
1-3 yrs 5.2-7.4
3-6 yrs 5.6-7.7
6-10 yrs 6.5-8.3
10-18 yrs 6.1-8.0
18-60 yrs 6.3-8.0
60 yrs+ 6.1-7.8
Albumin 0-4 days 2.9-4.6 g/dL
4 days-14 yrs 3.9-5.6
14-18 yrs 3.3-4.7
18-60 yrs 3.5-5.0
60-90 yrs 3.3-4.8
90 yrs+ 3.0-4.7
Globulin 1.8-3.5 g/dL
A/G Ratio 1.1-2.2
Bilirubin, Total mg/dL
0-30 days LT 11.7
1 mo-18 yrs LT 2.0
18-60 yrs 0.1-1.5
60-90 yrs 0.2-1.1
90 yrs+ 0.2-0.9
Alkaline Phosphatase 0-6 yrs 72-307 U/L
6-9 yrs 133-340
M 9-15 yrs 103-429
M 15-18 yrs 49-210
F 9-13 yrs 99-453
F 13-15 yrs 53-186
F 15-18 yrs 38-110
18 yrs+ 38-110
ALT (SGPT) 5-50 U/L
AST(SGOT) 0-6 yrs 20-60 U/L
6-10 yrs 20-40
10-18 yrs 14-40
18 yrs+ 5-40
Sodium 135-145 mmol/L
Potassium 0-30 days 3.9-6.9 mmol/L
1-12 mo 3.6-6.8
1-5 yrs 3.2-5.7
5-10 yrs 3.4-5.4
10 yrs+ 3.5-5.3
Chloride 98-109 mmol/L
C02 0-10 days 13-22 mmol/L
11 days-4 yrs 20-28
5+ yrs 22-31
Anion Gap 7-16 |
| CONNECTIVE TISSUE DISEASE (REFLEXIVE) | CTD | CTD | Multiplex luminex, Nephelometry, ELISA | ANA Negative
A multiplex screen for 11 autoantibodies
(dsDNA, Smith, Ribosomal P, Chromatin, RNP,
SmRNP, Scl-70, Centromere B, SSA, SSB and
J0-1) was performed and no autoantibodies
were detected. A negative multiplex ANA
does not rule out all possibility of a
connective tissue or autoimmune disease,
and further studies should be considered
if clinical suspicion is high.
DSDNA Autoantibody Negative LT 5 IU/mL
Indeterminate 5-9
Positive 10 or more
Smith Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
Ribosomal P Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
Chromatin Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
RNP Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
SMRNP Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
SCL-70 Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
Centromere B Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
SSA (RO) Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
SSB (LA) Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
JO-1 Autoantibody Negative LT 1.0 AI
antibody Positive 1.0 or more
Complement, C3 0-1 days 50-168 mg/dL
2-60 days 55-170
2-5 months 59-176
6-24 months 66-180
25-60 months 74-184
5-9 years 74-190
10-14 years 77-198
15+ years 90-200
Complement, C4 0-7 days 0.0-45.7 mg/dL
8-60 days 1.5-47.9
2-5 months 1.5-47.9
6-24 months 3.0-47.9
25-60 months 4.5-48.4
5-9 years 5.3-50.6
10-14 years 6.0-52.8
15+ years 15.0-55.0
Cyclic Citrullinated Negative LT 20 EU
Peptide Antibody, Weak Positive 20-39
IgG Mod Positive 40-59
Strong Positive 60 or more
Approximately 70% of patients
with RA are positive for CCP IgG,
while only 2% of random blood
donors and disease controls
are positive. The diagnostic
value of antibodies to
arthritis patients has not been
determined.
RA LT 20 IU/mL |
| CONNEXIN 26 TESTING (GJB2) SEQUENCE ANALYSIS | CON26 | CON26 | DNA Sequencing | Connexin 26 Not detected
No mutations detected within the coding region of the GJB2 gene. |
| CONSULT/REVIEW, FLUID | REVFL | REVFL | Visual Microscopic | Fluid, Interpretation
Fluid, Reviewed by |
| COOMBS, DIRECT | DCM | MDC | Hemagglutination | Direct Coombs Negative |
| COOMBS, DIRECT & INDIRECT | DICM | MDCIC | Hemagglutination | Direct Coombs Negative
Indirect Coombs Negative |
| COOMBS, INDIRECT (ANTIBODY SCREEN) | ABS | MABS | Hemagglutination | Antibody Screen Negative |
| COOMBS, INDIRECT (NON-CROSSMATCH) | ICM | MIC | Hemagglutination | Direct Coombs Negative |
| COPPER | COPPER | COP | AAS | Copper ug/dL
0-6 mo 20-70
7 mo-6 yrs 90-190
7-12 yrs 80-160
13-60 yrs M 70-140
13-60 yrs F 80-155
61+ yrs M 85-170
61+ yrs F 85-190 |
| COPPER, URINE | COPPER.UR | COPPUQ | ICP/MS | Collection Period h
Volume mL
Creatinine, Ur mg/dL
Creatinine, Ur mg/d
M 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81+ yrs 600-2000
F 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
81+ yrs 400-1300
Copper, Ur 0.2-8.0 ug/dL
Copper, Ur 3-50 ug/d
Copper, Ur ug/gCr
No reference range established |
| COPROPORPHYRIN ISOMERS I & III | COPI13 | COPI13 | HPLC | Collection Period hr
Volume mLs
Coproporphyrin Isomers ug/24h
I & III
M LT 16 yrs not established
16 yrs or more 24-150
F LT 16 yrs not established
16 yrs or more 8-110
% Coproporphyrin %
LT 16 yrs not established
16 yrs or more 20-45
Coproporphyrin Interp |
| CORDSTAT 12 DRUG SCREEN (REFLEXIVE) | UMB12 | UMB12 | LC-MS/MS, GC/MS | CordStat 12 Result Negative
Amphetamines Negative
Amphetamines LT 1.0 ng/g
Metamphetamine LT 1.0 ng/g
MDA LT 1.0 ng/g
MDMA LT 1.0 ng/g
MDEA LT 1.0 ng/g
Barbituates Negative
Butalbital LT 1.0 ng/g
Amobarbital LT 1.0 ng/g
Pentobarbital LT 1.0 ng/g
Secobarbital LT 1.0 ng/g
Phenobarbital LT 1.0 ng/g
Benzodiazepine Negative
Midazolam LT 2.0 ng/g
Oxazepam LT 2.0 ng/g
Alprazolam LT 2.0 ng/g
Temezepam LT 2.0 ng/g
Nordiazepam LT 2.0 ng/g
Diazepam LT 2.0 ng/g
Cocaine Negative
Benzoylecgonine LT 1.0 ng/g
Methadones Negative
Methadone LT 2.0 ng/g
EDDP LT 2.0 ng/g
Meperidine Negative
Meperidine LT 2.0 ng/g
Normeperidine LT 2.0 ng/g
Opiates Negative
Codeine LT 2.0 ng/g
Morphine LT 2.0 ng/g
Hydrocodone LT 2.0 ng/g
Hydromorphone LT 2.0 ng/g
6-MAM LT 2.0 ng/g
PCP Negative
Phencyclidine LT 1.0 ng/g
Oxycodone Negative
Oxycodone LT 2.0 ng/g
Oxymorphone LT 2.0 ng/g
Propoxyphene Negative
Propoxyphene LT 2.0 ng/g
Norpropoxphene LT 2.0 ng/g
Cannabinoids Negative
Carboxy-THC LT 50 pg/g
Tramadol Negative
Tramadol LT 2.0 ng/g
Certification
|
| CORDSTAT 5 DRUG SCREEN (REFLEXIVE) | UMB5 | UMB5 | LC-MS/MS, GC/MS | CordStat 5 Result Negative
Amphetamines Negative
Amphetamines LT 1.0 ng/g
Metamphetamine LT 1.0 ng/g
MDA LT 1.0 ng/g
MDMA LT 1.0 ng/g
MDEA LT 1.0 ng/g
Cocaine Negative
Benzoylecgonine LT 1.0 ng/g
Opiates Negative
Codeine LT 2.0 ng/g
Morphine LT 2.0 ng/g
Hydrocodone LT 2.0 ng/g
Hydromorphone LT 2.0 ng/g
PCP Negative
Phencyclidine LT 1.0 ng/g
Cannabinoids Negative
Carboxy-THC LT 50 pg/g
Certification |
| CORDSTAT 7 DRUG SCREEN (REFLEXIVE) | UMB7 | UMB7 | LC-MS/MS, GC/MS | CordStat 7 Result Negative
Amphetamines Negative
Amphetamines LT 1.0 ng/g
Metamphetamine LT 1.0 ng/g
MDA LT 1.0 ng/g
MDMA LT 1.0 ng/g
MDEA LT 1.0 ng/g
Barbituates Negative
Butalbital LT 1.0 ng/g
Amobarbital LT 1.0 ng/g
Pentobarbital LT 1.0 ng/g
Secobarbital LT 1.0 ng/g
Phenobarbital LT 1.0 ng/g
Cocaine Negative
Benzoylecgonine LT 1.0 ng/g
Methadones Negative
Methadone LT 2.0 ng/g
EDDP LT 2.0 ng/g
Opiates Negative
Codeine LT 2.0 ng/g
Morphine LT 2.0 ng/g
Hydrocodone LT 2.0 ng/g
Hydromorphone LT 2.0 ng/g
6-MAM LT 2.0 ng/g
PCP Negative
Phencyclidine LT 1.0 ng/g
Cannabinoids Negative
Carboxy-THC LT 50 pg/g
Certification
|
| CORDSTAT 9 DRUG SCREEN (REFLEXIVE) | UMB9 | UMB9 | LC-MS/MS, GC/MS | CordStat 9 Result Negative
Amphetamines Negative
Amphetamines LT 1.0 ng/g
Metamphetamine LT 1.0 ng/g
MDA LT 1.0 ng/g
MDMA LT 1.0 ng/g
MDEA LT 1.0 ng/g
Barbituates Negative
Butalbital LT 1.0 ng/g
Amobarbital LT 1.0 ng/g
Pentobarbital LT 1.0 ng/g
Secobarbital LT 1.0 ng/g
Phenobarbital LT 1.0 ng/g
Benzodiazepine Negative
Midazolam LT 2.0 ng/g
Oxazepam LT 2.0 ng/g
Alprazolam LT 2.0 ng/g
Temezepam LT 2.0 ng/g
Nordiazepam LT 2.0 ng/g
Diazepam LT 2.0 ng/g
Cocaine Negative
Benzoylecgonine LT 1.0 ng/g
Methadones Negative
Methadone LT 2.0 ng/g
EDDP LT 2.0 ng/g
Opiates Negative
Codeine LT 2.0 ng/g
Morphine LT 2.0 ng/g
Hydrocodone LT 2.0 ng/g
Hydromorphone LT 2.0 ng/g
6-MAM LT 2.0 ng/g
PCP Negative
Phencyclidine LT 1.0 ng/g
Propoxyphene Negative
Propoxyphene LT 2.0 ng/g
Norpropoxphene LT 2.0 ng/g
Cannabinoids Negative
Carboxy-THC LT 50 pg/g
Certification
|
| CORTISOL & CORTISONE, FREE URINE (QUANTITATIVE) | CCFUQ | CCFUQ | LC-MS/MS | Cortisol, Urine mcg/24h
LT 2 yrs not established
3-8 yrs 1.4-20.0
9-12 yrs 2.6-37.0
13-17 yrs 4.0-56.0
18 yrs or more 3.5-45.0
Cortisone, Urine mcg/24h
LT 2 yrs not established
3-8 yrs 5.5-41.0
9-12 yrs 9.9-73.0
13-17 yrs 15.0-108.0
18 yrs or more 17.0-129.0
Collection Period h
Volume mL |
| CORTISOL (ACTH STIMULATION 30 MINUTE & 60 MINUTE) | COR-STIM2 | CST3 | ICMA | Cortisol Baseline ug/dL
AM Sample 4.3-22.4
PM Sample 3.0-16.0
Time Drawn
Cortisol, Post #1 ug/dL
Time Drawn
Cortisol, Post #2 ug/dL
Normal post stimulation GT 20
Time Drawn |
| CORTISOL (ACTH STIMULATION) | COR-STIM | CST | ICMA | Cortisol Baseline ug/dL
AM Sample 4.3-22.4
PM Sample 3.0-16.0
Time Drawn
Cortisol Post-Stim ug/dL
Normal post stimulation GT 20
Time Drawn |
| CORTISOL (PAIRED SPECIMENS) | COR-2 | CORP | ICMA | Cortisol AM 4.3-22.4 ug/dL
Cortisol PM 3.0-16.0 ug/dL |
| CORTISOL, AM | CORAM | CORAM | ICMA | Cortisol, AM 4.3-22.4 ug/dL |
| CORTISOL, FREE URINE | COR-U | UFCUQ | ICMA | Collection Period h
Volume mL
Cortisol, Urine 10.0-80.0 ug/24h |
| CORTISOL, FREE URINE (RANDOM) | COR-R | UFCUR | ICMA | Cortisol, Urine Free ug/dL
No reference range established |
| CORTISOL, PM | CORPM | CORPM | ICMA | Cortisol, PM 3.0-16.0 ug/dL |
| CORTISOL, SALIVA | CORSAL | CORSAL | HPLC/Tandem MS | Cortisol, Saliva ug/dL
Children & Adults
8:00 am 0.025-0.600
Noon LT 0.010-0.330
4:00 pm 0.010-0.200
Midnight LT 0.01-0.090
|
| CORTISOL, SERUM FREE | FCORTS | FCORTS | Equilibrium Dialysis/ Electrochemiluminescent Immunoassay | Cortisol, Serum Free By report
|
| CORTISOL, URINE FREE BY LC-MS/MS | CUFAR | CUFAR | Tandem MS (LC-MS/MS) | Collection Period hrs
Volume mL
Creatinine, Urine mg/L
Creatinine, Urine mg/d
M 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81 yrs+ 600-2000
F 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
81 yrs+ 400-1300
Cortisol, Urine Free ug/gCr
F Prepubertal LT 25
18 yrs+ LT 25
Pregnancy LT 59
M Prepubertal LT 25
18 yrs+ LT 32
Cortisol, Urine Free ug/L
Cortisol, Urine ug/d
F 3-8 yrs LT 18
9-12 yrs LT 37
13-17 yrs LT 56
18 yrs+ LT 45
M 3-8 yrs LT 18
9-12 yrs LT 37
13-17 yrs LT 56
18 yrs + LT 60
|
| COTININE | NIC | NIC | ELISA | Cotinine Negative |
| COUMADIN | COUM | COUM | HPLC | Coumadin mcg/mL
Therapeutic 2.0-5.0
Toxic 10.0 or greater |
| COXIELLA BURNETII ANTIBODY, IGG PHASE 1 & 2 | QFEVRG | QFEVRG | IFA | Coxiella burnetti (Q Fever) Phase 1,
IgG LT 1:16 No antibody detected
Coxiella burnetti (Q Fever) Phase 2,
IgG LT 1:16 No antibody detected
Single phase II IgG titers of 1:256
and greater are considered evidence of
C. burnetii infection at some time
prior to the date of the serum
specimen. Phase 1 antibody titers of
1:16 and greater are consistent with
chronic infection or convalescent
phase of Q fever. |
| COXSACKIE A ANTIBODY PANEL | COXAB6 | COXAB6 | CF | Coxsackie A, Type 2 LT 1:8
Coxsackie A, Type 4 LT 1:8
Coxsackie A, Type 7 LT 1:8
Coxsackie A, Type 9 LT 1:8
Coxsackie A, Type 10 LT 1:8
Coxsackie A, Type 16 LT 1:8
Interpretive Criteria:
LT 1:8 Antibody not detected
1:8 or more Antibody detected
Single titers of 1:32 or more are
indicative of recent infection. Titers
of 1:8 or 1:16 may be indicative of
either past or recent infection since
CF antibody levels persist for only
a few months. A four-fold or greater
increase in titer between acute
and convalescent specimens confirms
the diagnosis. There is considerable
cross-reactivity among enteroviruses;
however, the highest titer is usually
associated with the infecting serotype. |
| COXSACKIE A9 VIRUS ANTIBODIES | COXAAB | COXAAB | CF | Coxsackie A9 Antibodies LT 1:8
Single positive Ab titers of 1:32 or
greater may indicate past or current
infection. Seroconversion or an
increase in titers between acute and
convalescent sera of at least fourfold
is considered strong evidence of
current or recent infection. |
| COXSACKIE B VIRUS ANTIBODY | COX B | COXB | Serum Neutralization | Source
Coxsackie B Ab LT 1:10 No antibody detected Titer
(Type 1)
Coxsackie B Ab LT 1:10 No antibody detected Titer
(Type 2)
Coxsackie B Ab LT 1:10 No antibody detected Titer
(Type 3)
Coxsackie B Ab LT 1:10 No antibody detected Titer
(Type 4)
Coxsackie B Ab LT 1:10 No antibody detected Titer
(Type 5)
Coxsackie B Ab LT 1:10 No antibody detected Titer
(Type 6)
Single positive antibody titers of
greater than or equal to 1:80 may
indicate past or current infection.
Seroconversion or an increase in titers
between acute and convalescent sera of
at least fourfold is considered strong
evidence of current or recent infection.
The clinical significance and criteria
for interpretation of results from CSF
have not been established. |
| CREATINE KINASE | CPK | CK | Enzymatic | CK (CPK) M 25-287 U/L
F 20-200 |
| CREATINE KINASE ISOENZYMES | ISOCK | ISOCK | Electrophoresis | Creatine Kinase, Total U/L
M 0-1 mo 108-564
1 mo-19 yrs 72-367
20+ yrs 20-200
F 0-1 mo 108-564
1 mo-19 yrs 72-367
20+ yrs 20-180
CK-MM 96-100 %
CK-MB 0-4
CK-BB 0 |
| CREATINE KINASE-MB | CKMB | CKMB | Enzymatic/MEIA | CK (CPK) Total
M 25-287 U/L
F 20-200
CK-MB 5.0 or less ng/mL
Relative Index %
3.0 or less
To be used only if
CK-MB and total CK
(CPK) are elevated. |
| CREATINE, SERUM OR PLASMA | KREATS | KREATS | Liquid Chromatography/Tandem Mass Spectrophotometry | Creatine 9.0-90.0 umol/L
Creatine mg/dL |
| CREATINE, URINE | CREATINE-U | CRTUQ | Enzymatic, Colorimetric | Collection Period h
Volume mLs
Creatine, Urine mg/24h
M 6-56
F 8-170
Creatinine, Urine g/24h
3-8 yrs 0.11-0.68
9-12 yrs 0.17-1.41
13-17 yrs 0.29-1.87
18+ yrs 0.63-2.50 |
| CREATININE | CRE | CRE | Enzymatic (IDMS Traceable) | Creatinine mg/dL
M 0.50-1.30
F 0.40-1.00
Estimated Golmerular Filtration Rate mL/min/1.73m2
LT 60 Chronic kidney disease, if found over a
3 month period.
LT 15 Kidney failure
For African Americans, multiply
the calculated GFR by 1.21
|
| CREATININE CLEARANCE | CRE CL | CRCL | Enzymatic (IDMS Traceable) | Height in
Weight lbs
Collection Period h
Volume mL
Creatinine M 0.50-1.30 mg/dL
F 0.40-1.00
Creatinine, Urine
M 0.8-2.0 g/24h
F 0.6-1.8
Creatinine Clearance
0-2 yrs M 51-73 F 51-73 mL/min
2-10 yrs M 64-92 F 64-92
10-12 yrs M 83-119 F 83-119
12-40 yrs M 97-137 F 88-128
40-50 yrs M 91-131 F 82-122
50-60 yrs M 85-125 F 76-116
60-70 yrs M 79-119 F 70-110
70-80 yrs M 73-113 F 64-104
80+ yrs M 67-107 F 58-98 |
| CREATININE CLEARANCE, 12HR | CRE CL.12 | CRCL12 | Enzymatic (IDMS Traceable) | Collection Period h
Volume mL
Creatinine mg/dL
M 0.50-1.30
F 0.40-1.00
Creatinine, Urine g/12h
No normals established for 12h
Creatinine Clearance
0-2 yrs M 51-73 F 51-73 mL/min
2-10 yrs M 64-92 F 64-92
10-12 yrs M 83-119 F 83-119
12-40 yrs M 97-137 F 88-128
40-50 yrs M 91-131 F 82-122
50-60 yrs M 85-125 F 76-116
60-70 yrs M 79-119 F 70-110
70-80 yrs M 73-113 F 64-104
80+ yrs M 67-107 F 58-98 |
| CREATININE CLEARANCE, 48HR | CRCL48 | CRCL48 | Enzymatic (IDMS Traceable) | Collection Period h
Volume mL
Creatinine mg/dL
M 0.50-1.30
F 0.40-1.00
Creatinine, Ur, 48h g/48h
No normals established for 48h
Creatinine Clearance mL/min
0-39 yrs M 97-137 F 88-128
40-49 yrs M 91-131 F 82-122
50-59 yrs M 85-125 F 76-116
60-69 yrs M 79-119 F 70-110
70-79 yrs M 73-113 F 64-104
80+ yrs M 67-107 F 58-98 |
| CREATININE, AMNIOTIC FLUID | CRE.A | CREAF | Enzymatic (IDMS Traceable) | Creatinine Amniotic Fluid mg/dL
Amniotic fluid creatinine increases
with gestational age. |
| CREATININE, FLUID | CRE.FLD | CREFL | Enzymatic (IDMS Traceable) | Creatinine, Fluid mg/dL
No reference range established.
Method not validated for body fluid.
Clinical correlation necessary. |
| CREATININE, URINE (QUANTITATIVE) | CRE-U | CREUQ | Enzymatic (IDMS Traceable) | Collection Period h
Volume mL
Creatinine, Ur g/24h
M 0.8-2.0
F 0.6-1.8 |
| CREATININE, URINE (RANDOM) | CRE-R | CREUR | Enzymatic (IDMS Traceable) | Creatinine, Urine mg/dL
No normals established |
| CRP | CRP | CRP | Immunoturbidimetric | CRP 1.5 or less mg/dL |
| CRYOFIBRINOGEN | CRFB | CRFB | Precipitation | Cryofibrinogen, 24 hours Negative
Cryofibrinogen, 48 hours Negative
Cryofibrinogen, 72 hours Negative
Cryofibrinogen, 7 days Negative |
| CRYOGLOBULIN | CRYO | CRYO | Precipitation | Cryoglobulin, 24 hours Negative
Cryoglobulin, 48 hours Negative
Cryoglobulin, 72 hours Negative
Cryoglobulin, 7 days Negative |
| CRYOGLOBULIN & CRYOFIBRINOGEN | CRGCRF | CRGCRF | Precipitation | Cryoglobulin, 24 hours Negative
Cryoglobulin, 48 hours Negative
Cryoglobulin, 72 hours Negative
Cryoglobulin, 7 days Negative
Cryofibrinogen, 24 hours Negative
Cryofibrinogen, 48 hours Negative
Cryofibrinogen, 72 hours Negative
Cryofibrinogen, 7 days Negative |
| CRYOGLOBULINS, SERUM AND PLASMA, REFLEX TO FRACTIONS | CRYOGF | CRYOGF | IEP | Cryoglobulins, Serum, Negative %ppt
Cryofibrinogen, Plasma Negative %ppt
|
| CRYPTOCOCCUS ANTIBODY | CRYPTO.AB | CRYPAB | IFA | Cryptococcus AB, IFA Titer
LT 1:16 Antibody Not Detected
GT or = to 1:16 Antibody Detected
Cryptococcal antibody, primarily directed
against a galactoxylomannan capsular antigen,
is often detectable in the early (pulmonary)
phase prior to antigenemia. Detectable levels
in convalescence are indicative of a good
prognosis. This assay shows crossreactivity
with sera containing Ab to Histoplasma &
Blastomyces. This test has not been cleared
or approved by the USDA. |
| CRYPTOCOCCUS ANTIBODY, CSF | CRYPTO.AB.CSF | CRYPSF | IFA | Cryptococcus Ab, IFA Titer
LT 1:1 Antibody Not Detected
GT or = to 1:1 Antibody Detected
Diagnosis of infections of the central
nervous system can be accomplished by
demonstrating the presence of intrathecally-
produced specific Ab. However, interpretation of
results is complicated by low Ab levels
found in CSF, passive transfer of Ab
from blood, & contamination via bloody taps.
This test has not been cleared or
approved by the USDA. |
| CRYPTOCOCCUS ANTIGEN, CSF | CRYPTO-CSF | CRYPT | LA | Source
Cryptococcus Ag, CSF Negative
Cryptococcus Ag, Status |
| CRYPTOCOCCUS ANTIGEN | CRYPTO | ACRYP | EIA | Cryptococcus Antigen Prelim
Cryptococcus Antigen Final Negative |
| CRYPTOSPORIDIUM ANTIGEN | CRYPAG | CRYPAG | EIA | Cryptosporidium Antigen Negative |
| CRYSTALS, FLUID | CRYST | CRYFL | Microscopic/Polarization | Crystals None Seen
Crystals ID |
| CRYSTALS, SYNOVIAL FLUID BATTERY | CRSSYN | CRSSYN | | Crystals, Synovial Fluid Battery
Crystals None seen
Crystal ID
Specific Gravity
Exudate 1.015 or greater
Transudate LT 1.015
Fibrin No longer performed |
| CSF PROFILE | CSF; Cerebral spinal fluid profile | SFEXM | | Tube Number
Xanthochromia
Color
Clarity
RBC No reference range M/L
Nucleated Cells
0-11 mo 0-3 M/L
1-4 yrs 0-20
5-15 yrs 0-10
16+ yrs 0-5
Number of cells seen
Segs
0-42 days 0-8 %
43+ days 0-6
Bands %
Lymphocytes
16+ yrs 40-80 %
Variant Lymphocytes %
Monocytes
16+ yrs 15-45 %
Histiocytes %
Eosinophils %
Basophils %
Others %
Non-Heme Cells
Nucleated RBC /100 WBCs
Note
Tube
Glucose (CSF)
0-10 yrs 60-80 mg/dL
11+ yrs 40-70
Protein (CSF)
LT 1 day 40-120 mg/dL
1-30 days 20-80
1 mo-adult 15-45
VDRL Nonreactive |
| CSF/SERUM IGG INDEX | IGG INDEX | IGGI | Nephelometry | IgG, CSF 0.5-7.7 mg/dL
Albumin, CSF 5-30 mg/dL
IgG, Serum mg/dL
0-4 mo 600-1560
5-9 mo 252-655
10-11 mo 300-780
1 yr 330-858
2 yrs 372-967
3 yrs 450-1170
4 yrs 504-1326
5 yrs 540-1404
6 yrs 552-1435
7+ yrs 600-1560
Albumin, Serum
0-4 days 2900-4600 mg/dL
4 days-14 yrs 3900-5600
14-18 yrs 3300-4700
18-60 yrs 3500-5000
60-90 yrs 3300-4800
90 yrs+ 3000-4700
CSF/Serum Index 0.25-0.75 |
| CULTURE, AFB (NO SMEAR) (REFLEXIVE) | CAFBNS | CAFBNS | Organism Isolation | Source
Culture, AFB Negative
Culture, Status |
| CULTURE, AFB (REFLEXIVE) | AFB | CAFB | Organism Isolation | Source
Culture, AFB Negative
Culture, Status |
| CULTURE, BETA STREP A SCREEN (REFLEXIVE) | CBSAS | CBSAS | Organism Isolation | Culture, Beta Strep A Screen Negative
Beta Strep A Screen, Status |
| CULTURE, BETA STREP B SCREEN (REFLEXIVE) | CBSBS | CBSBS | Organism Isolation | Culture, Beta Strep B Screen Negative
Beta Strep B Screen, Status |
| CULTURE, BLOOD (REFLEXIVE) | BLOOD | CBLD | Organism Isolation | Source
Culture, Blood Negative
Culture, Blood, Status |
| CULTURE, BLOOD DIPHASIC FUNGUS (REFLEXIVE) | CBF | CBF | Organism Isolation | Source
Culture, Blood Fungus Negative
Culture, Blood Fungus, Status |
| CULTURE, BODY FLUID (REFLEXIVE) | CULT.FLD | CFL | Organism Isolation | Source
Gram Stain
Culture, Fluid Negative
Culture, Fluid, Status |
| CULTURE, BORDETELLA PERTUSSIS (REFLEXIVE) | CBPERT | CBPERT | Culture | B. pertussis Result Negative
B. pertussis Status |
| CULTURE, CAMPYLOBACTER SCREEN | CCAMS | CCAMS | Organism Isolation | Source
Campylobacter Screen Negative
Campylobacter Screen, Status |
| CULTURE, E COLI 0157 WITH SHIGA TOXIN TEST (REFLEXIVE) | CECST | CECST | Culture and Immunochromographic | Culture, E.coli 0157 with Shiga Toxin Report
Culture, E.coli 0157 with Shiga Toxin Status |
| CULTURE, EAR (REFLEXIVE) | CULT.EAR | CEAR | Organism Isolation | Source
Gram Stain
Culture, Ear Negative
Culture, Ear, Status |
| CULTURE, EXTENDED BETA LACTAMASE (ESBL) CONFIRMATION | CESBLS | CESBLS | Disk diffusion | Culture, ESBL Confirmation Report
Culture, ESBL Confirmation Report Status |
| CULTURE, EYE (REFLEXIVE) | CULT.EYE | CEYE | Organism Isolation | Source
Gram Stain
Culture, Eye Negative
Culture, Eye, Status |
| CULTURE, FUNGUS (REFLEXIVE) | FUNG | CFC | Organism Isolation | Source
Fungus Stain
Culture, Fungus Negative
Culture, Fungus, Status |
| CULTURE, FUNGUS, SKIN, HAIR, NAILS (REFLEXIVE) | CFS | CFS | Culture | Source
Fungus, Skin, Hair, Nails Stain
Culture, Fungus, Skin, Hair, Nails Negative
Culture, Fungus, Skin, Hair, Nails Status |
| CULTURE, GENITAL (REFLEXIVE) | GEN | CGEN | Organism Isolation | Source
Gram Stain
Culture, Genital Negative
Culture, Genital, Status |
| CULTURE, LEGIONELLA (REFLEXIVE) | LEGION | CLEG | Organism Isolation | Source
Culture, Legionella Negative
Culture, Legionella, Status |
| CULTURE, LOWER RESPIRATORY (REFLEXIVE) | CLRSP | CLRSP | Organism Isolation | Source
Gram Stain
Culture, Lower Respiratory Negative
Culture, Lower Respiratory, Status |
| CULTURE, METHICILLIN RESISTANT STAPH AUREUS SCREEN (REFLEXIVE) | CMRSA | CMRSA | Organism Isolation | Source;
Culture, Methicillin Resistant Staph aureus Negative
Culture, Methicillin Resistant Staph aureus, Status |
| CULTURE, NEISSERIA GONORRHOEAE (REFLEXIVE) | CGC | CGC | Organism Isolation | Source
Gram Stain
Culture, Neisseria gonorrhoeae Negative
Culture, Neisseria gonorrhoeae, Status |
| CULTURE, RESPIRATORY CYSTIC FIBROSIS (REFLEXIVE) | CRCF | CRCF | Organism Isolation | Source
Culture, Respiratory, Cystic Fibrosis Negative
Culture, Respiratory, Cystic Fibrosis Status |
| CULTURE, STOOL WITH YERSINIA AND SHIGA TOXIN (REFLEXIVE) | CSTLYS | CSTLYS | Culture and Immunochromographic | Culture, Stool with Yersinia & Shiga Toxin, Result
Culture, Stool with Yersinia & Shiga Toxin, Status |
| CULTURE, STOOL, WITH SHIGA TOXIN TEST (REFLEXIVE) | CSTLST | CSTLST | Culture & Immunochromatographic | Culture, Stool, Report Negative
Culture, Stool, Status |
| CULTURE, TISSUE (REFLEXIVE) | CULT.TISSUE | CTIS | Organism Isolation | Source
Gram Stain
Culture, Tissue Negative
Culture, Tissue, Status |
| CULTURE, TRICHOMONAS | CTRICH | CTRICH | Culture & Microscopy | Trichomonas Culture Result
Trichomonas Culture Status |
| CULTURE, UPPER RESPIRATORY (REFLEXIVE) | CURSP | CURSP | Organism Isolation | Source
Culture, Upper Respiratory Negative
Culture, Upper Respiratory, Status |
| CULTURE, UREAPLASMA AND MYCOPLASMA | CURMY | CURMY | Organism Isolation | Culture, Ureaplasma urealyticum/Mycoplasma hominis Result
Culture, Ureaplasma urealyticum/Mycoplasma hominis Status |
| CULTURE, URINE COLONY COUNT (NO SMEAR) (REFLEXIVE) | CURNNS | CURNNS | Organism Isolation | Source
Culture, Urine Negative
Culture, Urine, Status |
| CULTURE, VANCOMYCIN RESISTANT ENTEROCOCCUS SCREEN (REFLEXIVE) | CVRE | CVRE | Organism Isolation | Source
Culture, Vancomycin Resistant Enterococcus, Result Negative
Culture, Vancomycin Resistant Enterococcus, Status |
| CULTURE, WOUND (REFLEXIVE) | WOUND | CWND | Organism Isolation, Aerobic, Anaerobic if appropriate | Source
Gram Stain
Culture, Wound Negative
Culture, Wound, Status |
| CULTURE, WOUND, DEEP (REFLEXIVE) | CWNDD | CWNDD | Organism Isolation. Aerobic, Anaerobic | Source
Gram Stain
Culture, Wound, Deep Negative
Culture, Wound, Deep, Status |
| CULTURE, YEAST SCREEN (REFLEXIVE) | YST-SCR | CYEST | Organism Isolation | Source
Gram Stain
Culture, Yeast Screen Negative
Culture, Yeast Screen, Status |
| CULTURE, YERSINIA SCREEN (REFLEX) | YERS.SCR | CYER | Organism Isolation | Source
Yersinia Screen Negative
Yersinia Screen, Status |
| CYANIDE | CYANIDE | CYANID | Spectrophotometric | Cyanide, Blood ug/mL
Normal LT 20
Potentially Toxic GT 50
Elevated values seldom indicate
toxicity for patients on nitro-
prusside therapy. |
| CYCLIC CITRULLINATED PEPTIDE ANTIBODY IGG | CCPABG | CCPABG | ELISA | Cyclic Citrullinated Peptide Ab, IgG EU
Negative LT 20
Weak positive 20-39
Moderate positive 40-59
Strong positive 60 or greater
Approximately 70% of patients with RA
are positive for CCP IgG, while only
2% of random blood donors and disease
controls are positive. The diagnostic
value of antibodies to CCP in juvenile
rheumatoid arthritis patients has not
been determined. |
| CYCLOSPORA DETECTION | CYCDET | CYCDET | FM | Cyclospora Detection Not detected
Cyclospora is a coccidian parasite that
inhabits the intestinal mucosa and is
a cause of prolonged non-bloody diarrheal
disease in humans. The organism is
spherical and 8 to 10 micrometers in
diameter. Infection by the organism is
found worldwide and occurs in birds,
insectivores, reptiles, and insects.
Outbreaks in humans have been associated
with ingestion of food, notably berries,
basil and sprouts. |
| CYCLOSPORINE A BY LC-MS/MS | CYC | CYC | Tandem Mass Spectrometry | Cyclosporine A by LC-MS/MS ng/mL
Renal transplant: therapeutic range 50-200
Other transplants: therapeutic range 150-300
Toxic GT 600
Cyclosporine -A is performed at PAML utilizing
LC-MS/MS technology. This method replaces the
HPLC method. Both methods measure the parent
compound only. Please note, the lower limit
of the therapeutic range has been decreased
and this assay has improved sensitivity.
Duplicate testing on both methods to re-baseline
patients is available upon request until
August 1, 2010. |
| CYCLOSPORINE, TDX (HEART TRANSPLANT) | CYCLO.WB.TDX | CYCTDX | CMIA | Cyclosporine TDX ng/mL
Therapeutic trough 150-250
Toxic GT 600 |
| CYSTATIN C | CYSC | CYSC | Nephelometry | Cystatin C mg/L
0-3 months 0.8-2.3
4-11 months 0.7-1.5
1-3 years 0.5-1.3
4-8 years 0.5-1.3
9-17 years 0.5-1.3
18+ years 0.5-1.0 |
| CYSTIC FIBROSIS CARRIER SCREEN & DIAGNOSIS REFLEX | CFSCRA | CFSCRA | PCR and OLA | Cystic Fibrosis Carrier Screen or Diagnosis,
Interpretation and Comments |
| CYSTIC FIBROSIS EXPAND MUTATION PANEL (GENZYME) | GENCFP | GENCFP | | Cystic Fibrosis Expanded Mutation Analysis Result |
| CYSTICERCOSIS ANTIBODY, CSF | CYSAB | CYSAB | ELISA | Cysticercosis Antibody, CSF LT 0.75
Interpretive Criteria
LT 0.75 Antibody not detected
0.75 or more Antibody detected
Cysticercosis is caused by infection
with the larval form (cysticercus) of
the pork tapeworm, Taenia solium.
Clinical manifectations of cyctericercosis
most commonly result from the lodging
of cysticerci in brain and neural
tissue. Common symptoms of neuro-
cysticercosis include seizures and
convulsions. Antibodies to other
parasitic infections, particularly
echinococcus, may crossreact in the
cysticersuc IgG ELISA. Confirmation
of positive ELISA results by the
cysticercus IfF antibody Western blot
is thus recommended. Diagnosis of
central nervous system infections can
be accomplished by demonstrating the
presence of intrathecally-produced
specific antibody. Interpretation of
results may be complicated by low
antibody levels froun in CSF, passive
transfer of antibody from blood, and
contamination via bloody taps. |
| CYSTICERCOSIS ANTIBODY, IGG, CSF | CYSGCF | CYSGCF | ELISA | Cysticercosis Antibody IgG, CSF OD
0.34 or less Negative-no significant
level of cysticercosis IgG antibody
detected.
0.35-0.50 Equivocal-questionable
presence of cysticercosis IgG. Repeat
testing in 10-14 days may be helpful.
0.51 or more Positive-IgG antibody
detected, which may suggest current
or past infection.
Diagnosis of central nervous system
infections can be accomplished by
demonstrating the presence of intrathe-
cally produced specific antibody.
Interpretation of results may be
complicated by low antibody levels
found in CSF, passive transfer of
antibody from blood, and contamination
via bloody taps. |
| CYSTICERCUS ANTIBODY | CYSTICERCUS.AB | CYSTAB | ELISA | Cysticercus Ab
LT 0.90 Antibody no detected.
0.90-1.15 Equivocal: Submission
of a second specimen
(collected 3-4 weeks
after initial specimen)
suggested if clinically
warranted.
GT 1.15 Antibody detected.
Cysticercosis is caused by infection
with the larval form (cysticercus) of
the pork tapeworm, Taenia solium.
Clinical manifestations of cysticercosis
most commonly result from the lodging of
cysticerci in brain & neural tissue.
Common symptoms of neuro-cysticercosis
include seizures and convulsions.
Antibodies from other parasitic
infections, particularly echinococcosis,
may crossreact in the cysticercus IgG
Elisa. Confirmation of positive Elisa
results by the cysticercus IgG Ab
western blot is thus recommended. |
| CYSTINE, URINE (QUANTITATIVE) | CYUQ | CYUQ | Ion Exchange Chromatography | Volume mLs
Collection Period h
Cystine, Urine umol/gCr
0-5 months 62-345
6-11 months 53-133
1-3 yrs 53-186
4-12 yrs 35-106
13 yrs and more 27-151
Creatinine, Urine mg/dL
Cystine, Urine mg/dL
Cystine, Urine mg/day |
| CYTOCHROME P450 CYP2D6 14 MUTATIONS & GENE DUPLICATION | CP450 | CP450 | Polymerase chain reaction/primer extension | CYP2D6 Predicted Phenotype
CYP2D6 Variant
CYP2D6 Variant
CYP2D6 Variant
CYP2D6 Variant
|
| CYTOGENETICS, CHROMOSOME ANALYSIS, AMNIOTIC FLUID | AFCYTO | | Cytogenetics | Chromosome Analysis, Amniotic Fluid
Separate Report to Follow |
| CYTOGENETICS, CHROMOSOME ANALYSIS, BONE MARROW, ASPIRATE/BONE CORE | BMCYTO | | Cytogenetics | Chromosome Analysis, Bone Marrow
Separate Report to Follow |
| CYTOGENETICS, CHROMOSOME ANALYSIS, FAMILY, PERIPHERAL BLOOD | PBFAM | | Cytogenetics | Chromosome Analysis, Peripheral Blood Family
Separate Report to Follow |
| CYTOGENETICS, CHROMOSOME ANALYSIS, HIGH RESOLUTION, PERIPHERAL BLOOD | HRPBCY | | Cytogenetics | Chromosome Analysis, Peripheral Blood High Resolution
Separate Report to Follow |
| CYTOGENETICS, CHROMOSOME ANALYSIS, LEUKEMIC BLOOD | LBCYTO | | Cytogenetics | Chromosome Analysis, Leukemic Blood
Separate Report to Follow |
| CYTOGENETICS, CHROMOSOME ANALYSIS, MOSAIC, PERIPHERAL BLOOD | MOPBCY | | Cytogenetics | Chromosome Analysis, Peripheral Blood Mosaic
Separate Report to Follow |
| CYTOGENETICS, CHROMOSOME ANALYSIS, MOSIAC, SOLID TISSUE | MOSTI | | Cytogenetics | Chromosome Analysis, Solid Tissue Mosiac
Separate Report to Follow |
| CYTOGENETICS, CHROMOSOME ANALYSIS, PLEURAL OR ASCITES FLUID | PLCYTO | | Cytogenetics | Chromosome Analysis, Plueral or Ascites Fluid
Separate Report to Follow |
| CYTOGENETICS, CHROMOSOME ANALYSIS, ROUTINE, PERIPHERAL BLOOD | PBCYTO | | Cytogenetics | Chromosome Analysis, Peripheral Blood Routine
Separate Report to Follow |
| CYTOGENETICS, CHROMOSOME ANALYSIS, SOLID TISSUE | STICYT | | Cytogenetics | Chromosome Analysis, Solid Tissue
Separate Report to Follow |
| CYTOGENETICS, CHROMOSOME ANALYSIS, SOLID TUMOR | STUCYT | | Cytogenetics | Chromosome Analysis, Solid Tumor Tissue
Separate Report to Follow |
| CYTOGENETICS, FISH DNA PROBES FOR GLIOMA | GLIOFI | | FISH | See separate report |
| CYTOGENETICS, TISSUE CULTURE, AMNIOTIC FLUID | AFTC | | Cytogenetics | Tissue Culture, Amniotic Fluid
Separate Report to Follow |
| CYTOGENETICS, TISSUE CULTURE, SOLID TISSUE | STITC | | Cytogenetics | Tissue Culture, Solid Tissue
Separate Report to Follow |
| CYTOKINE PANEL 12 BY MAFD [ARUP] | CYTPAN | CYTPAN | Multi-Analyte Fluorescent Detection | Interleukin 2 0-2 pg/mL
Interleukin 2 Receptor 0-1033
Interleukin 12 0-6
Interferon Gamma 0-5
Interleukin 4 0-5
Interleukin 5 0-5
Interleukin 10 0-18
Interleukin 13 0-5
Interleukin 1 Beta 0-36
Interleukin 6 0-5
Interleukin 8 0-5
Tumor Necrosis Factor Alpha 0-22
|
| CYTOMEGALOVIRUS ANTIBODY, IGG | CMVGL | CMVGL | CLIA | CMV Ab, IgG U/mL
LT 0.60 Negative No significant level
of IgG Ab detected.
0.60-0.69 Equivocal Repeat testing of a
second sample in 1-014
days may be helpful to
determine presence or
absence of infection.
0.70 or greater IgG Ab detected. May
indicate a recent or
past infection. |
| CYTOMEGALOVIRUS ANTIBODY, IGG & IGM | CMVGML | CMVGML | CLIA | CMV AB, IgG Negative LT 0.60 U/mL
CMV AB, IgM Negative LT 30.0 AU/mL |
| CYTOMEGALOVIRUS ANTIBODY, IGM | CMVML | CMVML | CLIA | CMV Ab, IgM AU/mL
LT 30.0 Negative No detectable IgM Abs.
A negative result does
not always rule out acute
infection as the IgM
response is not always
detectable in very early
is immunocompromised. If
exposure to CMV is suspected
a second sample should be
collected and tested in 7-14
days.
30.0-34.9 Equivocal Repeat testing in 10-14 days
may be helpful to determine
presence or absence of
infection.
35.0 or greater Positive IgM antibody detected. A
positive CMV IgM result is
generally indicative of acute
infection, reactivation or
persistent IgM production. |
| CYTOMEGALOVIRUS BY RT-PCR, QUALITATIVE | CMVRT | CMVRT | PCR | Cytomegalovirus Source
Cytomegalovirus Result by PCR
Not detected
A result of not detected does not rule out the
presence of PCR inhibitors in patient
specimens, or Cytomegalovirus concentrations
below the level of detection by the assay.
Cytomegalovirus Comment
This test is performed pursuant with Roche
Molecular Systems, Inc. |
| CYTOMEGALOVIRUS BY RT-PCR, QUANTITATIVE | CMVRTQ | CMVRTQ | Real-time PCR | Cytomegalovirus DNA, Quantitation LT 326 copies/mL
A result of LT 326 copies/mL does not rule
out the presence of PCR inhibitors in
patient specimens, or Cytomegalovirus
concentrations below the level of detection
of the assay.
|
| D-DIMER, QUANTITATIVE | XDIMQT | XDIMQT | Immuno-turbidimetric | D-Dimer, Quantitative ug/mL FEU
LT 0.5
This quantitative D-dimer assay has
been evaluated for screening for
venous thrombotic disease, and may be
useful in ruling out, but not ruling
in disease. Values less than 0.40 ug/mL
FEU have a negative predictive value
of GT 95% for ruling out large
pulmonary emoboli or proximal deep
vein thrombosis. Distal DVT are not
excluded. Rheumatoid factor may
falsely elevate the determined D-
dimer levels. |
| DANTRIUM | DANT | DANT | Spectrofluorometric | Dantrolene 0.2-3.5 mcg/mL |
| DENGUE FEVER VIRUS ANTIBODY, IGG & IGM | DENGUE | DENGUE | ELISA | Dengue Fever Virus Antibody, IgG IV
1.64 or less Negative. No significant
level of detectable Dengue Fever
Virus IgG Ab.
1.65-2.84 Equivocal. Questionable presence
of Abs.Repeat testing in
10-14 days may be helpful.
2.85 or more Positive. IgG Ab to Dengue
Fever Virus detected which
may indicate a current or
past infection.
Dengue Fever Virus Ab, IgM IV
1.64 or less Negative. No significant
level of detectableDengue Fever
Virus IgM Ab.
1.65-2.84 Equivocal. Questionable presence
of Antibody. Repeat testing in
10-14 days may be helpful.
2.85 or more Positive. IgM Ab to Dengue
Fever Virus detected which
may indicate a current or
recent infection.
The best evidence for current
infection is a significant
change on two appropriately
timed specimens where both
tests are done in the same
laboratory at the same time. |
| DEOXYCORTICOSTERONE | DEOCOR | DEOCOR | Extraction, Chromatography, RIA | Deoxycorticosterone ng/dL |
| DESIPRAMINE | DES | DESIP | HPLC | Desipramine ng/mL
Therapeutic 150-300
Toxic GT 499 |
| DEXAMETHASONE (SUPPRESSION-2) | DST2 | DST | ICMA | Cortisol Pre Suppression ug/dL
4.3-22.4
Time Drawn
Cortisol Post Suppression ug/dL
Normal patients suppress their
cortisol levels to LT 5.0 g/dL.
Time Drawn |
| DEXAMETHASONE (SUPPRESSION-3) | DST3 | DST3 | ICMA | Cortisol Pre-Suppression ug/dL
4.3-22.4
Time Drawn
Cortisol Post-Suppression #1 ug/dL
Normal patients suppress their
cortisol levels to LT 5.0
Time Drawn
Cortisol Post-Suppression #2 ug/dL
Time Drawn |
| DEXAMETHASONE (SUPPRESSION-4) | DST4 | DST4 | ICMA | Cortisol Pre-Suppression ug/dL
4.3-22.4
Time Drawn
Cortisol Post-Suppression #1 ug/dL
Normal patients suppress their
cortisol levels to LT 5.0.
Time Drawn
Cortisol Post-Suppression #2 ug/dL
Time Drawn
Cortisol Post-Suppression #3 ug/dL
Time Drawn |
| DEXAMETHASONE (SUPPRESSION-RANDOM) | DST1 | DST1 | ICMA | Cortisol ug/dL
Normal patients suppress their
cortisol levels to LT 5.0. |
| DHEA | DHYA | DHYA | HPLC/TMS | DHEA ng/mL
F Premature LT 40.000
0-1 day LT 11.000
2-6 days LT 8.700
7 days-1 mo LT 5.800
1-23 mo LT 2.900
2-5 yrs LT 2.300
6-7 yrs LT 3.400
8-9 yrs 0.120-2.700
10-11 yrs 0.130-3.690
12-13 yrs 0.810-6.340
14-15 yrs 1.230-7.630
16-17 yrs 1.460-9.510
18-40 yrs 1.330-7.780
41 yrs+ 0.630-4.700
Tanner Stage I 0.130-2.740
Tanner Stage II 0.600-5.380
Tanner Stage III 1.140-8.540
Tanner Stage IV-V 1.190-9.130
M Premature LT 40.000
0-1 day LT 11.000
2-6 days LT 8.700
7 days-1 mo LT 5.800
1-23 mo LT 2.900
2-5 yr LT 2.300
6-7 yr LT 3.400
8-9 yrs 0.092-2.460
10-11 yrs 0.300-3.810
12-13 yrs 0.058-4.110
14-15 yrs 0.870-6.640
16-17 yrs 1.210-7.630
18-40 yrs 1.330-7.780
41 yrs+ 0.630-4.700
Tanner Stage I 0.100-2.540
Tanner Stage II 0.320-3.960
Tanner Stage III 0.790-4.940
Tanner Stage IV-V 1.210-6.450 |
| DHEA, URINE | DHEAU | DHEAU | GC/MS | Collection Period h
Volume mL
DHEA, Urine 21-2710 ug/24h
DHEA, Urine ug/gCr
M 24-1640
F 13-730
Creatinine, Urine g/24h
3-8 yrs 0.11-0.68
9-12 yrs 0.17-1.41
13-17 yrs 0.29-1.87
17 + yrs 0.63-2.50 |
| DHEA-SO4 | DHEA-SO4 | DHEAS | ICMA | DHEA-SO4 ug/dL
M 0-6 days 90-504
7-30 days 27-358
1-11 mon 2-103
1-4 yrs 0-16
5-9 yrs 3-96
10-14 yrs 18-276
15-19 yrs 73-401
20-29 yrs 232-531
30-39 yrs 100-432
40-49 yrs 79-440
50-59 yrs 58-257
60-69 yrs 35-241
70 yrs + 23-145
F 0-6 days 90-504
7-30 days 27-358
1-11 mon 2-103
1-4 yrs 0-16
5-9 yrs 5-77
10-14 yrs 18-212
15-19 yrs 52-310
20-29 yrs 54-315
30-39 yrs 37-224
40-49 yrs 27-199
50-59 yrs 22-166
60-69 yrs 11-108
70 yrs + 8-75
Tanner Stage I
M 6-173
F 6-105
Tanner Stage II
M 23-216
F 11-200
Tanner Stage III
M 32-324
F 27-370
Tanner Stage IV & V
M 67-405
F 54-308
M |
| DIAZEPAM | VALIUM | DIAZ | GC | Diazepam Therapeutic 0.20-1.00 ug/mL
(Valium) Based on normal dosages
Nordiazepam Therapeutic 0.06-1.80 ug/mL
Based on normal dosages
Toxic GT 2.50 |
| DIC SCREEN, REFLEXIVE | DICB | DIC | Electromechanical, Microscopy | Protime sec
0-1 mo 13.0-20.0
2+ mo 10.9-14.8
Population Mean 13.4 sec
INR 0.9-1.2
Usual oral anitcoagulation range 2.0-3.0
High-level oral anticoagulation range 2.5-3.5
PTT sec
0-1 mo 40-50
2 mo-4 yrs 25-40
5+ yrs 26-36
PTT Population Mean 31 sec
Fibrinogen 211-419 mg/dL
Thrombin Time Patient 15.6-20.0 sec
Thrombin Time Control 15.6-20.0 sec
Thrombin Time PT/CT Mix sec
Thrombin Time PT/SO4 Mix sec
D-dimer, Quantitative LT 0.50 ug/mL FEU
Fibrinolysis Negative in 8 hr
Platelet Count K/uL
0-3 days 250-450
3-9 days 200-400
9-30 days 250-450
1-6 mo 300-750
6 mo-2 yrs 250-600
2-8 yrs 250-550
8-12 yrs 200-450
12-18 yrs 150-450
18 yrs+ 150-400
RBC Morphology
DIC Comment |
| DIFFERENTIAL SLIDE REVIEW BY PATH | DIF.PATH | PATHD2 | Microscopic | CBC with Manual Differential
Impression
Reviewed By |
| DIFFERENTIAL, MANUAL | DIF.AD | AMDIF2 | Microscopic | Differential
Segs %
0-1 day 33-70
1-7 days 15-50
7-30 days 15-45
1-12 mo 15-70
1-4 yrs 25-70
4-10 yrs 30-70
10-14 yrs 25-70
14-18 yrs 30-70
18 yrs+ 38-70
Segs, Abs K/uL
0-1 day 3.00-12.00
1-7 days 2.00-6.00
1 wk-1 yr 1.50-5.00
1-4 yrs 1.50-7.50
4-10 yrs 1.80-7.00
10-18 yrs 1.50-7.00
18 yrs+ 1.80-7.70
Bands %
0-18 yrs 0-9
18 yrs+ 0-8
Bands, Abs K/uL
0-1 day 0.00-1.50
1-7 days 0.00-1.20
7-30 days 0.00-0.50
1-12 mo 0.00-0.40
1-4 yrs 0.00-0.30
4-10 yrs 0.00-0.20
10-18 yrs 0.00-0.20
Lymphocytes %
0-1 day 10-35
1-7 days 15-70
1 wk-4 yrs 30-70
4-6 yrs 20-70
6-10 yrs 20-50
10-18 yrs 20-40
18 yrs+ 21-49
Lymphocytes, Abs K/uL
0-1 day 2.00-11.00
1-7 days 2.00-7.00
7-30 days 3.00-7.00
1-12 mo 1.50-8.50
1-4 yrs 1.50-5.00
4-10 yrs 1.20-5.00
10-18 yrs 1.10-4.50
18 yrs+ 1.00-5.00
Variant Lymph 0-6 %
Variant Lymphs, Abs K/uL
Monocytes %
0-18 yrs 0-10
18 yrs+ 3-11
Monocytes, Abs K/uL
0-1 day 0.00-1.10
1-7 days 0.00-0.90
7-30 days 0.00-0.60
1-12 mo 0.00-0.50
1-4 yrs 0.00-0.50
4-10 yrs 0.00-0.40
10-18 yrs 0.00-0.90
18 yrs+ 0.00-0.80
Eosinophils %
0-18 yrs 0-4
18 yrs+ 0-7
Eosinophils, Abs K/uL
0-1 day 0.00-0.40
1-7 days 0.00-0.50
7 days-1 yr 0.00-0.30
1-10 yrs 0.00-0.30
10-18 yrs 0.00-0.20
18 yrs+ 0.00-0.50
Basophils %
1-18 yrs 0-1
18 yrs+ 0-2
Basophils, Abs K/uL
0-7 days 0.00-0.10
1 wk-4 yrs 0.00-0.01
4-18 yrs 0.00-0.01
18 yrs+ 0.00-0.20
Metamyelocytes %
Myelocytes %
Promyelocytes %
Blast Cells %
Other %
NRBC /100WBC
Meg Frag /100WBC
RBC Morph
WBC Morph
Platelet Morph
Cells Counted |
| DIGITOXIN | DGTXN | DGTXN | Fluoresence Polar Immunoassay | Digitoxin ng/mL
Therapeutic 10.0-32.0
Toxic GT 35.0 |
| DIGOXIN | DIG | DIG | ICMA | Digoxin ng/mL
Therapeutic 0.8-2.0
Toxic GT 2.5
Increased risk of Digoxin toxicity
at levels GT 2.0 ng/mL, with a wide
zone of concentrations that may be
toxic in one individual and not in
another. The risk is greater with CHD
and with decreases in Potassium,
Calcium and Magnesium. Digoxin
distribution phase complete after
8-15 hours. |
| DIHYDROTESTOSTERONE | DHT | DHT | RIA/Extraction/Chromatography | Dihydrotestosterone ng/dL
Adult M 25-75
Adult F 5-30
Cord Blood M LT 2-8
Cord Blood F LT 2-5
1-6 months M 12-85
1-6 months F LT 5
Prepubertal M LT 5
Prepubertal F LT 5
Tanner Stages II-III M 3-33
Tanner Stages II-III F 5-19
Tanner Stages IV-V M 22-75
Tanner Stages IV-V F 3=3- |
| DILUTE RUSSELL VIPER VENOM (REFLEXIVE) | ADRVVT | ADRVVT | Electromechanical | dRVVT 31.8-45.7 sec
dRVVT Mix Ratio 0.0-1.2 Negative for Lupus Inhibitor Screen
dRVVT Confirm Ratio LT 1.2 Negative for Lupus Inhibitor Screen
dRVVT Confirm Mix Ratio LT 1.2 Negative for Lupus Inhibitor Screen
|
| DIPHTHERIA/TETANUS ANTIBODY | DIPTEN | DIPTEN | Multi-analyte Fluorescent Detection | Diphtheria Ab IU/mL
Antibody concentration
of GT 0.10 IU/mL is considered
protective against diphtheria.
Tetanus Ab IU/mL
Antibody concentration of
GT 0.10 IU/mL is considered
protective against tetanus. |
| DIRECT EXAM, MISC | MISCDE | MISCDE | | Source
Direct Exam, Misc Negative
Direct Exam, Status |
| DIRECT PLATELET ANTIBODIES, IGG & IGM | DIRPLT | DIRPLT | Flow Cytometry | Platelet Ab, Direct IgG Negative
Platelet Ab, Direct IgM Negative
Interpretation |
| DISACCHARIDASE ANALYSIS | DISAC | DISAC | Spectrphotometry | Lactase Normal 16.5-32.5 uM/min/gram protein
Abnormal LT 15.0
Sucrase Normal 29.0-79.8 uM/min/gram protein
Abnormal LT 25.0
Maltase Normal 98.0-223.6 uM/min/gram protein
Abnormal LT 100.0
Palatinase Normal 4.6-17.6 uM/min/gram protein
Abnormal LT 5.0
Interpretation |
| DISOPYRAMIDE | DISOP | DISOP | Immunoassay | Disopyramide ug/mL
Therapeutic 2.0-5.0
Toxic GT 7.0 |
| DNA CONTENT/CELL CYCLE ANALYSIS, MISCELLANEOUS | DNAMIS | DNAMIS | Flow Cytometry | Source
DNA Content
S-Phase Interpretation |
| DNA, DOUBLE STRANDED CRITHIDIA IFA | IFDNA | IFDNA | IFA-Crithidia | DNA Double Strand (Crithidia) Negative LT 1:10 |
| DORIDEN | DOR | GLUTET | GC/NPD | Doriden (Glutethimide) mcg/mL
Usual Sedative-Hypnotic 2-6 |
| DOXEPIN & METABOLITE | DOX | DOX | HPLC | Doxepin ng/mL
No reference range established for parent
drug. See Total for reference range, which
takes into account all metabolites.
Desmethyldoxepin ng/mL
No reference range established for this
metabolite. See Total for reference range,
which takes into account all metabolites.
Total Drug
Therapeutic 150-250 ng/mL
Toxic GT 499 ng/mL |
| DOXYLAMINE | DOXY | DOXY | GC-N/P Detector | Doxylamine LT 170 ng/mL
(following a single 25 mg dose) |
| DRUG & ALCOHOL SCREEN, SERUM (REFLEXIVE) | DRASER | DRASER | Elisa, Enzymatic | Ethanol mg/dL
Opiates ng/mL
Cocaine/Metabolites ng/mL
Benzodiazepines ng/mL
Cannabinoids ng/mL
Amphetamines ng/mL
Barbiturates ng/mL
Methadone ng/mL
Phencyclidine ng/mL
Propoxyphene ng/mL |
| DRUG FACILITATED SEXUAL ASSAULT PANEL | DSFA1 | DSFA1 | EMIT/Confirmation by GC/MS, LC/MS, TLC, GC/FID or Refract | Drug Survey
Comprehensive
Codeine positive cutoff 20 ng/mL
Morphine positive cutoff 20 ng/mL
Hydrocodone positive cutoff 20 ng/mL
Hydromorphone positive cutoff 20 ng/mL
Oxycodone positive cutoff 20 ng/mL
Oxymorphone positive cutoff 20 ng/mL
6 MAM (Heroin positive cutoff 10 ng/mL
metabolite)
Clonazepam ng/mL
Ketamine ng/mL
Flunitrazepam ng/mL
GHB mcg/mL
pH 3.0-11.0
Creatinine LT 19 mg/dL
Specific
Gravity |
| DRUG SCREEN, SERUM (REFLEXIVE) | DRUSER | DRUSER | Elisa | Opiates ng/mL
Cocaine/Metabolites ng/mL
Benzodiazepines ng/mL
Cannabinoids ng/mL
Amphetamines ng/mL
Barbiturates ng/mL
Methadone ng/mL
Phencyclidine ng/mL
Propoxyphene ng/mL |
| DRUGS OF ABUSE CONFIRMATION, QUANTITATIVE, OPIATES | OPSCON | OPSCON | Tandem Mass Spectrometry | 1) Drugs covered: codeine, dihydrocodeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone and oxymorphone. 2) Positive cutoff: 2 ng/mL. 3) For Medical purposes only: not valid for forensic use. |
| DSDNA AUTOANTIBODY | DNAMP | DNAMP | Multiplex luminex | DSDNA Auto- Negative LT 5 IU/mL
antibody Indeterminate 5-9
Positive 10 or more |
| DULOXETINE | DUL | DUL | HPLC/LC/MS/MS | Duloxetine Steady state trough plasma concentrations after 5 days of oral therapy were: ng/mL
20 mg twice daily 4-20
30 mg twice daily 8-48
40 mg twice daily 12-60 |
| DYPHYLLINE | DYP | DYP | HPLC | Dyphylline Therapeutic 10-20 mcg/mL |
| ECHINOCOCCUS ANTIBODY, IGG | ECHINO | ECHINO | ELISA | Echinococcus Ab IV
0.8 or less Negative No significant level
of Echinococcus IgG Ab
detected.
0.9-1.1 Equivocal Questionable presence of
Echinococcus IgG Ab
detected.
Repeat testing in 10-14
days may be helpful.
1.2 or more Positive Presence of IgG Ab
to Echinococcus detected,
suggestive of current or
past infection. |
| ECHOVIRUS ANTIBODY | ECHO | ECHO | Serum neutralization assay | Source
Echovirus Ab Type 6 LT 1:10
Echovirus Ab Type 7 LT 1:10
Echovirus Ab Type 9 LT 1:10
Echovirus Ab Type 11 LT 1:10
Echovirus Ab Type 30 LT 1:10
Single positive antibody titers of equal to
or greater than 1:80 may indicate past or
current infection. Seroconversion or an
increase in titers between acute and convalescent
sera of at least fourfold is considered
strong evidence of current or recent
infection.
CSF can be tested. However, the clinical
significance and criteria for interpretation
of results have not been established. |
| ECTOPIC PREGNANCY PANEL | ECTOPIC.PANEL | ECPANL | ICMA | Progesterone (Ectopic Evaluation) ng/mL
Beta HCG Quant (Ectopic Evaluation) mIU/mL
Ectopic pregnancy reference note
HCG GT or equal to 100,000 mIU/mL
and Progesterone GT or equal to
25.00 ng/mL suggests probable viable
intrauterine pregnancy. Progesterone
LT or equal to 5.00 ng/mL or abnormal
rising HCG suggests ectopic or non-
viable pregnancy. Progesterone GT
5.00 but LT 25.00 ng/mL is inconclusive,
correlate with ultrasound. |
| EHRLICHIA CHAFFEENSIS ANTIBODY, IGG & IGM | EHRLGM | EHRLGM | IFA | Ehrlichia chaffeensis IgG Ab
LT 1:64 Negative
1:64-1:128 Equivocal
1:256 or more Positive
Ehrlichia chaffeensis IgM Ab
LT 1:16 Negative
1:16 or more Positive |
| ELECTROLYTE & OSMOLALITY PROFILE, FECAL | FCELOS | FCELOS | ISE/Freezing Point Depression | Collection time hr
Fecal weight g
Fecal Magnesium 0-110 mg/dL
Fecal Magnesium 0-355 mg/d
Fecal Sodium Reference interval not established mmol/L
Fecal Potassium Reference interval not established mmol/L
Osmolality, Fecal 280-303 mOs/kg
Osmolality, Calculated mOs/kg
Osmolal Gap mOs/kg |
| ELECTROLYTES PANEL | EP | EP | ISE, Colorimetric | Sodium 135-145 mmol/L
Potassium 0-30 days 3.9-6.9 mmol/L
1-12 mo 3.6-6.8
1-5 yrs 3.2-5.7
5-10 yrs 3.4-5.4
10 yrs+ 3.5-5.3
Chloride 98-109 mmol/L
CO2 0-10 days 13-22 mmol/L
11 days-4 yrs 20-28
5+ yrs 22-31
Anion Gap 5-16 mmol/L |
| ELECTROLYTES, FECAL (NA,K,CL) | LYTST | LYTST | ISE | Stool
Sodium No normals established mmol/L
Potassium No normals established mmol/L
Chloride No normals established mmol/L |
| ELECTROPHORESIS, CITRATE GEL | CITGEL | CITGEL | Gel Electrophoresis | Citrate Gel Electrophoresis, Interpretation
Citrate Gel Electrophoresis, Reviewed by |
| ELECTROPHORESIS, FLUID | ELP.FLD | PELPFL | Agarose Gel ELP (high resolution) | Protein, Fluid No Normals established g/dL
Albumin, Fluid No Normals established g/dL
Alpha-1, Fluid No Normals established g/dL
Alpha-2, Fluid No Normals established g/dL
Beta-1, Fluid No Normals established g/dL
Beta-2, Fluid No Normals established g/dL
Gamma, Fluid No Normals established g/dL
Albumin, Fluid No Normals established %
Alpha-1, Fluid No normals established %
Alpha-2, Fluid No Normals established %
Beta-1, Fluid No Normals established %
Beta-2, Fluid No Normals established %
Gamma, Fluid No normals established % |
| ELECTROPHORESIS, PROTEIN | ELP | PELP | Agarose Gel ELP (high resolution) | Protein, Total g/dL
0-12 mo 4.3-6.9
1-3 yrs 5.2-7.4
3-6 yrs 5.6-7.7
6-10 yrs 6.5-8.3
10-18 yrs 6.1-8.0
18-60 yrs 6.3-8.0
60 yrs+ 6.1-7.8
Albumin 0-4 days 2.9-4.6 g/dL
4 days-14 yrs 3.9-5.6
14-18 yrs 3.3-4.7
18-60 yrs 3.5-5.0
60-90 yrs 3.3-4.8
90 yrs+ 3.0-4.7
Alpha-1 0.1-0.4 g/dL
Alpha-2 0.5-1.1 g/dL
Beta-1 0.4-0.8 g/dL
Beta-2 0.2-0.5 g/dL
Gamma 0.6-1.5 g/dL
Albumin 45.0-80.0 %
Alpha-1 1.0-6.0 %
Alpha-2 6.0-17.0 %
Beta-1 5.0-13.0 %
Beta-2 2.0-8.0 %
Gamma 7.5-24.0 %
Interpretation
Monoclonal Peak |
| ELECTROPHORESIS, PROTEIN (REFLEXIVE) | PELPIF | PELPIF | Agarose Gel ELP (high resolution) | Protein, Total g/dL
0-12 mo 4.3-6.9
1-3 yrs 5.2-7.4
3-6 yrs 5.6-7.7
6-10 yrs 6.5-8.3
10-18 yrs 6.1-8.0
18-60 yrs 6.3-8.0
60 yrs+ 6.1-7.8
Albumin 0-4 days 2.9-4.6 g/dL
4 days-14 yrs 3.9-5.6
14-18 yrs 3.3-4.7
18-60 yrs 3.5-5.0
60-90 yrs 3.3-4.8
90 yrs+ 3.0-4.7
Alpha-1 0.1-0.4 g/dL
Alpha-2 0.5-1.1 g/dL
Beta-1 0.4-0.8 g/dL
Beta-2 0.2-0.5 g/dL
Gamma 0.6-1.5 g/dL
Albumin 45.0-80.0 %
Alpha-1 1.0-6.0 %
Alpha-2 6.0-17.0 %
Beta-1 5.0-13.0 %
Beta-2 2.0-8.0 %
Gamma 7.5-24.0 %
Monoclonal Peak
Interpretation
Immunofixation Interp |
| ELECTROPHORESIS, PROTEIN, CSF | ELPC | ELPC | Electrophoresis | Total Protein, CSF 15-45 mg/dL
Pre-albumin 0.0-3.1 mg/dL
Albumin 8.4-34.2 mg/dL
Alpha-1 0.0-3.1 mg/dL
Alpha-2 0.0-5.4 mg/dL
Beta 0.0-8.1 mg/dL
Gamma 0.0-5.4 mg/dL |
| ELECTROPHORESIS, PROTEIN, RANDOM URINE , (REFLEXIVE) | PEURIF | PEURIF | Agarose Gel ELP (High resolution) | Random Urine Protein Electrophoresis,
Immunofixation, Random Urine, Interp if indicated |
| ELECTROPHORESIS, PROTEIN, URINE (REFLEXIVE) | PEPUIF | PEPUIF | Agarose Gel ELP (High resolution) | Protein, Urine, Quant 50-80 mg/24h
Urine Protein Electrophoresis
Immunofixation, Urine, Interp |
| ELECTROPHORESIS, SCAN, URINE (QUANTITATIVE) | SCANUQ | SCANUQ | Agarose Gel ELP (High Resolution) | Collection Period h
Volume mL
ELP Scan, Urine
Protein 50-80 mg/24h
Albumin mg/24h
Alpha-1 mg/24h
Alpha-2 mg/24h
Beta-1 mg/24h
Beta-2 mg/24h
Gamma mg/24h
Albumin %
Alpha-1 %
Alpha-2 %
Beta-1 %
Beta-2 %
Gamma % |
| ELECTROPHORESIS, SCAN, URINE (RANDOM) | SCANUR | SCANUR | Agarose Gel ELP (High Resolution) | ELP, Scan, Urine
Albumin %
Alpha-1 %
Alpha-2 %
Beta-1 %
Beta-2 %
Gamma % |
| ELECTROPHORESIS, URINE | ELP-U | PELPUQ | Agarose Gel ELP (High resolution) | Collection Period h
Volume mL
Protein, Urine, Quant 50-80 mg/24h
Interpretation |
| ELECTROPHORESIS, URINE (RANDOM) | ELP-R | PELPUR | Agarose Gel ELP(High Resolution) | Electrophoresis, Urine, Random |
| ENCEPHALITIS, EASTERN EQUINE ANTIBODY PANEL, IGG & IGM, CSF | EEECSF | EEECSF | IFA | Encephalitis, Eastern Equine Ab, IgG, CSF
LT 1:4
Encephalitis, Eastern Equine Ab, IgM, CSF
LT 1:4
Encephalitis, Eastern Equine Ab, CSF Interp
Specimens positive for arbovirus antibody
are CDC reportable. Please contact your
local public health agency.
Diagnosis of infections of the central
nervous system can be accomplished by
demonstrating the presence of
intrathecally-produced specific
antibody. However, interpreting results
is complicated by low antibody levels
found in CSF, passive transfer of
antibody from blood, and contamination
via bloody taps. The interpretation
of CSF results must consider CSF-serum
ratios of the infectious agent. |
| ENCEPHALITIS, EASTERN EQUINE ANTIBODY, IGG | EEEGAB | EEEGAB | IFA | Encephalitis, Eastern Equine Antibody, IgG
LT 1:16 No antibody detected
1:16 or more Antibody detected
Specimens positive for arbovirus antibody
are CDC-reportable. Please contact your
local public health agency.
Detection of IgG antibody indicates
either past or recent infection.
Human infections are seasonal, from
mid-summer to late summer, occurring
from New England to Texas. Minimal
cross-reactivity with other Group A
arboviruses; i.e. Western equine
encephalitis virus is observed. |
| ENCEPHALITIS, EASTERN EQUINE ANTIBODY, IGG & IGM | EEEAB | EEEAB | IFA | Eastern Equine Encephalitis Virus, IgG
LT 1:16
Eastern Equine Encephalitis Virus, IgM
LT 1:20
Specimens positive for arbovirus antibody
are CDC-reportable. Please contact your
local public health agency.
This highly sensitive test usually detects
IgG and/or IgM antibody in acute specimens.
Human infections are seasonal, from
mid-summer to late summer, occurring
from New England to Texas. Minimal
cross-reactivity with other Group A
arboviruses; i.e. Western equine
encephalitis virus is observed. |
| ENCEPHALITIS, EASTERN EQUINE ANTIBODY, IGG, CSF | EQEGCF | EQEGCF | IFA | Encephalitis, Eastern Equine Antibody, IgG CSF
LT 1:4
Interpretive Criteria
LT 1:4 Antibody not detected
1:4 or more Antibody detected
Specimens positive for arbovirus antibody
are CDC reportable. Please contact your
local public health agency.
Diagnosis of infections of the central
nervous system can be accomplished by
demonstrating the presence of
intrathecally-produced specific
antibody. However, interpreting results
is complicated by low antibody levels
found in CSF, passive transfer of
antibody from blood, and contamination
via bloody taps. The interpretation
of CSF results must consider CSF-serum
ratios of the infectious agent. |
| ENCEPHALITIS, EASTERN EQUINE ANTIBODY, IGM | EEEMAB | EEEMAB | IFA | Encephalitis, Eastern Equine Antibody, IgM
LT 1:20 No antibody detected
1:20 or more Antibody detected
Specimens positive for arbovirus antibody
are CDC-reportable. Please contact your
local public health agency.
Detection of IgM antibody indicates
recent or current infection.
Human infections are seasonal, from
mid-summer to late summer, occurring
from New England to Texas. Minimal
cross-reactivity with other Group A
arboviruses; i.e. Western equine
encephalitis virus is observed. |
| ENCEPHALITIS, EASTERN EQUINE ANTIBODY, IGM, CSF | EEEMCF | EEEMCF | IFA | Encephalitis, Eastern Equine Antibody, IgM CSF
LT 1:4
Specimens positive for arbovirus antibody
are CDC reportable. Please contact your
local public health agency.
Diagnosis of infections of the central
nervous system can be accomplished by
demonstrating the presence of
intrathecally-produced specific
antibody. However, interpreting results
is complicated by low antibody levels
found in CSF, passive transfer of
antibody from blood, and contamination
via bloody taps. The interpretation
of CSF results must consider CSF-serum
ratios of the infectious agent. |
| ENCEPHALITIS, ST LOUIS ANTIBODY | ENC.STLOUIS | ENCSTL | IFA | Encephalitis, St. Louis Antibody Titer
LT 1:16 A positive result for IgG
may suggest current or past
infection. |
| ENCEPHALITIS, ST. LOUIS ANTIBODY PANEL, IGG & IGM | SLEVAB | SLEVAB | IFA | St. Louis Encephalitis Virus, IgG
LT 1:16
St. Louis Encephalitis Virus, IgM
LT 1:20
Specimens positive for arbovirus
antibody are CDC reportable. Please
contact your local public health
agency.
This highly sensitive test usually
detects IgG and/or IgM antibody in
acute specimens. Human infections
are seasonal, from mid-summer to
late summer, occurring throughout
the southern, south-western, and
west-central states. Cross-reactivity
can occur with other Group B arbo-
viruses (Flavivirus), including
Dengue, Japanese encephalitis, Rio
Bravo, Powassan, and yellow fever. |
| ENCEPHALITIS, ST. LOUIS ANTIBODY PANEL, IGG & IGM, CSF | SLEVSF | SLEVSF | IFA | Encephalitis, St. Louis Ab, IgG, CSF
LT 1:4
Encephalitis, St. Louis Ab, IgM, CSF
LT 1:4
Encephalitis, St. Louis Ab, CSF Interp
IgG LT 1:4 Ab not detected
IgM LT 1:4 Ab not detected
Specimens positive for arbovirus antibody
are CDC reportable. Please contact your
local public health agency.
Diagnosis of infections of the central
nervous system can be accomplished by
demonstrating the presence of
intrathecally-produced specific
antibody. However, interpreting results
is complicated by low antibody levels
found in CSF, passive transfer of
antibody from blood, and contamination
via bloody taps. The interpretation
of CSF results must consider CSF-serum
ratios of the infectious agent. |
| ENCEPHALITIS, ST. LOUIS ANTIBODY, IGG, CSF | ENSTLG | ENSTLG | IFA | Encephalitis, St. Louis Antibody, IgG CSF
LT 1:1 A positive result for IgG may
suggest current or past infection.
This test is intended to be used as a
semi-quantitative means of detecting
St. Louis virus-specific IgG in CSF
samples in which there is a clinical
suspicion of St. Louis virus infection.
This test should not be used solely for
quantitative purposes, nor should the
results be used without correlation to
clinical history or other data. Because
other members of the Flaviviridae family
such as West Nile virus, show extensive
cross-reactivity with St. Louis virus,
serologic testing specific for these
specimens should also be performed. |
| ENCEPHALITIS, ST. LOUIS ANTIBODY, IGM | SLEVM | SLEVM | IFA | Encephalitis, St. Louis Antibody, IgM
LT 1:20
Interpretive Criteria
LT 1:20 Antibody not detected
1:20 or more Antibody detected
Specimens positive for arbovirus
antibody are CDC reportable. Please
contact your local public health
agency.
Detection of IgM antibody indicates
recent or current infections. Human
infections are seasonal, from mid-summer
to late summer, occuring throughout
the southern, south-western, and
west-central states. Cross-reactivity
can occur with other Group B arbo-
viruses (Flavivirus), including
Dengue, Japanese encephalitis, Rio
Bravo, Powassan, and yellow fever. |
| ENCEPHALITIS, ST. LOUIS ANTIBODY, IGM, CSF | ENSTLM | ENSTLM | IFA | Encephalitis, St. Louis Antibody, IgM CSF
LT 1:1 A positve result for IgM may
suggest current or recent infection.
This test is intended to be used as a
semi-quantitative means of detecting
St. Louis virus-specific IgM in CSF
samples in which there is a clinical
suspicion of St. Louis virus infection.
This test should not be used solely for
quantitative purposes, nor should the
results be used without correlation to
clinical history or other data. Because
other members of the Flaviviridae family
such as West Nile virus, show extensive
cross-reactivity with St. Louis virus,
serologic testing specific for these
specimens should also be performed. |
| ENCEPHALITIS, WESTERN EQUINE ANTIBODY | ENC.WEST | ENCW | IFA | Encephalitis, Western Equine Antibody Titer
LT 1:16 A positive result for IgG
may indicate current or
past infection. |
| ENCEPHALITIS, WESTERN EQUINE ANTIBODY PANEL, IGG & IGM, CSF | WEEGMC | WEEGMC | IFA | Encephalitis, Western Equine Ab, IgG, CSF
LT 1:4
Encephalitis, Western Equine Ab, IgM, CSF
LT 1:4
Encephalitis, Western Equine Ab, CSF Interp
Specimens positive for arbovirus antibody
are CDC reportable. Please contact your
local public health agency.
Diagnosis of infections of the central
nervous system can be accomplished by
demonstrating the presence of
intrathecally-produced specific
antibody. However, interpreting results
is complicated by low antibody levels
found in CSF, passive transfer of
antibody from blood, and contamination
via bloody taps. The interpretation
of CSF results must consider CSF-serum
ratios of the infectious agent. |
| ENDOMYSIAL (EMA) ANTIBODY, IGG | EDTG | EDTG | Immunofluorescence | Endomysial Ab, IgG Negative LT 1:2.5
IgG-EMA is generally only significant in those individuals
who are IgA deficient and thus cannot produce IgA-EMA.
Test performed by IMMCO Diagnostics Inc. |
| ENDOMYSIAL ANTIBODY, IGA (REFLEXIVE) | EMARX | EMARX | IFA/ELISA | Endomysial Ab, IgA, Screen
None detected
Endomysial antibodies are screened
using an ELISA tissue transglutaminase
(tTG) assay. All samples which are
positive are titered by IFA.
Endomysial Ab, IgA, Titer
None detected |
| ENTAMOEBA HISTOLYTICA ANTIBODY, IGG | AM-AB | AMOEBA | EIA | Entamoeba histolytica Ab, IgG IV
0.79 or less Negative-no significant level
of detectable E. histolytica I
IgG Ab.
0.80-1.19 Equivocal-repeat testing in
10-14 days may be helpful.
1.20 or more Positive-IgG Ab to E. histo-
lytica detected suggestive of
a current or recent infection.
Seroconversion between acute and convalescent
sera is considered strong evidence of recent
infection. The best evidence for infection
is a significant change on two appropriately
timed specimens where both tests are done
in the same laboratory at the same time. |
| ENTAMOEBA HISTOLYTICA ANTIGEN EIA | ENTHA | ENTHA | EIA | Entamoeba histolytica Antigen by EIA Negative |
| ENTEROVIRUS DETECTION BY RT-PCR | EVPCR | EVPCR | Real-Time PCR | Source
Enterovirus Detection by RT-PCR Not Detected
A result of not detected does not rule out the presence of PCR inhibitors in the patient specimen or Enterovirus nucleic acid in concentrations below the level of detection of the assay. This test performed pursuant to an agreement with Roche Molecular Systems, Inc. |
| EOSINOPHILS, SMEAR | NASAL | EOSBOD | Microscopic | Nasal Smear, Eosinophils /100 WBC
None seen to rare |
| EOSINOPHILS, URINE | EOS.UR | EOSUR | Microscopic | Eosinophils, Urine LT 1 % |
| EPIDERMAL (SKIN) ANTIBODY | EPIDAB | EPIDAB | IFA | Intercellular Substance Antibody LT 1:10 Titer
Basement Membrane Antibody LT 1:10 Titer
Interpretive Criteria
LT 1:10 Antibody not detected
1:10 or more Antibody detected
This assay tests for two antibody
specificities:
1) Autoantibodies to intercellular
substance of the epidermis. This
antibody strongly suggests the
diagnosis of pemphigus (all forms),
although it may be rarely present in
burn patients & trichophyton infections.
The rise and fall of the titer may be
indicative of relapse & remission of
the disease respectively.
2) Antibody to the dermal-epidermal
basement membrane. This antibody is
highly specific for bullous pemphigoid
and is present in 80% of these patients. |
| EPSTEIN BARR VIRUS ANTIBODY PANEL | EBPANL | EBPANL | CLIA | EBV Capsid Ab, IgG U/mL
Negative LT 18.0 No significant level of
IgG Ab detected.
Equivocal 18.0-21.9 Repeat testing of a sample
in 10-14 days may be helpful
in determing presence or absence
of infection.
Positive 22.0 or greater IgG antibody detected.
May indicate a recent or past
infection.Negative LT 18.0
EBV Capsid Ab, IgM U/mL
Negative LT 36.0
EBV Nuclear Ab U/mL
Negative LT 18.0
EBV Early Ab
Negative LT 9.0
Interpretation |
| EPSTEIN BARR VIRUS ANTIBODY TO EARLY ANTIGEN, DIFFUSE IGG | EBVEAL | EBVEAL | CLIA | EBV, Early AG, IgG Negative LT 9.0 No significant U/mL
level of EBV EA-D IgG Abs
detected.
Equivocal 9.0-10.9 Repeat testing of
second sample in 10-14 days
may be helpful to determine
presence or absence of
infection.
Positive 11.0 or greater. EBV EA-D IgG
Antibody detected. |
| EPSTEIN BARR VIRUS ANTIBODY TO NUCLEAR ANTIGEN, IGG | EBVNAL | EBVNAL | CLIA | EBV, Nuclear Ab, IgG U/mL
Negative LT 18.0 No significant level of
EBVA IgG Abs detected.
A negative result generally
excludes past EBV infection.
If exposure to EBV is suspected
a second sample should be collected
and tested in 7-10 days.
Equivocal 18.0-21.9 Repeat testing of a
second sample in 10-14 days may be
helpful to determine presence or
absence of infection.
Positive 22.0 or greater EBNA IgG Abs detected.
A positive result is indicative of past
infection. |
| EPSTEIN BARR VIRUS ANTIBODY TO VIRAL CAPSID ANTIGEN, IGG | EBVGL | EBVGL | CLIA | EBV Ab to Viral Capsid Antigen, IgG U/mL
Negative LT 18.0 No significant level of
IgG Ab detected.
Equivocal 18.0-21.9 Repeat testing of a sample
in 10-14 days may be helpful
in determing presence or absence
of infection.
Positive 22.0 or greater IgG antibody detected.
May indicate a recent or past
infection. |
| EPSTEIN BARR VIRUS ANTIBODY TO VIRAL CAPSID ANTIGEN, IGG & IGM | EBVGML | EBVGML | CLIA | Epstein Barr Virus Ab to Viral Capsid U/mL
Antigen, IgG
Negative LT 18.0 No significant level of
IgG Ab detected.
Equivocal 18.0-21.9 Repeat testing of a sample
in 10-14 days may be helpful
in determing presence or absence
of infection.
Positive 22.0 or greater IgG antibody detected.
May indicate a recent or past
infection.
Epstein Barr Virus Ab to Viral Capsid U/mL
Antigen, IgM Negative LT 36.0 |
| EPSTEIN BARR VIRUS ANTIBODY TO VIRAL CAPSID ANTIGEN, IGM | EBVML | EBVML | CLIA | EBV Capsid Ab, IgM U/mL ISR
LT 36.0 Negative No detectable IgM Abs. If
exposure to EBV is suspected,
a second sample should be
collected and tested in 7-14
days.
36.0-43.9 Equivocal Repeat testing in 10-14 days
may be helpful to determine
absence or presence of
infection.
44.0 or greater Positive IgM antibody detected. Specific
IgM Abs are usually found in
patients with recent primary
infection, but may also be
found in patients with re-
activated infection.
Suggestive of current
or recent infection. |
| EPSTEIN BARR VIRUS BY PCR | EBVPCR | EBVPCR | PCR | Epstein Barr Virus by PCR
Negative-EBV DNA not detected by PCR.
Positive-EBV DNA detected by PCR.
This test is performed pursuant to an
agreement with Roche Molecular Systems,
Inc. |
| EPSTEIN BARR VIRUS, QUANTITATIVE PCR, WHOLE BLOOD | EBVQWB | EBVQWB | Polymerase Chain Reaction | EBV Quant Source
EBV QuantLOG LT 2.6 LOG
The quantitative range of this
assay is 2.6-7.6 log copies/mL
(390-39,000,000 copies/mL).
A negative result (LT 2.6 log
copies/mL or less than 390 copies
/mL) does not rule out the
presence of PCR inhibitors in
the patient specimen or EBV DNA
nucleic acid in concentrations
below the level of detection of
the assay. Inhibition may also
lead to underestimation of viral
quantitation. No international
standard is currently available
for calibration of this assay.
Caution should be taken when
interpreting results generated by
different assy methodologies.
EBV DNA, Quant Not Detected
Interp
Analyte specific reagents (ASR)
are used in many laboratory tests
necessary for standard medical care
and generally do not require U.S.
Food & Drug Administration approval.
This test was developed and its
performance characteristics determined
by ARUP Lab, Inc. It has not been
approved or cleared by the U.S. Food
& Drug Administration. This test
should not be regarded as investigational
or for research use. This test is
performed pursuant to an agreement
with Roche Molecular Systems, Inc.
EBV Quant DNA copies/mL
copies/mL |
| EPSTEIN BARR VIRUS, QUANTITATIVE PCR | EBVQNT | EBVQNT | Polymerase Chain Reaction | EBV Quant Source
EBV QuantLOG LT 2.6 LOG
The quantitative range of this
assay is 2.6-7.6 log copies/mL
(390-39,000,000 copies/mL).
A negative result (LT 2.6 log
copies/mL or less than 390 copies
/mL) does not rule out the
presence of PCR inhibitors in
the patient specimen or EBV DNA
nucleic acid in concentrations
below the level of detection of
the assay. Inhibition may also
lead to underestimation of viral
quantitation. No international
standard is currently available
for calibration of this assay.
Caution should be taken when
interpreting results generated by
different assy methodologies.
EBV DNA, Quant Not Detected
Interp
Analyte specific reagents (ASR)
are used in many laboratory tests
necessary for standard medical care
and generally do not require U.S.
Food & Drug Administration approval.
This test was developed and its
performance characteristics determined
by ARUP Lab, Inc. It has not been
approved or cleared by the U.S. Food
& Drug Administration. This test
should not be regarded as investigational
or for research use. This test is
performed pursuant to an agreement
with Roche Molecular Systems, Inc.
EBV Quant DNA copies/mL
copies/mL |
| ERYTHROPOIETIN | ERY | ERTH | ICMA | Erythropoietin 3.5-24.0 mIU/mL
The erythropoietin reference range is
based on data from healthy adults with
normal hematocrit values. |
| ESCITALOPRAM | ESCI | ESCI | GC | Escitalopram Steady state peak plasma levels for ng/mL
patients on regimen of 10 or 30 mg/day:
21 and 64 ng/mL respectively, and occur at
approximately 4 hours post dose. This test
is not chiral specific. Patients who have
taken racemic Citalopram (Celexa), as opposed to
Escitalopram (Lexapro), within the past 3 days may
have falsely elevated values. |
| ESTERASE STAIN, ACETATE | SS.NSE | CSAE | Cytochemical Stain | Esterase Stain, Acetate
Source
Stain Negative
Interp
Reviewed by |
| ESTERASE STAIN, COMBINED | SS.CE | CSCE | Cytochemical Stain | Esterase Stain, Combined
Source
Stain Negative
Interp
Reviewed by |
| ESTERASE, STAIN, CHLOROACETATE | SS.SE | CSCAE | Cytochemical Stain | Esterase Stain, Chloroacetate
Source
Stain Negative
Interp
Reviewed by |
| ESTRADIOL | ESTRADIOL | EDIOL | ICMA | Estradiol pg/mL
M 0-56
F Follicular 0-160
Mid-follicular 0-84
Late-follicular 34-400
Luteal 27-246
Post-menopausal 0-35
Post-menopausal 0-93
treated
This method may be used for patients
taking hormone replacement therapy. |
| ESTRADIOL BY LC-MS/MS | ESTMCP | ESTMCP | LC/TMS | Estradiol by TMS pg/mL
Tanner Stages
I Male LT 8
II Male LT 10
III Male 1-35
IV AND V Male 3-35
I Female LT 56
II Female 2-133
III Female 12-277
IV and V Female 2-259
Male 7-9 yrs LT 7
Male 10-12 yrs LT 11
Male 13-15 yrs 1-36
Male 16-17 yrs 3-34
Male 18+ yrs 10-42
Female 7-9 yrs LT 36
Female 10-12 yrs 1-87
Female 13-15 yrs 9-249
Female 16-17 yrs 2-266
Female 18+ yrs Pre-menopausal
Early Follicular 30-100
Late Follicular 100-400
Luteal 50-150
Post-Menopausal 2-21
|
| ESTRIOL, UNCONJUGATED | ESTRIOL | ESTFR | Immunometric | Estriol, Unconjugated ng/mL
Patient variation is considerable. Serial
sampling is most valuable. 35-50% day to day
decrease is significant and may suggest fetal
distress. |
| ESTROGENS, FRACTIONATED | ESTF | ESTF | ICMA/RIA/Calculation | Estrone pg/mL
Male LT 80
Female Early follicular 0-150
Late follicular 100-250
Luteal 0-200
Post-menopausal 15-103
Estradiol pg/mL
Male 0-56
Female Early follicular 0-160
Late follicular 34-400
Luteal 27-246
Post-menopausal 0-35
Estrogens, Total pg/mL
Male LT 136
Female Early follicular 0-310
Late follicular 134-650
Luteal 27-446
Post-menopausal 15-138 |
| ESTRONE | ESTN | ESTN | RIA | Estrone pg/mL
Male LT 80
Female Early follicular 0-150
Late follicular 100-250
Luteal 0-200
Post-menopausal 15-103 |
| ETHOSUXIMIDE | ETHO | ETHO | EIA | Ethosuximide ug/mL
Therapeutic 40-100
Toxic GT 150 |
| ETHOTOIN | ETHOTOIN | ETHOT | GC | Ethotoin (Peganone) ug/mL
Therapeutic 5-50
Toxic GT 55 |
| ETHYL GLUCURONIDE, URINE | ETGU | ETGU | EIA | Ethyl Glucuronide, Urine Negative ng/mL |
| ETHYL GLUCURONIDE/ETHYL SULFATE BY LC-MS/MS | ETGA | ETGA | LC-MS/MS | ETG positive cutoff 250 ng/mL
ETS positive cutoff 150 ng/mL |
| EUGLOBULIN LYSIS | EUGLO | EUGLYS | Clot Lysis | Euglobulin Lysis, Patient GT 2.0 h
Euglobulin Lysis, Control h |
| EXTRACTABLE NUCLEAR AUTOANTIBODIES | ENAMP | ENAMP | Multiplex luminex | SM Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
RNP Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
SMRNP Autoantibody Negative LT 1.0 AI
Positive 1.0 or more |
| FACTOR 10 INHIBITORS, QUANTITATIVE (REFLEXIVE) | F10INH | F10INH | Electromechanical | Protime, Patient sec
0-1 mon 13.0-20.0
2+ mon 10.9-14.8
Protime, Population Mean 13.4 sec
13.7
PTT sec
0-1 mon 40-50
2 mon-4 yrs 25-40
5+ mon 26-31
PTT, Population Mean 31 sec
Deep venous thrombosis or pulmonary
embolism therapeutic heparin levels
of 0.3-0.7 Units/mL anti-factor Xa
levels usually correspond to an aPTT
of 60-85 seconds. Acute cardiac
syndrome therapeutic range based on
heparin levels of 0.2 to 0.5 ususally
correspond to an aPTT of 55-77 seconds.
Protime 1/1 Mix sec
PT Control Plasma sec
PTT 1/1 Mix sec
PTT Control Plasma sec
Factor X 45-155 %
Factor 10 Inhibitors Negative Inhibitor Units |
| FACTOR 11 INHIBITORS, QUANTITATIVE (REFLEXIVE) | F11INH | F11INH | Electromechanical | Protime, Patient sec
0-1 mon 13.0-20.0
2+ mon 10.9-14.8
Protime, Population Mean 13.4 sec
13.7
PTT sec
0-1 mon 40-50
2 mon-4 yrs 25-40
5+ mon 26-31
PTT, Population Mean 31 sec
Deep venous thrombosis or pulmonary
embolism therapeutic heparin levels
of 0.3-0.7 Units/mL anti-factor Xa
levels usually correspond to an aPTT
of 60-85 seconds. Acute cardiac
syndrome therapeutic range based on
heparin levels of 0.2 to 0.5 ususally
correspond to an aPTT of 55-77 seconds.
Protime 1/1 Mix sec
PT Control Plasma sec
PTT 1/1 Mix sec
PTT Control Plasma sec
Factor XI 65-135 %
Factor 11 Inhibitors Negative Inhibitor Units |
| FACTOR 12 INHIBITORS, QUANTITATIVE (REFLEXIVE) | F12INH | F12INH | Electromechanical | Protime, Patient sec
0-1 mon 13.0-20.0
2+ mon 10.9-14.8
Protime, Population Mean 13.4 sec
13.7
PTT sec
0-1 mon 40-50
2 mon-4 yrs 25-40
5+ mon 26-31
PTT, Population Mean 31 sec
Deep venous thrombosis or pulmonary
embolism therapeutic heparin levels
of 0.3-0.7 Units/mL anti-factor Xa
levels usually correspond to an aPTT
of 60-85 seconds. Acute cardiac
syndrome therapeutic range based on
heparin levels of 0.2 to 0.5 ususally
correspond to an aPTT of 55-77 seconds.
Protime 1/1 Mix sec
PT Control Plasma sec
PTT 1/1 Mix sec
PTT Control Plasma sec
Factor XII 50-150 %
Factor 12 Inhibitors Negative Inhibitor Units |
| FACTOR 2 INHIBITORS, QUANTITATIVE (REFLEXIVE) | F02INH | F02INH | Electromechanical | Protime, Patient sec
0-1 mon 13.0-20.0
2+ mon 10.9-14.8
Protime, Population Mean sec
13.4
PTT sec
0-1 mon 40-50
2 mon-4 yrs 25-40
5+ mon 26-31
PTT, Population Mean 31 sec
Deep venous thrombosis or pulmonary
embolism therapeutic heparin levels
of 0.3-0.7 Units/mL anti-factor Xa
levels usually correspond to an aPTT
of 60-85 seconds. Acute cardiac
syndrome therapeutic range based on
heparin levels of 0.2 to 0.5 ususally
correspond to an aPTT of 55-77 seconds.
Protime 1/1 Mix sec
PT Control Plasma sec
PTT 1/1 Mix sec
PTT Control Plasma sec
Factor II 80-117 %
Factor 2 Inhibitors Negative Inhibitor Units |
| FACTOR 5 INHIBITORS, QUANTITATIVE (REFLEXIVE) | F05INH | F05INH | Electromechanical | Protime, Patient sec
0-1 mon 13.0-20.0
2+ mon 10.9-14.8
Protime, Population Mean 13.4 sec
13.7
PTT sec
0-1 mon 40-50
2 mon-4 yrs 25-40
5+ mon 26-31
PTT, Population Mean 31 sec
Deep venous thrombosis or pulmonary
embolism therapeutic heparin levels
of 0.3-0.7 Units/mL anti-factor Xa
levels usually correspond to an aPTT
of 60-85 seconds. Acute cardiac
syndrome therapeutic range based on
heparin levels of 0.2 to 0.5 ususally
correspond to an aPTT of 55-77 seconds.
Protime 1/1 Mix sec
PT Control Plasma sec
PTT 1/1 Mix sec
PTT Control Plasma sec
Factor V 50-150 %
Factor 5 Inhibitors Negative Inhibitor Units |
| FACTOR 7 INHIBITORS, QUANTITATIVE (REFLEXIVE) | F07INH | F07INH | Electromechanical | Protime, Patient sec
0-1 mon 13.0-20.0
2+ mon 10.9-14.8
Protime, Population Mean 13.4 sec
13.7
PTT sec
0-1 mon 40-50
2 mon-4 yrs 25-40
5+ mon 26-31
PTT, Population Mean 31 sec
Deep venous thrombosis or pulmonary
embolism therapeutic heparin levels
of 0.3-0.7 Units/mL anti-factor Xa
levels usually correspond to an aPTT
of 60-85 seconds. Acute cardiac
syndrome therapeutic range based on
heparin levels of 0.2 to 0.5 ususally
correspond to an aPTT of 55-77 seconds.
Protime 1/1 Mix sec
PT Control Plasma sec
PTT 1/1 Mix sec
PTT Control Plasma 65-135 %
Factor 7 Inhibitors Negative Inhibitor Units |
| FACTOR 9 INHIBITORS, QUANTITATIVE (REFLEXIVE) | F09INH | F09INH | Electromechanical | Protime, Patient sec
0-1 mon 13.0-20.0
2+ mon 10.9-14.8
Protime, Population Mean 13.4 sec
13.7
PTT sec
0-1 mon 40-50
2 mon-4 yrs 25-40
5+ mon 26-31
PTT, Population Mean 31 sec
Deep venous thrombosis or pulmonary
embolism therapeutic heparin levels
of 0.3-0.7 Units/mL anti-factor Xa
levels usually correspond to an aPTT
of 60-85 seconds. Acute cardiac
syndrome therapeutic range based on
heparin levels of 0.2 to 0.5 ususally
correspond to an aPTT of 55-77 seconds.
Protime 1/1 Mix sec
PT Control Plasma sec
PTT 1/1 Mix sec
PTT Control Plasma sec
Factor IX 60-140 %
Factor 9 Inhibitors Negative Inhibitor Units |
| FACTOR II | FAC2 | F02ACT | Electromechanical | Factor II 80-117 % |
| FACTOR IX | FAC9 | F09ACT | Electromechanical | Factor IX 60-140 % |
| FACTOR V | FAC5 | F05ACT | Electromechanical | Factor V 50-150 % |
| FACTOR V LEIDEN MUTATION | FVMUT | FVLMUT | PCR | Factor V Leiden, Method
Factor V Leiden, Result
Factor V Leiden, Interpretation
Factor V Leiden, Comment
Factor V Leiden, Comment
This test is FDA approved and is
intended for in vitro diagnostic use.
This test is performed pursuant to an
agreement with Roche Molecular Systems.
This test is performed by real-
time PCR using the Roche LightCycler
instrument. The product of PCR is
detected by fluorescence produced when
a specific pair of probes, each labeled
with a fluorophore, binds to the PCR
product in close proximity. |
| FACTOR VII | FAC7 | F07ACT | Electromechanical | Factor VII 65-135 % |
| FACTOR VIII (COAGULANT ACTIVITY) | FAC8AS | F08ACT | Electromechanical | Factor VIII Coagulant Activity 55-150 % |
| FACTOR VIII INHIBITOR (QUANTITATIVE) | FAC8.INH | F08INH | Electromechanical | Factor VIII Inhibitor Negative Bethseda Units |
| FACTOR X | FAC10 | F10ACT | Electromechanical | Factor X 45-155 % |
| FACTOR XI | FAC11 | F11ACT | Electromechanical | Factor XI 65-135 % |
| FACTOR XII | FAC12 | F12ACT | Electromechanical | Factor XII 50-150 % |
| FACTOR XIII | FAC13 | F13 | Urea Solubility | Factor XIII No clot dissolution |
| FAT STAIN (OIL RED O) | FAT.ST | OROSTN | Cytochemical Stain | Source
Fat Stain Interpretation
Fat Stain Reviewed by |
| FAT, FECAL QUANTITATIVE | FATQNT | FATQNT | Nuclear Magnetic Resonance Spectrometry | Collection Period hr
Fecal Total Weight g
Fecal Fats
0-5 yrs 0.0-2.0 g/24h
6 yrs & more 0.0-6.0 |
| FAT, STOOL | STL-FAT | FAT | Microscopic | Source
Fat, Stool Negative
Fat, Stool, Status |
| FATTY ACID PROFILE, PEROXISOMAL | FATTYA | FATTYA | GC/MS Stable isotope | C22:0 96.3 or less umol/L
C24:0 91.4 or less umol/L
C26:0 1.30 or less umol/L
C24:0/C22:0 1.39 or less Ratio
C26:0/C22:0 0.023 or less Ratio
Pristanic Acid umol/L
0-4 mo 0.60 or less
5-8 mo 0.84 or less
9-12 mo 0.77 or less
13-24 mo 1.47 or less
GT 24 mo 2.98 or less
Phytanic Acid umol/L
0-4 mo 5.28 or less
5-8 mo 5.70 or less
9-12 mo 4.40 or less
13-24 mo 8.62 or less
GT 24 mo 9.88 or less
Pristanic Acid/Phytanic Acid Ratio Ratio
0-4 mo 0.35 or less
5-8 mo 0.28 or less
9-12 mo 0.23 or less
13-24 mo 0.24 or less
GT 24 mo 0.39 or less |
| FATTY ACIDS PROFILE, ESSENTIAL | FAP | FAP | GC/MS Stable isotope dilution | Fatty Acids Profile Essential
Separate Report to Follow |
| FATTY ACIDS, FREE | FATTY | FATTYF | Spectrophotometry | Free Fatty Acids mmol/L
0-30 days 0.43-1.37
1 mo-10 yrs 0.50-0.90
11+ yrs 0.10-0.60 |
| FECAL IMMUNOCHEMICAL TEST (FIT) FOR OCCULT BLOOD | IFOBT | IFOBT | Immunoassay | Fecal Occult Blood by FIT Negative |
| FECAL LEUKOCYTE STAIN | FEC-LEUK | FL | Gram Stain/Methylene Blue | Source
Fecal Leukocyte Stain Negative
Fecal Leukocyte Stain, Status |
| FELBAMATE | FELBAMATE | FELB | HPLC | Felbamate ug/mL
Not well established
The proposed therapeutic range for
seizure control is 30-60 ug/mL.
Parmacokinetics varies widely,
particularly with co-medication,
age and/or compromised renal
function. No critical value has
been defined. |
| FENTANYL AND NORFENTANYL IN URINE BY LC/MS/MS | FENTU | FENTU | Liquid Chromatography Tandom Mass Spectrometry LC/MS/MS | Positive cutoffs Fentanyl 5.0 ng/ml Norfentanyl 10 ng/ml. |
| FERRITIN | FERR | FERR | ICMA | Ferritin M 20-350 ng/mL
F 6-250 |
| FETAL FIBRONECTIN | FFN | FFN | Solid Phase Immunosorbent Assay | Fetal Fibronectin Negative |
| FETAL HEMOGLOBIN F | FETALF | FETALF | Flow Cytometry | Source
Fetal Hemoglobin F 0.00-0.10 % |
| FIBRIN MONOMER | FIB.MONOMER | FIBMON | Protamine Paracoagulant Precipitant | Fibrin Monomer Negative |
| FIBRINOGEN | XFIB | XFIB | Electromechanical | Fibrinogen 211-419 mg/dL
Abnormalities of fibrinogen function may
result in low reported levels.
Additional testing, including thrombin
times, may be useful in interpreting
low fribrinogen levels. |
| FIBRINOGEN REFLEX TO THROMBIN TIME | QFIB | QFIB | Electromechanical | Fibrinogen 211-419 mg/dL
Thrombin Time Patient 15.6-20.0 sec
Thrombin Time Control 15.6-20.0 sec
Thrombin Time PT/CT Mix sec
Thrombin Time PT/PSO4 Mix sec |
| FIBRINOLYSIS | FIBLYS | FIBLYS | Plasma Clot Lysis | Fibrinolysis Negative in 8 hours |
| FIBRONECTIN AGGREGATES, IGA | FIBRON | FIBRON | ELISA, Nephelometry | IgA mg/dL
Cord Blood 0
1-3 mo 0-19
4-6 mo 2-35
7-14 mo 10-50
15-35 mo 17-70
3-12 yrs 23-208
13+ yrs 70-407
Fibronectin Aggregates IgA EIA Units
LT 3.0
Interpretive Criteria
LT 3.0 Aggregates not detected
3.0 or more Aggregates detected
Aggregates consisting of IgA complexed
fibronectin are found in sera of most
patients with Henoch Schonlein purpura.
Detection of these aggregate is based
on their specific attachment to a
fragment of type I collagen. |
| FISH ANIRIDIA | FIPAX6 | | FISH | FISH, Aniridia
Separate Report to Follow |
| FISH FOR HER2 GENE AMPLIFICATION | FISHER | | In situ hybridization | FISH HER-2/NEU
Separate Report to Follow |
| FK 506 | FK506 | FK506 | CMIA | FK 506 ng/mL
No established reference range.
Therapeutic range for Tacrolimus
not clearly defined. Target 12 hr
trough whole blood concentrations
are 5 to 20 ng/mL early post
transplant. Higher concentrations
show an increased incidence of
adverse effects. |
| FLECAINIDE | FLEC | FLEC | HPLC | Flecainide 0.20-1.00 ug/mL
Toxic GT 1.50 |
| FLEXERIL | FLEXERIL | FLEX | GC | Flexeril Therapeutic 3-36 ng/mL
Daily regimen of 30 mg |
| FLU A, FLU B, and RSV by PCR | RESPCR | RESPCR | Real-Time PCR | Influenza A Not Detected
Influenza B Not Detected
Respiratory Synctial Virus Not Detected
A result of Not Detected does not rule out the possibility of influenza or RSV infection and
should not be used as the sole basis for treatment or management decisions. |
| FLUNITRAZEPAM & METABOLITE URINE (REFLEX) | FLUNCO | FLUNCO | HPLC, LC-MS/MS | Flunitrazepam, Urine ng/mL
Norflunitrazepam, Urine ng/mL
7-Amino Flunitrazepam, Urine ng/mL
In urine approximately 10% of an oral
dose is excreted as 7-Amino Flunitrzaepam
Flunitrazepam, Urine Confirmation ng/mL
Norflunitrazepam, Urine, Confirmation ng/mL
7-Amino Flunitrazepam Urine Confirmation ng/mL |
| FLUORESCENT PARASITE SMEAR | CRYSM | CRYSM | Concentration/Mod. Acid Fast Stain | Fluorescent Parasite Smear Negative
Report Status |
| FLUORESCENT POLARIZATION, AMNIOTIC FLUID | FL.POLAR | FPOLAF | Fluorescence Polarization | Fluorescence Polarization mPOL
Mature 260 or less
Transitional 261-289
Immature 290 or more |
| FLUORESCENT TREPONEMAL ANTIBODY (REFLEXIVE) | FTA.ARUP | FTA | IFA | FTA, Serum, IgG Nonreactive |
| FLUORIDE | FLUORIDE | FLUOR | Ion Chromatography | Fluoride LT 0.2 mg/L |
| FLUORIDE, URINE | FLUOR.EXP.U | FLUUR | ISE/Colorimetric | Creatinine, Urine mg/L
Adults 300-3400 mg/L (mean 1000)
0.3-3.4 g/L (mean 1 g/L)
1000-1600 mg/day
1.0-1.6 g/day
Fluoride, Urine Normal 0.2-3.2 mg/L
Fluoride, Urine mg/gCr
Biological exposure index (ACGIH)
Prior to shift 3
End of shift 10 |
| FLUOXETINE & NORFLUOXETINE | FLUOX | FLUOX | HPLC | Fluoxetine 50-480 ng/mL
Norfluoxetine 50-450 ng/mL
Dose related ranges are based on
20-60 mg doses. |
| FLUPHENAZINE | FLUPHENAZINE | FLUPH | HPLC | Fluphenazine ng/mL
Therapeutic 0.2-2.0
A dosage reduction should be
considered with levels GT 2.8. |
| FLURAZEPAM | DALMANE-Q | FLURAZ | GC | Flurazepam ug/mL
N-Desalkyflurazepam 0.01-0.14
Toxic GT 0.30
Based on normal dosages. |
| FLUVOXAMINE | LUVOX | LUVOX | GC | Fluvoxamine ng/mL
78-920 (mean of 510) Steady state level
following a daily regimen of 150-300 mg/day. |
| FOLATE | FOLATE | FOL | ICMA | Folate ng/mL
Deficient 0.4-3.4
Indeterminate 3.5-5.3
Normal 5.4-24.0 |
| FOLATE, RBC | FOL-R | RBCFOL | ICMA | Folate, RBC ng/mL
Deficient 0-144
Indeterminate 145-279
Normal 280-800 |
| FOLLICLE STIMULATING HORMONE, PITUITARY | FSH | FSH | ICMA | FSH mIU/mL
M 7-9 yrs 0.3-2.3
10-12 yrs 0.5-4.4
13-15 yrs 1.0-6.7
16-17 yrs 0.8-7.0
18 yrs + 1.4-11.2
Tanner Stage I 0.3-2.6
Tanner Stage II 0.5-4.3
Tanner Stage III 0.9-5.8
Tanner Stage IV-V 0.9-7.3
F 7-9 yrs 0.4-4.0
10-12 yrs 0.6-7.5
13-15 yrs 0.9-8.2
16-17 yrs 0.4-8.9
18 yrs+
Follicular 3.2-11.3
Midcycle peak 4.2-19.4
Luteal phase 1.5-6.9
Postmenopausal 23.2-121.3
Tanner Stage I 0.5-7.6
Tanner Stage II 0.5-8.0
Tanner Stage III 0.5-8.0
Tanner Stage IV-V 0.6-8.4
|
| FONDAPARINUX | FONDAP | FOND | Anti-Xa Chromogenic | Fondaparinux mg/L
Fondaparinux levels have not been
validated for therapeutic use.
However, at 2.5 mg daily 0.2 to
0.4 mg/L are expected and at 7.5 mg
daily 0.5-1.5 mg/L are expected. |
| FOOD PANEL II IGG [IBT] | FD2IBT | FD2IBT | ImmunoCap FEIA - IGG | Barley IgG LT 6.1 mcg/mL
Barley IgG Class
Beef IgG LT 3.4
Beef IgG Class
Casein IgG LT 5.7
Casein IgG Class
Chicken IgG LT 1.9
Chicken IgG Class
Chocolate/Cacao IgG LT 26.6
Chocolate/Cacao Class
Codfish/Scrod IgG LT 2.4
Codfish/Scrod IgG Class
Corn IgG LT 2.7
Corn IgG Class
Egg White IgG LT 41.6
Egg White IgG Class
Malt IgG LT 8.6
Malt IgG Class
Oat IgG LT 2.3
Oat IgG Class
Orange IgG LT 4.2
Orange IgG Class
Peanut IgG LT 7.6
Peanut IgG Class
Pork IgG LT 5.0
Pork IgG Class
Potato White IgG LT 3.0
Potato White IgG Class
Rye Food IgG LT 5.7
Rye Food IgG Class
Soybean IgG LT 3.8
Soybean IgG Class
Tomato IgG LT 3.9
Tomato IgG Class
Wheat IgG LT 15.1
Wheat IgG Class
Yeast (Saccharomyces cerevisiae) IgG LT 5.5
Yeast (Saccharomyces cerevisiae) IgG Class |
| FORMIC ACID | FORM | FA | IC | Formic Acid 0-12 mcg/mL |
| FORMIC ACID, URINE | FORM-U | FAUQ | Gas Chromatography | Collection Period h
Volume mLs
Creatinine, Urine
ACGIH normal range in adults mg/L
300-3400 mg/L (mean 1000 mg/L)
0.3-3.4 g/L (mean 1 g/L)
1000-1600 mg/day (1.0-1.6 g/day)
Formic Acid, Urine 5-36 g/mL
Normal range for 95% of population
Formic Acid, Urine
Occupational exposure threshold mg/gCr
following exposure to methanol:
80 mg formic acid/g creatinine
collected before the shift at the
end of the workweek. |
| FRAGILE X SYNDROME ANALYSIS | REF.FRAGX | FRAGX | | Fragile X Mutation Analysis |
| FRANCISELLA TULARENSIS ANTIBODY | FTULAB | FTULAB | Direct Agglutination | Francisella tularensis Ab Titer
LT 1:20 |
| FREE LIGHT CHAINS GAMMOPATHY DIAGNOSTIC PANEL | GAMPAN | GAMPAN | Nephelometry/Agarose Gel ELP, IFE | Kappa FLC 0.33-1.94 mg/dL
Lambda FLC 0.57-2.63
Kappa/Lambda 0.26-1.65
FLC Ratio Results obtained by using The
Binding Site reagents on a Beckman
Coulter Immage 800 analyzer.
Protein, Total g/dL
0-12 mo 4.3-6.9
1-3 yrs 5.2-7.4
3-6 yrs 5.6-7.7
6-10 yrs 6.5-8.3
10-18 yrs 6.1-8.0
18-60 yrs 6.3-8.0
60 yrs+ 6.1-7.8
Albumin 0-4 days 2.9-4.6 g/dL
4 days-14 yrs 3.9-5.6
14-18 yrs 3.3-4.7
18-60 yrs 3.5-5.0
60-90 yrs 3.3-4.8
90 yrs+ 3.0-4.7
Alpha-1 0.1-0.4 g/dL
Alpha-2 0.5-1.1 g/dL
Beta-1 0.4-0.8 g/dL
Beta-2 0.2-0.5 g/dL
Gamma 0.6-1.5 g/dL
Albumin 45.0-80.0 %
Alpha-1 1.0-6.0 %
Alpha-2 6.0-17.0 %
Beta-1 5.0-13.0 %
Beta-2 2.0-8.0 %
Gamma 7.5-24.0 %
Interpretation
Monoclonal Peak
Immunofixation Interpretation |
| FREE T-3 | FT3 | FT3 | ICMA | Free T3 2.3-4.2 pg/mL |
| FREE T-4 | FREE T4 | FT4 | ICMA | Free T4 ng/dL
Birth-7 days 1.4-3.3
8 days-1 month 0.6-2.5
1-12 months 0.7-1.4
12 mon-18 yrs 0.6-1.2
18 yrs+ 0.7-1.5 |
| FREE THYROXINE (T4) [UW] | T4DDUW | T4DDUW | Chemiluminescence | Thyroxine (Free) 0.6-1.2 ng/dL |
| FRUCTOSAMINE | FRUCTO | FRUCTO | Colorimetric | Fructosamine 180-280 umol/L |
| FRUCTOSE, SEMEN | FRUCTOSE | FRUC | Spectrophotometry | Fructose, Semen 91-520 mg/dL |
| FTA-ABS (MONTANA) | MONFTA | MONFTA | VDRL; VDRL , Quantitative; FTA (ABS). | VDRL
VDRL, Quantitative
FTA (ABS) |
| FUNGAL ANTIBODY PROFILE | FUNGAL SER | FUNGCF | CF | Fungal Antibody Panel
Blastomyces Ab LT 1:8 Titer
Coccidioides Ab LT 1:2 Titer
Histoplasma Mycelia Ab LT 1:8 Titer
Histoplasma Yeast Ab LT 1:8 Titer
Aspergillus Ab LT 1:8 Titer |
| FUROSEMIDE, (QUANTITATIVE) | FURUQ | FURUQ | HPLC | Furosemide mcg/mL
Up to 40 mcg/mL following a single
oral dose of 40 mg. |
| GABAPENTIN | GABAP | GABAP | HPLC | Gabapentin ug/mL
Not well established
The proposed therapeutic range for
seizure control is 2-10 ug/mL.
Concentrations that exceed 25 ug/mL
may contribute to adverse effects.
Pharmacokinetics of gabapentin varies
widely among patients, particularly
those with compromised renal function. |
| GALACTOSE, URINE | GAL-U | GALUR | Enzymatic | Galactose, Urine LT 30 mg/dL |
| GAMMA GLUTAMYL TRANSFERASE | GGT | GGT | Colorimetric | GGT U/L
0-2 days 19-270
3-5 days 13-198
6-10 days 0-130
11 days-4 mo 4-120
5 -12 mo 5-65
13 mo-16 yrs 0-23
17-19 yrs 0-35
20+yrs 5-65 |
| GANGLIOSIDE ASIALO GM1, GM2, GD1, GQ1 | GM1COM | GM1COM | ELISA | Asialo GM1 IV
Ganglioside GM1 Ab IgG/IgM IV
Ganglioside GM2 Ab IgG/IgM IV
Ganglioside GD1a Ab IgG/IgM IV
Ganglioside GD1b Ab IgG/IgM IV
Ganglioside GQ1b Ab IgG/IgM
29 or less Negative
30-50 Weak Positive
51-150 Positive
151 or more Strong Positive |
| GASTRIN | GAS | GAST | ICMA | Gastrin 13-115 pg/mL |
| GASTRIN, SAMPLE 1 | GAS.S1 | GAST1 | ICMA | Gastrin, #1 pg/mL
Gastrin, Time 1 |
| GASTRIN, SAMPLE 2 | GAS.S2 | GAST2 | ICMA | Gastrin, #2 pg/mL
Gastrin, Time 2 |
| GASTRIN, SAMPLE 3 | GAS.S3 | GAST3 | ICMA | Gastrin, #3 pg/mL
Gastrin, Time 3 |
| GASTRIN, SAMPLE 4 | GAS.S4 | GAST4 | ICMA | Gastrin, #4 pg/mL
Gastrin, Time 4 |
| GASTRIN, SAMPLE 5 | GAS.S5 | GAST5 | ICMA | Gastrin, #5 pg/mL
Gastrin, Time 5 |
| GASTRIN, SAMPLE 6 | GAS.S6 | GAST6 | ICMA | Gastrin, #6 pg/mL
Gastrin, Time 6 |
| GASTRIN, SAMPLE 7 | GAS.S7 | GAST7 | ICMA | Gastrin, #7 pg/mL
Gastrin, Time 7 |
| GASTRIN, SAMPLE 8 | GAS.S8 | GAST8 | ICMA | Gastrin, #8 pg/mL
Gastrin, Time 8 |
| GENERAL HEALTH | GHPNA | GHPNA | | Comprehensive Metabolic Panel
CBC
TSH |
| GENERAL HEALTH PANEL (REFLEXIVE) | GHPNAR | GHPNAR | | Comprehensive Metabolic Panel
CBC
TSH (Reflex) |
| GENOMIC DNA ISOLATION & STORAGE | DNAISO | DNAISO | | Genomic DNA Concentration ng/uL
Date Completed
Comment |
| GENTAMICIN (PAIRED) | GENT2 | GENTIN | Immunoturbidimetric, Colorimetric | Gentamicin, Trough ug/mL
1.0-2.0
Toxic GT 2.0
Gentamicin Time, Trough h
Gentamicin, Peak ug/mL
5.0-10.0
Toxic GT 12.0
Gentamicin Time, Peak h
|
| GENTAMICIN (SINGLE) | GENT | GENR | Immunoturbidimetric, Colorimetric | Gentamicin ug/mL
Trough 1.0-2.0
Toxic GT 2.0
Peak 5.0-10.0
Toxic GT 12.0
|
| GENTAMICIN, PEAK | GENT.PK | GENPK | Immunoturbidimetric, Colorimetric | Gentamicin, Time of last dose
Gentamicin, Peak 5.0-10.0 ug/mL
Toxic GT 12.0
|
| GENTAMICIN, TROUGH | GENT.TR | GENTR | Immunoturbidimetric, Colorimetric | Gentamicin, Trough 1.0-2.0 ug/mL
Toxic GT 2.0
|
| GIARDIA ANTIBODY, IGG, IGA & IGM | GIAAGM | GIAAGM | IFA | Giardia lamblia Ab, IgG LT 1:16
Giardia lamblia Ab, IgA LT 1:16
Giardia lamblia Ab, IgM LT 1:20
Interpretation
Recent or current infection by Giardia
lamblia is suggested by either
detection of IgM Ab or a four-fold
increase in IgG and/or IgA Ab titers
between acute & convalescent sera.
Positive IgG and/or IgA titers without
detectable IgM suggest past infection. |
| GIARDIA LAMBLIA ANTIGEN | GIARDIA.AG | GIAAG | ELISA | Source
Giardia Lamblia Ag Negative
Giardia Lamblia Ag, Status |
| GLIPIZIDE | GLIPI | GLIPI | HPLC | Glipizide ng/mL
Peak serum level following a single oral 5 mg
dose: 0.1-.05 at 1.6 hours post dose. Plasma
insulin concentrations were shown to increase
only when the plasma Glipizide concentrations
exceeded 0.2 ng/mL |
| GLOMERULAR BASEMENT MEMBRANE ANTIBODY | GLBMAB | GLBMAB | ELISA | Glomerular Basement Membrane Ab Units
0-20 Negative
21-30 Weak Positive
GT 30 Moderate-Strong Positive
This test is designed for the in-vitro
measurement of specific IgG auto-
antibodies against the glomerular
basement membrane (GBM). It is intended
as an aid in the diagnosis of Good-
pasture's syndrome. Some patients with
other renal diseases may exhibit
positive results. Glomerular Basement
Membrane antibodies are not found in
normal healthy individuals.
Results were obtained with the QUANTA
Lite GBM ELISA assay.
Values obtained from different
manufacturers' assays cannot be used
interchangeably. The magnitude of the
reported IgG levels cannot be correlated
to an endpoint titer. |
| GLOMERULAR FILTRATION PROFILE | GFP24 | GFP | Enzymatic (IDMS Traceable), Colorimetric, Calculation | Height in
Weight lbs
Collection Period h
Volume mL
Creatinine mg/dL
M 0.50-1.30
F 0.40-1.00
Creatinine, Urine g/24h
M 0.8-2.0
F 0.6-1.8
Protein, Urine mg/24h
50-80 at rest
LT 250 following intense exercise
Protein/Creatinine Ratio Ratio
LT 0.2
Creatinine Clearance mL/min
0-39 yrs M 97-137 F 88-128
40-49 yrs M 91-131 F 82-122
50-59 yrs M 85-125 F 76-116
60-69 yrs M 79-119 F 70-110
70-79 yrs M 73-113 F 64-104
80+ yrs M 67-107 F 58-98 |
| GLOMERULAR FILTRATION PROFILE (12HR) | GFP.12 | GFP12 | Enzymatic (IDMS Traceable), Colorimetric, Calculation | Height in
Weight lbs
Collection Period h
Volume mL
Creatinine mg/dL
M 0.50-1.30
F 0.40-1.00
Creatinine, Urine g/12h
No normals established for 12 h
Protein, Urine mg/12h
No normals established for 12 h
Protein/Creatinine Ratio Ratio
LT 0.2
Creatinine Clearance
0-39 yrs M 97-137 F 88-128 mL/min
40-49 yrs M 91-131 F 82-122
50-59 yrs M 85-125 F 76-116
60-69 yrs M 79-119 F 70-110
70-79 yrs M 73-113 F 64-104
80+ yrs M 67-107 F 58-98 |
| GLOMERULAR FILTRATION RATE, ESTIMATED | GFR | GFR | Calculation | Glomerular Filtration Rate mL/min/1.73m2
Estimated
LT 60 Chronic kidney disease, if
found over a 3-month period.
LT 15 Kidney failure
For African Americans, multiply the
calculated GFR by 1.21. |
| GLUCAGON | GLUC | GLUG | RIA | Glucagon 40-130 ng/L |
| GLUCOSE CHALLENGE, PREGNANT (1HR) | GCT.PG | GCTPG | Hexokinase | Glucose, 1 hr (Pregnant) 50-129 mg/dL
Presumptive Gestational Diabetes Mellitus:
130 mg/dL or greater (identifies 90%
of patients with GDM)
140 mg/dL or greater (identifies 80%
of patients with GDM)
These threshold values apply to a blood
glucose drawn 1 hour after a 50 gram
oral glucose load. An abnormal result
must be verified by either a 3-hour
(100 gram) or a 2-hour (75 gram) glucose
tolerance test for gestational diabetes. |
| GLUCOSE TOLERANCE, 2 HR | GTOL2 | GTOL2 | Hexokinase | Glucose, Fasting mg/dL
0-2 days premature 30-80
0-2 days fullterm 40-90
2 days-1 month 60-105
Adult 65-99
Glucose, 2 hr
LT 140 mg/dL Normoglycemia
140-199 mg/dL Impaired glucose tolerance
200 mg/dL or more Indicates diabetes
if confirmed on a subsequent
day.
These criteria apply to the 2 hour
(75 gram) ADA glucose tolerance
testing protocol for non-pregnant
adults. |
| GLUCOSE TOLERANCE, PREGNANT (2HR) | GTT2PG | GTT2PG | Hexokinase | Two or more or the following threshold
values must be met or exceeded to
confirm gestational diabetes:
Glucose, Fasting 95 mg/dL
Glucose, 1 hr 180 mg/dL
Glucose, 2 hr 155 mg/dL
These criteria apply to the 2-hour
(75 gram) ADA glucose tolerance
testing protocol for gestational
diabetes. |
| GLUCOSE TOLERANCE, PREGNANT (3HR) | GTT3.PG | GTPG | Hexokinase | Glucose, Pregnant
Two or more of the following threshold
values must be met or exceeded to
confirm gestational diabetes:
Fasting 95 mg/dL
1 hour 180 mg/dL
2 hour 155 mg/dL
3 hour 140 mg/dL
These criteria apply to the 3-hour
(100 gram) ADA glucose tolerance testing
protocol for gestational diabetes. |
| GLUCOSE, CSF | GLU-C | GLUSF | Enzymatic | Glucose, CSF mg/dL
0-10 yrs 60-80
GT 10 yrs 40-70 |
| GLUCOSE, FASTING OR RANDOM | GLU | GLU | Hexokinase | Glucose 0-2 d premature 30-80 mg/dL
0-2 d fullterm 40-90
2 days-1 mo 60-105
Adult 65-99
Pregnant Female 65-94
ADA Diagnostic Categories for non-
pregnant adults:
Impaired fasting glucose: 100-125
mg/dL.
A fasting glucose result of 126
mg/dL or greater indicates diabetes
if the abnormality is confirmed on
a subsequent day.
A random glucose result of GT 200
mg/dL indicates diabetes if the
abnormality is confirmed on a subsequent day. |
| GLUCOSE, FLUID | GLU-FLD | GLUFL | Enzymatic | Glucose, Fluid mg/dL
Serous Fluid equal to the serum glucose value.
Synovial Fluid LT 10 mg/dL when compared to the serum
glucose value.
Method not validated for body fluid.
Clinical correlation necessary. |
| GLUCOSE, RANDOM | GLURAN | GLURAN | Hexokinase | Ranges as they appear on report:
Glucose, Random mg/dL
0-2 days premature 30-80
0-2 days full term 40-90
2 days to 1 month 60-105
Adults 65-99
A random glucose result of GT 200 mg/dL
indicates diabetes if the abnormality
is confirmed on a subsequent day.
ADA diagnostic comments:
Glucose mg/dL
0-2 days premature 30-80
0-2 days fullterm 40-90
2 days-1 month 60-105
Adult 65-99
Pregnant 65-94
ADA Diagnostic Categories for nonpregnant
adults:
Impaired fasting glucose 100-125 mg/dL
A fasting glucose result of 126 mg/dL or
greater indicates diabetes if the
abnormality is confirmed on a subsequent
day.
A random glucose of 200 mg/dL or greater
in a symptomatic patient indicates diabetes
if the abnormality is confirmed on a
subsequent day. Confirmation by a fasting
glucose is preferred. |
| GLUCOSE, SPECIFIC | GLU.SPECIFIC | GLUSP | Hexokinase | Ranges as they appear on report:
Glucose mg/dL
0-2 days premature 30-80
0-2 days full term 40-90
2 days to 1 month 60-105
Adults 65-99
ADA diagnostic comments:
Glucose mg/dL
0-2 days premature 30-80
0-2 days fullterm 40-90
2 days-1 month 60-105
Adult 65-99
Pregnant 65-94
ADA Diagnostic Categories for nonpregnant
adults:
Impaired fasting glucose 100-125 mg/dL
A fasting glucose result of 126 mg/dL or
greater indicates diabetes if the
abnormality is confirmed on a subsequent
day.
A random glucose result of GT 200 mg/dL
indicates diabetes if the abnormality
is confirmed on a subsequent day. |
| GLUCOSE, URINE (QUALITATIVE) | GLC | GLUD | Colorimetric | Glucose, Urine Negative mg/dL |
| GLUCOSE, URINE (QUANTITATIVE) | GLU-U | GLUUQ | Enzymatic | Collection Period h
Volume mL
Glucose, Urine 0-500 mg/24h |
| GLUCOSE, URINE (RANDOM) | GLU-R | GLUUR | Hexokinase | Glucose, Urine mg/dL
No normal range established. |
| GLUCOSE-6-PHOSPHATE DEHYDROGENASE | G6PD | G6PD | Colorimetric | Glucose-6-Phosphate Dehydrogenase
Normal |
| GLUCOSE-6-PHOSPHATE DEHYDROGENASE [ARUP] | G6ARUP | G6ARUP | Enzymatic | Glucose-6-Phosphate Dehydrogenase 7.0-20.5 U/gHgb |
| GLUTAMIC ACID DECARBOXYLASE ANTIBODY | GADCAB | GADCAB | ELISA | Glutamic Acid Decarboxylase Antibody U/mL
0.0-5.0 |
| GLUTAMINES, CSF | GLUTAMINE | GLUTSF | Anion Exchange Chromatography | Glutamine, CSF 246-958 um/L |
| GLYBURIDE | GLY | GLY | HPLC | Glyburide mcg/mL
Peak level following single 5 mg oral dose:
Approximately 0.4 mcg/mL |
| GLYCOHEMOGLOBIN | GLHGB | GLYCO | HPLC | Hgb A1c 4.0-6.0 Non-diabetic %
The American Diabetes Association
considers a result of LT 7% to be
the goal of diabetic therapy.
When results are consistently
GT 8%, the ADA suggests reevaluation
of the treatment regimen. The
testing method used is certified
traceable to the Diabetes Control
and Complications Trial reference
method.
Estimated Average Glucose mg/dL
The ADA considers an eAG result of LT 154 mg/dL
to be the goal of diabetic therapy. Estimated
Average Glucose calculated from hemoglobin A1c
by use of the ADA recommended formula. |
| GM 1 ANTIBODY PANEL | GM1.AB | GM1AB | ELISA | GM1 Ab IgG IV
29 or less Negative
30-50 Weak positive
51-150 Positive
151 or more Strong positive
GM1 Ab IgM IV
29 or less Negative
30-50 Weak positive
51-150 Positive
151 or more Strong positive
Asialo GM1 Ab IgG IV
29 or less Negative
30-50 Weak positive
51-150 Positive
151 or more Strong positive
Asialo GM1 Ab IgM IV
29 or less Negative
30-50 Weak positive
51-150 Positive
151 or more Strong positive
Elevated antibody levels to ganglio-
sidemonosialic acid (GM1), and the
neutral glycolipid, asialo GM1 are
associated with motor or senorimotor
neuropathies, particularly multifocal
motro neuropathy. Anti-GM1 may occur
as IgM (polyclonal or monoclonal) or
IgG antibodies. There antibodies may
also be found in patients with diverse
connective tissue diseases as well as
normal individuals. These tests by
themselves are not diagnostic and
should be used in conjunction with
other clinical parameters to confirm
disease. |
| GOLD | GOLD | GOLDS | GFAAS | Gold mcg/mL
Normal LT 2.5
Therapeutic 3000-8000 |
| GRANULOCYTE ANTIBODIES | GRANAB | GRANAB | Indirect Immunofluorescence | Granulocyte Antibodies Negative |
| GROWTH HORMONE ANTIBODIES | HGHAB | HGHAB | HGH-I125 Binding Capacity | Growth Hormone Antibodies Negative |
| GUAIAC TEST FOR OCCULT BLOOD | OC.BLD | OCBLD | Colorimetric | Occult Blood Negative |
| GUAIAC TEST FOR OCCULT BLOOD X 2 | OC.BLD2 | OCBLD2 | Colorimetric | Occult Blood
Spec #1 Negative
Spec #2 Negative |
| GUAIAC TEST FOR OCCULT BLOOD X 3 | OC.BLD3 | OCBLD3 | Colorimetric | Occult Blood
Spec #1 Negative
Spec #2 Negative
Spec #3 Negative |
| HAEMOPHILUS INFLUENZAE TYPE B ANTIBODY, IGG | H.INFB.AB | HFLUBG | Multi-Analyte Fluorescent Detection | Haemophilus Influenzae Type B Ab ug/mL
LT 1.0 Antibody concentration not
protective.
1.0 or more Antibodies to H. influenzae B
detected suggestive of
protection. |
| HALOPERIDOL | HALDOL | HAL | HPLC | Haloperidol ng/mL
Adult Therapeutic 2.0-15.0
The therapeutic range relates to the
management of psychoses; lower con-
centrations may be therapeutic for
Tourette and mania. The toxic range
is not well established. Some patients
experience toxicity within the
therapeutic range. |
| HANTAVIRUS IGG & IGM ANTIBODIES (REFLEXIVE) | HANTA | HANTA | ELISA | Hantavirus Antibody, IgG 1.10 or less
Hantavirus Antibody, IgM 1.10 or less
Interpretive Criteria
1.10 or less Antibody not detected
GT 1.10 Antibody detected
Two major groups of hantaviruses are
recognized based on clinical
presentation. The first group includes
Sin Nombre Virus, which causes
hantavirus pulmonary syndrome, a
severe and possibly fatal form of acute
respiratory distress. A second group
of hantaviruses (including Seoul,
Hantaan, Dobrava, and Puumala viruses)
causes hemorrhagic fever with renal
syndrome, a condition not typically
seen in the United States. Sera are
initially screened for IgG and IgM
antibodies recognizing the nucleo-
capsid protein common to all hanta-
viruses. All screen IgM positive
samples are then tested for SNV-
specific IgM; any screen IgM positive
samples that are also screen IgG
positive are tested for SNV-specific
IgG, as well as SNV-specific IgM.
Samples that are screen IgG positive
but screen IgM negative are not
subjected to SNV-specific IgG testing,
since the lack of IgM rules out acute
SNV infection. A positive screening
result but a negative SNV-specific
antibody result may indicate either
reactivity to a hantavirus other than
SNV or false positive reactivity. A
small number of SNV IgM positive (but
screen IgG negative) samples represent
false positive reactivity associated
with acute cytomegalovirus or Epstein
Barr virus infection.
|
| HAPTOGLOBIN | HAPTO | HAPT | Nephelometry | Haptoglobin 37-308 mg/dL |
| HAPTOGLOBIN BY PCR | HAPPCR | | PCR/ Fluorescent monitoring | HAPTO PCR Specimen
Haptoglobin by PCR and FRET
This test is performed pursuant to an agreement
with Roche Molecular Systems, Inc. This test was
performed pursuant to an agreement with Alteon, Inc. |
| HCG QUANTITATIVE TUMOR MARKER | HCGTM | HCGTM | Chemiluminescence | HCG Quantitative Tumor Marker IU/L
Male LT 4
Female LT 6
This result cannot be interpreted as
absolute evidence of the presence or
absence of malignant disease. This
result is not interpretable as a
tumor marker in pregnant females. |
| HCG QUANTITATIVE, BETA | HCG-QUANT | BHCGQ | ICMA | HCG-Quant Beta Subunit
Non-pregnant females LT 5 mIU/mL
Minimum detectable concentration
of HCG is 2.0 mIU/mL.
**Representative Reference Intervals**
After Fert. After LMP mIU/mL
2 Wks 4 Wks 5-450
3 Wks 5 Wks 50-7000
4 Wks 6 Wks 1000-50000
5-12 Wks 7-14 Wks 5000-290000
13-24 Wks 15-26 Wks 4000-250000
25-38 Wks 27-41 Wks 3000-100000
HCG values in early normal pregnancy double
every 48 hours. |
| HCG, BETA | HCG | PRG | ICMA | Pregnancy Test (Beta HCG) mIU/mL
Negative LT 5
Positive 5 or greater |
| HCV FIBROSURE | HCVFS | HCVFS | | Fibrosure Score 0.00-0.21
Fibrosure Stage
Necroinflammat Activity Score 0.00-0.17
Necroinflammat Activity Grade
Alpha 2-Macroglobulins, QN 110-276 mg/dL
Haptoglobin 34-200 mg/dL
Apolipoprotein A-1 M 110-180
F 110-205
Bilirubin, Total 24 hrs old 0.0-8.0 mg/dL
48 hrs old 0.0-13.2
72 hrs old 0.0-15.6
96 hr to 1 mo 0.0-16.6
GT 1 mo old 0.0-1.2
GGT M 0-65 IU/L
F 0-60
ALT (SGPT) M 0-55 IU/L
F 0-40 |
| HDL | HDL | HDL | Elimination/Enzymatic | HDL mg/dL
LT 40 Low
40-59 Within normal limits
60 or more High
HDL Cholesterol greater than or equal
to 60 mg/dL is considered to be a
'negative' risk factor, serving to
remove one risk factor from the total
count.
LDL (calculated) mg/dL
LT 100 Optimal
100-129 Near or above normal
130-159 Borderline high
160-189 High
190 or more Very high
To calculate 10-year cardiac risk for
the patient, go to http://www.paml.com,
click on testing, then on ranges/
algorithms, and then on lipid results. |
| HEAT SHOCK PROTEIN 70 BY WB [ARUP] | HSP70 | HSP70 | Western Blot | Heat Shock Protein 70 by WB Negative |
| HEAVY METALS, QUANTITATIVE | HVY | HVYMTL | AA/ICP-MS | Heavy Metals, Blood
Arsenic 0.0-62.0 ug/L
Potentially toxic GT 600
Lead, Venous, Normal ug/dL
0-14 yrs 0.0-9.9
15+ yrs 0.0-24.9
Mercury 0-10 ug/L |
| HEAVY METALS, QUANTITATIVE, URINE | HVY-U | HMUQ | Electrothermal (Flameless) AAS and Mercury Hydride | Collection Period h
Volume mL
Lead, Urine ug/L
Lead, Urine ug/24h
Normal LT 80
Inconclusive 80-125
Abnormal GT 125
Up to 125 ug/24h is probably
not associated with lead poisoning.
Mercury, Urine ug/L
Mercury, Urine ug/24h
Non-exposed LT 20
Potentially toxic GT 150
Arsenic, Urine ug/L
Arsenic, Urine 5-50 ug/24h |
| HEAVY METALS, URINE (RANDOM) | HVY.RU | HMUR | Electrothermal (Flameless) AAS and Mercury Hydride | Lead, Urine No normals established ug/L
Mercury, Urine No normals established ug/L
Arsenic, Urine No normals established ug/L |
| HELICOBACTER PYLORI ANTIBODY IGA | HPAIGA | HPAIGA | EIA | Helicobacter pylori Ab, IgA EV
1.7 or less Negative: no significant level of IgA
Ab to H. pylori detected.
1.8-2.2 Equivocal: Repeat testing in 10-14 days
may be helpful.
2.3 or more Positive_IgA Ab to H. pylori detected,
suggestive of acitve infection.
Helicobacter pylori IgG and IgA Ab
seroconversion occur together after
60 days. Samples which have a high
titer of both IgG and IgA Abs to H.
pylori in symptomatic individuals may
be considered to represent an acitve
infecction. However, a positive H.pylori
IgA result can only infer active infection
and should be confirmed by bacterial
isolation or other diagnostic testing. |
| HELICOBACTER PYLORI ANTIBODY | HELICO.AB | HPYG | EIA | Helicobacter pylori Ab, IgG ISR
LT 0.91 Negative-no significant level
of IgG antibody to H. pylori
detected.
0.91-1.09 Equivocal serological results.
Suggest follow up H. pylori
breath test or stool antigen
testing.
GT 1.09 Positive-A positive serologic
result for H. pylori cannot
distinguish current from
previous infection, and cannot
be used to assess response to
therapy. Breath testing or
stool antigen testing can be
used for these purposes. |
| HELICOBACTER PYLORI ANTIBODY, IGG & IGA | HPYGA | HPYGA | EIA | Helicobacter pylori AB, IgA EV
Negative 1.7 or less
No significant level of
IgA AB to H. pylori detected.
Equivocal 1.8-2.2
Repeat testing in 10-14
days may be helpful.
Positive 2.3 or greater
IgA AB to H. pylori detected,
suggestive of active infection.
Helicobacter pylori IgG and IgA
AB serconversion occur together
after 60 days. Samples which have
a high titer of both IgG and IgA Abs
to H. pylori in symptomatic individuals
may be considered to represent an
active infection and should be
confirmed by bacterial isolation or
other diagnositc testing.
Helicobacter pylori, IgG EV
Negative 1.7 or less
No significant level of IgG AB to
H. pylori detected.
Equivocal 1.8-2.2
Repeat testing in 10-14 days may be
helpful.
Positive 2.3 or greater
IgG AB to H. pylori detected,
suggestive of previous exposure
or active infection. |
| HELICOBACTER PYLORI ANTIBODY, IGM | HPMAG | HPMAG | ELISA | Helicobacter pylori Antibody, IgM EV
0.8 or less Negative-no significant
level of IgM antibody to H. pylori
detected.
0.9-1.1 Equivocal-Repeat testing
in 10-14 days may be helpful.
1.2 or more Positive-IgM antibody to
H. pylori detected, suggestive of
active infection.
Gastric colonization by Helicobacter
pylori has been implicated in the
development of some cases of gastritis
and peptic or duodenal ulcer. The
critical utility of H. pylori IgM
antibody measurement has not been
clearly established. |
| HELICOBACTER PYLORI ANTIGEN, STOOL | HPSA | HPSA | EIA | Helicobacter pylori Ag Stool Negative
Helicobacter pylori Ag Stool, Status |
| HELICOBACTER PYLORI BREATH TEST | HPYBT | HPYBT | Infared spectrophotometry | Helicobacter Pylori Breath Test Negative |
| HELICOBACTOR PYLORI SCREEN | HELICO.SCR | HPS | Culture | Source
Helico pylori Screen
Helico pylori Screen, Status |
| HELPER SUPPRESSOR | HSSUB | HSSUB | Flow Cytometry | Source
WBC K/uL
0 days 9.0-30.0
1-7 days 5.0-21.0
7-30 days 5.0-19.5
1-12 mo 6.0-17.5
1-2 yrs 5.0-15.5
2-4 yrs 6.0-15.5
4-6 yrs 5.0-13.5
6-10 yrs 4.5-13.5
10-14 yrs 5.0-11.0
14-18 yrs 4.5-11.0
18 yrs+ 4.0-11.0
Lymphocytes Newborn 9.0-46.0 %
1-3 days 16.0-46.0
4-7 days 26.0-56.0
8-14 days 33.0-63.0
15-60 days 41.0-71.0
2-11 mo 46.0-76.0
1-4 yrs 35.0-76.0
5-12 yrs 23.0-57.0
13-18 yrs 20.0-50.0
19+ yrs 15.0-45.0
Lymphs, Abs Newborn 2.00-11.00 K/uL
1-3 days 2.00-11.50
4-7 days 2.00-17.00
8-14 days 2.00-17.00
15-60 days 2.50-16.50
2-11 mo 4.00-13.50
1-4 yrs 2.00-10.50
5-12 yrs 1.50-7.00
13-18 yrs 1.20-5.20
19+ yrs 1.00-3.40
CD4 0-5 mo 50.0-57.0 %
6-11 mo 49.0-55.0
12-17 mo 46.0-51.0
24-29 mo 38.0-46.0
30-35 mo 33.0-44.0
3 yrs 27.0-57.0
CD4 Abs 0-5 mo 2800-3900 /uL
6-11 mo 2600-3500
12-17 mo 2300-2900
18-23 mo 1900-2500
24-29 mo 1500-2200
30-35 mo 1200-2000
3 yrs 560-2700
4+ yrs 490-1400
CD8 %
0-3 yrs 8.0-31.0
3-4 yrs 14.0-34.0
4+ yrs 12.0-38.0
CD8 Abs /uL
0-3 yrs 350-2500
3-4 yrs 330-1400
4+ yrs 225-900
CD4/CD8 Ratio to 1.0
0-3 yrs 1.17-6.22
3-4 yrs 0.98-3.24
4+ yrs 1.00-3.00
Note
Note |
| HEMATOCRIT | HCT | CRIT | Automated | Hematocrit %
0-3 days 45.0-67.0
3-7 days 42.0-66.0
7-14 days 39.0-63.0
14-30 days 31.0-55.0
30-60 days 28.0-42.0
2-6 mo 29.0-41.0
6-24 mo 33.0-39.0
2-6 yrs 34.0-40.0
6-12 yrs 35.0-45.0
12-18 yrs M 37.0-49.0
18 yrs+ M 40.0-50.0
12-18 yrs F 36.0-46.0
18 yrs+ F 35.0-46.0 |
| HEMOGLOBIN | HGB | HB | Automated | Hemoglobin g/dL
0-3 days 14.5-22.5
3-7 days 13.5-21.5
7-14 days 12.5-20.5
14-30 days 10.0-18.0
30-60 days 9.0-14.0
2-5 mo 10.5-13.5
6-24 mo 11.5-13.5
2-6 yrs 11.5-13.5
6-12 yrs 11.5-15.5
12-18 yrs M 13.0-16.0
18 yrs+ M 13.7-16.7
12-18 yrs F 12.0-16.0
18 yrs+ F 11.6-15.5 |
| HEMOGLOBIN & HEMATOCRIT | H&H | HH | Automated | Hemoglobin g/dL
0-3 days 14.5-22.5
3-7 days 13.5-21.5
7-14 days 12.5-20.5
14-30 days 10.0-18.0
30-60 days 9.0-14.0
2-5 mo 10.5-13.5
6-24 mo 11.5-13.5
2-6 yrs 11.5-13.5
6-12 yrs 11.5-15.5
12-18 yrs M 13.0-16.0
18 yrs+ M 13.7-16.7
12-18 yrs F 12.0-16.0
18 yrs+ F 11.6-15.5
Hematocrit %
0-3 days 45.0-67.0
3-7 days 42.0-66.0
7-14 days 39.0-63.0
14-30 days 31.0-55.0
30-60 days 28.0-42.0
2-6 mo 29.0-41.0
6-24 mo 33.0-39.0
2-6 yrs 34.0-40.0
6-12 yrs 35.0-45.0
12-18 yrs M 37.0-49.0
18 yrs+ M 40.0-50.0
12-18 yrs F 36.0-46.0
18 yrs+ F 35.0-46.0 |
| HEMOGLOBIN & HEMATOCRIT, FLUID | H&H.FLD | HHFL | Automated | Hemoglobin, Fluid g/dL
No reference range established
Hematocrit, Fluid %
No reference range established |
| HEMOGLOBIN A2, QUANTITATIVE | A2 | A2QT | HPLC | Hemoglobin A2 %
0-3 mo 0.0-3.6
4+ mo 1.0-3.8 |
| HEMOGLOBIN F, QUANTITATIVE | HGBF | FQT | HPLC | Hemoglobin F %
0-30 days 61.0-88.5
1 mo 45.7-67.3
2 mo 29.4-60.8
3 mo 14.8-55.9
4 mo 9.4-28.5
5 mo 2.3-22.4
6-11 mo 2.3-13.0
1 yr 1.3-5.0
13 mo+ 0.0-2.0 |
| HEMOGLOBIN S, QUANTITATIVE | HGBS | SQT | HPLC | Hemoglobin S %
No reference range established. |
| HEMOGLOBIN, QUANTITATIVE, PLASMA | HGB.PLASMA | PHGBQT | Spectrophotometry | Plasma Hgb mg/dL
(quantitative) 0-10
90% of population LT 10 mg/dL, 10% of
population LT 20 mg/dL. Reference values
are difficult to define, since hemo-
globin concentration depends heavily
on the care by which the sample was
obtained and processed. |
| HEMOGLOBIN, URINE | HGBU | HGBU | Spectrophotometry | Hemoglobin, Urine None detected mg/dL
Hemoglobin is normally not detected
in urine. |
| HEMOGLOBINOPATHY/THALASSEMIA PANEL (REFLEXIVE) | HGB.THAL.PANEL | HGTHAL | Ion Exchange/HPLC | Hemoglobin A2 %
0-3 mo 0.0-3.6
4+ mo 1.0-3.8
Hemoglobin F %
0-30 days 61.0-88.5
1 mo 45.7-67.3
2 mo 29.4-60.8
3 mo 14.8-55.9
4 mo 9.4-28.5
5 mo 2.3-22.4
6-11 mo 2.3-13.0
1 yr 1.3-5.0
13 mo+ 0.0-2.0
Hgb Other
Hgb S (Relative) %
Brilliant Cresyl Blue
No longer performed
ZPP/Heme Ratio umol/mol
23-78
Kleinhauer Betke Stain
Hemoglobin S Solubility
Negative
Monoclonal C
Citrate Gel Electro
Monoclonal E
Cellulose Electro
Unstable Hgb
Slide Interpretation
Interpretation
Reviewed By |
| HEMOGRAM WITH PLATELET, AUTOMATED | AUT | AHEMP2 | Automated | WBC K/uL
0 days 9.0-30.0
1-7 days 5.0-21.0
7-30 days 5.0-19.5
1-12 mo 6.0-17.5
1-2 yrs 5.0-15.5
2-4 yrs 6.0-15.5
4-6 yrs 5.0-13.5
6-10 yrs 4.5-13.5
10-14 yrs 5.0-11.0
14-18 yrs 4.5-11.0
18 yrs+ 4.0-11.0
RBC M/uL
0-3 days 4.00-6.60
3-7 days 3.90-6.30
7-14 days 3.60-6.20
14-30 days 3.00-5.40
30-60 days 2.70-4.90
2-6 mo 3.10-4.50
6-24 mo 3.70-5.30
2-6 yrs 3.90-5.30
6-12 yrs 4.00-5.20
12-18 yrs M 4.50-5.30
18 yrs+ M 4.30-5.70
12-18 yrs F 4.10-5.10
18 yrs+ F 3.80-5.20
Hemoglobin g/dL
0-3 days 14.5-22.5
3-7 days 13.5-21.5
7-14 days 12.5-20.5
14-30 days 10.0-18.0
30-60 days 9.0-14.0
2-5 mo 10.5-13.5
6-24 mo 11.5-13.5
2-6 yrs 11.5-13.5
6-12 yrs 11.5-15.5
12-18 yrs M 13.0-16.0
18 yrs+ M 13.7-16.7
12-18 yrs F 12.0-16.0
18 yrs+ F 11.6-15.5
Hematocrit %
0-3 days 45.0-67.0
3-7 days 42.0-66.0
7-14 days 39.0-63.0
14-30 days 31.0-55.0
30-60 days 28.0-42.0
2-6 mo 29.0-41.0
6-24 mo 33.0-39.0
2-6 yrs 34.0-40.0
6-12 yrs 35.0-45.0
12-18 yrs M 37.0-49.0
18 yrs+ M 40.0-50.0
12-18 yrs F 36.0-46.0
18 yrs+ F 35.0-46.0
MCV fL
0-3 days 95.0-121.0
3-7 days 88.0-126.0
7-14 days 86.0-124.0
14-30 days 85.0-123.0
30-60 days 77.0-115.0
2-6 mo 74.0-108.0
6-24 mo 70.0-86.0
2-6 yrs 75.0-87.0
6-12 yrs 77.0-95.0
12-18 yrs M 78.0-98.0
12-18 yrs F 78.0-102.0
18 yrs+ 80.0-100.0
MCH pg
0-3 days 31.0-37.0
3-30 days 28.0-37.0
30-60 days 26.0-34.0
2-6 mo 25.0-35.0
6-24 mo 23.0-31.0
2-6 yrs 24.0-30.0
6-12 yrs 25.0-33.0
12-18 yrs 25.0-35.0
18 yrs+ 27.0-34.0
MCHC g/dL
0-3 days 29.0-37.0
3-14 days 28.0-37.0
14-60 days 29.0-37.0
2-24 mo 30.0-36.0
2-18 yrs 31.0-37.0
18 yrs+ 32.0-35.5
RDW %
0-7 days 11.0-18.0
7-60 days 11.0-17.0
2-6 mo 11.0-16.5
6-24 mo 11.0-16.0
2-6 yrs 11.0-15.0
6-18 yrs 11.0-14.5
18 yrs+ 11.0-15.0
Platelet Count K/uL
0-3 days 250-450
3-9 days 200-400
9-30 days 250-450
1-6 mo 300-750
6 mo-2 yrs 250-600
2-8 yrs 250-550
8-12 yrs 200-450
12-18 yrs 150-450
18 yrs+ 150-400 |
| HEMOSIDERIN, URINE | HSIDU | HSIDU | Microscopic stain | Hemosiderin, Urine Negative |
| HEPARIN ASSAY | HEPARIN | HEPASY | Chromogenic | Heparin Level IU/mL
Therapeutic Range 0.30-0.70 |
| HEPARIN INDUCED THROMBOCYTOPENIA ANTIBODY | HITA | HITA | EIA | Heparin Induced Negative
Thromboctopenia
Antibody
Interpretation
Negative-Immunoassays for heparin
antibodies are considered sensitive
(GT 90%); however, false-negatives
can occur. If clinically indicated,
repeat testing with a new sample in
several days is suggested. When
negative immunoassays occur within a
strong clinical setting, functional
testing for HIT may be indicated.
Positive-Immunoassays for heparin
antibodies are considered sensitive
(GT 90%); however, the presence of
antibody alone does not determine
clinical heparin-induced thrombo-
cytopenia. Results of this assay
should be used in conjunction with
clinical findings and to assess
management.
Equivocal-If clinically indicated,
repeat immunoassay testing for heparin
antibodies with a new sample in
several days is suggested. |
| HEPARIN INDUCED THROMBOCYTOPENIA FUNCTIONAL | HITFUN | HITFUN | Indirect Platelet Aggregation | Heparin Induced Thrombocytopenia, Negative
Functional
The HIT test is specific, but has a
sensitivity of only about 36%. A positive
test supports the diagnosis of HIT,
but a negative results does not
exclude it. |
| HEPATIC FUNCTION PANEL | HFPA | HFPA | Colorimetric, Enzymatic | Protein, Total g/dL
0-12 mo 4.3-6.9
1-3 yrs 5.2-7.4
3-6 yrs 5.6-7.7
6-10 yrs 6.5-8.3
10-18 yrs 6.1-8.0
18-60 yrs 6.3-8.0
60 yrs+ 6.1-7.8
Albumin g/dL
0-4 days 2.9-4.6
4 days-14 yrs 3.9-5.6
14-18 yrs 3.3-4.7
18-60 yrs 3.5-5.0
60-90 yrs 3.3-4.8
90 yrs+ 3.0-4.7
Bilirubin, Total mg/dL
0-30 days LT 11.7
1 mo-18 yrs LT 2.0
18-60 yrs 0.1-1.5
60-90 yrs 0.2-1.1
90 yrs+ 0.2-0.9
Bilirubin, Direct 0.0-0.4 mg/dL
Alkaline Phosphatase U/L
0-6 yrs 72-307
6-9 yrs 133-340
9-15 yrs M 103-429
15-18 yrs M 49-210
9-13 yrs F 99-453
13-15 yrs F 53-186
15-18 yrs F 38-110
18 yrs+ 38-110
AST U/L
0-6 yrs 20-60
6-10 yrs 20-40
10-18 yrs 14-40
18 yrs+ 5-40
ALT(SGPT) 5-50 U/L |
| HEPATITIS A DIAGNOSTIC PANEL (REFLEXIVE) | HAVABP | HAVABP | ICMA | Hepatitis A Virus Antibody, Total Nonreactive
Interpretation |
| HEPATITIS A VIRUS ANTIBODY, IGM | HAVABM | HAVABM | ICMA | Hepatitis A Virus Antibody, IgM Nonreactive |
| HEPATITIS A VIRUS ANTIBODY, TOTAL | HAVABT | HAVAB | ICMA | Hepatitis A Virus Antibody, Total Nonreactive |
| HEPATITIS A, B, C (REFLEXIVE) | ABCHEP | ABCHEP | ICMA | Hepatitis A Virus Ab, Total Nonreactive
Hepatitis A Virus Ab, IgM Nonreactive
HBs Antigen Screen Nonreactive
HBs Antigen Confirmation Nonreactive
Hepatitis B Core Ab, Total Nonreactive
Hepatitis B Core Ab, IgM Nonreactive
Hepatitis C Ab Screen Nonreactive
Interpretation |
| HEPATITIS B CORE ANTIBODY, IGM | HBCORE.IGM | HBCABM | ICMA | Hepatitis B Core Ab, IgM Nonreactive |
| HEPATITIS B CORE ANTIBODY, TOTAL | HBCORET | HBCAB | ICMA | Hepatitis B Core Ab, Total Nonreactive |
| HEPATITIS B CORE ANTIBODY, TOTAL TO HEPATITIS B CORE IGM (REFLEXIVE) | HBCABR | HBCABR | ICMA | Hepatitis B Core Ab, Total Nonreactive
Hepatitis B Core Ab, IgM Nonreactive |
| HEPATITIS B DNA ULTRASENSITIVE QUANTITATIVE BY RT-PCR | HEPBDQ | HEPBDQ | RT-PCR | HBV DNA Quant Result IU/mL
Not detected
This result does not rule out the presence of HBV DNA
below the limit of detection of this assay. Inaccurate
results can occur due to improper specimen handling or
the presence of PCR inhibitors in the patient sample.
HBV DNA Quant Log 10 Value IU/mL
Not Detected
HBV DNA Quant Methodology
This assay is performed using real time
PCR by the COBAS TaqMan HBV IVD test.
HBV DNA Quant Comment
The reportable range of this test is
29-11,000,000,000 IU/mL (Log 10 1.5-10.0).
The limit of detection is 10 IU/mL.
|
| HEPATITIS B E ANTIBODY | ANTI-HBE | HBEAB | EIA | Hepatitis Be Ab Nonreactive |
| HEPATITIS B E ANTIGEN | HBEAG | HBEAG | EIA | HBeAg Nonreactive |
| HEPATITIS B SURFACE ANTIBODY | ANTI-HBS | HBSAB | ICMA | Hepatitis B Surface Ab IV
LT 1.00 Non-immune
1.00 or more Indicates vaccine
response to HBV
infection
An Index Value (IV) of 1.00 is
equivalent to 10 mIU/mL. Samples
with an IV or 1.00 or greater are
considered reactive (protected) in
accordance with the CDC Guidelines. |
| HEPATITIS B SURFACE ANTIGEN (REFLEXIVE) | HBSAG | HBSAG | ICMA | HBsAg Screen Nonreactive
HBsAg Confirmation |
| HEPATITIS B SURFACE ANTIGEN CONFIRMATION | HBSAG.CONFIRM | HBSAGC | ICMA Neutralization | HBsAg Confirmation |
| HEPATITIS C ANTIBODY | HEP-C | HCVAB | ICMA | Hepatitis C Ab Nonreactive |
| HEPATITIS C ANTIBODY BY RIBA | HCRIBA | HCRIBA | Recombinant Immunoblot (RIBA HCV 3.0) | Hepatitis C Ab (RIBA 3.0) Negative
Negative for HCV antibodies. No anti-
bodies were detected to the HCV proteins.
hSOD is a control that detects auto-
antibodies to human superoxide dismutase.
HCV causes the majority of parentally
transmitted non-A, non-B hepatitis.
Most patients infected with HCV develop
antibodies within 3 months of infection.
Recent studies show that nearly 90% of
HCV infections become chronic. If this
specimen has a repeatedly reactive EIA
result, testing for HCV RNA will determine
if the patient is currently infected.
An FDA liscensed recombinant immunoblot
assay was used. |
| HEPATITIS C VIRUS GENOTYPING BY PCR & LINE PROBE ASSAY (REFLEXIVE) | HCVGTY | HCVGTY | PCR & Line Probe Genotyping (LIPA). | HCV Genotype by PCR & Line Probe Assay Specimen HCV RNA level is below the
limit of detection of this assay. |
| HEPATITIS C VIRUS RNA QUANTITATIVE BY BDNA 3.0 | HEPCQB | HEPCQB | Branched Chain DNA | Hepatitis C Virus RNA by bDNA 3.0
Not detected IU/mL
Reportable range is
615-7,700,000 IU/mL
Hepatitis C Virus RNA by bDNA 3.0
Not detected Log10
Reportable range is 2.8-6.9 Log10.
A patient value of Not detected indicates that the patient
viral load is below the quantitative limit of the assay.
This test is useful to establish baseline
viral load, predict therapeutic response,
and guide duration of therapy. Quantitative
HCV RNA tests are recommended only if active
HCV infection has been confirmed, and
should not be used to diagnose HCV infection.
A negative result does not exclude low-level
viremia. |
| HEPATITIS C VIRUS RNA QUANTITATIVE BY BDNA REFLEX TO GENOTYPING | HCVBGT | HCVBGT | Viral load by branched chain DNA and HCV Genotyping by Line Probe Assay. | Hepatitis C RNA Quantitative by bDNA 3.0 Not detected IU/mL
Reportable range for Hepatitis C
RNA Quantitation by bDNA is
615-7,700,000 IU/mL
Hepatitis C RNA Quantitative by bDNA 3.0 Not detected log10
Reportable range for Hepatitic C
RNA Quantitation by bDNA is
2.8-6.9 log10
A patient value for Not detected
indicates that the patient viral
load is below the quantitative limit
of this assay.
This test is useful to establish
baseline viral load, predict
therapeutic response, and guide
duration of therapy. Quantitative
HCV RNA tests are recommended only
confirmed, and should not be used
to diagnose HCV infection. A negative
result does not exclude low-level
virema.
HCV Genotype by PCR & Line Probe Assay Specimen HCV RNA level is below the
limit of detection of this assay. |
| HEPATITIS C VIRUS RNA QUANTITATIVE BY PCR , HIGHLY SENSITIVE, REFLEX TO GENOTYPING | HCVPGT | HCVPGT | PCR Ampliprep/TaqMan HCV Test & PCR/LiPA | HCV RNA Viral Load Result Not detected LogIU/mL
HCV RNA Viral Load Result Not detected IU/mL
Reportable rande HCV RNA 1.6 to 7.8
LogIU/mL (43-69,000,000 IU/mL)
This test is intended for use as an
aid in management of HCV-infected
individuals undergoing anti-viral
therapy. The COBAS Ampliprep/COBAS
TaqMan HCV test is not intended for use
as a screening test for the presence of
HCV in blood or blood products or as a
diagnostic test to confirm the presence of
HCV infection.
HCV Genotype by PCR & Line Probe Assay Specimen HCV RNA level is below the
limit of detection of this assay. |
| HEPATITIS C VIRUS RNA QUANTITATIVE BY PCR, HIGHLY SENSITIVE | HCVRQT | HCVRQT | PCR: Ampliprep/TaqMan HCV Test | Hepatitis C Viral RNA Viral Load Result Not detected Log IU/mL
Hepatitis C Viral RNA Viral Load Result Not detected IU/mL
Reportable range HCV RNA 1.6 to 7.8
Log IU/mL (43-69,000,000 IU/mL).
This test is intended for use as an aid
in management of HCV-infected individuals
undergoing anti-viral therapy. The COBAS
Ampliprep/COBAS TaqMan test is not
intended for use as a screening test for
the presence of HCV in blood or blood products
or as a diagnostic test to confirm the
presence of HCV infection.
. |
| HEPATITIS D ANTIBODY, TOTAL | HEPDAB | HEPDAB | EIA | Hepatitis D Virus Antibody, Total
Negative
Interpretive Criteria
Negative-Antibody not detected.
Equivocal-Submission of a second
specimen (collected 3-4 weeks after
initial specimen) suggested if
clinically warranted.
Positive-Antibody detected.
Hepatitis D virus (HDV) infection
occurs in association with HBV
infection. A positive result for
HDV total antibody may indicate either
acute or chronic HDV infection. HDV
antibodies appear transiently during
acute infection, and typically
disappear with resolution of the
infection. In contrast, HDV antibodies
usually persist in chronic infection.
Measurment of HDV IgM may help distinguish
acute from chronic infection. |
| HEPATITIS DELTA ANTIGEN | HDAG | HDAG | EIA | Hepatitis Delta Antigen Negative
HDV infection occurs only in
association with HBV infection. Acute
HDV infection reflects either HDV
acquisition at the same time of acute
HBV infection (coinfection), or recent
exposure to HDV in a patient with
chronic HBV infections (superinfection).
HDV antigen is deteced transiently
during the early phase of acute HDV
infection, but typically disappears as
HDV-specific antibodies arise. |
| HEPATITIS E VIRUS, IGM | HEPEM | HEPEM | ELISA | Hepatitis E Virus IgM Nonreactive
HEV infection is responsible for some
cases of non-A, non-B, non-C hepatitis.
Found primarily in Asia, Africa, Mexico,
and Central America. HEV is mainly
transmitted via contaminated water. |
| HEPATITIS PANEL, ACUTE (REFLEXIVE) | HEPACU | HEPACU | ICMA | Hepatitis A Virus Ab, IgM Nonreactive
Hepatitis B Surface Antigen Nonreactive
Hepatitis B Surface Antigen
Confirmation
Hepatitis B Core Antibody, IgM Nonreactive
Hepatitis C Antibody Nonreactive
Interpretation |
| HEPATITIS PANEL, CHRONIC (REFLEXIVE) | HEPCHR | HEPCHR | ICMA | Hepatitis A Virus Total Nonreactive
Hepatitis B Surface Antigen Nonreactive
Hepatitis B Surface Antigen
Confirmation
Hepatitis B Core Antibody Nonreactive
Hepatitis B Surface Ab IV
LT 1.00 Non-immune
1.00 or more Indicated vaccine
response or
response to HBV
infection.
An Index Value (IV) of 1.00 is equivalent to
10 mIU/mL. Samples with an IV of 1.00 or
greater are considered reactive
(protected) in accordance with the
CDC Guidelines.
Hepatitis C Antibody Screen Nonreactive
Interpretation |
| HEPATITIS PANEL, HBV PROGNOSIS (REFLEXIVE) | HBCHR | HBCHR | ICMA | Hepatitis B Surface Antigen Nonreactive
Hepatitis B Surface Antigen
Confirmation
Hepatitis Be Antigen Nonreactive
Hepatitis Be Antibody Nonreactive
Hepatitis B Surface Ab IV
LT 1.00 Non-immune
1.00 or more Indicates vaccine response
or response to HBV infection.
An Index Value (IV) of 1.00 is equivalent
to 10 mIU/mL. Samples with an IV of 1.00
or greater are considered reactive
(protected) in accordance with the CDC
Guidelines.
Interpretation |
| HEPTIMAX | HEPTI | HEPTI | PCR/TMA | Heptimax HCV RNA LT 5 IU/mL
Heptimax HCV RNA LT 0.7 LogIU/mL
Reportable range 5 IU/mL to 69,000,000 IU/mL.
This test was performed using the COBAS
Ampliprep/Cobas TaqMan HCV test kit (Roche
Molecular Systems, Inc), |
| HEREDITARY HEMOCHROMATOSIS | HHPCR3 | HHCPCR | PCR | Hereditary Hemochromatosis Result
Genotype
Interpretation
Patients receiving genetic testing
should consider genetic counseling.
Counseling of potentially affected
family members may also be warranted.
Comment
Patient DNA is assayed for the C282Y,
H63D and S65C point mutations in the
HFE gene by polymerase chain reaction
(PCR). |
| HERPES SIMPLEX VIRUS CULTURE | HSVELV | HSVELV | ELVIS Culture | Source
HSV Culture No Herpes simplex virus isolate
HSV Culture, Status |
| HERPES SIMPLEX VIRUS DETECTION BY RT-PCR | HSVRTP | HSVRTP | Real-time PCR | Source
Herpes Simplex Virus DNA Not detected
Comment
Comment Analyte Specific Reagents (ASR) are used in
many laboratory tests necessary for standard
medical care and generally do not require U.S.
Food & Drug Administration approval. This test
was developed and its performance characteristics
determined by PAML Laboratories. It has not
been approved by the FDA. This test should not
be regarded as investigational or for research
use. This test is performed pursuant to an
agreement with Roche Molecular Systems. |
| HERPES SIMPLEX VIRUS 1/2 DETECTION AND DIFFERENTIATION BY RT-PCR | HSVRTD | HSVRTD | Real-time PCR | Source
Herpes Simplex Virus DNA Type 1 Not detected
Herper Simplex Virus DNA Type 2 Not detected
Comment
Comment Analyte Specific Reagents (ASR) are used in
many laboratory tests necessary for standard
medical care and generally do not require U.S.
Food & Drug Administration approval. This test
was developed and its performance characteristics
determined by PAML Laboratories. It has not
been approved by the FDA. This test should not
be regarded as investigational or for research
use. This test is performed pursuant to an
agreement with Roche Molecular Systems. |
| HERPES SIMPLEX VIRUS BY WESTERN BLOT | HSVUWB | HSVUWB | Western Blot | Herpes Simplex Virus by Western Blot Source
Herpes Simplex Virus by Western Blot Result
Herpes Simplex Virus by Western Blot Interpretation |
| HERPES SIMPLEX VIRUS CULTURE & TYPING (REFLEXIVE) | HSVETP | HSVETP | ELVIS Culture | Source
HSV Culture No Herpes simplex virus isolate
HSV Culture, Status |
| HERPES SIMPLEX VIRUS I & II TYPE-SPECIFIC ANTIBODY, IGG-HERPESELECT® | HERP I&II.IGG | HSVG | EIA | HSV I IgG Type-Specific Ab IV
LT 0.90 Negative-No significant
level of detectable IgG
Ab to HSV Type I Glycoprotein
G.
0.90-1.10 Indeterminate-Questionable
presence of Ab to HSV Type I
Glycoprotein G. Repeat testing
may be helpful.
GT 1.10 Positive-IgG Ab to HSV Type I
Glycoprotein detected. May
indicate a current or past
infection.
HSV II IgG Type-Specific Ab IV
LT 0.90 Negative-No significant
level of detectable IgG
Ab to HSV Type II Glycoprotein
G.
0.90-1.10 Indeterminate-Questionable
presence of Ab to HSV Type II
Glycoprotein G. Repeat testing
may be helpful.
GT 1.10 Positive-IgG Ab to HSV Type II
Glycoprotein detected. May
indicate a current or past
infection. |
| HERPES SIMPLEX VIRUS IGG 1 & 2 DIFFERENTIATION BY IMMUNOBLOT-HERPSELECT | HSVB12 | HSVB12 | Immunoblot | HSV 1 & 2 IgG Negative
Negative for antibody to HSV 1 and HSV 2 by Immunoblot. No evidence of past infection
with HSV 1 or 2. Individuals infected with HSV may not exhibit detectable IgG Ab to
glycoprotein G in the early stages of infection and 5-10% of infections may occur
with glycoprotein G-deficient virus.
Detection of antibody presence in these cases may only be possible using a nontype-
specific screening test. All results from this and other serologies must be
correlated with clinical history, epidemiological data, and other date available to
the attending physician in making the differentiation between HSV type 1 and HSV type
2 infection. |
| HERPES SIMPLEX VIRUS IGM ANTIBODY | HSVIGM | HSVIGM | EIA | Herpes Simplex Virus IgM Antibody OD
LT 0.91 Negative-No clinically
significant level of HSV
IgM Ab detected.
0.91-1.09 Indeterminate-Unable to
determine the presence or
absence of HSV IgM Ab.
Repeat testing in 10-14
days may be helpful.
GT 1.09 Positive-IgM Ab to HSV
detected. May indicate
current or recent infection
or reactivation. |
| HERPES SIMPLEX VIRUS TYPE-SPECIFIC 1 IGG-HERPESELECT® | HSV1G | HSV1G | EIA | HSV I IgG Type-Specific Ab IV
LT 0.90 Negative-No significant
level of detectable IgG
Ab to HSV Type I Glycoprotein
G.
0.90-1.10 Indeterminate-Questionable
presence of Ab to HSV Type I
Glycoprotein G. Repeat testing
may be helpful.
GT 1.10 Positive-IgG Ab to HSV Type I
Glycoprotein detected. May
indicate a current or past
infection. |
| HERPES SIMPLEX VIRUS TYPE-SPECIFIC 2 IGG-HERPESELECT® | HSV2G | HSV2G | EIA | HSV II IgG Type-Specific Ab IV
LT 0.90 Negative-No significant
level of detectable IgG
Ab to HSV Type 2 Glycoprotein
G.
0.90-1.10 Indeterminate-Questionable
presence of Ab to HSV Type 2
Glycoprotein G. Repeat testing
may be helpful.
GT 1.10 Positive-IgG Ab to HSV Type 2
Glycoprotein detected. May
indicate a current or past
infection. |
| HERPES SIMPLEX VIRUS TYPE-SPECIFIC I & II IGG-HERPESELECT® & HERPES SIMPLEX VIRUS IGM ANTIBODY | HSGM | HSGM | EIA | HSV I IgG Type-Specific Ab IV
LT 0.90 Negative-No significant
level of detectable IgG
Ab to HSV Type I Glycoprotein
G.
0.90-1.10 Indeterminate-Questionable
presence of Ab to HSV Type I
Glycoprotein G. Repeat testing
may be helpful.
GT 1.10 Positive-IgG Ab to HSV Type I
Glycoprotein detected. May
indicate a current or past
infection.
HSV II IgG Type-Specific Ab IV
LT 0.90 Negative-No significant
level of detectable IgG
Ab to HSV Type II Glycoprotein
G.
0.90-1.10 Indeterminate-Questionable
presence of Ab to HSV Type II
Glycoprotein G. Repeat testing
may be helpful.
GT 1.10 Positive-IgG Ab to HSV Type II
Glycoprotein detected. May
indicate a current or past
infection.
Herpes Simplex Virus IgM Antibody OD
LT 0.91 Negative-No clinically
significant level of HSV
IgM Ab detected.
0.91-1.09 Indeterminate-Unable to
determine the presence or
absence of HSV IgM Ab.
Repeat testing in 10-14
days may be helpful.
GT 1.09 Positive-IgM Ab to HSV
detected. May indicate
current or recent infection
or reactivation. |
| HERPES VIRUS 7, IGG & IGM AB PANEL | HSV7GM | HSV7GM | IFA | Herpes Simplex Virus 7, IgG LT 1:160
Herpes Simplex Virus 7, IgM LT 1:20 |
| HERPESVIRUS 6 ANTIBODY, IGG | HER6AB | HER6AB | ELISA | Herpesvirus 6 Ab, IgG IV
0.89 or less Negative-no significant
level of detectable HHV-6 IgG antibody.
0.90-1.10 Equivocal-questionable
presence of HHV-6 IgG antibody. Repeat
testing in 10-14 days may be helpful.
1.11 or more Positive-IgG antibody
to HHV-6 detected, which may indicate
current or past infection.
The best evidence for current infection
is a significant change on two appropriately
timed specimens, where both tests are done in
the same laboratory at the same time. |
| HERPESVIRUS 6 ANTIBODY, IGG & IGM | HEV6GM | HEV6GM | IFA | Herpesvirus 6 Antibody, IgG
LT 1:10 Antibody not detected
Herpesvirus 6 Antibody, IgM
LT 1:20 Antibody not detected
Interpretation
Human Herpesvirus 6 (HHV-6) infects
T-lymphocytes, and has been identified
as an etiologic agent of exanthema
subitum. Rises in antibody titers to
HHV-6 have been detected during
infection with other viruses. In sero-
epidemilogy studies of the prevalence
of exposure usuing serum screening
dilutions of 1:10, the detection of
IgG Antibody in a mid-life population
approches 100%. Due to this high pre-
valence of HHV-6 Antibody, correlations
of single IgG titers with specific
diseases are of little clinical value.
Evidence of acute infection or re-
activation of HHV-6 is demonstrated by
a significant rise or seroconversion
of IgG and IgM titers. |
| HERPESVIRUS 6 DNA, PCR | HHV6PC | HHV6PC | PCR | Herpesvirus 6 DNA Not detected
The detection of human herpesvirus 6
DNA is based upon the amplification of
specific HHV-6 genomic DNA sequences
by PCR from total DNA extracted from
the specimen. The diagnosis of HHV-6
infection should not rely solely upon
the result of a PCR assay. A positive
PCR result should be considered in
conjunction with clinical presentation
and additional established diagonstic
tests prior to establishing a diagnosis.
A negative PCR result indicated only
the absence of HHV-6 DNA in the sample
tested and does not exclude the diagnosis
of disease. This test is performed
pursuant to a license agreement with
Roche Molecular Systems, Inc. |
| HEXOSAMINIDASE A & TOTAL, LEUKOCYTE | TAYSACHS.PREG | HEXAL | Heat Inactivation & Fluorometric | Hexosaminidase A & Total, Leukocyte
Separate Report to Follow |
| HIGH MOLECULAR WEIGHT KININOGEN ASSAY (HMW KININOGEN) | FITGZ | FITGZ | Clot | HMW Kininogen Assay 65-135 % |
| HIGH SENSITIVITY CRP | HCRP | HCRP | Nephelometry | High Sensitivity CRP mg/L
Low risk LT 1.0
Average risk 1.0-3.0
High risk GT 3.0
Relative risk categories follow the
recommendations of the American Heart
Association and the CDC. Measurement
of hsCRP should be done twice (averaging
results), optimally two weeks apart,
in metabolically stable patients. If
the hsCRP level is GT 10 mg/L, the test
should be repeated and the patient
examined for non-cardiovascular sources
of inflammation, such as infection. |
| HIGH SENSITIVITY CRP & CHOLESTEROL PROFILE | HCRPP | HCRPP | Enzymatic, Nephelometry | High Sensitivity CRP mg/L
Low risk LT 1.0
Average risk 1.0-3.0
High risk GT 3.0
Relative risk categories follow the
recommendations of the American Heart
Association and the CDC. Measurement
of hsCRP should be done twice (averaging
results), optimally two weeks apart,
in metabolically stable patients. If
the hsCRP level is GT 10 mg/L, the test
should be repeated and the patient
examined for non-cardiovascular sources
of inflammation, such as infection.
Cholesterol mg/dL
LT 200 Desirable
200-239 Borderline high
240 or more High
HDL mg/dL
LT 40 Low
40-59 Within normal limits
60 or more High
HDL Cholesterol greater than or equal
to 60 mg/dL is considered to be a
"negative" risk factor, serving to
remove one risk factor from the total
count. |
| HISTAMINE | HIST | HIST | EIA | Histamine (Blood) 140-890 nmol/L |
| HISTAMINE, PLASMA | HISTP | HISTP | EIA | Histamine, Plasma 0-6 nmol/L |
| HISTAMINE, URINE | HIST-U | HISTUR | EIA | Collection Period h
Volume mL
Creatinine, Ur mg/dL
Histamine, Ur nmol/L
Histamine, Ur 0-386 nmol/g |
| HISTONE ANTIBODY | HISTONE | HISTOG | ELISA | Histone Antibody (Hrana) U
LT 1.0 None detected
1.0-1.5 Inconclusive
1.6-2.5 Positive
GT 2.5 Strong positive |
| HISTOPLASMA ANTIBODY | HISTO.CF | HISCF | CF | Histoplasma Ab Mycelial (CF) Titer
No antibody detected
Histoplasma Ab Yeast (CF) Titer
No antibody detected |
| HISTOPLASMA ANTIBODY PANEL | HISABP | HISABP | CF/ID | Histoplasma Ab Mycelia, CF
LT 1:8 No antibody detected.
Histoplasma Ab Yeast, CF
Lt 1:8 No antibody detected.
Greater than or equal to 1:8 with
either antigen are generally considered]
presumptive evidence of histoplasmosis.
Greater than 1:32 or rising titers
indicate strong presumptive evidence
of histoplasmosis.
Titer of greater than or equal to 1:8
with one or both antigens may occur;
yeast phase regarded as more sensitive.
Approximately 90-95% of cases have
positive titers to one or both antigens.
Titers to mycelial antigen are higher
in chronic infection. Cross reactions,
ususally lower titers, may occur with
fungal disease. Rising titers suggest
progression of infection. Skin tests in
individuals previously exposed may
cause titer elevation in 17-20% of cases.
Histoplasma Ab, ID
None detected.
In general immunodiffusion measures IgG
and a postive result may suggest active
or recent infection. |
| HISTOPLASMA ANTIGEN | HISAG | HISAG | EIA | Histoplasma Antigen ng/mL
Negative None detected
Positive, Low LT 0.6-3.9
Positive, Mod 4.0-19.9
Positive, High 20.0-39.0 or more |
| HISTOPLASMA PRECIPITIN ANTIBODY | HISTO.AB | HISID | Immunodiffusion | Histoplasma Precipitin Ab by ID
None detected
The immunodiffusion test can detect
precipitins to specific Histoplasma
protein antigens (M and H). The M
band often appears first and may
occur without the H band. M
precipitin is found in about 70%
of both acute and chronic histo-
plasmosis cases. Both M and H occur
together in only about 10% of
patients. |
| HIV-1 DNA, QUALITATIVE BY PCR | HIV.DNA.PCR | HIVDPC | PCR | HIV 1 PCR Not detected
The detection of human immunodeficiency
virus type 1 (HIV-1) proviral DNA is
based on the amplification of specific
HIV-1 proviral genomic DNA sequences by
PCR from total DNA extracted from the
specimen. The diagnosis of HIV-1 infection
should not rely solely upon the result
of a PCR assay. A positive PCR result
should be considered in conjunction with
clinical presentation and additional
established diagnostic tests prior to
establishing a diagnosis. A negative
PCR result indicates only the absence
of HIV-1 proviral DNA in the sample
tested and does not exclude the
diagnosis of disease.
This test was performed using a kit that
has not been cleared or approved by the FDA.
The analytical performance characteristics of
this test have been determined by Focus
Diagnostics. This test should not be used
for diagnosis without confirmation by
other medically established means.
. |
| HLA B27 (REFLEXIVE) | HLA B27 | HLAB27 | Flow cytometry | HLA-B27 Negative |
| HLA-B*5701 GENOTYPING | HLA57 | HLA57 | PCR and Fluorescence Monitoring | HLA-B*5701 Specimen
HLA-B*5701 Genotyping Negative |
| HLA-DQB GENOTYPING | HLADQB | HLADQB | PCR/Sequence specific Oligo probe. | Class II locus DQB, Allele 1
Class II locus DQB, Allele 2
HLA-DQ Oligotyping Inter
The presence of a disease
associated HLA combination does
not establish a diagnosis. If less
than 2 alleles are reported for a
locus, the patient is likely
homozygous. Rare diagnostic errors
can occur due to primer or probe
site mutations. This test is not
sufficient for comprehensive HLA
evaluation for clinical
hematopoietic stem cell
transplantation. Counseling and
informed consent are recommended
for genetic testing. Consent forms
are available online at
www.aruplab.com. |
| HLAB*1502 TYPING | HB1502 | HB1502 | PCR/Sequence Specific Probes | HLA B* 1502 Typing Negative |
| HOMOCYSTEINE, CARDIAC RISK | HOMCY | HOMCY | FPIA | Homocysteine 4.0-12.0 umol/L |
| HOMOCYSTINE, URINE | HOMO-U | HOMOUQ | Spectrophotometric | Collection Period hr
Volume mL
Creatinine, Ur mg/dL
Creatinine, Ur mg/d
M 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81+ yrs 600-2000
F 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
81+ yrs 400-1300
Homocystine, Ur mg/L
Homocystine, Ur 0-53 mg/gCr
Homocystine, Ur 0-32 mg/d |
| HUMAN GROWTH HORMONE | HGH | HGH | ICMA | HGH 0-10 ng/mL |
| HUMAN GROWTH HORMONE, SAMPLE 1 | HGH.S1 | GH1 | ICMA | HGH, #1 0-10 ng/mL
HGH, Time 1 |
| HUMAN GROWTH HORMONE, SAMPLE 2 | HGH.S2 | GH2 | ICMA | HGH, #2 ng/mL
HGH, Time 2 |
| HUMAN GROWTH HORMONE, SAMPLE 3 | HGH.S3 | GH3 | ICMA | HGH, #3 ng/mL
HGH, Time 3 |
| HUMAN GROWTH HORMONE, SAMPLE 4 | HGH.S4 | HGH4 | ICMA | HGH, #4 ng/mL
HGH, Time 4 |
| HUMAN GROWTH HORMONE, SAMPLE 5 | HGH.S5 | HGH5 | ICMA | HGH, #5 ng/mL
HGH, Time 5 |
| HUMAN GROWTH HORMONE, SAMPLE 6 | HGH.S6 | HGH6 | ICMA | HGH, #6 ng/mL
HGH, Time 6 |
| HUMAN GROWTH HORMONE, SAMPLE 7 | HGH.S7 | HGH7 | ICMA | HGH, #7 ng/mL
HGH, Time 7 |
| HUMAN GROWTH HORMONE, SAMPLE 8 | HGH.S8 | HGHP8 | ICMA | HGH, #8 ng/mL
HGH, Time 8 |
| HUMAN IMMUNODEFICIENCY VIRUS 1 ULTRA SENSITIVE VIRAL LOAD BY PCR | HIVUS | HIVUS | RT-PCR: Ampliprep/TaqMan HIV-1 Test | HIV-1 Viral Load Result log copies/mL
Not detected
HIV-1 Viral Load Result copies/mL
Not detected
HIV-1 Viral Load Comment
Reportable range HIV-1 RNA 1.7 to 7.0
log copies/mL (48 to 10,000,000 copies/mL).
This assay was performed using the FDA approved
Roche COBAS AmpliPrep/COBAS TaqMan HIV-1
Test.
This test is intended for use in con-
junction with other laboratory markers
as a prognostic indicator for patients
with HIV-1 infection. It may also be
used to aid in the assessment of viral
response to an antiretrovial treatment
as measured by changes in plasma HIV-1
RNA levles. A three fold (0.5 log) change
in copies/mLs is usually considered to
be clinically significant. This test
is performed pursuant to an agreement
with Roche Molecular Systems, Inc. |
| HUMAN IMMUNODEFICIENCY VIRUS 1 ULTRASENSITIVE VIRAL LOAD BY BDNA | HIVQBD | HIVQBD | Branched Chain DNA | HIV-1 Ultrasensitive RNA bDNA copies/mL
Not detected
Reportable Range is 75-500,000 copies/mL
HIV-1 Ultrasensitive RNA bDNA Log10
Not detected
Reportable Range is 1.9-5.7 log10.
A patient value of Not detected indicates
that the patient viral load is below the
quantitative limit of the assay.
This test is intended for use in con-
junction with clinical presentation &
other laboratory markers as a prog-
nostic indicator for patients with HIV
-1 infection. Plasma HIV-1 RNA assays
may also be used to monitor patients
on antiretroviral therapies. Increasing
viral load levels have been shown to
correlate with progression of HIV
disease. A sustained 3-fold or 0.5 Log
10 increase or decrease in HIV-1 RNA
levels generally reflects a bio-
logically relevant change in viral
replication. This test is not intended
to be used as a screening test for HIV
or as a diagnostic test to confirm or
rule out HIV infection. |
| HUMAN IMMUNODEFICIENCY VIRUS-1 & 2 ANTIBODY (VIROLOGY SEROLOGY) (REFLEXIVE) | 12HIVR | 12HIVR | ICMA | HIV-1/HIV-2 Nonreactive
HIV-1 Western Blot
Interpretation
p18 Band Absent
p24 Band Absent
p31 Band Absent
p40 Band Absent
gp41 Band Absent
p51/55 Band Absent
p65 Band Absent
gp 120/160 Band Absent
|
| HUMAN IMMUNODEFICIENCY VIRUS-1 GENOTYPE PLUS [SPECIALTY] | HIVGT1 | HIVGT1 | PCR | Resistance Associated RT Mutations
Zidovudine (AZT)
Didanosine (ddl)
Lamivudine
Stavudine(d4T)
Abacavir (ABC)
Tenofovir (TDF)
Nevirapine (NVP)
Efavirenz(EFV)
Resistance Associated PR Mutations
Saquinavir + Ritonavir (SQV)
Indinavir (IDV)
IDV/r
Nelfinavir (NFV)
Amprenavir (APV)/Fosamprenavir (FPV)
APV/r or FPV/r
Lopinavir + Ritonavir (LPV/r)
Atazanavir (ATV)
Atazanavir + Ritonavir (ATV/r)
Tipranavir + Ritonavir (TPV/r)
Darunavir + Ritonavir |
| HUMAN IMMUNODEFICIENCY VIRUS-1, WESTERN BLOT | 1HIVWB | 1HIVWB | Western Blot | HIV-1 Western Blot
Western Blot Interpretation
p18 Band Absent
P24 Band Absent
P31 Band Absent
P40 Band Absent
gp41 Band Absent
p51/55 Band Absent
p65 Band Absent
gp 120/160 Band Absent |
| HUMAN IMMUNODEFICIENCY VIRUS-2 ANTIBODY, EIA | HIV2AB | HIV2AB | EIA | HIV-2 Ab, EIA
Separate Report to Follow |
| HUMAN IMMUNODEFICIENCY VIRUS-2 ANTIBODY, IMMUNOBLOT | HIV2WB | HIV2WB | Immunoblot | HIV-2 Ab, Immunoblot
Separate Report to Follow |
| HUMAN PAPILLOMAVIRUS DNA PROBE HIGH RISK | HPVDG | HPVDG | Invader | Source
HPV High Risk Result Negative for High RisK Human Papillomavirus.
A negative test for the HPV high risk probe on
a cervical specimen indicates a low probability
of infection with HPV types 16,18,31,33,35,39,
45,51,52,56,58,59, 66 and 68.
A negative result does not exclude infection
with a genotype not included in the Hologic HPV test panel,
a level of infection below the limit of detection of this test,
or a sampling error.
The Hologic Cervista HPV HR assay
has not been validated for non-cervical specimens,
although positive results may be accurate, false
negative test results may occur. |
| HUMAN PAPILLOMAVIRUS GENOTYPE 16/18 | HVPGNT | HPVGNT | Invader | HPV Source
HPV Genotype Result Type 16 Not Detected
Type 18 Not Detected |
| HUMAN PLACENTAL LACTOGEN | HPLA | HPLA | EIA | Human Placental Lactogen ug/mL
M 0.0-0.10
F Non-pregnant 0.0-0.10
F 1st trimester 0.20-2.10
2nd trimester 0.50-6.70
3rd trimester 4.50-12.80 |
| HUMAN T-LYMPHOTROPIC VIRUS TYPES I/II ANTIBODIES (REFLEXIVE) HTLV I/II | 12HTLV | 12HTLV | EIA/Western Blot | HTLV I/II Nonreactive |
| HUMORAL IMMUNITY PANEL 1 | HUMIMM | HUMIMM | Neph, Multi-analyte fluoresence detection | Diphtheria Ab, IgG Antibody concentration of GT 0.1 is usually IU/mL
considered protective.
Tetanus Ab, IgG Antibody concentration of GT 0.1 is usually IU/mL
considered protective.
Pneumococcal Serotype 1, IgG ug/mL
Pneumococcal Serotype 3, IgG ug/mL
Pneumococcal Serotype 4, IgG ug/mL
Pneumococcal Serotype 5, IgG ug/mL
Pneumococcal Serotype 6B, IgG ug/mL
Pneumococcal Serotype 7F, IgG ug/mL
Pneumococcal Serotype 8, IgG ug/mL
Pneumococcal Serotype 9N, IgG ug/mL
Pneumococcal Serotype 9V, IgG ug/mL
Pneumococcal Serotype 12F, IgG ug/mL
Pneumococcal Serotype 14, IgG ug/mL
Pneumococcal Serotype 18C, IgG ug/mL
Pneumococcal Serotype 19F, IgG ug/mL
Pneumococcal Serotype 23F, IgG ug/mL
Pneumococcal Serotype Interpretation All serotypes tested are present in the 23-valent
pure polysaccharide pneumococcal vaccine. Serotypes
4, 6B, 9V, 14, 18C, 19F and 23F are contained in the
conjuated pneumococcal vaccine. Long-term protection
is generally thought to be associated with a 1 month
vaccine response of at least 1 ug/mL in children & adults.
Responder status is determined once reaching the
minumin level of 1 ug/mL according to the ratio
of postvaccianation to prevaccination concentration of
pneumococcal IgG antibody as follows:
A ratio of LT two-fold is considered a non-responder.
A ratio of two-to-four-fold is a weak responder.
A ratio of fourfold is a good responder.
.
IgA 0-30 days 1-7 mg/dL
1 mo 1-53
2 mo 3-47
3 mo 5-46
4 mo 4-72
5 mo 8-83
6 mo 8-67
7-8 mo 11-89
9-11 mo 16-83
1 yr 14-105
2 yrs 14-122
3 yrs 22-157
4 yrs 25-152
5-7 yrs 33-200
8-9 yrs 45-234
10 yrs + 68-378
IgG 0-30 days 611-1542 mg/dL
1 mo 241-870
2 mo 198-577
3 mo 169-558
4 mo 188-536
5 mo 165-781
6 mo 206-676
7-8 mo 208-868
9-11 mo 282-1026
1 yr 331-1164
2 yrs 407-1009
3 yrs 423-1090
4 yrs 444-1187
5-7 yrs 608-1229
8-9 yrs 584-1509
10 yrs + 68-1632
IgM 0-30 days 0-24 mg/dL
1 mo 19-83
2 mo 16-100
3 mo 23-85
4 mo 26-96
5 mo 31-103
6 mo 33-97
7-8 mo 32-120
9-11 mo 39-142
1 yr 41-164
2 yrs 46-160
3 yrs 45-190
4 yrs 41-186
5-7 yrs 46-197
8-9 yrs 49-230
10 yrs + 60-263
IgG Subclass 1 Cord blood 435-1084 mg/dL
0-2 mo 218-498
3-5 mo 143-394
6-8 mo 190-388
9-23 mo 288-880
2 yrs 170-950
3-4 yrs 290-1065
5-6 yrs 330-1065
7-8 yrs 225-1100
9-10 yrs 390-1235
11-12 yrs 380-1420
13-14 yrs 165-1440
IgG Subclass 2 Cord blood 143-453 mg/dL
0-2 mo 40-167
3-5 mo 23-147
6-8 mo 37-60
9-23 mo 30-327
2 yrs 22-440
3-4 yrs 28-315
5-6 yrs 57-345
7-8 yrs 42-375
9-10 yrs 61-430
11-12 yrs 73-455
13-14 yrs 71-460
15 yrs + 124-549
IgG Subclass 3 Cord blood 27-146 mg/dL
0-2 mo 4-23
3-5 mo 4-70
6-8 mo 12-62
9-23 mo 13-82
2 yrs 4-69
3-4 yrs 4-71
5-6 yrs 8-126
7-8 yrs 9-107
9-10 yrs 10-98
11-12 yrs 16-194
13-14 yrs 12-178
15 yrs + 21-134
IgG Subclass 4 Cord blood 1-47 mg/dL
0-2 mo 1-33
3-5 mo 1-14
6-8 mo 1-16
9-23 mo 1-65
2 yrs 0-120
3-4 yrs 0-90
5-6 yrs 2-116
7-8 yrs 0-138
9-10 yrs 1-95
11-12 yrs 1-153
13-14 yrs 2-143
15 yrs + 7-89 |
| HUNTINGTON DISEASE DNA SCREEN | HUNDUW | HUNDUW | PCR Capillary Electrophoresis | HD allele 1
HD allele 2
HD Clinical Information
HD Interpretation |
| HYDROCODONE, FREE, UNCONJUGATED | HYDROCODONE | HYDCOD | GC/MS | Hydrocodone, Free Unconjugated ng/mL
Following a single 10 mg oral dose
Up to 32 ng/mL at 1.5 hours post dose.
This test is for clinical use only. |
| HYDROMORPHONE, FREE (REFLEXIVE) | HYDMCO | HYDMCO | LC/MS/MS, HPLC | Hydromorphone, Free ng/mL
Hydromorphone, Free Confirmation ng/mL
Expected range during treatment of
severe pain: 1-49 ng/mL |
| HYDROXYCHLOROQUININE | PLAQ | PLAQ | HPTLC | Hydroxychloroquinine 0.1-1.0 mcg/mL |
| HYDROXYPROLINE, TOTAL, URINE | HYDROXYPROLINE.T | HPTUQ | Ion Exchange Chromatography | Collection Period hr
Volume mL
Hydroxyproline, Total 38-500 umol/d
Creatinine, Ur mg/dL
Creatinine, Ur mg/d
M 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81+ yrs 600-2000
F 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
81+ yrs 400-1300 |
| HYPERCOAGULATION CONSULT EXTENDED PANEL (REFLEXIVE) | HYPCEA | HYPCE | See individual components | Homocysteine, Cardiac Risk 4.0-12.0 umol/L
PT 20210, Method
PT 20210, Result
PT 20210, Interpretation
PT 20210, Comment
PT 20210, Comment
Cardiolipin Ab, IgG LT 23 GPL
Cardiolipin Ab, IgM LT 11 MPL
APC Resistance GT 2.0
Protein C Activity 70-145 %
Protein S Activity 65-140 %
Anti-Thrombin III Activity 85-126 %
Anti-Thrombin III Antigen 22-33 mg/dL
PT, Patient sec
0-1 mo 13.0-20.0
2+ mo 10.9-14.8
PT, PT/CT Mix sec
Thrombin Time, Patient 15.6-20.0 sec
TT, PT/PS Mix sec
PTT, Patient sec
0-1 mo 40-50
2 mo-4 yr 25-40
5+ yrs 26-36
PTT, Control sec
PTT, PT/CT Mix sec
PNP 0.0-7.0 sec
dRVVT 31.8-45.7 sec
dRVVT Mix Ratio LT 1.2
dRVVT Confirm Ratio LT 1.2
dRVVT Confirm Mix Ratio LT 1.2
Hypercoagulation Consult Basic Interpretation
Hypercoagulation Reviewed By |
| HYPERCOAGULATION CONSULTATION, BASIC (REFLEXIVE) | HYPERC | HYPERC | Clot-based, Chromogenic, Immuno-turbid | APC Resistance GT 2.0
Protein C Activity 70-145 %
Protein S Activity 65-140 %
Anti-thrombin III Activity 85-126 %
Anti-thrombin III Antigen 21-33 mg/dL
PT, Patient sec
0-1 mo 13.0-20.0
2+ mo 10.9-14.8
PT, PT/CT Mix sec
Thrombin Time, Patient 12.0-17.0 sec
TT, PT/PS Mix sec
PTT, Patient sec
0-1 mo 40-50
2 mos-4 yrs 25-40
5+ yrs 26-36
PTT, Control sec
PTT, PT/CT Mix sec
PNP 0.0-7.0 sec
dRVVT 31.8-45.7 sec
dRVVT Mix Ratio LT 1.2
dRVVT Confirm Ratio LT 1.2
dRVVT confirm mix Ratio LT 1.2
Hypercoagualtion Consult, Basic
Interpretation
Review |
| HYPERSENSITIVE PNEUMONITIS EXTENDED PANEL (FARMER'S LUNG PANEL) | HYPEXT | HYPEXT | ID/Immunocap | Aspergillus fumigatus #1 None detected
Aspergillus fumigatus #6 None detected
Aureobasidium pullulans None detected
Pigeon Serum None detected
Micropolyspora faeni None detected
Thermoactinomyces vulgaris #1 None detected
Aspergillus flavus None detected
Aspergillus fumigatus #2 None detected
Aspergillus fumigatus #3 None detected
Saccharomonospora viridis None detected
Thermoactinomyces candidus None detected
Thermoactinomyces sacchari None detected
Allergen-Animal Feather Mix, IgE Negative
Allergen-Beef, IgE LT 0.35 kU/L
Allergen-Pork, IgE LT 0.35 kU/L
Allergen-Fungi/Mold Phoma betae IgE
Allergen, Interp Immunocap Score
|
| HYPERSENSITIVE PNEUMONITIS I | HLDP | HPNEUM | ID | Aspergillus Fumigatus #1 None detected
Aspergillus Fumigatus #6 None detected
Aurebasidium Pullulans None detected
Pigeon Serum None detected
Micropolyspora Faeni None detected
Thermoactinomyces Vulgaris #1 None detected |
| HYPERSENSITIVE PNEUMONITIS II | HPENII | HPENII | ID | Aspergillus flavus None detected
Aspergillus fumigatus #2 None detected
Aspergillus fumigatus #3 None detected
Saccharomonospora viridis None detected
Thermoactinomyces candidus None detected
Thermoactinomyces sacchari None detected |
| HYPERTHYROID PROFILE | HYPERA | HYPER | ICMA | FTI 5.0-12.0
T3 Uptake 22.5-37.0 %
T4 ug/dL
M 0-30 days 3.0-14.3
1-12 mo 5.2-16.3
1-5 yrs 5.5-11.4
5-10 yrs 5.3-10.5
10-15 yrs 4.5-10.3
15-18 yrs 4.9-8.8
F 0-30 days 3.0-13.3
1-12 mo 4.6-13.3
1-5 yrs 6.3-12.8
5-10 yrs 5.3-10.8
10-15 yrs 4.9-10.0
15-18 yrs 5.1-10.0
Adults 18 yrs+ 5.0-12.0
T3 By ICMA TBG Corrected 80-200 ng/dL |
| HYPOGLYCEMICS PANEL | HGLYP | HGLYP | LC/MS/MS | Acetohexamide ng/mL
Chlorpropamide ng/mL
Glimepiride ng/mL
Glipizide ng/mL
Glyburide ng/mL
Nateglinide ng/mL
Repaglinide ng/mL
Tolazamide ng/mL
Tolbutamide ng/mL |
| HYPOTHYROID PROFILE | HYPOA | HYPO | ICMA | FTI 5.0-12.0
T3 Uptake 22.5-37.0 %
T4 ug/dL
M 0-30 days 3.0-14.3
1-12 mo 5.2-16.3
1-5 yrs 5.5-11.4
5-10 yrs 5.3-10.5
10-15 yrs 4.5-10.3
15-18 yrs 4.9-8.8
F 0-30 days 3.0-13.3
1-12 mo 4.6-13.3
1-5 yrs 6.3-12.8
5-10 yrs 5.3-10.8
10-15 yrs 4.9-10.0
15-18 yrs 5.1-10.0
Adults 18 yrs+ 5.0-12.0
TSH uIU/mL
M 0-30 days 0.52-16.00
1 mo-5 yrs 0.55-7.10
5-18 yrs 0.37-6.00
F 0-30 days 0.72-13.10
1 mo-5 yrs 0.46-8.10
5-18 yrs 0.36-5.80
18 yrs+ 0.40-5.00 |
| IA-2 ANTIBODY | IA2A | IA2A | RIA | IA-1 Antibody Negative 0.8 or less Kronus Units/mL
Positive GT 0.8
Kronus Units are arbitrary.
Kronus Units/mL = U/mL |
| IBUPROFEN | IBU | IBU | HPLC | Ibuprofen Not well established ug/mL
No therapeutic or toxic range has been
established. Peak plasma levels of 10-50
ug/mL may be seen with normal dosage.
Draw between 1 and 1.5 hours post dose.
Concentrations greater than 200 ug/mL
may be associated with toxicity. |
| ICA 512 AUTOANTIBODIES | ICA512 | ICA512 | Immunoprecipitation | ICA 512 Autoantibodies LT 1 U/mL |
| ID CULTURE AFB | AFB.ID | AFBID | | Source
ID AFB Result
ID AFB Status |
| ID FUNGUS (MOLD) | FUNGID | FUNGID | Culture | Source
ID Fungus (Mold) Result
ID Fungus (Mold) Status |
| ID ORGANISM WITH SUSCEPTIBILITY (REFLEXIVE) | CIDS | CIDS | Culture, Susceptibility | Source
ID Organism with Susceptibility Result
ID Organism with Susceptibility Status |
| ID ORGANISM, BLOOD/BODY FLUID | CBDFID | CBDFID | Culture | ID Organism Blood/Body Fluid Result
ID Organism Blood/Body Fluid Status |
| ID ORGANISM, BLOOD/FLUID & SUSCEPTIBILITY (REFLEX) | CBFIDS | CBFIDS | Culture | Source
ID Organism Blood/Fluid & Susceptibility Result
ID Organism Blood/Fluid & Susceptibility Status |
| ID ORGANISM, RESPIRATORY | CRID | CRID | Culture | Source
ID Organism Respiratory Result
ID Organism Respiratory Status |
| ID ORGANISM, RESPIRATORY & SUSCEPTIBILITY (REFLEX) | CRIDS | CRIDS | Culture | Source
ID Organism Respiratory & Susceptibility Result
ID Organism Respiratory & Susceptibility Status |
| ID ORGANISM, URINE | CORGUR | CORGUR | | Source
ID Organism Urine Result
ID Organism Urine Status |
| ID ORGANISM, URINE WITH SUSCEPTIBILITY (REFLEXIVE) | CURIDS | CURIDS | Culture, Susceptibility | Source
ID Organism, Urine with Susceptibility Result
ID Organism, Urine with Susceptibility Status |
| ID YEAST (REFLEX) | YID | YID | Culture | Source
Yeast ID Result
Yeast ID Status |
| IGF BINDING PROTEIN-1, [ESOTERIX] | IGFBP1 | IGFBP1 | RIA | IGF Binding Protein-1 ng/mL
Prepubertal Range
Fasting 30-1000
Random 10-500
Pubertal
Fasting 20-200
Random 20-100
Adults
Fasting 10-150
Random 0-40
|
| IGF BINDING PROTEIN-3 | IGFB3 | IGFB3 | RIA in dilute serum | IGF Binding Protein-3 mg/L
Premature Range Mean
0-1 mon 0.3-1.4 0.9
2-3 mon 0.9-2.3 1.6
4-5 mon 0.4-2.2 1.5
6-11 mon 1.0-2.3 1.5
Fullterm
0-1 mon 0.4-1.7 0.9
2-3 mon 0.5-2.1 1.3
4-5 mon 0.6-2.4 1.4
6-11 mon 0.5-2.4 1.4
12 mon-4 years 0.8-3.0 2.1
5-6 years 1.5-3.4 2.4
7-8 years 2.1-4.2 3.0
9-11 years 2.0-4.8 3.3
12-13 years 2.1-6.2 3.8
14-15 years 2.2-5.9 4.2
16-18 years 2.5-4.8 3.8
19-30 years 2.0-4.2 3.0
31-70 years 1.9-3.6 2.7 |
| IGF BINDING PROTEIN-3 | IGFB3A | IGFB3A | Chemiluminescent Immunoassay | IGF Binding Protein-3 ng/mL
Age - MALE Range
0-12 mo 1039-4169
1-3 yrs 972-4123
4-5 yrs 1706-5082
6-7 yrs 1838-4468
8-9 yrs 1932-5858
10-11 yrs 1828-6592
12-13 yrs 2134-6598
14-15 yrs 2330-6550
16-17 yrs 2380-6400
18-19 yrs 2340-6632
20-24 yrs 2404-5948
25-29 yrs 2614-5792
30-34 yrs 2500-5806
35-39 yrs 2474-5208
40-44 yrs 2360-5560
45-49 yrs 2314-5700
50-54 yrs 2528-5050
55-59 yrs 2482-5460
60-64 yrs 2592-4770
65 yrs+ 2698-5688
Tanner Stage I 1878-6190
Tanner Stage II 2112-6208
Tanner Stage III 2372-6602
Tanner Stage IV-V 2336-6414
Age - FEMALE
0-12 mo 1039-3169
1-3 yrs 1500-4225
4-5 yrs 2092-4936
6-7 yrs 2188-4996
8-9 yrs 2072-55-4
10-11 yrs 2456-6992
12-13 yrs 2838-6846
14-15 yrs 2654-6680
16-17 yrs 2756-6908
18-19 yrs 2700-6492
20-24 yrs 3032-5992
25-29 yrs 2926-5858
30-34 yrs 2878-6650
35-39 yrs 2786-6084
40-44 yrs 2514-6014
45-49 yrs 2838-4954
50-54 yrs 2562-5596
55-59 yrs 2574-5914
60-64 yrs 2684-5130
65 yrs + 2465-5274
Tanner Stage I 2314-6086
Tanner Stage II 2732-6738
Tanner Stage III 2870-7068
Tanner Stage IV-V 2756-7232
|
| IMIPRAMINE & METABOLITE | IMI | IMDES | HPLC | Imipramine ng/mL
No reference range established for parent
drug. See Total for reference range, which
takes into account all metabolites.
Desipramine ng/mL
Therapeutic 150-300
Toxic GT 499
Total Drug ng/mL
Therapeutic 150-250
Toxic GT 499 |
| IMMUKNOW CELL FUNCTION ASSAY | IMMUKN | IMMUKN | Cell culture/Chemiluminescence | ImmuKnow Cell Response Low 225 or less ATP Level ng/mL
Moderate 226-524 ATP Level
Strong 525 or more ATP Level |
| IMMUNE COMPLEX PROFILE I | IM-COM I | IMCOM | FC/ELISA | Raji Cell Assay LT 33 ugE/mL
C1Q Binding
LT 4 ugE/mL is considered negative for
circulation complement binding immune
complexes. |
| IMMUNOFIXATION | IEP | IEP | Immunofixation ELP/High Resolution | Protein, Total g/dL
0-12 mo 4.3-6.9
1-3 yrs 5.2-7.4
3-6 yrs 5.6-7.7
6-10 yrs 6.5-8.3
10-18 yrs 6.1-8.0
18-60 yrs 6.3-8.0
60 yrs+ 6.1-7.8
Albumin 0-4 days 2.9-4.6 g/dL
4 days-14 yrs 3.9-5.6
14-18 yrs 3.3-4.7
18-60 yrs 3.5-5.0
60-90 yrs 3.3-4.8
90 yrs+ 3.0-4.7
Alpha-1 0.1-0.4 g/dL
Alpha-2 0.5-1.1 g/dL
Beta-1 0.4-0.8 g/dL
Beta-2 0.2-0.5 g/dL
Gamma 0.6-1.5 g/dL
Albumin 45.0-80.0 %
Alpha-1 1.0-6.0 %
Alpha-2 6.0-17.0 %
Beta-1 5.0-13.0 %
Beta-2 2.0-8.0 %
Gamma 7.5-24.0 %
Interpretation
Monoclonal Peak
Immunofixation Interpretation |
| IMMUNOFIXATION, URINE | IEP-U | IEPUQ | Immunofixation ELP/High Resolution | Collection Period h
Volume mL
M 800-1800 mL/24h
F 600-1600
Protein, Urine, Quant
50-80 at rest mg/h
LT 250 after intense exercise
Elp Urine,Interpretation
Immunofixation Interp, Ur |
| IMMUNOFIXATION, URINE (RANDOM) | IEP-RU | IEPUR | Immunofixation ELP/High Resolution | ELP Urine Interp
Immunofixation Urine Interp |
| IMMUNOFIXATION, URINE/SERUM | IEP.SU | IEPSUQ | Immunofixation ELP/High Resolution | Collection Period h
Volume mL
ELP
Serum ELP interpretation
Serum IEP interpretation
Urine ELP interpretation
Urine IEP interpretation |
| IMMUNOFIXATION, URINE/SERUM (RANDOM) | IEP.SU-R | IEPSUR | Immunofixation ELP/High Resolution | ELP, Serum
ELP, Serum Interpretation
Monoclonal Peak
Immunofixation Serum Interp
ELP Urine Interp
Immunofixation Urine Interp |
| IMMUNOGLOBULIN A | IGA | IGA | Nephelometry | IgA mg/dL
0-4 mo No normals established
5-9 mo 14-77
10-11 mo 16-90
1 yr 21-113
2 yrs 27-153
3 yrs 31-176
4 yrs 34-194
5 yrs 40-225
6 yrs 54-297
7 yrs 66-374
8 yrs 68-387
9 yrs 71-387
10+ yrs 80-450 |
| IMMUNOGLOBULIN D | IMGD | IMGD | Nephelometry | Immunoglobulin D 15.3 or less mg/dL
IgD is one of the five classes of
immunoglobulins. IgD is mainly found
on the surface of B-cells and may
help regulate B-cell function. IgD
likely serves as an early B-cell
antigen receptor; however,
the function of the circulation IgD
is largely unknown. |
| IMMUNOGLOBULIN E, TOTAL | IGEC | IGEC | FEIA | IgE kU/L
0-11 mo 1.4-52.3
1-4 yrs 0.4-351.6
5-10 yrs 0.5-393.0
11-15 yrs 1.9-170.0
16+ yrs 0.0-158.0
Minimum detectable concentration is
2.0 kU/L. |
| IMMUNOGLOBULIN G | IGG | IGG | Nephelometry | IgG mg/dL
0-4 mo 600-1560
5-9 mo 252-655
10-11 mo 300-780
1 yr 330-858
2 yrs 372-967
3 yrs 450-1170
4 yrs 504-1326
5 yrs 540-1404
6 yrs 552-1435
7+ yrs 600-1560 |
| IMMUNOGLOBULIN G, CSF | IGG-C | IGGSF | Nephelometry | IgG, CSF 0.5-7.7 mg/dL |
| IMMUNOGLOBULIN G, SUBCLASSES | IGGSB | IGGSB | Nephelometry | IgG Subclass 1 mg/dL
0-2 mo 218-498
3-5 mo 143-394
6-8 mo 190-388
9-23 mo 288-880
2 yrs 170-950
3-4 yrs 290-1065
5-6 yrs 330-1065
7-8 yrs 225-1100
9-10 yrs 390-1235
11-12 yrs 380-1420
13-14 yrs 165-1440
15+ yrs 240-1118
IgG Subclass 2 mg/dL
0-2 mo 40-167
3-5 mo 23-147
6-8 mo 37-60
9-23 mo 30-327
2 yrs 22-440
3-4 yrs 28-315
5-6 yrs 57-345
7-8 yrs 42-375
9-10 yrs 61-430
11-12 yrs 73-455
13-14 yrs 71-460
15+ yrs 124-549
IgG Subclass 3 mg/dL
0-2 mo 4-23
3-5 mo 4-70
6-8 mo 12-62
9-23 mo 13-82
2 yrs 13-69
3-4 yrs 4-71
5-6 yrs 8-126
7-8 yrs 9-107
9-10 yrs 10-98
11-12 yrs 16-194
13-14 yrs 12-178
15+ yrs 21-134
IgG Subclass 4 mg/dL
0-2 mo 1-33
3-5 mo 1-14
6-8 mo 1-16
9-23 mo 1-65
2 yrs 0-120
3-4 yrs 0-90
5-6 yrs 2-116
7-8 yrs 0-138
9-10 yrs 1-95
11-12 yrs 1-153
13-14 yrs 2-143
15+ yrs 7-89
The total IgG (mg/dL) can be derived
from the sum of the subclass IgG1,
IgG2, IgG3, and IgG4 values. However,
a confirmatory and more precise total
IgG is available by the nephelometric
method for quantitative total IgG. |
| IMMUNOGLOBULIN M | IGM | IGM | Nephelometry | IgM mg/dL
0-4 mo 4-30
5-9 mo 12-132
10-11 mo 20-226
1+ yrs 25-275 |
| IMMUNOGLOBULINS, A, G & M | AGM | IGGAM | Nephelometry | IgA mg/dL
0-4 mo No normals established
5-9 mo 14-77
10-11 mo 16-90
1 yr 21-113
2 yrs 27-153
3 yrs 31-176
4 yrs 34-194
5 yrs 40-225
6 yrs 54-297
7 yrs 66-374
8 yrs 68-387
9 yrs 71-387
10+ yrs 80-450
IgG mg/dL
0-4 mo 600-1560
5-9 mo 252-655
10-11 mo 300-780
1yr 330-858
2 yrs 372-967
3 yrs 450-1170
4 yrs 504-1326
5 yrs 540-1404
6 yrs 552-1435
7+ yrs 600-1560
IgM mg/dL
0-4 mo 4-30
5-9 mo 12-132
10-11 mo 20-226
1+ yr 25-275 |
| IMMUNOPHENOTYPING ONE ANTIBODY | IP1AB | IP1AB | Flow Cytometry | Source
Result
Note |
| IMMUNOPHENOTYPING TWO ANTIBODIES | IP2AB | IP2AB | Flow Cytometry | Source
Result
Note |
| IMMUNOPHENOTYPING, ACUTE LEUKEMIA | IPHAL | IPHAL | Flow Cytometry | Immunophenotyping, Acute
Leukemia Result |
| IMMUNOPHENOTYPING, CHRONIC LYMPHOCYTIC LEUKEMIA | IPHCLL | IPHCLL | Flow Cytometry | Immunophenotyping, Chronic
Lymphocytic Leukemia Result |
| IMMUNOPHENOTYPING, HAIRY CELL LEUKEMIA | IPHHC | IPHHC | Flow Cytometry | Immunophenotyping, Hairy
Cell Leukemia Result. |
| IMMUNOPHENOTYPING, LYMPHOMA | IPHLY | IPHLY | Flow Cytometry | Immunophenotyping,
Lymphoma Result |
| IMMUNOPHENOTYPING, MISCELLANEOUS | IPHMI | IPHMI | Flow Cytometry | Immunophenotyping,
Misc Result |
| IMMUNOPHENOTYPING, MULTIPLE MYELOMA | IPHMM | IPHMM | Flow Cytometry | Immunophenotyping,
Multiple Myeloma
Result |
| IMMUNOPHENOTYPING, NEUROBLASTOMA | IPHNE | IPHNE | Flow Cytometry | Immunophenotyping,
Neuroblastoma Result |
| IMMUNOPHENOTYPING, PEDIATRIC LEUKEMIA | IPHPLK | IPHPLK | Flow Cytometry | Immunophenotyping,
Pediatric Leukemia
Result |
| INDICANS, URINE (QUALITATIVE) | INDIC | INDIC | Colorimetric | Indicans, Urine Qualitative Negative |
| INFLAMMATORY BOWEL DISEASE DIFFERENTIATION PANEL | IBDD | IBDD | ELISA, IFA | S. cerevisiae, IgG Units
20.0 or less Negative
20.1-24.9 Equivocal
25.0 or more Positive
S. cerevisiae, IgA Units
20.0 or less Negative
21.0-24.9 Equivocal
25.0 or more Positive
ANCA, Atypical Pattern
LT 1:20 Not significant |
| INFLUENZA A & B VIRUS ANTIGEN | FLABAG | FLABAG | EIA | Source
Influenza A and B Virus Antigen Negative
Influenza A and B Virus Antigen Status |
| INFLUENZA A & B VIRUS ANTIGEN BY DFA, REFLEX TO VIRAL CULTURE | FLUDFA | FLUDFA | DFA reflex to Culture | Source
Viral Culture and DFA Stain Negative for Influenza A & B.
No virus isolated
Report Status |
| INFLUENZA A VIRUS, IGG | FLUAG | FLUAG | ELISA | Influenza A Virus Antibody, IgG IV
0.89 or less Negative-no significant
level of influenza A virus IgG
antibody detected.
0.90-1.10 Equivocal-questionable
presence of influenza A virus IgG
antibody detected. Repeat testing in 1
0-14 days may be helpful.
1.11 or more Positive-IgG antibody
to influenza A virus detected, which
may suggest current or past infection. |
| INFLUENZA B VIRUS, IGG | FLUBG | FLUBG | ELISA | Influenza B Virus Antibody, IgG IV
0.89 or less Negative-no significant
level of influenza B virus IgG
antibody detected.
0.90-1.10 Equivocal-questionable
presence of influenza B virus IgG
antibody detected. Repeat testing in 1
0-14 days may be helpful.
1.11 or more Positive-IgG antibody
to influenza B virus detected, which
may suggest current or past infection. |
| INHIBIN A | INHA | INHA | ELISA | Inhibin A (Dimer) pg/mL
Female Normal Cycling
Early follicular phase (-14 to -10) 1.8-17.3
Mid-follicular phase (-9 to -4) 3.5-31.7
Late follicular phase (-3 to -1) 9.8-90.3.3
Mid-cycle (day 0) 16.9-91.8
Early luteal ( 1 to 3) 16.1-97.5
Mid-luteal (4-11) 3.9-87.7
Late luteal (12 to 14) 2.7-47.1
IVF Peak levels 354.2-1690.0
PCOS
Ovulatory 5.7-16.0
Postmenopausal LT 7.9
Male LT 2.1
This assay is performed using the
Beckman Coulter Unicel DxI Assay.
Values may be elevated during normal
pregnancy. Preclampsia, Down syndrome,
and some cancers may increase Inhibin-A
values. |
| INHIBIN B | INHB | INHB | ELISA | Inhibin B pg/mL
Male 0-6 yrs 40-630
7-10 yrs 35-170
11-18 yrs 50-475
19-45 yrs 40-450
46 yrs & more LT 10-200
Female 0-6 yrs LT 10-73
7-10 yrs LT 10-130
11-12 yrs LT 10-186
13-18 yrs LT 10-360
Premenopausal LT 10-290
Follicular LT 10-290
Postmenopausal GT or equal to 16
This assay is performed using the DSL Inhibin B ELISA
kit. Values obtained with different assay methods or
kits cannot be used interchangeably.
|
| INSULIN ANTIBODIES, SERUM | INSULA | INSULA | RIA | Insulin AB, serum 0.00-0.02 nmol/L
|
| INSULIN ASSAY | INS | INS | ICMA | Insulin, fasting 6-27 uIU/mL |
| INSULIN LIKE GROWTH FACTOR 1 | ILGF1 | ILGF1 | Chemiluminesence DPC Immulite | Insulin Like Growth Factor ng/mL
1 yr 55-327
2 yrs 51-303
3 yrs 49-289
4 yrs 49-283
5 yrs 50-286
6 yrs 52-297
7 yrs 57-316
8 yrs 64-345
9 yrs 74-388
10 yrs 88-452
11 yrs 111-551
12 yrs 143-693
13 yrs 183-850
14 yrs 220-972
15 yrs 237-996
16 yrs 226-903
17 yrs 193-731
18 yrs 163-584
19 yrs 141-483
20 yrs 127-424
21-25 yrs 116-358
26-30 yrs 117-329
31-35 yrs 115-307
36-40 yrs 109-284
41-45 yrs 101-267
46-50 yrs 94-252
51-55 yrs 87-238
56-60 yrs 81-225
61-65 yrs 75-212
66-70 yrs 69-200
71-75 yrs 64-188
76-80 yrs 59-177
81-85 yrs 55-166
Tanner stages & IGF-1 in Children ng/mL
M I 63-279
F I 49-342
M II 75-420
F II 115-428
M III 94-765
F III 145-760
M IV 192-861
F IV 244-787
M V 171-814
F V 143-859 |
| INSULIN, FREE & TOTAL | INS.F&T | INSFT | ICMA | Insulin Free 3-19 uIU/mL
Insulin Total 3-19 uIU/mL
This assay reacts on a nearly
equimolar basis with the analogs
insulin aspart, insulin glargine,
and insulin lispro.
To convert to pmol/L, multiply
uIU/mL by 6.0. |
| INSULIN, SAMPLE 1 | INS.S1 | INSLN1 | ICMA | Insulin, #1 6-27 uIU/mL
Insulin, Time 1 |
| INSULIN, SAMPLE 2 | INS.S2 | INSLN2 | ICMA | Insulin, #2 uIU/mL
Insulin, Time 2 |
| INSULIN, SAMPLE 3 | INS.S3 | INSLN3 | ICMA | Insulin, #3 uIU/mL
Insulin, Time 3 |
| INSULIN, SAMPLE 4 | INS.S4 | INSLN4 | ICMA | Insulin, #4 uIU/mL
Time, #4 |
| INSULIN, SAMPLE 5 | INS.S5 | INSLN5 | ICMA | Insulin, #5 uIU/mL
Insulin, Time 5 |
| INSULIN, SAMPLE 6 | INS.S6 | INSLN6 | ICMA | Insulin, #6 uIU/mL
Insulin, Time 6 |
| INSULIN, SAMPLE 7 | INS.S7 | INSLN7 | ICMA | Insulin, #7 uIU/mL
Insulin, Time 7 |
| INTERFERON-BETA, IGG | INFBEG | INFBEG | ELISA | Interferon-Beta Used for Treatment
Interferon-Beta, IgG LT 4.0 Units
Some multiple sclerosis patients
receiving recombinant interferon-
beta (IFNb) develop IFNb-specific
antibodies that may block the
therapeutic effect of the treatment.
This assay screens for IgG antibodies
capable of binding to IFNb; all samples
with detectable IFNb binding antibodies
should be tested for IFNb neutralizing
antibodies. |
| INTERLEUKIN 2 RECEPTOR SOLUBLE BY MAFD | I2MAFD | I2MAF | Multi-Analyte Fluorescence Detection | Interleukin 2 Receptor by MAFD
0-1033 pg/mL
Results are to be used for research
purposes or in attempts to understand
the pathophysiology of immune infectious
or inflammatory disorders. |
| INTERLEUKIN 6 RECEPTOR SOLUBLE BY MAFD | I6MAFD | I6MAF | Multi-Analyte Fluorescence Detection | Interleukin 6 Receptor by MAFD
0-5 pg/mL
Results are to be used for research
purposes or in attempts to understand
the pathophysiology of immune infectious
or inflammatory disorders. |
| INTRINSIC FACTOR BLOCKING ANTIBODY | IBF | IFBAB | ELISA | Intrinsic Factor Blocking Ab Negative |
| IODIDE, URINE | IODUQ | IODUQ | IC | Iodide, Urine Usually 0.01-0.8 mg/L |
| IRON BINDING CAPACITY | IBC | IBC | Colorimetric | Total Iron ug/dL
M 35-190
F 30-150
Iron Binding Capacity ug/dL
M 230-430
F 250-450
% Saturation
M 20-55 %
F 15-50 |
| IRON STAIN | FESTN | FESTN | Cytochemical Stain | Source
Bone Marrow, Iron
Red Cell, Iron |
| IRON, LIVER TISSUE | IRN.LVR | IRNLVR | ICP/MS | Iron (Liver Tissue) ug/g
M 200-2400 ug/g dry weight
F 400-1600 ug/g dry weight
Iron Index LT 1.0 umol/g/yr
Results of hepatic iron index LT 1.0 are
normal, indicating no iron accumulation.
Results between 1.0 and 1.9 suggest mild,
nonspecific iron accumulation as may be seen
in alcoholic liver disease or heterozygous
hemochromatosis. Results GT 1.9 indicate
homozygous hemochromatosis or transfusion-
related iron overload. Chronic blood loss or
frequent phlebotomy will decrease the hepatic
iron index. |
| IRON, TOTAL | IRN | FE | Colorimetric | Iron ug/dL
M 35-190
F 30-150 |
| IRON, URINE | IRN-U | IRONUQ | ICPES | Collection Period Hrs
Volume mLs
Iron, Urine 100-300 ug/specimen |
| ISOAGGLUTININ TITER, ANTI-A | ISOAT | ISOAT | Automated hemagglutination | Isoagglutinin Titer, Anti-A Titer |
| ISOAGGLUTININ TITER, ANTI-B | ISOBT | ISOBT | Automated hemagglutination | Isoagglutinin Titer, Anti-B Titer |
| ISONIAZID | ISON | ISON | HPLC | Isoniazid mcg/mL
Usual Therapeutic 1.0-7.0
Toxic GT 20 |
| ITRACONAZOLE, ANTIFUNGAL LEVEL | ITRAC | ITRAC | HPLC | Itraconazole ug/mL
Hydroxyitraconazole ug/mL
Normal therapeutic levels of
Itraconazole:
Peak 200 mg PO 1x/day 1.0
Trough 200 mg PO 1x/day 0.4
Peak 200 mg PO 2x/day 2.9-2.2
Trough 200 mg PO 2x/day 1.4-1.8
Itraconazole is an antifungal drug
useful for the treatment of blasto-
mycosis, histoplasmosis, coccidioido-
mycosis, sporotrichosis, ringworm,
tinea versicolor, and aspergillosis,
as well as for therapy for oral and
esophageal candidiasis (thrush). It
is available as a 100 mg capsule and
a 10 mg/mL oral solution. Oral absorp-
tion of the capsule is significantly
enhanced by taking it with food. Peak
plasma concentrations are attained in
1.5-4 hours following oral administration.
Blood levels of itraconazole are
reduced in patients taking antacids,
H2 blockers, or omeprazole, and in
those patients being treated with
isoniazid, ripampin, rifabutin,
phenytoin, or phenobabrital. Hydroxy-
itraconazole, a metabolite of
itraconazole, appears in blood in
amounts approximately twice that of
the parent drug, and has antifungal
activity and pharmacokinetics similar
to those of the parent compound. Plasma
concentrations of itraconazole measured
by HPLC are thus approximately 3.5 times
lower than those determined by bioassay.
Levels (measured by HPLC) of both
itraconazole and hydroxyitraconazole
are provided for you to allow full
understanding of effectiveness of
itraconazole therapy. |
| JAK2 (V617F) | JAK2M | JAK2M | PCR | JAK2 (V617F) Mutation Result Not detected
The JAK2 (V617F) point mutation was not
detected by PCR analysis. A negative result
does not rule out the presence of the
mutation in this patient's sample. This
assay is limited to detecting the presence
of the mutation in samples whereby at
least 5% of target sequences isolated
contain the JAK2 V617F mutation.
|
| JC VIRUS BY PCR | JCVPCR | JCVPCR | PCR | JC Virus By PCR Not detected |
| JO-1 AUTOANTIBODY | JO1MP | JO1MP | Multiplex luminex | JO-1 Autoantibody Negative LT 1.0 AI
Positive 1.0 or more |
| KAPPA/LAMBDA FREE LIGHT CHAINS WITH RATIO | FLCR | FLCR | Nephelometry | Kappa FLC 0.33-1.94 mg/dL
Lambda FLC 0.57-2.63
Kappa/Lambda 0.26-1.65
FLC Ratio Results obtained by using The
Binding Site reagents on a Beckman
Coulter Immage 800 analyzer. |
| KAPPA/LAMBDA LIGHT CHAIN RATIO | KAPPA.LAMBDA | KLR | Nephelometry | Kappa Light Chain 574-1276 mg/dL
Lambda Light Chain 269-638 mg/dL
Kappa/Lambda Ratio 1.47-2.95 Ratio |
| KELL ANTIGEN | KELL.AG | KELLAG | Tube Agglutination | Kell Antigen
Separate Report to Follow |
| KEPPRA | KEP | KEP | GC/NPD | Keppra 5-30 ug/mL
The proposed therapeutic range for
seizure control is 5-30 ug/mL.
Pharmacokinetics of levetiracetam
are affected by renal function. The
relationship between serum concen-
trations and toxicity is not known. |
| KETAMINE & METABOLITE, SERUM (REFLEXIVE) | KETACO | KETACO | GC/MS | Ketamine ng/mL
Norketamine ng/mL
Ketamine, Confirmation ng/mL
500-6500 ng/mL reported level during
anesthesia.
Norketamine, Confirmation ng/mL
The intravenous administration of 2
ng/kg of ketamine followed by
continuous infusion of 41 mcg/kg/min
produced an average steady-state
plasma concentration of 2200 ng
ketamine/mL and a average peak nor-
ketamine level of 1050 ng/mL which
occurred near the end of the 3-hour
infusion. |
| KETONES, URINE | KTN | KETUD | Colorimetric | Ketones, Urine Negative mg/dL |
| KIDNEY STONE RISK PANEL II, URINE [ARUP] | KSRPU2 | KSRPU2 | Spectrophotometry, Enzymatic, ISE/Titration, Ion Exchange | Collection time hr
Total Volume mL
Creatinine, urine mg/dL mg/dL
Creatinine, urine mg/d M 3-8 yrs 140-700 mg/d
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81+ yrs 600-2000
F 3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
81+ yrs 400-1300
Citric Acid, urine mg/L mg/L
Citric Acid, urine mg/d 18+ yrs 320-1240 mg/d
Calcium, urine mg/dL mg/dL
Calcium, urine mg/d Calcium free diet: 5-40 mg/d
Low calcium diet (800 mg/d or less) 50-150
Average calcium diet (about 800 mg/d 100-250
High calcium diet (800 mg/d or greater) GT 250
Oxalate, urine mg/L mg/L
Oxalate, urine mg/d 0-12 yrs 13-38 mg/d
M 13+ yrs 7-44
F 13+ yrs 4-31
Uric Acid, urine mg/dL mg/dL
Uric Acid, urine mg/d 250-750 mg/d
Cystine, urine uM/gCr 0-5 mon 62-345 uM/gCr
6-11 mon 53-133
1-3 yrs 53-186
4-12 yrs 35-106
13+ yrs 27-151
Magnesium, urine mg/dL mg/dL
Magnesium, urine mg/d 12-199 mg/d
Phosphorus, urine mg/dL mg/dL
Phosphorus, urine mg/d 400-1300 mg/d
Potassium, urine mmol/L mmol/L
Potassium, urine mmol/d 25-125 mmol/d
Chloride, urine mmol/L mmol/L
Chloride, urine mmol/d 140-250 mmol/d
Sodium, urine mmol/L mmol/L
Sodium, urine mmol/d 51-286 mmol/d |
| KIDNEY STONE RISK PANEL, URINE [ARUP] | KSRPU | KSRPU | Spectrophotometry, Enzymatic | Collection time hr
Total Volume mL
Creatinine, urine mg/dL
Creatinine, urine mg/d M 3-8 yrs 140-700 mg/d
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81+ yrs 600-2000
F 3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
81+ yrs 400-1300
Citric Acid, urine mg/L
Citric Acid, urine mg/d 18+ yrs 320-1240
Calcium, urine mg/dL
Calcium, urine mg/d Calcium free diet: 5-40 mg/d
Low calcium diet (800 mg/d or less) 50-150 mg/d
Average calcium diet (about 800 mg/d 100-250 mg/d
High calcium diet (800 mg/d or greater) GT 250 mg/d
Oxalate, urine mg/L
Oxalate, urine mg/d 0-12 yrs 13-38 mg/d
M 13+ yrs 7-44
F 13+ yrs 4-31
Uric Acid, urine mg/dL
Uric Acid, urine mg/d 250-750 mg/d |
| KLEIHAUER BETKE (STAT ONLY) | KB | KBS | Acid Elution | Source
Fetal Cells %
Newborn 61.00-88.50
1 mo 45.70-67.30
2 mo 29.40-60.80
3 mo 14.80-55.90
4 mo 9.40-28.50
5 mo 2.30-22.40
6-11 mo 2.30-13.00
12 mo 1.30-5.00
13+ mo 0.00-0.90 |
| KOH WET MOUNT | KOH | KOHPRP | Microscopic | Source
KOH Preparation |
| KRAS MUTATION DETECTION BY SEQUENCE ANALYSIS, CODONS | KRASSQ | KRASSQ | PCR and sequence analysis | KRAS Result A KRAS mutation was not detected. |
| LACOSAMIDE, SERUM/PLASMA | LACOS | LACOS | HPLC/LC-MS/MS | Lacosamide mcg/mL
Following a sing 200 mg dose administered as a 30-minute
infusion, a 60-minute infusion, or orally as a tablet to 24
make subjectsm mean maximum plasma lacosamide oncentrations
were 5.95+/- 1.49, 5.38 +/- 1.10 and 12.46 +/- t.60 mcg.mL,
respectively. Mean plasma concentrations follwoing maintenance doses:
200 mg/day 4.99+/-2.51
400 mg/day 9.35+/-4.22
600 mg/day 12.46+/-5.60 |
| LACTIC ACID, ARTERIAL | LACT.A | LAART | Enzymatic | Lactic Acid, Arterial 0.5-1.6 mmol/L |
| LACTIC ACID, CSF | LACT.CSF | LASF | Enzymatic | Lactic Acid, CSF 0.6-2.2 mmol/L |
| LACTIC ACID, VENOUS | LACT | LA | Enzymatic | Lactic Acid, Venous 0.5-2.2 mmol/L |
| LACTOFERRIN, FECAL BY ELISA | LACSTL | LACSTL | ELISA | Lactoferrin, Fecal by ELISA Negative
A positive result is indicative of the
presence of lactoferrin, a marker for
fecal leukocytes. A negative result
does not exclude the presence of
intestional inflammation. |
| LACTOSE TOLERANCE | LACTOSE | LACTOL | Enzymatic | Fasting mg/dL
30 min mg/dL
45 min mg/dL
60 min mg/dL
90 min mg/dL
Dose g
Lactose Tolerance mg/dL
Peak glucose rise (highest glucose
level minus fasting glucose level)
Normal GT 30
Inconclusive 20-30
Lactose intolerance LT 20
(consistent with lactase deficiency
or idiopathic sprue) |
| LAMELLAR BODY COUNTS | LBC | LBC | Automated Cell Count | Lamellar Body Counts Mature GT 50000 Lamellar bodies/uL
Transitional 35000-50000
Immature LT 35000 |
| LAMELLAR BODY COUNTS (REFLEXIVE) | LBCR | LBCR | Automated Cell Count. TLC, Enzymatic (IDMS Traceable) | Lamellar Body Counts Mature GT 50000 Lamellar bodies/uL
Transitional 35000-50000
Immature LT 35000
L/S Ratio
Phosphatidylglycerol
Creatinine, AF Creatinine increases with mg/dL
gestational age
Appearance
Color
RBC
Risk Comment For diabetic patients, risk is minimal
when L/S is GT 3.0 and PG is present. |
| LAMOTRIGINE | LAMI | LAMI | PETIA | Lamotrigine 3.0-14.0 ug/mL
The proposed therapeutic range for
seizure control is 3.0-14.0 ug/mL.
Concentrations that exceed 15.0 ug/mL
may contribute to adverse effects.
Pharmacokinetics varies widely,
particularly with co-medications and/
or compromised renal function. |
| LAXATIVE SCREEN, STOOL | LAX.STOOL | LAXSTL | TLC, AES, ICP, FAAS | Anthraquinones None detected mcg/g
Bisacodyl None detected mcg/g
Oxyphenisatin None detected mcg/g
Phenolphthalein None detected mcg/g
Oils
Magnesium 0.5-10 mg/g
Phosphorus 1.4-22 mg/g |
| LD | LDH | LD | Enzymatic | LD U/L
0-4 days 290-816
4-10 days 545-2105
10 days-24 mo 180-453
24 mo-12 yrs 110-311
12-60 yrs 100-200
60-90 yrs 110-221
90 yrs+ 99-299 |
| LD ISOENZYMES BY ELECTROPHORESIS | LDISO | LDISO | Enzymatic/ELP | LDH, Total U/L
0-30 days 200-465
1-17 mo 200-450
18 mo-10 yrs 165-430
11-16 yrs 127-287
17 yrs & older 105-230
LD1 14-27 %
LD2 29-42 %
LD3 16-22 %
LD4 8-15 %
LD5 6-23 % |
| LD, CSF | LDSF | LDSF | Enzymatic | LD, CSF LT 20 U/L |
| LD, FLUID | LDH.FLD | LDFL | Enzymatic | LD, Fluid U/L
Exudate 200 or greater
Transudate LT 200
Method not validated for body fluid.
Clinical correlation necessary. |
| LDL CHOLESTEROL, DIRECT | DLDL | DLDL | Elimination/Enzymatic | LDL Cholesterol, Direct mg/dL
LT 100 Optimal
100-129 Near or above optimal
130-159 Borderline high
160-189 High
190 or more Very high |
| LDL PARTICLE SIZE | LDLPS | LDLPS | | LDL Particle Size
Separate Report to Follow |
| LEAD AND ZPP OSHA PROFILE | OSHAPR | OSHAPR | AAS/Hematofluorometric | Lead, Blood, Industrial ug/dL
0-16 yrs LT 10
17+ yrs LT 40
Zinc Protoporphyrin umol/mol
23-78
ZPP-OSHA Calculation ug/dL
13-46
Note
No of Tests ug/dL Lead Action Required
1 40.0 or Notification of
greater workers in writing;
medical examination
of workers and
consultation.
3 (average) 50.0 or Removal of worker
greater job with potential
lead exposure.
1 60.0 or Removal of worker
greater from job with potential
lead exposure.
2 40.0 or Reinstatement of worker
less in job with potential
lead exposure is based
on symptoms and medical
evaluation.
Federal lead construction standards require workers
to be notified and removed from job at lead levels
of 50 ug/dL and higher until a physician authorizes
return. OSHA requirements in effect since 1978 call
for the measurement of whole blood lead and zinc
protoporphyrin (ZPP NCCLS document C42-A, Nov. 1996)
to evaluate the occupational exposure to lead. OSHA
requires ZPP whole blood testing in units of ug/dL.
For adults, conversion of ZPP units to ug/dL whole
blood assumes a hematocrit of 45%.
Conversion factor: mol/mol heme x 0.584 = ug/dL. |
| LEAD, SERUM | LEAD.S | PBSNMS | GFAAS | Lead, Serum mcg/dL
Normal Up to 2
Whole blood or urine are the OSHA &
ACGIH/BEI recommended standard
Specimens for monitoring uptake of
inorganic lead and not serum lead. |
| LEAD, URINE (QUANTITATIVE) | LEAD-U | PBUQ | Electrothermal (Flameless) AAS | Collection Period h
Volume mL
Lead, Urine ug/L
Lead, Urine ug/24h
Normal LT 80
Inconclusive 80-125
Toxic GT 125
Urine lead up to 125 is probably not
associated with lead poisoning. |
| LEAD, URINE (RANDOM) | LEAD-RU | PBUR | Electrothermal (Flameless) AAS | Lead, Random Urine ug/L
No normals established |
| LEAD, WHOLE BLOOD | LEAD | PB | Electrothermal (Flameless) AAS | Lead, Blood ug/dL
17+ yrs LT 25
GT 70 Critical High
0-16 yrs LT 10 (CDC Guidelines) |
| LEFLUNOMIDE AS METABOLITE | LEF | LEF | HPLC/LC/MS | Teriflunomide ng/mL
Women who are being treated with Leflunomide
and desire to become pregnant it is recommended
that the plasma Teriflunomide levels be LT 20
mg/mL by two separate tests taken at least 14
days apart.
Mean steady state trough plasma concentrations
of Teriflunomide from patients on daily regimens
of 5, 10, or 25 mg of Leflunomide were 8,800,
18,000 and 63,000 ng/mL, respectively. The
minimum effective concentration is reported to
be 13,000 ng/mL.
|
| LEGIONELLA ANTIBODY, IGG/IGM/IGA | LEG | LEGAB | ELISA | Legionella Ab, IgG/IgM/IgA ODR
LT 0.91 Negative Antibodies to
Legionella pneumophila
serogroups 1-6 not detected.
0.91-1.09 Equivocal Testing of a
second specimen in 3 to 9
weeks suggested.
GT 1.09 Positive Suggestive of
Legionella pneumophila
infection. |
| LEGIONELLA FA STAIN | LEGION.FA | LEGSM | IFA/Stain | Source
Legionella FA Stain Negative
Legionella FA Stain, Status |
| LEGIONELLA PNEUMOPHILA ANTIGEN, URINE | LEGAGU | LEGAGU | ELISA | Legionella Antigen, Urine Negative
This assay detectd Legionella pneumo-
phila serogroup one (1) antigen. A
negative test result does not rule out
the possibility of Legionella infection
due to other subgroups or species of
Legionella. A positive result may
indicate a recent or remote infection
with serogroup 1. |
| LEGIONELLA PNEUMOPHILA ANTIBODY 1-6, IGM | LEGABM | LEGABM | IFA | Legionella pneumophila Antibody 1-6, IgM
LT 1:16
IgM antibody to Legionella pneumo-
phila serotypes 1-6 is measured
using an IgM-specific conjugate.
It is recommended that the IgM test
always be performed in conjunction
with IgG antibody test. The IgM
response to Legionella tends to
develop concurrently with the IgG
response and may remain elevated as
long as the IgG response remains
elevated. Cross-reactions have
been described with several species
of bacteria and mycoplasma. |
LEGIONELLA SPECIES BY PCR  | LEGPCR | LEGPCA | PCR | Source
Legionella by PCR
Negative Legionella sp DNA not detected by PCR.
Positive Legionella sp DNA detected by PCR.
This test is performed pursuant to an agree-
ment with Roche Molecular Systems, Inc. |
| LEISHMANIA PANEL | LEISIB | LEISIB | IFA | L. donovani, IgG LT 1:16
L. donovani, IgM LT 1:20
Interpretation
L. braziliensis, IgG LT 1:16
L. braziliensis, IgM LT 1:20
Interpretation
L. mexicana, IgG LT 1:16
L. mexicana, IgM LT 1:20
Interpretation
L. tropicalis, IgG LT 1:16
L. tropicalis, IgM LT 1:20
Interpretation
|
| LEPTIN | LEPTNA | LEPTNA | ELISA | Leptin ng/mL
M 0.5-12.7
F 3.9-30.0 |
| LEPTOSPIROSIS ANTIBODY | LEPTOSPIROSIS | LEPT | IHA | Leptospira Ab Titer
LT 1:50 No antibody detected
1:50 Borderline positve-patients
should be evaluated for
clinical correlation with
active of recent leptospirosis.
Suggest repeat testing in 2-3 weeks.
1:100 or greater Positive-suggestive of current or
recent leptospirosis. |
| LEUCINE AMINOPEPTIDASE | LEUCINE | LEUCIN | Spectrophotometric | Leucine Aminopeptidase U/mL
M 1.1-3.4
F 1.2-3.0 |
| LEUKOCYTE ALKALINE PHOSPHATASE STAIN | SS.LAP | LAP | Cytochemical Stain | Source
Leukocycte Alkaline Phosphatase Stain 13-70
LAP Interpretation
Reviewed by |
| LH/FSH | LH/FSH | LHFSH | ICMA | LH mIU/mL
M 7-9 yrs 0.0-0.7
10-12 yrs 0.0-3.4
13-15 yrs 0.3-5.6
16-17 yrs 1.1-9.0
18 yrs+ 1.7-8.6
Tanner Stage I 0.0-1.0
Tanner Stage II 0.0-3.6
Tanner Stage III 0.2-6.4
Tanner Stage IV-V 0.9-8.3
F 7-9 yrs 0.0-0.7
10-12 yrs 0.0-6.8
13-15 yrs 0.3-23.0
16-17 yrs 0.0-26.4
18 yrs+
Follicular 2.4-12.6
Mid-cycle 14.00-95.6
Luteal phase 1.0-11.4
Post menopausal 7.7-58.5
Tanner Stage I 0.0-9.3
Tanner Stage II 0.0-16.0
Tanner Stage III 0.0-23.0
Tanner Stage IV-V 0.0-19.1
FSH mIU/mL
M 7-9 yrs 0.3-2.3
10-12 yrs 0.5-4.4
13-15 yrs 1.0-6.7
16-17 yrs 0.8-7.0
18 yrs + 1.4-11.2
Tanner Stage I 0.3-2.6
Tanner Stage II 0.5-4.3
Tanner Stage III 0.9-5.8
Tanner Stage IV-V 0.9-7.3
F 7-9 yrs 0.4-4.0
10-12 yrs 0.6-7.5
13-15 yrs 0.9-8.2
16-17 yrs 0.4-8.9
18 yrs+
Follicular 3.2-11.3
Midcycle peak 4.2-19.4
Luteal phase 1.5-6.9
Postmenopausal 23.2-121.3
Tanner Stage I 0.5-7.6
Tanner Stage II 0.5-8.0
Tanner Stage III 0.5-8.0
Tanner Stage IV-V 0.6-8.4
|
| LIBRIUM | LIB | LIB | HPLC | Librium ug/mL
Therapeutic 0.5-3.0
Based on dosages up to 100 mg
Toxic GT 5.0
Nordiazepam ug/mL
Therapeutic 0.06-1.80
Based on normal dosages
Toxic GT 2.50 |
| LIDOCAINE | LIDOCN | LIDOCN | EIA | Lidocaine ug/mL
Therapeutic 1.5-5.0
Toxic GT 6.0 |
| LIPASE | LIPASE | LIPA | Colorimetric | Lipase 7-60 @ 37C U/L |
| LIPASE, FLUID | LIPAFL | LIPAFL | Enzymatic | Lipase, fluid No reference range established U/L
Method not validated for this fluid. Clinical correlation necessary. |
| LIPASE, URINE | LIPAU | LIPAU | Enzymatic/Colorimetric | Lipase, Random Urine 4 or less U/L |
| LIPID ASSOCIATED SIALIC ACID | LASA | LASA | Spectrophotometric | LASA 0-20 mg/dL |
| LIPID PROFILE | LIPID | LIPID | Enzymatic | Cholesterol mg/dL
LT 200 Desirable
200-239 Borderline high
240 or more High
Triglycerides mg/dL
LT 150 Normal
150-199 Borderline high
200-499 High
500 or more Very high
HDL mg/dL
LT 40 Low
40-59 Within normal limits
60 or more High
HDL Cholesterol greater than or equal
to 60 mg/dL is considered to be a
'negative' risk factor, serving to
remove one risk factor from the total
count.
LDL (calculated) mg/dL
LT 100 Optimal
100-129 Near or above normal
130-159 Borderline high
160-189 High
190 or more Very high
To calculate 10-year cardiac risk for
the patient, go to http://www.paml.com,
click on testing, then on ranges/
algorithms, and then on lipid results |
| LIPID PROFILE & LP-PLA2 (PLAC) | LIPID2 | LIPID2 | Enzymatic, ELISA | Cholesterol mg/dL
LT 200 Desirable
200-239 Borderline high
240 or more High
Triglycerides mg/dL
LT 150 Normal
150-199 Borderline high
200-499 High
500 or more Very high
HDL mg/dL
LT 40 Low
40-59 Within normal limits
60 or more High
HDL Cholesterol greater than or equal
to 60 mg/dL is considered to be a
'negative' risk factor, serving to
remove one risk factor from the total
count.
LDL (calculated) mg/dL
LT 100 Optimal
100-129 Near or above normal
130-159 Borderline high
160-189 High
190 or more Very high
To calculate 10-year cardiac risk for
the patient, go to http://www.paml.com,
click on testing, then on ranges/
algorithms, and then on lipid results.
LP-PLA2 (PLAC) 0-200 ng/mL
A new consensus panel recommends a cutoff
value of 200 ng/mL for Lp-PLA2 (PLAC).
Patients at moderate or high risk for CVD
based on ATPIII criteria who also have an
Lp-PLA2 value GT 200 ng/mL should be shifted
from high to very high risk. This will lower
the LDL goal for these patients. |
| LIPOPROTEIN (A) | LPA | LPA | Rate Nephelometry | Lipoprotein (a) LT 30 mg/dL
22-74 African-American |
| LIPOPROTEIN ELECTROPHORESIS | LIPELP | LIPELP | Electrophoresis, Spectrometry | Cholesterol mg/dL
2-18 years LT 170
GT 18 years LT 200
Triglycerides mg/dL
5-19 years LT 130
GT 19 years LT 150 Normal
150-199 Borderline high
200-499 High
GT 499 Very high
Chylomicrons Normal
Beta Lipoproteins %
42.3-69.5
Pre Beta Lipoprotiens %
2.0-31.2
Alpha Lipoproteins %
15.1-39.9
Appearance Clear
Interpretation |
| LISTERIA ANTIBODY | LISAB | LISAB | CF | Listeria Antibody LT 1:8 No antibody detected.
1:8 or more Antibody detected.
Single titers of 1:8 or greater are
suggestive of listeria infection.
A four-fold or greater increase
in titer between acute and convalescent
specimens confirms the diagnosis.
|
| LITHIUM | LI | LI | Spectrophotometric | Lithium Therapeutic 0.5-1.5 mmol/L
Toxic GT 2.0 |
| LIVER CYTOSOL AUTOANTIBODIES (LC-1) | LIVCYT | LIVCYT | EIA | Liver Cytosol Autoantibodies U/mL
LT 15 |
| LORAZEPAM | LOR | LOR | HPLC | Lorazepam ng/mL
Therapeutic 50-240 |
| LOW MOLECULAR WEIGHT HEPARIN | LMW.HEPARIN | HEPLMW | Chromogenic | Anti Xa IU/mL
Enoxaparin
Target peak concentration for
prophylaxis 0.2-0.4
Target peak concentration for
treatment, 2 doses daily 0.6-1.0
Target peak concentration for
treatment, 1 dose daily 1.3-2.0
Dalteparin IU/mL
Target peak concentration for
prophylaxis 0.2-0.4
Target peak concentration for
treatment, 2 doses daily 0.6-1.0
Target peak concentration for
treatment, 1 dose daily 0.85-1.25 |
| LOXAPINE | LOXA | LOXA | HPLC | Loxapine ng/mL
Peak concentration following a single
oral 25 mg dose 6-13 at 1-2 h post dose.
Peak plasma concentrations following
an equivalent IM dose are similar. |
| LP-PLA2 (PLAC) | PLACA2 | PLACA2 | ELISA | LP-PLA2 (PLAC) 0-200 ng/mL
A new consensus panel recommends a cutoff
value of 200 ng/mL for Lp-PLA2 (PLAC).
Patients at moderate or high risk for CVD
based on ATPIII criteria who also have an
Lp-PLA2 value GT 200 ng/mL should be shifted
from high to very high risk. This will lower
the LDL goal for these patients. |
| LSD, (REFLEXIVE) | LSDSCO | LSDSCO | IA, LC-MS/MS | LSD, Serum ng/mL
LSD, Serum Confirmation ng/mL
No normals established |
| LSD, URINE (REFLEXIVE) | LSDUCO | LSDUCO | IA, LC-MS/MS | LSD, Urine ng/mL
LSD, Urine Confirmation ng/mL
No normals established |
| LUPUS ANTICOAGULANT (REFLEXIVE) | LUPUS | ACTLUP | Electromechanical | PT, Patient
0-1 mo 13.0-20.0 sec
2+mo 10.9-14.8
Pt, PT/NL Mix sec
Thrombin T, Pt 15.6-20.0 sec
TT, Pt/Ps Mix sec
PTT, Patient
0-1 mo 40-50 sec
2 mo-4 yrs 25-40
5+ yrs 26-36
aPTT, Control sec
aPTT, PT Ct Mix sec
PNP 0.0-7.0 sec
dRVVT 31.8-45.7 sec
dRVVT mix ratio 0.0-1.2
dRVVT confirm ratio LT 1.2
dRVVT confirm mix ratio LT 1.2 |
| LUTEINIZING HORMONE | LH | LH | ICMA | LH mIU/mL
M 7-9 yrs 0.0-0.7
10-12 yrs 0.0-3.4
13-15 yrs 0.3-5.6
16-17 yrs 1.1-9.0
18 yrs+ 1.7-8.6
Tanner Stage I 0.0-1.0
Tanner Stage II 0.0-3.6
Tanner Stage III 0.2-6.4
Tanner Stage IV-V 0.9-8.3
F 7-9 yrs 0.0-0.7
10-12 yrs 0.0-6.8
13-15 yrs 0.3-23.0
16-17 yrs 0.0-26.4
18 yrs+
Follicular 2.4-12.6
Mid-cycle 14.00-95.6
Luteal phase 1.0-11.4
Post menopausal 7.7-58.5
Tanner Stage I 0.0-9.3
Tanner Stage II 0.0-16.0
Tanner Stage III 0.0-23.0
Tanner Stage IV-V 0.0-19.1
|
| LYME (B. BURGDORFERI ) ANTIBODY, IGG/IGM REFLEX | LYMER | LYMER | EIA/WB | Lyme (B. burgdorferi) Antibody, IgG/IgM
LT 0.91 Negative
No antibodies to B.burgdorferi detected. Per CDC
guidelines, if EIA test is negative, Western Blot
should not be performed.
0.91-1.09 Equivocal
GT 1.09 Positive
Antibodies to B.burgdorferi detected.
B. burgdorferi AB by WB, IgG
Negative
B. burgdorferi AB by WB, IgM
Negative
Interp for Lyme IgG by WB Positive-Presence of
any of 5 bands of 18, 23, 28, 30, 39,
41, 45, 58, 66 or 93 kDa. Negative-Any pattern
that fails to meet the positive criteria.
Interp for Lyme IgM by WB Positive-Presence of
any 2 bands of 23, 39 or 41 kDa. If
antibodies to the 37 kDa antigen are present
it is considered to be an additional criteria
band. Negative-Any pattern which fails to meet
the positive criteria.
|
| LYME (B. BURGDORFERI) ANTIBODY, CSF | LYMECF | LYMECF | ELISA | Lyme (B.burgdorferi) Ab, CSF LIV
0.99 or less Negative-Antibody to Borrelia
burgdorferi not detected.
1.00-120 Equivocal-Repeat testing in
10-14 days may be helpful.
1.21 or more Positive-Probable presence of
antibody to Borrelia burgdorferi
detected. |
| LYME (B. BURGDORFERI) ANTIBODY, IGG/IGM BY WESTERN BLOT | LYMCON | LYMEWB | Western Blot | B. burgdorferi AB by WB, IgG
Negative
B. burgdorferi AB by WB, IgM
Negative
Interp for Lyme IgG by WB Positive-Presence of
any of 5 bands of 18, 23, 28, 30, 39,
41, 45, 58, 66 or 93 kDa. Negative-Any pattern
that fails to meet the positive criteria.
Interp for Lyme IgM by WB Positive-Presence of
any 2 bands of 23, 39 or 41 kDa. If
antibodies to the 37 kDa antigen are present
it is considered to be an additional criteria
band. Negative-Any pattern which fails to meet
the positive criteria. |
| LYME CSF & SERUM [STONY BROOK] | LYME.CSF&SER.SB | IDXSB | ELISA | Lyme Serum and CSF |
| LYSOZYME | MUR | LYSOZ | RID | Lysozyme 9-17 ug/mL |
| MAG ANTIBODY, IGM | MAGMAB | MAGMAB | Dual ELISA | SGPG Ab, IgM Index
LT 1.00 Antibody not detected
1.00 or more Antibody detected
MAG Ab, IgM Index
LT 1.00 Antibody not detected
1.00 or more Antibody detected
This assay was developed and its
performance characteristics determined
by Focus Technologies. It has not been
cleared or approved by the FDA. The
FDA has determined that such clearance
or approval is not necessary. |
| MAGNESIUM | MAG | MG | Colorimetric | Magnesium 1.5-2.4 mg/dL |
| MAGNESIUM, FECAL | MGFEC | MGFEC | Spectrophotometry | Fecal Weight g
Collection Time-Fecal Specimen hr
Fecal Magnesium 0-110 mg/dL
Fecal Magnesium 0-355 mg/d
Fecal Total Weight g
Collection Time-Fecal Specimen hr |
| MAGNESIUM, FLUID | MAG.FLD | MGFL | Colorimetric | Magnesium, Fluid mg/dL
No reference ranges established.
Method not validated for body fluid.
Clinical Correlation necessary. |
| MAGNESIUM, QUANTITATIVE, URINE | MAG-U | MGUQ | Colorimetric | Collection Period h
Volume mL
Magnesium, Urine 72-120 mg/24h |
| MAGNESIUM, RBC | MGRBC | MGRBC | FAAS | Magnesium, RBC 3.0-6.1 mg/dL |
| MAGNESIUM, URINE (RANDOM) | MAG-R | MGUR | Colorimetric | Magnesium, Urine, Random mg/dL
No normals established |
| MALARIA ANTIBODY IGG | MALIGG | MALIGG | ELISA | Malaria Antibody, Total 0.00-1.00 IV |
| MANGANESE | MAN.S | MANG | ICP/MS | Manganese 0.0-2.0 ug/L
Less than 5% of manganese present
in circulation resides in the serum. |
| MANGANESE, BLOOD | MAN.BLD | MANBLD | ICP/MS | Manganese, Blood 4.2-16.5 ug/L |
| MANGANESE, QUANTITATIVE, URINE | MAN-U | MANUQ | ICP/MS | Collection Period hr
Volume mL
Creatinine, Ur mg/dL
Creatinine, Ur mg/d
M 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81+ yrs 600-2000
F 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
81+ yrs 400-1300
Manganese, Ur 0.0-2.0 ug/L
Manganese, Ur 0.0-2.0 ug/d
Manganese, Ur ug/gCr
No reference range established
Urine manganese values do not
correlate well with exposure or
adverse effects. |
| MAPROTILINE | LUD | LUD | GC/NPD | Maprotiline ng/mL
Following daily oral doses of 50,
100 & 150 mg in the steady state mean
blood concentrations were 70, 140 &
220 ng/mL respectively. |
| MATERNAL CELL CONTAMINATION, MOLECULAR ANALYSIS | MCCMA | MCCMA | Microsatellite PCR and Fragment Analysis | Maternal Cell Contamination
Result/Interpretation |
| MATERNAL SCREEN, FIRST TRIMESTER [ARUP] | MSSFT | MSSFT | ICMA/ELISA | Patient hCG IU/L
MoM for hCG
Patient PAPP-A mIU/L
MoM for PAPP-A
Nuchal translucency mm
MoM for Nuchal Translucency
Interp
Previous downs
Maternal age at delivery yrs
Estimated due date
Gestational age (exact) wks
Maternal weight lb
Maternal race
Number of fetuses
Crown rump length cm
Sonographer certification number
Sonographer name
Ultrasound date
|
| MATERNAL SCREEN, INTEGRATED, SPECIMEN # 2 | MSSIS2 | MSSIS2 | ICMA/ELISA | Maternal age at Delivery yrs
Estimated Due Date
Gestational Age (Exact) wks
Insulin Req
Maternal Diabetes
Family Hx Neural Tube Defect
Maternal Race
Number of Fetuses
Crown Rump Length cm
Sonographer Cert No
Sonographer Name
Ultrasound Date
Maternal Weight lb
Patient AFP ng/ml
MoM for AFP
Patient hCG IU/L
MoM for hCG
Patient uE3 ng
MoM for uE3
Dimeric Inhibin A pg/mL
MoM for DIA
Patient PAPP-A mIU/L
MoM for PAPP-A
Nuchal Translucency mm
MoM for Nuchal Translucency
Interp |
| MATERNAL SCREEN, INTEGRATED, SPECIMEN #1 | MSINT1 | MSINT1 | Chemiluminescent Immunoassay | Patient's mIU/L
PAPP-A
MoM for PAPP-A
Nuchal mm
Translucency
MoM for NT
Maternal
Screen Interp
Previous Downs
Maternal Age yrs
at delivery
Estimated Due
Date
Gestational weeks
Age (exact)
Maternal lbs
Weight
Maternal Race
Number of
Fetuses
Crown Rump cm
Length
Sonographer
Certification
Number
Sonographer
Name
Ultrasound
Date
Best date to
draw sample
#2 by
External Desc.
Except Test |
| MATERNAL SCREEN, SEQUENTIAL, SPECIMEN # 1 [ARUP] | MSSEQ1 | MSSEQ1 | Chemiluminescent Immunoassay | Patient''s HCG IU/L
MoM for HCG
Patient''s mIU/L
PAPP-A
MoM for PAPP-A
Nuchal mm
Translucency
MoM for NT
Maternal
Screen Interp
Previous Downs
Maternal Age year
at Delivery
Estimated Due
Date
Gestational weeks
Age (exact)
Maternal
Weight lbs
Maternal Race
Number of
Fetuses
Crown Rump cm
Length
Sonographer
Certification
Number
Sonographer
Name
Ultrasound
Date
Best Date to
Draw Sample
#2 by
EER Maternal
Screening,
Sequential,
Specimen 1 |
| MATERNAL SCREEN, SEQUENTIAL, SPECIMEN # 2 [ARUP] | MSSS2 | MSSS2 | ICMA/ELISA | Maternal age at Delivery yrs
Estimated Due Date
Gestational Age (Exact) wks
Insulin Req Maternal Diabetes
Family Hx Neural Tube Defect
Maternal Race
Number of Fetuses
Crown Rump Length cm
Sonographer Cert No
Sonographer Name
Ultrasound Date
Maternal Weight lb
Patient AFP ng/ml
MoM for AFP
Patient hCG IU/L
MoM for hCG
Patient uE3 ng
MoM for uE3
Dimeric Inhibin A pg/mL
MoM for DIA
Patient PAPP-A mIU/L
MoM for PAPP-A
Nuchal Translucency mm
MoM for Nuchal Translucency
Interp |
| MECONIUM 12 DRUG SCREEN PLUS ALCOHOL | MEC12A | MEC12A | EMIT/Confirm with GC/MS | Amphetamines ng/g
Amphetamine, GC/MS ng/g
Methamphetamine, GC/MS ng/g
MDA, GC/MS ng/g
MDMA, GC/MS ng/g
Cocaines ng/g
Cocaine, GC/MS ng/g
Cocaethylene, GC/MS ng/g
Benzoylecgonine, GC/MS ng/g
Metahydrozy-bze, GC/MS ng/g
Opiates ng/g
Codeine, GC/MS ng/g
Morphine, GC/MS ng/g
Hydrocodone, GC/MS ng/g
Hydromorphone, GC/MS ng/g
Phencyclidine ng/g
PCP, GC/MS ng/g
Cannabinoids ng/g
Carboxy-THC, GC/MS ng/g
Barbiturates ng/g
Butalbital, GC/MS ng/g
Amobarb, GC/MS ng/g
Pentobarb, GC/MS ng/g
Secobarb, GC/MS ng/g
Phenobarb, GC/MS ng/g
Methadones ng/g
EDDP, GC/MS ng/g
Methadone, GC/MS ng/g
Benzodiazepines ng/g
Oxamzepam, GC/MS ng/g
Propoxyphene ng/g
Nor-PPX, GC/MS ng/g
Meperidine ng/g
Normeperidine, GC/MS ng/g
Oxycodone ng/g
Oxycodone, GC/MS ng/g
Tramadol ng/g
Tramadol, GC/MS ng/g
Fatty Acid Ethyl Esters ng/g
Fatty Acid ETH Esters, GC/MS ng/g |
| MECONIUM 5 DRUG + ALCOHOL SCREEN (REFLEXIVE) | MEC5A | MEC5A | EMIT/Confirm with GC/MS | Amphetamines ng/g
Amphetamine, GC/MS ng/g
Methamphetamine, GC/MS ng/g
MDA, GC/MS ng/g
MDMA, GC/MS ng/g
Cocaines ng/g
Cocaine, GC/MS ng/g
Cocaethylene, GC/MS ng/g
Benzoylecgonine, GC/MS ng/g
Metahydrozy-bze, GC/MS ng/g
Opiates ng/g
Codeine, GC/MS ng/g
Morphine, GC/MS ng/g
Hydrocodone, GC/MS ng/g
Hydromorphone, GC/MS ng/g
Phencyclidine ng/g
PCP, GC/MS ng/g
Cannabinoids ng/g
Carboxy-THC, GC/MS ng/g
Fatty Acid ETH Esters, GC/MS ng/g |
| MECONIUM 5 DRUG SCREEN (REFLEXIVE) | MEC5 | MEC5 | EMIT/Confirm with GC/MS | Amphetamines ng/g
Amphetamine, GC/MS ng/g
Methamphetamine, GC/MS ng/g
MDA, GC/MS ng/g
MDMA, GC/MS ng/g
Cocaines ng/g
Cocaine, GC/MS ng/g
Cocaethylene, GC/MS ng/g
Benzoylecgonine, GC/MS ng/g
Metahydrozy-bze, GC/MS ng/g
Opiates ng/g
Codeine, GC/MS ng/g
Morphine, GC/MS ng/g
Hydrocodone, GC/MS ng/g
Hydromorphone, GC/MS ng/g
Phencyclidine ng/g
PCP, GC/MS ng/g
Cannabinoids ng/g
Carboxy-THC, GC/MS ng/g |
| MECONIUM 9 DRUG SCREEN (REFLEXIVE) | MEC9SC | MEC9SC | EMIT/Confirm with GC/MS | Amphetamines ng/g
Amphetamine, GC/MS ng/g
Methamphetamine, GC/MS ng/g
MDA, GC/MS ng/g
MDMA, GC/MS ng/g
Cocaines ng/g
Cocaine, GC/MS ng/g
Cocaethylene, GC/MS ng/g
Benzoylecgonine, GC/MS ng/g
Metahydrozy-bze, GC/MS ng/g
Opiates ng/g
Codeine, GC/MS ng/g
Morphine, GC/MS ng/g
Hydrocodone, GC/MS ng/g
Hydromorphone, GC/MS ng/g
Phencyclidine ng/g
PCP, GC/MS ng/g
Cannabinoids ng/g
Carboxy-THC, GC/MS ng/g
Barbiturates ng/g
Amobarb, GC/MS ng/g
Pentobarb, GC/MS ng/g
Secobarb, GC/MS ng/g
Phenobarb, GC/MS ng/g
Methadones ng/g
EDDP, GC/MS ng/g
Methadone, GC/MS ng/g
Benzodiazepines ng/g
Oxamzepam, GC/MS ng/g
Propoxyphene ng/g
Nor-PPX, GC/MS ng/g |
| MELANIN, URINE | MELURS | MELURS | Colorimetric | Melanin, Urine Negative |
| MELANOCYTE STIMULATION HORMONE, ALPHA | AMSH | AMSH | RIA | Melanocyte Stimulation Hormone, Alpha
0.0-5.0 pg/mL |
| MENINGOENCEPHALITIS COMPREHENSIVE PANEL | MENPAN | MENPAN | IFA, CF, ELISA, MAID | Meningoencephalitis Comprehensive Panel
Separate Report to Follow |
| MENORRHAGIA EVALUATION (REFLEXIVE) | MENEVL | MENEVL | Electromechanical, LIA, Platelet Agg | Protime sec
0-1 mon 13.0-20.0
2+ mon 10.9-14.8
Pop Mean 13.4 sec
INR 0.9-1.2
2.0-3.0 Usual oral
anticoagulation range.
2.5-3.5 High level
oral anticoagulation
range.
PTT, Patient sec
0-1 mo 40-50
2 mos-4 yrs 25-40
5+ yrs 26-36
PTT, Pop.mean 31 sec
Deep venous thrombosis or pulmonary
embolism therapeutic heparin levels
of 0.3 to 0.7 Units/mL anti-factor
Xa levels usually correspond to an
aPTT of 60-85 seconds. Acute cardiac
syndrome therapeutic range based on
heparin levels of 0.2 to 0.5
usually correspond to an aPTT of
55 to 75 seconds.
PT 1/1 Mix sec
PT Control Plasma sec
PTT 1/1 Mix sec
PTT Control Plasma sec
von Willebrand Factor %
GT 40 % Activity
von Willebrand Factor Antigen %
50-165
Factor VIII Coagulant Activity %
55-150 % Activity
Factor XI 65-135 % |
| MEPERIDINE | MER | MEP | GC | Meperidine mcg/mL
Expected analgesic range 0.1-0.6
Normeperidine mcg/mL
Up to 0.5
This test is for clinical use only. |
| MEPERIDINE BY GC/MS | MSMEP | MSMEP | GC/MS | Meperidine positive cutoff 100 ng/mL
Normeperidine positive cutoff 100 ng/mL |
| MEPERIDINE SCREEN ( REFLEX) | MEPU | MEPU | EIA/Confirmation by GC/MS | Meperidine positive cutoff 200 ng/mL
|
| MEPHENYTOIN & METABOLITE | MEPHE | MEPHE | HPLC | Mephenytoin mcg/mL
No reference range established
Normephenytoin mcg/mL
No reference range established |
| MEPHOBARBITAL | MEBARAL | MEPHOB | GC | Mephobarbital 0-3 ug/mL
Concentrations are seen with normal
metabolism. |
| MEPROBAMATE & CARISOPRODOL | MEPROBAMATE | CARMEP | GC/MS | Meprobamate Therapeutic 5-20 ug/mL
Toxic GT 40
Carisoprodol Therapeutic LT 8 ug/mL
Toxic 8 or more |
| MEPROBAMATE, URINE | MEPROB | MEPROB | GC/MS | Meprobamate, Urine 1-5 ug/mL |
| MERCAPTOPURINE, SERUM | MERCAP | MERCAP | HPLC | Mercaptopurine ng/mL
Following a single 75 mg/sq meter
mercaptopurine dose: 40-280 ng/mL at
0.5-4 hours post-dose (peak).
Following oral regimen of 50-100 mg/
day: 50-80 ng/mL at 1 hour post-dose
(peak).
Mercaptopurine can be administered
as a drug (antineplastic) and it is
also a metabolite of azathioprine
(immunosuppressive). |
| MERCURY, SERUM/PLASMA | HGQT | HGQT | ICP/MS | Mercury, Serum, Quantitative mcg/mL
Normal up to 6 |
| MERCURY, URINE | HGUQT | HGUQT | ICP/MS | Collect Time, hr
Total Volume, mL
Creatinine, mg/dL
Creatinine,Urine mg/d
3-8 yrs M 140-700 F 140-700
9-12 yrs M 300-1300 F 300-1300
13-17 yrs M 500-2300 F 400-1600
18-50 yrs M 1000-2500 F 700-1600
51-80 yrs M 800-2100 F 500-1400
81 yrs + M 600-2000 F 400-1300
Mercury, Urine ug/L
Mercury, Urine ug/day
Mercury, Urine per gm creatinine LT 35.0 ug/gCR
|
| MERCURY, URINE (QUANTITATIVE) | MERC-U | HGUQ | Mercury Hydride AAS | Collection Period h
Volume mL
Mercury, Urine ug/L
Mercury, Urine ug/24h
Non Exposure LT 20
Inconclusive 20-150
Potentially Toxic GT 150
The concentration of mercury at which
toxicity is expressed is widely
variable among patients. 50 ug/24h is
the lowest concentration at which
toxicity may be apparent. |
| MERCURY, URINE (RANDOM) | MERC-RU | HGUR | Mercury Hydride AAS | Mercury, Urine, Random ug/L
No normals established |
| MERCURY, WHOLE BLOOD | MERC | MERC | AA/ICP-MS | Mercury, Blood 0-10 ug/L
This test measures total mercury,
whereas the reference interval
relates to inorganic mercury
concentrations. Dietary and non-
occupational exposure to organic
mercury species may contribute to
an elevated total mercury result. |
| METABOLIC SCREEN, URINE | METABOLIC.SCR | METSUR | HPLC | Metabolic Screen
Separate Report to Follow |
| METALS/METALLOIDS PANEL, BLOOD | METALS | METALS | GFAAS/AAS | Cadmium ug/L
Minimum (OSHA) action level for
enhanced medical surevillance:
GT 5 ug/L.
Mercury ug/L
Recommended biological exposure
index (ACGIH): 15 ug/L in blood
collected at end of shift at end
of work week.
Tellurium ug/dL
3.3 (Usual average blood) |
| METANEPHRINES, PLASMA FREE | METPL | METPL | HPLC | Normetanephrine 0.0-0.89 nmol/L
Metanephrine 0.0-0.49 nmol/L
Interpretation
Patients with essential hypertension
and plasma concentrations of
normetanephrine & metanephrine below
0.9 nmol/L and 0.5 nmol/L, respectively
can be reliably excluded from further
testing for the detection of a pheno-
chromocytoma. The majority of patients
with a phenochromocytoma have a plasma
normetanephrine concentration in excess
of 1.1 nmol/L. The presence of
increased concentrations of the
analytes serves as confirmation for
the diagnosis of the tumor. |
| METANEPHRINES, TOTAL, URINE | MET | METTUQ | HPLC/Electrochemical Detection | Collection Period h
Volume mL
Metanephrines, Total Urine mg/24h
0.140-0.785 |
| METANEPHRINES, URINE (FRACTIONATED) | MET.FRAC | METUQ | HPLC/Electrochemical Detection | Collection Period h
Volume mL
Metanephrines 0.052-0.341 mg/24h
Normetanephrine 0.088-0.444 mg/24h
Metanephrines, Total 0.140-0.785 mg/24h
Patients on Buspirone therapy will show falsely elevated metanephrine levels. |
| METANEPHRINES, URINE (RANDOM) | METAUR | METAUR | HPLC/Electro Det/Enzymatic (IDMS traceable) | Creatinine, Urine Random No reference range established mg/dL
Metanephrine, Urine Random No reference range established mg/L
Metanephrine, Urine Random ug/gCr
3-8 years 47-240
9-12 years 40-220
13-17 years 33-145
Adults 31-140
Normetanephrine No reference range established mg/dL
Normetanephrine ug/gCr
3-8 years 62-705
9-12 years 81-583
13-17 years 95-375
Adults 47-310
Total Metanephrines No reference range established mg/dL
Patients on Buspirone
therapy will show falsely elevated
metanephrine levels.
Please note: A 24-hr urine collection is the
preferred specimen. These reference ranges
for random urine collections are based on
literature review. |
| METHADONE & METABOLITE, SERUM | METMB | METMB | LC/TMS | Methadone & Metabolite
Drugs covered: methadone & EDDP
(methadone metabolite)
Positive cutoff: 10 ng/mL
Usual stabilization range of methadone
in narcotic withdrawal patients:
50-1000 ng/mL (trough level).
Methadone EDDP has no
apparent pharmacological activity. |
| METHAQUALONE | METHA | METHA | GC/MS | Methaqualone mcg/mL
Reported blood levels associated with:
Erratic driving 2-12
Mild Toxicity 2-16
Unconsciousness GT 8 |
| METHEMOGLOBIN (QUANTITATIVE) | METHGB QUAN | CMHGB | Colorimetric/Co-oximeter | Hemoglobin g/dL
0-3 days 14.5-22.5
3-7 days 13.5-21.5
7-14 days 12.5-20.5
14-30 days 10.0-18.0
30-60 days 9.0-14.0
2-6 mo 10.5-13.5
6-24 mo 11.5-13.5
2-6 yrs 11.5-13.5
6-12 yrs 11.5-15.5
12-18 yrs M 13.0-16.0
18 yrs+ M 13.7-16.7
12-18 yrs F 12.0-16.0
18 yrs+ F 11.6-15.5
COHgb 1-3 Values may be %
slightly higher in smokers
Methemoglobin 0.4-1.5 % |
| METHOTREXATE | MTX | MTX | FPIA | Methotrexate umol/L
Interpretation depends on dosing
and draw times as well as target
level for the disease being treated. |
| METHSUXIMIDE | CELONTIN | MSUX | GC | Methsuximide ug/mL
Therapeutic LT 1
Normethsuximide ug/mL
Therapeutic 10-40
Total ug/mL
Therapeutic 10-40
Toxic GT 60 |
| METHYLMALONIC ACID, QUANTITATIVE, SERUM | MMAMS | MMAMS | LC/MS/MS | Methylmalonic Acid 0.00 0.40 umol/L |
| METHYLMALONIC ACID, URINE | MAUQ | MAUQ | GC/MS | Collection Period hr
Volume mL
Creatinine, Urine mg/dL
Creatinine, Urine mg/d
M 0-2 yrs not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
GT 80 yrs 600-2000
F 0-2 yrs not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
GT 80 yrs 400-1300
Methylmalonic Acid, Urine umol/L
Methylmalonic Acid, Urine 0.0-3.6 mmol/moLCr |
| METHYLPHENIDATE | RIT | RITA | LC/MS/MS | Methylphenidate ng/mL
8-22 ng/mL (1-2 h Post 10-20 mg
oral dose).
Methylphenidate Metabolite ng/mL
80-250 ng/mL (In children given
10-15 mg oral dose). |
| METHYLPHENIDATE, URINE | RIT-U | RITAUR | LC/MS | Methylphenidate, Urine ng/mL
Adult 100-900 ng/mL in the 8 hours
following a 25 mg oral dose to adults.
Concentration as high as 3300 ng/mL
have been reported in the 6 hour
urine of children following a 10 mg
dose.
Methylphenidate Metabolite, Urine ng/mL
Concentrations as high as 64000 ng/mL
have been reported in the 6 hour
urine in children following a 10 mg
dose. |
| MEXILETINE | MEXI | MEXI | GC | Mexiletine ug/mL
Therapeutic 1.0-2.0
Potentially Toxic 1.5-3.0 |
| MICROALBUMIN, URINE (24-HOUR) | M.ALB | MALBUQ | Immunoturbidimetric | Collection Period h
Volume mL
Microalbumin, Urine mg/L
LT 18
Microalbumin, Excretion Rate ug/min
0-20
Microalbumin, 24h Excretion mg/24h
0-30 |
| MICROALBUMIN-CREATININE RATIO | MALBCR | MCUC | Immunoturbidimetric, Enzymatic (IDMS Traceable), Calculation | Microalbumin, Random Urine mg/L
LT 18
Creatinine, Random Urine mg/dL
No normals established
Microalbumin/Creatinine Ratio mg/g
LT 30 Normal-Repeat yearly.
30-300 Increased risk for
diabetic nephropathy. Two of three
A/C ratios in this range indicate
microalbuminuria and
GT 300 Two of three A/C ratios
in this range confirms
overt clinical nephropathy. |
| MICROSOMAL ANTIBODY LIVER/KIDNEY | MICROLK | LKM | IFA | Microsomal Ab Liver/Kidney Titer
Negative LT 1:20 |
| MICROSPORIDIA STAIN BY MODIFIED TRICHROME | MICROSPORIDIA | MCSPR | Microsporidia Stain by Modified Trichrome | Microsporidia Source
Microsporidia Stain Negative |
| MIRTAZAPINE (QUANTITATIVE) | MIRTQ | MIRTQ | GC | Mirtazapine ng/mL
Steady-state levels following a daily
regimen:
Dose Peak Range Trough Range
(mg) (0.7-4.8 hr)
15 27-51 4.3-12
30 56-104 11-25
45 84-142 17-39
60 117-199 24-52
75 137-225 28-64
Elimination half-life: 20-40 hours. |
| MITOCHONDRIAL ANTIBODIES | MA | MA | IFA | Mitochondrial Ab
Negative LT 1:20 |
| MITOCHONDRIAL M2 ANTIBODY, IGG | MM2AB | MM2AB | ELISA | Mitochondrial M2 Antibody, IgG Units
20.0 or less Negative
20.1-24.0 Equivocal
25.0 or more Positive |
| MOBAN | MOB | MOB | LC/MS/MS | Moban (Molindone) ng/mL
Steady state plasma levels from patient doses
of 100 to 400 mg/day: 39-874 ng/mL with
high interpatient variability. |
| MOLYBDENUM | MOBD | MOBD | GFAAS | Molybdenum LT 3 mcg/mL |
| MONOCLONAL PROTEIN STUDY, SERUM | MPSMAY | MPSMAY | BIURET/ELP/IMMUNOFIXATION | Total Protein 6.3-7.9 g/dL
Albumin 3.4-4.7 g/dL
Alpha-1 globulin 0.1-0.3 g/dL
Alpha-2 globulin 0.6-1.0 g/dL
Beta-globulin 0.7-1.2 g/dL
Gamma-globulin 0.6-1.6 g/dL
A/G Ratio
M Spike
M Spike
Impression
Immunofixation No monoclonal protein detected |
| MONONUCLEOSIS TEST | MON | MONO | HA | Mono Test Negative |
| MORICIZINE | MOR | MOR | HPLC | Moricizine ug/mL
Steady state trough 0.02-0.18
(with 200 mg dose 3 times/dose)
Peak: 0.48-1.54 (1-3 hrs following
single 500 mg oral dose) |
| MOTOR & SENSORY NEUROPATHY EVALUATION | MOTSEN | MOTSEN | ELISA, DUAL ELISA, IFA/WB, IFE | Motor & Sensory Neuropathy Evaluation
Separate Report to Follow |
| MRSA NASAL SCREEN BY PCR (REFLEXIVE) | MRSPCA | MRSPCR | PCR with reflex to culture | MRSA PCR Result
MRSA PCR Status |
| MTHFR C677T AND A1298C, INVADER | MTINV | MTINV | Invader | MTHFR Result
Negative for C677T and A1298C mutations.
A negative result does not rule out other
causes for hyperhomocysteinemia, coronary
artery disease or venous thrombosis.
MTHFR Comment
Genomic DNA from patient samples is tested
for the C677T and A1298C mutations by the
Invader assay from Third Wave Techologies.
This assay uses Cleavase enzyme to recognize
and cleave specific structures formed by the
interaction of two oligonucleotides with a
nucleic acid target.
MTHFR Comment
This test was developed and its performance
characteristics determined by SHMC. It has
not been cleared or approved by the U.S.
Food and Drug Administration. The FDA has
not determined that such clearance or approval
is necessary. This test is used for clinical
purposes. It should not be regarded as investi-
gational or for research. This laboratory is
certified under CLIA '88 as qualified to perform
high-complexity clinical testing. |
| MULTIPLE SCLEROSIS COMPREHENSIVE PANEL | MS.COMP | MSPAN | ELISA/Isoelectric Focusing | Multiple Sclerosis Panel
IgG, serum mg/dL
0-30 days 611-1542
1 mo 241-870
2 mo 198-577
3 mo 169-558
4 mo 188-536
5 mo 165-781
6 mo 206-676
7-8 mo 208-868
9-11 mo 282-1026
1 yr 331-1164
2 yrs 407-1009
3 yrs 423-1090
4 yrs 444-1187
5-7 yrs 608-1229
8-9 yrs 584-1509
10+ yrs 768-1632
IgG, CSF 0.0-6.0 mg/dL
Albumin, Serum 3500-5200 mg/dL
Albumin, CSF 0-35 mg/dL
Albumin Index 0.0-9.0 ratio
CSF IgG
Synthesis Rate 0.0-8.0 mg/d
IgG Index 0.28-0.66 ratio
CSF IgG/Albumin 0.09-0.25 ratio
CSF Oligoclonal
Bands Negative
Myelin Basic
Protein 0.07-4.10 ng/mL
Interpretation |
| MUMPS VIRUS ANTIBODY, IGG | MUMPSG | MUMPSG | ELISA | Mumps Virus Antibody, IgG OD
0.90 or less Negative-No significant level of
detectable mumps virus Ab.
0.91-1.09 Equivocal-Repeat testing in 10-
14 days may be helpful.
1.10 or more Positive-IgG Ab to mumps virus
detected, which may indicate a current or
previous exposure/immunization to mumps
virus. Positive IgG Ab levels in the absence
of current clinical symptoms may indicate
immunity. |
| MUMPS VIRUS ANTIBODY, IGM | MUMPSM | MUMPSM | EIA | Mumps Virus Antibody, IgM IV
0.79 or less Negative-No significant
level of detectable IgM Ab to Mumps
Virus.
0.80-1.20 Equivocal-Borderline
levels of IgM Ab to Mumps virus.
Repeat testing in 10-14 days may be
helpful.
1.21 or greater Positive-Presence of
IgM Ab to Mumps virus detected.
However, low levels of IgM antibodies
may occasionally persist for more than
12 months post-infection or immuni-
zation. |
| MYCOBACTERIUM TUBERCULOSIS SUSCEPTIBILITY | TBSUSC | TBSUSC | Bactec 460 direct susceptibility | Mycobacterium tuberculosis Susceptibility
Result
Myocobacterium tuberculosis Susceptibility
Status |
| MYCOPHENOLIC ACID | MCPA | MCPA | HPLC | Mycophenolic Acid 1.0-5.0 ug/mL
MPA does not have well established
or therapeutic ranges. Dosing of 2 g/day gives
trough values of 1.0-3.5 ug/mL while
3 g/day gives values up to 5.0 ug/mL.
Trough levels between 2.0-4.0 ug/mL
have been suggested to maximize
efficacy and minimize adverse effects. |
| MYCOPLASMA ANTIBODY IGG, PAIRED | MPNG2 | MPNG2 | IFA | M. pneumoniae IgG, Acute Ab Titer
Date Drawn
M. pneumoniae IgG, Conv Ab Titer
Date Drawn
Interpretation |
| MYCOPLASMA PNEUMONIAE ANTIBODY, IGG | MYCO | MPNG | IFA | Mycoplasma pneumoniae Ab, IgG LT 1:32 Titer
Interpretation |
| MYCOPLASMA PNEUMONIAE ANTIBODY, IGG & IGM | MYCO.IGG.IGM | MPNGM | IFA | Mycoplasma pneumoniae Ab, IgG LT 1:32 Titer
Mycoplasma pneumoniae Ab, IgM LT 1:16 Titer
Interpretation |
| MYCOPLASMA PNEUMONIAE ANTIBODY, IGM | MYCO.IGM | MPNM | IFA | Mycoplasma pneumoniae Ab, IgM LT 1:16 Titer |
| MYCOPLASMA PNEUMONIAE BY PCR | MYCPCR | MYCPCR | PCR | Source
Mycoplasma pneumoniae by PCR Negative
Interpretation
Negative Mycoplasma pneumoniae
DNA not detected by PCR.
Positive Mycoplasma pneumoniae
DNA detected by PCR.
This test is performed pursuant to an agree-
ment with Roche Molecular Systems, Inc. |
| MYELIN BASIC PROTEIN | MBP | MBPROT | ELISA | Myelin Basic Protein 0.00-1.10 ng/mL |
| MYELOPEROXIDASE ANTIBODY | MPO | MPO | EIA | Myeloperoxidase Antibody LT 9.0 U/mL |
| MYOGLOBIN | MYOGLOBIN | MYO | Chemiluminescence Assay | Myoglobin 0-116 ng/mL |
| MYOGLOBIN, QUANTITATIVE, URINE | MYOGLOBIN-U | MGNPUR | Electrochemiluminescent Immunoassay | Myoglobin, Urine mg/L
Negative 0-1
1-15 mg/L Associated with vigorous
exercise, myocardial infarction,
mild muscle injury, and other
conditions. GT 15 mg/L at risk of
acute renal failure. Usual results
less than 1 mg/L. |
| MYOSITIS ASSESSOR, JO-1 AUTOANTIBODIES | MYAJO1 | MYAJO1 | RIPA, EIA | PL-7 Autoantibodies Not detected
PL-12 Autoantibodies Not detected
Mi-2 Autoantibodies Not detected
Ku Autoantibodies Not detected
EJ Autoantibodies Not detected
OJ Autoantibodies Not detected
SRP Autoantibodies Not detected
Jo-1 Autoantibodies LT 1.0 Index |
| N-TELOPEPTIDES, CROSS-LINKED, SERUM | NTXSER | NTXSER | ELISA | N-Telopeptide, Cross-Linked, Serum nM BCE
F Premenopausal adult 6.2-19.0
M 25+ years 5.4-24.2
The target value for treated post-
menopausal adult females is the
same as the premenopausal reference
interval.
BCE=Bone Collagen Equivalent |
| N-TELOPEPTIDES, CROSS-LINKED, URINE | NTX | NTX | EIA | NTX nmol BCE/mmolCr
M 3-63
F 5-65
This range represents normal bone
metabolism in a population of
healthy pre-menopausal women.
For postmenopausal women, the
following risk factors apply for a
decrease in bone mineral density if
not treated with hormone replacement
therapy
NTX Value Relative Risk
18-38 1.4
39-51 2.5
52-67 3.8
68-188 17.3
Post-menopausal women with baseline
NTx values greater than 38 have been
shown to experience the greatest
improvement in spinal bone mass
after one year on hormone replace-
ment therapy. |
| NAPROXEN | NAP | NAP | HPLC | Naproxen ug/mL
30-90 Anti-inflammatory or analesgic
range. |
| NARCOLEPSY PANEL | NARC | NARC | PCR | Narcolepsy HLA DNA Panel
Separate Report to Follow |
| NARDIL | NAR | NARDIL | GC | Nardil (Phenelyzine) ng/mL
Reported serum levels from patients
on therapeutic doses are normally in
the range of 1-100 ng/mL. |
| NATURAL KILLER CELL PANEL | IPHNK | IPHNK | Flow Cytometry | Natural Killer Cell
Panel Result |
| NEFAZODONE, QUANTITATIVE | NEFAZQ | NEFAZQ | HPLC | Nefazodone mcg/mL
Steady-state peak levels (at approxi-
mately 1.2 hours post-dose) following
a daily regimen:
50 mg bid 0.08-0.39
100 mg bid 0.46-1.2
200 mg bid 1.6-3.9 |
| NEISSERIA GONORRHOEAE ANTIBODY | GON-AB | GONAB | CF | Neisseria Gonorrhoeae Ab, CF Titer
LT 1:8
Interpretive Criteria
LT 1:8 Antibody not detected.
1:8 or greater Antibody detected.
Titers GT or equal to 1:8 suggest either gonococcal
infection or asymptomatic colonization. Antibodies
recognizing Neisseria gonorrhoeae are apparently
unprotective, since reinfection frequently occurs. |
| NEISSERIA GONORRHOEAE BY AMPLIFIED DETECTION (APTIMA) | APTNG | APTNG | TMA | Source
Neisseria gonorrhoeae by APTIMA
Not detected |
| NEUROMYELITIS OPTICA (NMO) AUTOANTIBODIES, IGG | NMOIG | NMOIG | Indirect Immunofluorescence Assay (IFA) | NMO-IgG, Serum Negative
|
| NEURON SPECIFIC ENOLASE | NSEN | NSEN | ELISA | Neuron Specific Enolase 3.7-8.9 ug/L
This assay is performed using the
CanAG Neuron Specific Enolase
Enzyme Immunoassay.
Results obtained with different
assay methods or kits cannot be
used interchangeably. |
| NEUTROPHIL ASSOCIATED ANTIBODY | ANETAB | ANETAB | Flow Cytometry | Neutrophil Associated Ab Negative
Neutrophil associated antibody
may cause neutropenia in various autoimmune
disorders including Felty's
Syndrome, SLE and drug-induced
neutropenia. Febrile transfusion
reactions and isoimmune neonatal
neutropenia may also be caused by
antibodies to neutrophil-specific
antigens or HLA antigens. Circulating
antibodies in patient's
serum are measured by flow
cytometry after incubation with normal
neutrophils. Values greater
than 2 standard deviations of the
control population are interpreted
as 'weakly positive' and greater
than 3 standard deviations,
'positive'. |
| NEUTROPHIL OXIDATIVE BURST ASSAY | NEUOXB | NEUOXB | Flow Cytometry | Neutrophil Oxidative Burst Assay
See separate report |
| NEWBORN SCREENING (WASHINGTON) | PKUNSR | PKUNSR | MS/MS, Fluoroimmunoassay, Colorimetric, IEF, Fluorametric Assay | CAH LT 60.0 ng/mL
Hemoglobinopathy FA or AF Phenotype
Biotinidase Full Enzyme Activity
Galactosemia Full Enzyme Activity
Homocystinuria LT 80 umol/L blood
MCAD Deficiency LT 0.5 umol/L blood
Maple Syrup Urine LT 350 umol/L blood
Disease
PKU LT 180 umol/L blood
CH (TSH) LT 20.0 uIU/mL
Cystic Fibrosis LT 70 ng/mL blood
All findings based on
child's age, birthweight,
or transfusion status. |
| NIACIN (VITAMIN B3) | NIACI | NIACI | HPLC/Solid Phase Extraction | Niacin ug/mL
10 yrs and more Normal 0.50-8.45
Low LT 0.50
High GT 8.45
LT 10 yrs Normal 0.50-8.91
Low LT 0.50
High GT 8.91 |
| NICKEL | NISER | NISER | ICP-MS | Nickel 10.0 or less ug/L
Serum nickel testing is intended
to detect potentially toxic
exposure. |
| NICKEL, QUANTITATIVE, URINE | NICUQ | NICUQ | ICP/MS | Collection Period hr
Total Volume mls
Creatinine, Urine mg/dL
Creatinine, Urine mg/d
M 3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81 yrs + 600-2000
F 3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
81 yrs+ 400-1300
Nickel, Urine 0.0-5.2 ug/L
Nickel, Urine 0.0-6.4 ug/d
Nickel, Urine No reference ug/gCR
interval |
| NICOTINE & METABOLITE, SERUM/PLASMA | NICMSP | NICMSP | LC-Tandem Mass Spectrometry | Nicotine Unexposed LT 2 ng/mL
Passive LT 2
Abstinent LT 2
Acitve 30-50
Cotinine Unexposed LT 2 ng/mL
Passive LT 8
Abstinent LT 2
Active 200-800
3-OH-Cotinine Unexposed LT 2 ng/mL
Passive LT 2
Abstinent LT 2
Active 100-500
Unexposed = Non tabacco user
Passive = Passive Exposure
Abstinent = Abstinent user for more
than 2 weeks.
Active = Active tabacco use.
The absence of expectd drug(s) and or drug metabolite
(s) may indicate non-compliance, inappropriate timing
of specimen collection relative to drug administration,
poor drug absorption, or limitations of testing. The
concentration value must be GT or equal to the cutoff
to be reported as positive. Interpretive questions
should be directed to the lab. |
| NMP 22 | NMP22 | NMP22 | EIA | NMP22 0.0-10.0 U/mL
The NMP22 assay is intended as an aid
in the management of patients with
transitional cell carcinoma of the
urinary tract (TCC/UT). It is used
after surgical treatment to identify
patients with residuual or rapidly
recurring TCC/UT. |
| NMR LIPOPROFILE | NMRLP | NMRLP | Spectrophotometric | LDL-P Low LT 1000 nmol/L
Moderate 1000-2199
Borderline high 1300-1599
High 1600-2000
Very high GT 2000
LDL-C Optimal LT 100 mg/dL
Near or above 100-129
Optimal
Borderline high 130-159
High 160-190
Very high GT 190
HDL-C Desirable 40 or more mg/dL
Triglycerides Desirable LT 150 mg/dL
Total Cholesterol Desirable LT 200 mg/dL
HDL-P (Total) umol/L
Small LDL-P nmol/L
LDL Size nm
Large VLDL-P nmol/L
Small VLDL-P nmol/L
Large HDL-P umol/L
VLDL Size nm
LDL Size nm
HDL Size nm
LP-IR Score 0-100 |
| NOROVIRUS GROUP 1 & 2 RT-PCR | NOROPC | NOROPC | RT-PCR | Norovirus 1 by RT-PCR Not detected
Norovirus 2 by RT-PCR Not detected
A result of not detected does not rule out the presence
of PCR inhibitors in the patient specimen or norovirus nucleic
acid in concentrations below the level of detection of the
assay. This test is performed pursuant to an agreement with
Roche Molecular Systems, Inc. |
| NORTH DAKOTA FOOD PANEL [IBT] | NDIGGI | NDIGGI | ImmunoCap FEIA-IGG | Casein IgG LT 2 mcg/mL
Casein IgG Class
Corn IgG LT 2
Corn IgG Class
Egg White IgG LT 2
Egg White IgG Class
Orange IgG LT 2
Orange IgG Class
Soybean IgG LT 2
Soybean IgG Class
Wheat IgG LT 2
Wheat IgG Class
Yeast(Saccharomyces cerevisiae) IgG LT 2
Yeast (Saccharomyces cerevisiae) IgG Class
|
| NORTRIPTYLINE | NOR | NORT | HPLC | Nortriptyline ng/mL
Therapeutic 50-150
Toxic GT 499 |
| OBSTETRIC PANEL | OB.PANEL | OBPANL | Hemagglutination, ICMA, Automated, FLOC | CBC
ABO
RH
Antibody Screen Negative
RPR Nonreactive
Hepatitis B Surface Antigen Nonreactive
Rubella, IgG
LT 5 Presumed non-immune IU/mL
5-9 Equivocal
10 or greater Presumed immune |
| OCCULT BLOOD, URINE | BLD | BLDUD | Colorimetric | Hemoglobin, Urine Negative |
| OLANZAPINE | OLANZ | OLANZ | HPLC | Olanzapine 5-75 ng/mL |
| OLIGOCLONAL BAND PROFILE | OLIBND | OLIBND | Isoelectric Focusing/ Nephelometry/IF | IgG, Serum mg/dL
0-30 days 611-1542
1 mo 241-870
2 mo 198-577
3 mo 169-558
4 mo 188-536
5 mo 165-781
6 mo 206-676
7-8 mo 208-868
9-11 mo 282-1026
1 yr 331-1164
2 yrs 407-1009
3 yrs 423-1090
4 yrs 444-1187
5-7 yrs 608-1229
8-9 yrs 584-1509
10+ yrs 768-1632
IgG, CSF 0.0-6.0 mg/dL
Albumin, CSF 0-35 mg/dL
Albumin, Index 0.0-9.0 ratio
IgG Index 0.28-0.66 ratio
CSF IgG/Albumin Ratio 0.09-0.25 ratio
CSF Oligoclonal Bands Negative
Interpretation
CSF IgG Synthesis 8.0 or mg/d
Rate less
Albumin, Serum 3500-5200 mg/dL
|
| OLIGOCLONAL BANDS, CSF/SERUM | OLIGB | OLIGB | Isoelectric Focusing/Immunofixation | CSF Band Oligob Negative
Interpretation |
| OPIATE COMPLIANCE PANEL 7 | CPOP7 | CPOP7 | Tandem Mass Spectrometry | Codeine positive cutoff 20 ng/mL
Morphine positive cutoff 20 ng/mL
Hydrocodone positive cutoff 20 ng/mL
Hydromorphone positive cutoff 20 ng/mL
Oxycodone positive cutoff 20 ng/mL
Oxymorphone positive cutoff 20 ng/mL
6 MAM (Heroin positive cutoff 10 ng/mL
Metabolite) |
| OPIATES, (REFLEXIVE) | OPISCO | OPISCO | ELISA, GC/MS | Opiates ng/mL
6-Monoacetylmorphine, Free ng/mL
Coedine, Free ng/mL
Therapeutic range 30-120
Dihydrocodeine/Hydrocodol, Free ng/mL
Usual therapeutic range 50-100
Hydrocodone, Free ng/mL
Following a single 10 mg dose
Up to 39 ng/mL
Hydromorphone, Free ng/mL
Peak plasma concentrations ranged
from 18-27 ng/mL (mean 22 ng/mL)
one hour after a 4 mg oral dose.
Morphine, Free ng/mL
Usual range following therapeutic
doses: 10-70 ng/mL
Oxycodone, Free ng/mL
Peak plasma concentrations 1 hr
after a single immediate-release
tablet preparation containing 5 mg
Oxycodone: 9-38 ng/mL.
Peak plasma concentrations within
2.5 hours after 10 mg of a immediate
release preparation of Oxycodone: 13-46
ng/mL.
Mean peak plasma concentrations
following a single dose of a 40 to
80 mg controlled release Oxycodone
preparation: 39-100 ng/mL.
Toxicity may be significant at
greater than 200 ng/mL. However,
concentrations associated with
toxicity are variable and depend
on an individual's tolerance to
the drug.
Oxymorphone, Free ng/mL |
| OPIATES, FREE & TOTAL | OPIFRT | OPIFRT | GC/MS | 6-Monoacetylmorphine, Free ng/mL
Codeine, Free ng/mL
Therapeutic 3-120
Dihydrocodeine/Hydrocodol, Free ng/mL
Usual therapeutic range 50-100
Hydrocodone, Free ng/mL
Following a single 10-mg oral
dose up to 39
Hydromorphone, Free ng/mL
Peak plasma concentrations ranged
from 18-27 (mean 22) one hour after
a 4-mg oral dose
Morphine, Free ng/mL
Usual range following therapeutic
10-70
Oxycodone, Free ng/mL
Peak plasma levels following a
single oral 4.5 mg dose 17-36
Oxymorphone, Free ng/mL
Dihydrocodeine/Hydrocodol, Total ng/mL
Oxycodone, Total ng/mL
Codeine, Total ng/mL
Hydrocodone, Total ng/mL
Hydromorphone, Total ng/mL
Morphine, Total ng/mL
Total morphine concentrations
include unconjugated morphine
plus conjugated metabolites,
primarily the inactive morphine-3-
glucuronide and the active morphine-
6-glucuronide. Typically the con-
centrations of the conjugated
metabolites in the blood exceed
that of the parent drug. |
| ORAL FLUID 5 (REFLEXIVE) | ORAL5 | ORAL5 | Tandem Mass Spectrometry/GC | Amphetamine Screen Cutoff 50 ng/mL
Amphetamine Cutoff 10.0 ng/mL
Methamphetamine Cutoff 10.0 ng/mL
MDA Cutoff 10.0 ng/mL
MDMA Cutoff 10.0 ng/mL
Cocaine Screen Cutoff 20 ng/mL
Benzoylecgonine Cutoff 3.0 ng/mL
Cocaine Cutoff 2.0 ng/mL
Opiates Screen Cutoff 40 ng/mL
Codeine Cutoff 2.0 ng/mL
Morphine Cutoff 2.0 ng/mL
Hydrocodone Cutoff 2.0 ng/mL
Hydromorphone Cutoff 3.0 ng/mL
6-MAM Cutoff 2.0 ng/mL
Oxycodone Cutoff 2.0 ng/mL
PCP Screen Cutoff 10 ng/mL
Phencyclidine Cutoff 10.0 ng/mL
Cannabinoids Screen Cutoff 4 ng/mL
Native THC Cutoff 2.0 ng/mL
Certification |
| ORAL FLUID 9 (REFLEXIVE) | ORAL9 | ORAL9 | Tandem Mass Spectrometry/GC | Amphetamine Screen Cutoff 50 ng/mL
Amphetamine Cutoff 10.0
Methamphetamine Cutoff 10.0
MDA Cutoff 10.0
MDMA Cutoff 10.0
Barbiturates Screen Cutoff 100 ng/mL
Butalbital Cutoff 50.0
Amobarbital Cutoff 50.0
Pentobarbital Cutoff 50.0
Secobarbital Cutoff 50.0
Phenobarbital Cutoff 50.0
Benzodiazepines Screen Cutoff 10 ng/mL
Oxazepam Cutoff 5.0
Alprazolam Cutoff 5.0
Temazepam Cutoff 5.0
Nordiazepam Cutoff 5.0
Diazepam Cutoff 5.0
Cocaine Screen Cutoff 20 ng/mL
Benzoylecgonine Cutoff 3.0
Cocaine Cutoff 2.0
Methadone Screen Cutoff 50 ng/mL
EDDP Cutoff 25.0
Methadone Cutoff 25.0
Opiates Screen Cutoff 40 ng/mL
Codeine Cutoff 2.0
Morphine Cutoff 2.0
Hydrocodone Cutoff 2.0
Hydromorphone Cutoff 3.0
6-MAM Cutoff 2.0
Oxycodone Cutoff 2.0
PCP Screen Cutoff 10 ng/mL
Phencyclidine Cutoff 10.0
Propoxyphene Screen Cutoff 50 ng/mL
Propoxyphene Cutoff 10.0
Norpropoxyphene Cutoff 10.0
Cannabinoids Screen Cutoff 4 ng/mL
Native THC Cutoff 2.0
Certification |
| ORGANIC ACIDS, URINE | ORAU | ORAU | GC/MS | Lactic LT 1 mo LT 121 mg/gC
1 mo-1 yr LT 95
GT 1 yr LT 80
*Pyruvic LT 1 mo LT 60 mg/gC
1 mo-1 yr LT 60
GT 1 yr LT 51
3-OH-Butyric LT 1 mo LT 150 mg/gC
1 mo-1 yr LT 150
GT 1 yr LT 150
Acetoacetic LT 1 mo LT 59 mg/gC
1 mo-1 yr LT 59
GT 1 yr LT 59
Ethylmalonic LT 1 mo LT 32 mg/gC
1 mo-1 yr LT 26
GT 1 yr LT 19
Fumaric LT 1 mo LT 39 mg/gC
1 mo-1 yr LT 40
GT 1 yr LT 40
Glutaric LT 1 mo LT 20 mg/gC
1 mo-1 yr LT 28
GT 1 yr LT 29
3-Methylglutaric LT 1 mo LT 10 mg/gC
1 mo-1 yr LT 10
GT 1 yr LT 10
3-Methylglutaconic LT 1 mo LT 35 mg/gC
1 mo-1 yr LT 45
GT 1 yr LT 45
Adipic LT 1 mo LT 24 mg/gC
1 mo-1 yr LT 64
GT 1 yr LT 25
2-Ketoglutaric LT 1 mo LT 448 mg/gC
1 mo-1 yr LT 544
GT 1 yr LT 153
Suberic LT 1 mo LT 42 mg/gC
1 mo-1 yr LT 46
GT 1 yr LT 32
Sebacic LT 1 mo LT 38 mg/gC
1 mo-1 yr LT 25
GT 1 yr LT 14
Interpretation |
| ORGANISM IDENTIFICATION | ORG.ID | CORG | | Source
Organism ID
Organism, Status |
| ORGANISM SENSITIVITY, EACH ORGANISM | SUSC | SUSC | | Source
Organism Sens Negative
Organism Sens, Status |
| OSMOLALITY | OSMOLAL | OSM | Freezing Point Depression | Osmolality 275-295 mOsm/kg |
| OSMOLALITY, FECAL | FECOSM | FECOSM | Freezing Point | Osmolality, Fecal 220-280 mosmol/kg |
| OSMOLALITY, QUANTITATIVE, URINE | OSMOLAL-U | OSMUQ | Freezing Point Depression | Collection Period h
Volume mL
Osmolality, Urine 300-900 mOsm/kg |
| OSMOLALITY, URINE (RANDOM) | OSMOLAL-R | OSMUR | Freezing Point Depression | Osmolality, Urine, Random mOsm/kg
50-1200 |
| OSTEOCALCIN | OSTEOCALCIN | OSTEO | Electrochemiluminescent Immunoassay | Osteocalcin ng/mL
M 7-9 yrs 66-182
10-12 yrs 85-232
13-15 yrs 70-336
16-17 yrs 43-237
18 yrs & older 11-50
F 7-9 yrs 73-206
10-12 yrs 77-262
13-15 yrs 33-222
16-17 yrs 24-99
18 yrs & older 11-50 |
| OVA AND PARASITES | O/P | OP | Microscopic | Source
Ova & Parasites Negative
Ova & Parasites, Status |
| OVARY ANTIBODY, (REFLEXIVE) | OVAB | OVAB | IFA | Anti-Ovary Antibody Negative
Anti-Ovary Antibody Titer Titer |
| OXALATE, QUANTITATIVE, URINE | OXALATE-UR | OXUQ | Enzymatic | Collection Period h
Volume mL
Oxalate, Urine mg/24h
0-14 yrs 13-38
Male 15+ yrs 7-44
Female 15+ yrs 4-31 |
| OXALATE, SERUM | OXASER | OXASER | Enzymatic | Oxalate, Serum mol/L
Normally up to 27 |
| OXALATE, URINE (RANDOM) | OXALATE.R | OXUR | Enzymatic | Oxalate, Urine, Random mg/L
No reference range established |
| OXCARBAZEPINE METABOLITE | OXCAR | OXCAR | HPLC/DAD | 15-35 micrograms per milliter (ug/ml) |
| PAIN MANAGEMENT 10 PANEL (REFLEXIVE) | PMP2 | PMP2 | EMIT, LC-MS/MS | Alcohol Screen positive cutoff 20 mg/dL
Alcohol positive cutoff 20 mg/dL
Amphetamines Screen positive cutoff 500 ng/mL
Amphetamine positive cutoff 250 ng/mL
Methamphetamine positive cutoff 250 ng/mL
Cannabinoids Screen positive cutoff 20 ng/mL
Cannabinoids positive cutoff 15 ng/mL
Cocaine Screen positive cutoff 150 ng/mL
Benzoylecgonine positive cutoff 100 ng/mL
Codeine positive cutoff 20 ng/mL
Morphine positive cutoff 20 ng/mL
Hydrocodone positive cutoff 20 ng/mL
Hydromorphone positive cutoff 20 ng/mL
Oxycodone positive cutoff 20 ng/mL
Oxymorphone positive cutoff 20 ng/mL
Heroin positive cutoff 10 ng/mL
PCP Screen positive cutoff 25 ng/mL
Phencyclidine positive cutoff 25 ng/mL
Propoxyphene Screen positive cutoff 300 ng/mL
Norpropoxyphene positive cutoff 300 ng/mL
Barbiturates Screen positive cutoff 200 ng/mL
Amobarbital positive cutoff 200 ng/mL
Butalbital positive cutoff 200 ng/mL
Pentobarbital positive cutoff 200 ng/mL
Phenobarbital positive cutoff 200 ng/mL
Secobarbital positive cutoff 200 ng/mL
Benzodiazepines Scr positive cutoff 200 ng/mL
Oxazepam positive cutoff 200 ng/mL
Temazepam positive cutoff 200 ng/mL
Lorazepam positive cutoff 200 ng/mL
Alpha-hydroxy positive cutoff 50 ng/mL
Alprazolam
Methadone Screen positive cutoff 300 ng/mL
Methadone positive cutoff 300 ng/mL
Metabolite (EDDP)
Oxidants positive cutoff 200 ug/mL
pH
Creatinine mg/dL
Specific Gravity
|
| PAIN MANAGEMENT 13 PANEL (REFLEXIVE) | PMP3 | PMP3 | EMIT, LC-MS/MS | Alcohol Screen positive cutoff 20 mg/dL
Alcohol positive cutoff 20 mg/dL
Amphetamines Screen positive cutoff 500 ng/mL
Amphetamine positive cutoff 250 ng/mL
Methamphetamine positive cutoff 250 ng/mL
Cannabinoids Screen positive cutoff 20 ng/mL
Cannabinoids positive cutoff 15 ng/mL
Cocaine Screen positive cutoff 150 ng/mL
Benzoylecgonine positive cutoff 100 ng/mL
Codeine positive cutoff 20 ng/mL
Morphine positive cutoff 20 ng/mL
Hydrocodone positive cutoff 20 ng/mL
Hydromorphone positive cutoff 20 ng/mL
Oxycodone positive cutoff 20 ng/mL
Oxymorphone positive cutoff 20 ng/mL
Heroin positive cutoff 10 ng/mL
PCP Screen positive cutoff 25 ng/mL
Phencyclidine positive cutoff 25 ng/mL
Propoxyphene Screen positive cutoff 300 ng/mL
Norpropoxyphene positive cutoff 300 ng/mL
Barbiturates Screen positive cutoff 200 ng/mL
Amobarbital positive cutoff 200 ng/mL
Butalbital positive cutoff 200 ng/mL
Pentobarbital positive cutoff 200 ng/mL
Phenobarbital positive cutoff 200 ng/mL
Secobarbital positive cutoff 200 ng/mL
Benzodiazepines Scr positive cutoff 200 ng/mL
Oxazepam positive cutoff 200 ng/mL
Temazepam positive cutoff 200 ng/mL
Lorazepam positive cutoff 200 ng/mL
Alpha-hydroxy positive cutoff 50 ng/mL
Alprazolam
Methadone Screen positive cutoff 300 ng/mL
Methadone positive cutoff 300 ng/mL
Metabolite (EDDP)
Meperidine Screen positive cutoff 200 ng/mL
Meperidine positive cutoff 100 ng/mL
Normeperidine positive cutoff 100 ng/mL
Tramadol Screen positive cutoff 200 ng/mL
Tramadol positive cutoff 100 ng/mL
Acetaminophen positive cutoff 2.5 ug/mL
Oxidants positive cutoff 200 ug/mL
pH
Creatinine mg/dL
Specific Gravity
|
| PAIN MANAGEMENT 17 PANEL (REFLEXIVE) | PMP4 | PMP4 | EMIT, LC-MS/MS | Alcohol Screen positive cutoff 20 mg/dL
Alcohol positive cutoff 20 mg/dL
Amphetamines Screen positive cutoff 500 ng/mL
Amphetamine positive cutoff 250 ng/mL
Methamphetamine positive cutoff 250 ng/mL
Cannabinoids Screen positive cutoff 20 ng/mL
Cannabinoids positive cutoff 15 ng/mL
Cocaine Screen positive cutoff 150 ng/mL
Benzoylecgonine positive cutoff 100 ng/mL
Codeine positive cutoff 20 ng/mL
Morphine positive cutoff 20 ng/mL
Hydrocodone positive cutoff 20 ng/mL
Hydromorphone positive cutoff 20 ng/mL
Oxycodone positive cutoff 20 ng/mL
Oxymorphone positive cutoff 20 ng/mL
Heroin positive cutoff 10 ng/mL
PCP Screen positive cutoff 25 ng/mL
Phencyclidine positive cutoff 25 ng/mL
Propoxyphene Screen positive cutoff 300 ng/mL
Norpropoxyphene positive cutoff 300 ng/mL
Barbiturates Screen positive cutoff 200 ng/mL
Amobarbital positive cutoff 200 ng/mL
Butalbital positive cutoff 200 ng/mL
Pentobarbital positive cutoff 200 ng/mL
Phenobarbital positive cutoff 200 ng/mL
Secobarbital positive cutoff 200 ng/mL
Benzodiazepines Scr positive cutoff 200 ng/mL
Oxazepam positive cutoff 200 ng/mL
Temazepam positive cutoff 200 ng/mL
Lorazepam positive cutoff 200 ng/mL
Alpha-hydroxy positive cutoff 50 ng/mL
Alprazolam
Methadone Screen positive cutoff 300 ng/mL
Methadone positive cutoff 300 ng/mL
Metabolite (EDDP)
Meperidine Screen positive cutoff 200 ng/mL
Meperidine positive cutoff 100 ng/mL
Normeperidine positive cutoff 100 ng/mL
Tramadol Screen positive cutoff 200 ng/mL
Tramadol positive cutoff 100 ng/mL
Acetaminophen positive cutoff 2.5 ug/mL
Fentanyl positive cutoff 2 ng/mL
Norfentanyl positive cutoff 2 ng/mL
Carisoprodol positive cutoff 2.5 ug/mL
Meprobamate positive cutoff 2.5 ug/mL
Bupreneorphine positive cutoff 25 ng/mL
Norbuprenorphine positive cutoff 25 ng/mL
ETS/ETG Screen positive cutoff 250 ng/mL
ETG positive cutoff 250 ng/mL
ETS positive cutoff 150 ng/mL
Oxidants positive cutoff 200 ug/mL
pH
Creatinine mg/dL
Specific Gravity
|
| PAIN MANAGEMENT 7 PANEL (REFLEXIVE) | PMP1 | PMP1 | EMIT, LC-MS/MS | Alcohol Screen positive cutoff 20 mg/dL
Alcohol positive cutoff 20 mg/dL
Amphetamines Screen positive cutoff 500 ng/mL
Amphetamine positive cutoff 250 ng/mL
Methamphetamine positive cutoff 250 ng/mL
Cannabinoids Screen positive cutoff 20 ng/mL
Cannabinoids positive cutoff 15 ng/mL
Cocaine Screen positive cutoff 150 ng/mL
Benzoylecgonine positive cutoff 100 ng/mL
Codeine positive cutoff 20 ng/mL
Morphine positive cutoff 20 ng/mL
Hydrocodone positive cutoff 20 ng/mL
Hydromorphone positive cutoff 20 ng/mL
Oxycodone positive cutoff 20 ng/mL
Oxymorphone positive cutoff 20 ng/mL
Heroin positive cutoff 10 ng/mL
PCP Screen positive cutoff 25 ng/mL
Phencyclidine positive cutoff 25 ng/mL
Propoxyphene Screen positive cutoff 300 ng/mL
Norpropoxyphene positive cutoff 300 ng/mL
Oxidants positive cutoff 200 ug/mL
pH
Creatinine mg/dL
Specific Gravity
|
| PANCREATIC ELASTASE, FECAL | PANEF | PANEF | ELISA | Pancreatic Elastase, Fecal ug/g
201-500 Normal
100-200 Moderate to mild
pancreatic insufficiency
99 or less Severe exocrine pancreatic
insufficiency |
| PANCREATIC POLYPEPTIDE | PAN POLY | PANPEP | RIA/Extraction | Pancreatic Polypeptide pg/mL
LT 3 yrs not established
3-9 yrs 519 or less
10-13 yrs 361 or less
14-17 yrs 297 or less
18-29 yrs 480 or less
30-39 yrs 70-400
40-49 yrs 70-430
50-62 yrs 100-780
GT 62 yrs not established |
| PARAINFLUENZA ANTIBODY 1, 2, 3, IGG & IGM | PAR123 | PAR123 | ELISA | Parainfluenza Virus 1 Ab,IgG IV
0.89 or less Negative-no significant
level of parainfluenza virus 1 IgG Ab
detected.
0.90-1.10 Equivocal-questionable
presence of parainfluenza virus 1 IgG Ab
detected. Repeat testing in 10-14
days may be helpful.
1.11 of more Positive-IgG antibody
to parainfluenza virus 1 detected,
which may suggest current or past
infection.
Parainfluenza Virus 1 Ab,IgM IV
0.89 or less Negative-no significant
level of parainfluenza virus 1 IgM Ab
detected.
0.90-1.10 Equivocal-questionable
presence of parainfluenza virus 1 IgM Ab
detected. Repeat testing in 10-14
days may be helpful.
1.11 or more Positive-IgM antibody
to parainfluenza virus 1 detected,
which may suggest current or past
infection.
Parainfluenza Virus 2 Ab,IgG IV
0.89 or less Negative-no significant
level of parainfluenza virus 2 IgG Ab
detected.
0.90-1.10 Equivocal-questionable
presence of parainfluenza virus 2 IgG Ab
detected. Repeat testing in 10-14
days may be helpful.
1.11 or more Positive-IgG antibody
to parainfluenza virus 2 detected,
which may suggest current or past
infection.
Parainfluenza Virus 2 Ab,IgM IV
0.89 or less Negative-no significant
level of parainfluenza virus 2 IgM Ab
detected.
0.90-1.10 Equivocal-questionable
presence of parainfluenza virus 2 IgM Ab
detected. Repeat testing in 10-14
days may be helpful.
1.11 or more Positive-IgM antibody
to parainfluenza virus 2 detected,
which may suggest current or past
infection.
Parainfluenza Virus 3 Ab,IgG IV
0.89 or less Negative-no significant
level of parainfluenza virus 3 IgG Ab
detected.
0.90-1.10 Equivocal-questionable
presence of parainfluenza virus 3 IgG Ab
detected. Repeat testing in 10-14
days may be helpful.
1.11 or more Positive-IgG antibody
to parainfluenza virus 3 detected,
which may suggest current or past
infection.
Parainfluenza Virus 3 Ab,IgM IV
0.89 or less Negative-no significant
level of parainfluenza virus 3 IgM Ab
detected.
0.90-1.10 Equivocal-questionable
presence of parainfluenza virus 3 IgM Ab
detected. Repeat testing in 10-14
days may be helpful.
1.11 or more Positive-IgM antibody
to parainfluenza virus 3 detected,
which may suggest current or past
infection. |
| PARASITE IDENTIFICATION, MACROSCOPIC | PARID | PARID | Macroscopic Inspection | Source
Parasite ID
Parasite ID Status |
| PARATHYROID HORMONE-RELATED PEPTIDE | PTHP | PTHP | ICMA | PTH Related Peptide LT 2.0 pmol/L |
| PAROXETINE | PAROXETINE | PAROX | GC | Paroxetine (Paxil) ng/mL
Trough steady-state plasma levels in
adult patients have great interindiv-
idual variability. The following
steady-state data is from patients on
a daily single dose regimen
Daily Dose (mg) Trough Mean +/-SD
20 49 +/- 26
30 86 +/- 61
40 129 +/- 86
50 117 +/- 90
Elderly patients typically achieve
higher trough steady-state concen-
trations versus adult patients. |
| PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PANEL (PNH PANEL) | PNHPAN | PNHPAN | Flow Cytometry | PNH Panel Result |
| PARVOVIRUS B19 ANTIBODY PANEL, ELISA/PCR | B19ABP | B19ABP | ELISA & RT-PCR | Parvovirus, IgG LT 0.90 Antibody not detected
Parvovirus, IgM LT 0.90 Antibody not detected
Interpretation
Parvovirus B19 DNA, Qualitative PCR
Not detected |
| PARVOVIRUS B19 ANTIBODY, IGG | PARVOG | PARVOG | EIA | Parvovirus B19 Ab, IgG IV
GT 1.09 Positive
0.91-1.09 Equivocal
LT 0.91 Negative |
| PARVOVIRUS B19 ANTIBODY, IGG & IGM | PRVOGM | PRVOGM | EIA | Parvovirus B19 Ab, IgG IV
GT 1.09 Positive
0.91-1.09 Equivocal
LT 0.91 Negative
Parvovirus B19 Ab, IgM IV
GT 1.09 Positive
0.91-1.09 Equivocal
LT 0.91 Negative |
| PARVOVIRUS B19 ANTIBODY, IGM | PARVOM | PARVOM | EIA | Parvovirus B19 Ab, IgM IV
GT 1.09 Positive
0.91-1.09 Equivocal
LT 0.91 Negative |
| PARVOVIRUS B19 BY PCR | HPVPCR | HPVPCR | PCR | Parvovirus, B19 by PCR
Negative-Parvovirus DNA not detected by PCR.
Positive-Parvovirus DNA detected by PCR.
This test is performed pursuant to an
agreement with Roche Molecular Systems,
Inc. |
| PCCA TITER & WB CONFIRMATION | PCCON | PCCON | IFA & Western blot | PCCA Titer LT 1:40
PCCA Western Blot Negative |
| PCCA TITER & WB CONFIRMATION, SF | PSFCON | PSFCON | IFA & Western blot | PCCA Titer, SF LT 1:1
PCCA Western Blot Negative |
| PENTOBARBITAL | PENTO | PENTO | GC | Pentobarbital ug/mL
Therapeutic Range Sedation 1-5
Toxic GT 7
Intracranial Pressure (ICP) Therapy
25-35 |
| PEROXIDASE STAIN | SS.PER | CSMPO | Cytochemical Stain | Myeloperoxidase Source
Myeloperoxidase Stain Negative
Myeloperoxidase Interp
Myeloperoxidase Reviewed By |
| PERPHENAZINE | PER | PERPH | HPLC | Perphenazine (Tinlafar) 0.8-2.4 ng/mL |
| PH, FLUID | PHFLD | PHFL | pH meter or dipstick | pH, Fluid
Serous fluid 6.8-7.6
Synovial fluid Parallels serum |
| PH, STOOL | STL.PH | STPH | | Source
pH, Stool
pH, Stool, Status |
| PH, URINE | UPH | PHUD | Colormetric | PH, Urine 5.0-7.5 |
| PHENOBARBITAL | PHB | PHB | LA | Phenobarbital ug/mL
Therapeutic 15.0-40.0
Toxic GT 50.0 |
| PHENOL EXPOSURE, (QUANTITATIVE) | PHEXPU | PHEXPU | GC, Colorimetry | Creatinine, Urine mg/L
A.C.G.I.H. normal range in adults:
300-3400 mg/L (mean 1000)
0.3-3.4 g/L (mean )
1000-1600 mg/day (1.0-1.6 g/day)
Phenol, Urine mg/L
LT 10 mg/L in unexposed individuals
LT 30 mg/L when chronically exposed
to 0.5-4.0 ppm Benzene in air.
Average 200 mg/L during chronic
exposure to 25 ppm Benzene in air.
Phenol, Urine mcg/gCR
Biological exposure index for monitoring
exposure to phenol: 250 mg total
phenol/g creatinine measured in an
end of shift specimen. |
| PHENOLPHTHALEIN, FECAL | PHENST | PHENST | Colorimetric | Phenolphthlein, Feces Negative |
| PHENYLALANINE (QUANTITATIVE) | PHEN-Q | PHEN | Ion Exchange Chromatography | Phenylalanine umol/L
0-1 yr 30-100
GT 1 yr 30-80 |
| PHENYTOIN | DIL | DIL | LA | Phenytoin ug/mL
Therapeutic 10.0-20.0
Toxic GT 25.0 |
| PHENYTOIN, FREE & TOTAL | DIL.FREE | DILFR | FPIA | Phenytoin, Free ug/mL
1.0-2.0
Toxic 3.0 or more
Phenytoin, Total ug/mL
10.0-20.0
Toxic GT 25.0
% Free 1.0-13.0 %
International reference calibrators
implemented on March 01, 2010.
Expect results to be 10-15%
higher than with previous
calibrators. No change in
therapeutic range. |
| PHOSPHATIDYLSERINE, ANTIBODIES, IGA, IGG, IGM | APSAGM | APSAGM | ELISA | Antiphosphatidylserine, IgA Negative LT 20 APS U/mL
Positive 20 or more
Antiphosphatidylserine, IgG Negative LT 11 GPS U/mL
Positive 11 or more
Antiphosphatidylserine IgM Negative LT 25 MPS U/mL
Positive 25 or more
The presence of phosphatidylserine
antibodies may be associated with
antiphospholipid syndrome characterized
by recurrent fetal loss, thrombosis and
thrombocytopenia. |
| PHOSPHOLIPIDS, SERUM/PLASMA | PHOSPHO | PHOSPH | Spectrophotometric | Phospholipids 160-300 mg/dL |
| PHOSPHORUS | PHO | PHOS | Colorimetric | Phosphorus mg/dL
0-10 days 4.2-9.6
10 days-24 mo 4.2-7.2
24 mo-12 yrs 4.2-5.9
12-60 yrs 2.5-4.8
60 yrs+ M 2.1-3.9
60 yrs+ F 2.6-4.4 |
| PHOSPHORUS, QUANTITATIVE, URINE | PHO-U | PHOSUQ | Colorimetric | Collection Period h
Volume mL
Phosphorus, Urine 400-1300 mg/24h |
| PHOSPHORUS, URINE (RANDOM) | PHO-R | PHOSUR | Colorimetric | Phosphorus, Urine, Random mg/dL
No normals established |
| PINWORM PREPARATION | PINW | PIN | Microscopic | Source
Pinworm Prep Negative
Pinworm Prep, Status |
| PLASMINOGEN | PLASMINOGEN | PLASM | Chromogenic | Plasminogen 71-144 % |
| PLASMINOGEN ACIVATOR INHIBITOR-1, 4G/5G GENOTYPING | PAI1G | PAI1G | PCR-RFLP | PAI-1 Results
PAI-1 Interpretation
PAI-1 Comments |
| PLASMINOGEN ACTIVATOR INHIBITOR 1 | PAI1 | PAI1 | Bioimmunoassay | Plasminogen Activator Inhibitor 1
22.0 or less IU/mL
The reference interval was
established based on fasting
samples drawn between 8 am
and 12 pm.Plasminogen
Activator Inhibitor 1 has
a diurnal variation, with
higher values in the
morning and decreased values
in the afternoon.
PAI-1 is alsoan acute phase
reactant. |
| PLATELET AGGREGATION, WHOLE BLOOD (REFLEXIVE) | WBPAGG | WBPAGG | Lumi-aggregation, Whole Blood | ADP Aggregation, Patient 5.1-27.3 Ohms
ADP Aggregation, Control 5.1-27.3 Ohms
ADP Secretion, Patient 0.2-1.9 nM
ADP Secretion, Control 0.2-1.9 nM
Collagen Low Aggregation, Pat 14.6-39.8 Ohms
Collagen Low Aggregation, Cont 14.6-39.8 Ohms
Collagen Low Secretion, Patient 0.5-2.2 nM
Collagen Low Secretion, Control 0.5-2.2 nM
Thrombin Secretion, Patient 0.8-2.5 nM
Thrombin Secretion, Control 0.8-2.5 nM
Ristocetin High Aggregation, Pat 5.1-14.9 Ohms
Ristocetin High Aggregation, Con 5.1-14.9 Ohms
Ristocetin Low Aggregation, Pat 0 Ohms
Ristocetin Low Aggregation, Cont 0 Ohms
Type 1 VWD Mixing Study, Risto Hi Ohms
Type 2 VWD Mixing Study, Risto Lo Ohms
Collagen High Aggregation, Pat 18.5-41.0 Ohms
Collagen High Aggregation, Cont 18.5-41.0 Ohms
Collagen High Secretion, Patient 0.7-2.4 nM
Collagen High Secretion, Control 0.7-2.4 nM
Arachidonic Acid Aggregation,Pat 7.0-25.8 Ohms
Arachidonic Acid Aggregation,Con 7.0-25.8 Ohms
Arachidonic Acid Secretion, Pat 0.4-1.9 nM
Arachidonic Acid Secretion, Con 0.4-1.9 nM
Platelet Count, Patient k/uL
0-3 days 250-450
3-9 days 200-400
9-30 days 250-450
1-6 months 300-750
6 mon-2 years 250-600
2-8 years 250-550
8-12 years 200-450
12-18 years 150-250
18+ years 150-400
Reviewed by
Interpretation
Note |
| PLATELET ANTIBODY (INDIRECT) | PLT.AB | PLTABD | ELISA | Platelet Antibody Detection Indirect Negative
Negative for HLA AlloAbs & Plt-specific Abs.
This is the primary test for detection
of platelet-specific antibodies.
It is not recommended for the diagnosis
of immune thrombocytopenia purpura (ITP).
This test will detect both allo and auto-
antibodies, but will not distinguish
between them.
Results of this test should be used in
conjunction with clinical findings and
other serological tests.
Antibodies directed to antigens found
on platelets are associated with many
different clinical situations. ITP is
a destructive thrombocytopenia caused
by autoantibodies. Neonatal alloimmune
thrombocytopenia (NATP) and post-
transfusion purpura (PTP) are diseases
where thromobocytopenia is caused by
platelet-specific alloantibodies. HLA
alloantibodies do not cause thrombocyto-
penia, but are commonly associated with
refractoriness to platelet transfusions.
This test is designed to detect anti-
bodies to platelet glycoproteins
IIb/IIa (HPA-1 a/1b[P1A1 and P1A2],
HPA-3a/3b, and HPA-4a), Ia/IIA
(HPA-5a/5b), Ib/IX and IV. In addition
this test will also detect antibodies
to HLA Class I antigens (HLA-A-B).
Testing for neonatal alloimmune
thrombocytopenia should be performed
using maternal serum, since platelet
antibody may not be detected in
neonatal serum. False-negative results
are common in infant samples. |
| PLATELET ANTIGEN GENOTYPING (HPA-1) | PLTAGT | PLTAGT | PCR | Platelet Antigen Genotyping (HPA-1)
Platelet Antigen Genotyping (HPA-1), Interpretation |
| PLATELET COUNT | PLT | PLTCNT | Automated | Platelet Count K/uL
0-3 days 250-450
3-9 days 200-400
9-30 days 250-450
1-6 mo 300-750
6 mo-2 yrs 250-600
2-8 yrs 250-550
8-12 yrs 200-450
12-18 yrs 150-450
18 yrs+ 150-400 |
| PLATELET FUNCTION SCREEN | PFSCN | PFSCN | PFA-100 | Platelet Function Screen
Collagen/Epinephrine 82-205 sec
Collagen/ADP 58-122 sec |
| PLATELET P2Y12 FUNCTION | P2Y12 | P2Y12 | VerifyNow Platelet Aggregation for P2Y12 Inhibition | Platelet Function P2Y12 PRU
Platelet Funciton Base 194-418 PRU
P2Y12 Inhibition
Test results are reported in percent
inhibition.
Therapeutic: Higher percen inhibition
associated with expected antiplatelet
effect.
Presurgical: less than 20% inhibition. |
| PML/RARA T (15;17) BY RT-PCR, QUANT | PMLR | PMLR | RT-PCR | PML Result
PML Quantitative result
This assay detects and quantifies
PML-RARa transcript level resulting
from a t(15;17) fusion mutation in
acute promyelocytic leukemia (APL).
This assay detects all three gene
fusion patterns: type A (short, S-
form, bcr-3), Type B (long, L-form,
bcr-1), and Type B variant
(variable, V-form, bcr-2).
Limit of detection: 1 in 10,000 cells.
Results of this test must always be
interpreted in the context of
morphologic and other relevant
data, and should not be used alone
for a diagnosis of malignancy. |
| PNEUMOCOCCAL ANTIBODY, IGG | PNEUAB | PNEUAB | Multi analyte fluorescent detection | Pneumococcal Ab ug/mL
Pneumococcal Serotype 1, IgG
Pneumococcal Serotype 3, IgG
Pneumococcal Serotype 4, IgG
Pneumococcal Serotype 5, IgG
Pneumococcal Serotype 6B, IgG
Pneumococcal Serotype 7F, IgG
Pneumococcal Serotype 8, IgG
Pneumococcal Serotype 9N, IgG
Pneumococcal Serotype 9V, IgG
Pneumococcal Serotype 12F, IgG
Pneumococcal Serotype 14, IgG
Pneumococcal Serotype 18C, IgG
Pneumococcal Serotype 19F, IgG
Pneumococcal Serotype 23F, IgG
Pneumococcal Serotype Interpretation
All serotypes tested are present in
the 23-valent pure polysaccharide
pneumococcal vaccine. Serotypes 4,
6B, 9V, 14, 18C, 19F, and 23F are
contained in the heptavalent con-
jugated pneumococcal vaccine.
Long-term protection is generally
thought to be associated
with a post-booster response of
1 ug/mL in children and adults.
Responder status is determined
according to the ratio of post-
vaccination to pre-vaccination
concentration of Pneumococcal IgG
antibody as follows:
A ratio of LT two-fold is considered a
non-responder.
A ratio of two-to fourfold is a weak
responder.
A ratio of GT or equal to fourfold is a
good responder.
A response to GT 50% of the antigens
contained in the vaccination is
indicative of a normal response. |
| PNEUMOCYSTIS FA STAIN | PNEUMO.FA | PNESM | Direct FA Stain | Source
Pneumocystis FA Stain Negative
Pneumocystis FA Stain, Status |
| POLIOVIRUS ANTIBODIES | POLIOA | POLIOA | Serum Neutralization Assay | Poliovirus Ab Type 1
Poliovirus Ab Type 2
Poliovirus Ab Type 3
LT 1:10 - No significant level of detectable poliovirus antibodies.
1:10 or greater - Antibody to poliovirus detected, which may represent
prior immunization or current or past infection.
The clinical significance of and the criteria for
interpretation of results may require
consultation with an Infectious Disease Specialist.
In immunized individuals, the significance
of a low antibody titer to
poliovirus 3 (the least immunogenic
vaccine serotype) is unclear. |
| POLYCHLORINATED BIPHENYLS | PCBS | PCBS | GC | Polychlorinated Biphenyls ppb
Based on Aroclor 1260.
General population Up to 30
Average 6 |
| POLYMYOSITIS (PM-SCL) ANTIBODY | POLYMY | POLYMY | ID | Polymyositis (PM-SCL) Antibody
Negative
Interpretive Criteria
Negative Antibody not detected
Positive Antibody detected |
| PORPHOBILINOGEN DEAMINASE, RBC | URO-1-SYN | PBGD | Fluorometric/Enzymatic | Porphobilinogen Deaminase, RBC mU/g hgb
Adults 2.10-4.30 |
| PORPHOBILINOGEN, URINE (QUANTITATIVE) | PBG | PBGUQ | Column Chromatography/Spectrophotometry | Collection Period h
Volume mL
Porphobilinogen 0.0-2.0 mg/24h |
| PORPHOBILINOGEN, URINE (RANDOM) | PBG.R | PBGUR | Column Chromatography/Spectrophotometry | Porphobilinogen, Urine, Random mg/L
No reference range established |
| PORPHYRINS PROFILE, PLASMA (REFLEXIVE) | PORPHM | PORPHM | Extraction, Scanning Fluorometry & HPLC | Porphyrins, Total Plasma 1.0 or less mcg/dL
Uroporphyrin, Plasma 1.0 or less mcg/dL
Heptacarboxylporphyrin, 1.0 or less mcg/dL
Plasma
Hexacarboxylporphyrin, 1.0 or less mcg/dL
Pentacarboxylporphyrin, 1.0 or less mcg/dL
Plasma
Corproporphyrin, Plasma 1.0 or less mcg/dL
Protoporphyrin, Plasma 1.0 or less mcg/dL
Interpretation |
| PORPHYRINS, FECAL | PORPST | PORPST | HPLC | Coproporphyrin, Feces 0-45 nmol/g
Protoporphyrins, Feces 0-100 nmol/g
Interpretation |
| PORPHYRINS, FRACTIONATION (RBC) | POR.RBC | PORRBC | HPLC | Protoporphyrin 16-60 ug/dL
Coproporphyrin 2 or less ug/dL
Uroporphyrins 2 or less ug/dL
Heptacarboxylporphyrins 1 or less ug/dL
Hexacarboxylporphyrins 1 or less ug/dL
Pentacarboxylporphyrins 1 or less ug/dL |
| PORPHYRINS, SERUM TOTAL | PORS | PORS | Scanning Fluorometry | Porphyrins, Total Serum 0-15 nmol/L
Interpretation |
| PORPHYRINS, URINE (QUANTITATIVE) | POR | PORUQ | Column chromatography/Spectrophotography | Collection Period h
Volume mL
Uroporphyrin ug/24h
M LT 50
F LT 25
Coproporphyrin ug/24h
M LT 110
F LT 78 |
| PORPHYRINS, URINE (QUANTITATIVE) + PBG | POR.PBG | PPBGUQ | HPLC/Column Chromatography/Spectrophotography | Collection Period h
Volume mL
Uroporphyrin ug/24h
M LT 50
F LT 25
Coproporphyrin ug/24h
M LT 110
F LT 78
Porphobilinogen mg/24h
0.0-2.0 |
| PORPHYRINS, URINE (RANDOM) | POR.R | PORUR | HPLC | Uroporphyrin ug/dL
No reference range established
Coproporphyrin ug/dL
No reference range established |
| PORPHYRINS, URINE (RANDOM) +PBG | POR.PBG.R | PPBGUR | HPLC/Column Chromatography/Spectrophotography | Uroporphyrin ug/dL
No reference range established
Coproporphyrin ug/dL
No reference range established
Porphobilinogen mg/L
No reference range established |
| POTASSIUM | POT | K | ISE | Potassium mmol/L
0-30 days 3.9-6.9
1-12 mo 3.6-6.8
1-5 yrs 3.2-5.7
5-10 yrs 3.4-5.4
10 yrs+ 3.5-5.3 |
| POTASSIUM, FLUID | POTFLD | KFL | ISE | Potassium, Fluid mmol/L
CSF 70% of plasma level
Gastric About 10
Other fluid No reference range established.
Method not validated for body fluid.
Clinical correlation necessary. |
| POTASSIUM, QUANTITATIVE, URINE | POT-U | KUQ | ISE | Collection Period h
Volume mL
Potassium, Urine 25-125 mmol/24h |
| POTASSIUM, STOOL | STLK | STLK | ISE | Potassium, Stool mmol/L
Not established |
| POTASSIUM, URINE (RANDOM) | POT-R | KUR | ISE | Potassium, Urine, Random mmol/L
No normals established |
| PRE-ALBUMIN | PRE-ALB | PAB | Nephelometry | Pre-Albumin 18-45 mg/dL |
| PREGABALIN, SERUM/PLASMA | PREGAS | PREGAS | HPLC | Pregabalin Not detected mcg/mL
Therapeutic drug concentrations have not been
established for any indication at this tiem.
Mean peak plasma concentrations up to 9.5
mcg/mL have been reported approximately 1 hour
post administration of up to 300 mg orally. |
| PREGNANCY TEST | PRG | PRGU | EIA | Pregnancy Test mIU/mL
Negative LT 25
Positive 25 or greater
The following comment will be appended to all
negative pregnancy results.
Levels of hCG greater than 300,000 mIU/mL (about
4-12 weeks gestation) may cause false-
negative results. Consider quantitative serum hCG
test to confirm negative screening result if
clinical picture suggests pregnancy. |
| PREGNENOLONE | PRGNEN | PRGNEN | LC-MS/MS | Pregnenolone ng/dL
F 7-9 yrs 14-150
10-12 yrs 19-220
13-15 yrs 22-210
16-17 yrs 22-229
18+ yrs 15-132
Tanner Stage I 15-171
Tanner Stage II 22-229
Tanner Stage III 34-215
Tanner Stage IV-V 26-235
M 7-9 yrs 13-205
10-12 yrs 15-151
13-15 yrs 18-197
16-17 yrs 17-228
Tanner Stage I 13-156
Tanner Stage II 12-143
Tanner Stage III 16-214
Tanner Stage IV-V 19-201 |
| PREKALLIKREIN (FLETECHER FACTOR) | PREKAL | PREKAL | Clot | Prekallikrein 65-135 %
(Fletcher Factor) |
| PRENATAL PROFILE | PRENAT | PRENAT | Hemagglutination/Floc | ABO
RH
Antibody Screen Negative
RPR Nonreactive |
| PRENATAL RISK ASSESSMENT | PRASCR | PRASCR | Immunometric/Elisa | Gestational Age
Maternal Age at Term
Maternal Weight
Race
Diabetic
IVF Donor Birthdate
Gestation
Screening Status
DS Screen Result
DS Risk (at mid-trimester)
DS Risk for Maternal Age
DS Risk as Equivalent Age
DS Risk Interp
OSB Screen Result
OSB Patient Risk
OSB Population Risk
OSB Risk Interp
Trisomy 18 Screen Result
Trisomy 18 Patient Risk
Trisomy 18 Risk Interp
Interpretation Note
AFP MoM
Unconjugated Estriol MoM
HCG MoM
AFP ng/mL
Estriol, Unconjugated ng/mL
HCG IU/mL
|
| PRENATAL RISK QUAD SCREEN | QDSCR | QDSCR | Immunometric/Elisa | Gestational Age
Maternal Age at Term
Maternal Weight
Race
Diabetic
IVF Donor Birthdate
Gestation
Screening Status
DS Screen Result
DS Risk (at mid-trimester)
DS Risk for Maternal Age
DS Risk as Equivalent Age
DS Risk Interp
OSB Screen Result
OSB Patient Risk
OBS Population Risk
OSB Risk Interp
Trisomy 18 Screen Result
Trisomy 18 Patient Risk
Trisomy 18 Risk Interp
Interpretation Note
AFP MoM
Unconjagated Estriol MoM
HCG MoM
Inhibin A MoM
AFP ng/mL
Unconjugated Estriol ng/mL
HCG IU/mL
Dimeric Inhibin A pg/mL |
| PRIMIDONE | PRM | PRPH | LA & Enzymatic | Phenobarbital ug/mL
Therapeutic 15.0-40.0
Toxic GT 50.0
Primidone ug/mL
Therapeutic 5.0-12.0
Toxic GT 15.0 |
| PROBRAIN NATRIURETIC PEPTIDE, NT | PBNPAR | PBNPAR | Electrochemiluminescent Immunoassay | NT-ProBNP Natriuretic Peptide pg/mL
0-74 yrs LT 125
75 yrs+ LT 450 |
| PROCAINAMIDE & NAPA | PROC | PROC | FPIA | Procainamide 4.0-10.0 ug/mL
Toxic GT 16.0 ug/mL
NAPA No range established ug/mL
Total Drug 10.0-30.0 ug/mL
Toxic GT 40.0 ug/mL |
| PROGESTERONE | PROGES | PROGES | ICMA | Progesterone ng/mL
M 0.28-1.22
F
Follicular 0.15-1.40
Luteal 3.34-25.56
Mid-luteal 4.44-28.03
Post-menopausal 0.00-0.73
Pregnancy
1st trimester 11.22-90.00
2nd trimester 25.55-89.40
3rd trimester 48.40-422.50
Women using oral contraceptives
have suppressed progesterone
levels. Minimum detectable
concentration is 0.15 ng/mL. |
| PROINSULIN | PROINSULIN | PROINS | ICMA | Proinsulin 3-20 pmol/L |
| PROLACTIN | PROLAC | PRL | ICMA | Prolactin ng/mL
M 1.6-18.8
F 1.4-24.2 |
| PROLONGED APTT EVALUATION (REFLEXIVE) | PROPTT | PROPTT | Electromechanical Clot Detection | aPTT, Patient 0-1 mon 40-50 sec
2 mon-4 yrs 25-40
5+ yrs 26-36
Heparinase 26-38 sec
aPTT
aPTT, Control sec
aPTT, Pt/Clt Mix sec
PT, Platelet 0-1 mon 13.0-20.0 sec
2+ mon 10.9-14.8
PT, Pt/Clt Mix sec
TT, Patient 15.6-20.0 sec
TT, Pt/PSO4 Mix sec
PNP 0-7 sec
dRVVT 31.8-45.7 sec
dRVVT Mix 0.0-1.2 sec
dRVVT Confirm Ratio LT 1.2
dRVVT Confirm Mix Ratio LT 1.2
Factor VIII 55-150 %
Factor VIII Inbibitor Negative
Quantitative
von Willebrand Factor 50-165 %
Antigen
von Willebrand Factor GT 40
Activity
Factor IX 60-140 %
Factor XI 65-135 %
Factor XII 50-150 %
Interpretation
Reviewed By
|
| PROPAFENONE | PROPAFENONE | PROPAF | HPLC | Propafenone ug/mL
Therapeutic 0.50-2.00
Critical value GT 2.00 |
| PROPOXYPHENE & METABOLITE, SERUM (REFLEXIVE) | PROOXY | PROOXY | GC/MS | Propoxyphene & Metabolite
Propoxyphene & Metabolite
Drugs covered: propoxyphene and
norpropoxyphene.
Positive cutoff: 50 ng/mL.
Average serum concentrations on daily
regimen of 65 mg, three times perday,
drawn 2 hours after last dosage:
Propoxyphene 420 ng/mL
Norpropoxyphene (25-50% analgesic
activity) 1,450 ng/mL |
| PROSTATIC ACID PHOSPHATASE | PROSPA | PROSPA | ICMA | Prostatic Acid 0.0-3.5 ng/mL
Phosphatase
The SiemensImmulite PAP chemiluminescent
immunoassay is used. Results
obtained with different assay methods
or kits cannot be used interchangeably.
Measurement of PAP has been shown to
be clinically relevant with prostatic
adenomacarcinoma. Benign prostatic
hyperplasia, prostate massage, and
prostatic infarction may result in
elevated PAP concentrations.
The PAP assay value, regardless of
level, should not be interpreted as
evidence of the presence or absence
of malignant disease. |
| PROSTATIC SPECIFIC ANTIGEN | PSA | PSA | ICMA | Prostatic Specific Antigen ng/mL
M 0-54 yrs 0.00-2.50
55-59 yrs 0.00-3.40
60-64 yrs 0.00-4.10
65-69 yrs 0.00-5.10
70+ yrs 0.00-5.60 |
| PROSTATIC SPECIFIC ANTIGEN (REFLEXIVE) | PSAR | PSAR | ECLIA | Total PSA ng/mL
M 0-54 yrs 0.00-2.50
55-59 yrs 0.00-3.40
60-64 yrs 0.00-4.10
65-69 yrs 0.00-5.60
70+ yars 0.00-5.60
Free PSA ng/mL
Free/Total PSA Ratio %
Ratios GT 20% suggest benign.
Ratios between 10% and 20% show
substantial overlap in benign &
malignant conditions.
Ratios LT 10% suggest carcinoma.
The ratio is most clinically useful
in the total PSA range of 4.0-10.0
ng/mL. |
| PROSTATIC SPECIFIC ANTIGEN, FREE & TOTAL | FPSA | RATPSA | ECLIA | Total PSA ng/mL
M 0-54 yrs 0.00-2.50
55-59 yrs 0.00-3.40
60-64 yrs 0.00-4.10
65-69 yrs 0.00-5.10
70+ yrs 0.00-5.60
Free PSA ng/mL
Free/Total %
PSA Ratio
Ratios GT 20% suggest benign. Ratios between
10% & 20% show substantial overlap in benign &
malignant conditions.
Ratios LT 10% suggest carcinoma.
The ratio is most clinically useful in the
total PSA range of 4-10 ng/mL. |
| PROSTATIC SPECIFIC ANTIGEN, POST RADICAL | PSAPR | PSAPR | ICMA | Prostatic Specific Antigen,
Post Radical
LT 0.05 ng/mL
After radical prostatectomy, a PSA
value of less than 0.05 ng/mL indicates
no detectable residual disease. |
| PROTEIN C + S ACTIVITY | PROT.C+S.FUNC | ACTPCS | Clotting Assay | Protein C, Activity 70-145 %
Protein S, Activity 65-140 % |
| PROTEIN C, ACTIVITY | PROCF | ACTPC | Clotting Assay | Protein C, Activity 70-145 % |
| PROTEIN C, ANTIGEN | PROT.C | AGPC | ELISA | Protein C Antigen 70-140 % |
| PROTEIN S, ACTIVITY | PROSF | ACTPS | Clotting Assay | Protein S, Activity 65-140 % |
| PROTEIN S, ANTIGEN | PRO.S | AGPS | Immuno-turbidometric | Protein S Antigen, Total %
70-140
Protein S Antigen, Free
Male 67-170
Female 52-150 |
| PROTEIN S, ANTIGEN FREE | PSFREE | PSFREE | Immuno-turbidometric | Protein S Antigen Free %
Male 67-170
Female 52-150
Treatment with Vitamin K antagonists,
such as coumadin may cause a decrease
in Protein S values. |
| PROTEIN S, ANTIGEN TOTAL | PSTOT | PSTOT | Immuno-turbidometric | Protein S Antigen Total 70-140 %
Treatment with vitamin K antagonists,
such as coumadin may cause a decrease
in Protein S values. |
| PROTEIN, CSF | PRO-C | TPSF | Colorimetric | Protein, CSF mg/dL
LT 1 day 40-120
1-30 days 20-80
1 mo-adult 15-45 |
| PROTEIN, FLUID | PRO-FLD | TPFL | Colorimetric | Protein, Fluid g/dL
Exudate 3.0 or greater
Transudate LT 3.0
Synovial Lt 3.0
Method not validated for body fluid.
Clinical correlation necessary. |
| PROTEIN, QUANTITATIVE, URINE | PRO-U | PROUQP | Colorimetric | Collection Period h
Volume mL
Protein, Urine
50-80 At Rest mg/24h
LT 250 Following intense exercise
Protein/Creatinine Ratio LT 0.2 Ratio |
| PROTEIN, TOTAL | PRO | TP | Colorimetric (Biuret) | Protein, Total g/dL
0-12 mo 4.3-6.9
1-3 yrs 5.2-7.4
3-6 yrs 5.6-7.7
6-10 yrs 6.5-8.3
10-18 yrs 6.1-8.0
18-60 yrs 6.3-8.0
60 yrs+ 6.1-7.8 |
| PROTEIN, URINE (12 HR) | PRO-U.12 | PROUQ1 | Colorimetric | Collection Period h
Volume mL
Protein, Urine
No normals established for 12 hr mg/12h
Protein/Creatinine Ratio LT 0.2 Ratio |
| PROTEIN, URINE (RANDOM) | PRO-R | PROUR | Colorimetric | Protein, Urine mg/dL
No normals established |
| PROTEIN/CREATININE, URINE (RANDOM) | PRO-RU | PRCR | Colorimetric, Enzymatic (IDMS Traceable),Calculation | Creatinine, Urine mg/dL
No normals established
Protein, Urine mg/dL
No normals established
Protein/Creatinine Ratio LT 0.2 Ratio |
| PROTEINASE 3 ANTIBODY | PR3AB | PR3AB | EIA | Proteinase 3 Antibody LT 3.5 U/mL |
| PROTHROMBIN 20210 MUTATION | PRMUT | PROMUT | PCR | Prothrombin 20210, Method
Prothrombin 20210, Result
Prothrombin 20210, Interpretation
Prothrombin 20210, Comment
Prothrombin 20210, Comment
This test is FDA approved and is
intended for in vitro diagnostic use.
This test is performed pursuant to an
with Roche Molecular Systems,
This test is performed by real-
time PCR using the Roche LightCycler
instrument. The product of PCR is
detected by fluorescence produced when
a specific pair of probes, each labeled
with a fluorophore, binds to the PCR
product in close proximity. |
| PROTHROMBIN FRAGMENT 1+2, MONOCLONAL | PTF12M | PTF12M | ELISA | Prothrombin Fragment 1+2, 87-325 pmol/L
Monoclonal |
| PROTIME | PT | PT | Electromechanical | PT, Patient sec
0-1 mo 13.0-20.0
2+ mo 10.9-14.8
PT, Pop. Mean 13.4 sec
PT, INR
0.9-1.2
2.0-3.0 Usual oral anticoagulation range.
2.5-3.5 High level oral anticoagulation range. |
| PROTIME MIXING STUDY | PTMXS | PTMXS | Optical Densitry Endpoint | Protime, Patient 0-1 mon 13.0-20.0 sec
2+ mon 10.9-14.8
Protime, Patient/Control Mix sec
A protime that is not within 3 seconds
of the control plasma may suggest an
inhibitor.
Protime, Control Plamsa sec |
| PROTOPORPHYRIN FREE ERYTHROCYTE | PROTO | PROTOF | HPLC with Fluorescence Detection | Free Protoporphyrin ug/dL
LT 20 ug/dL packed cells
Zinc-complexed Protoporphyrin ug/dL
LT 60 ug/dL packed cells |
| PROTRIPTYLINE | PROT | PROTRI | HPLC | Protriptyline ng/mL
Therapeutic 70-240
Toxic GT 400 |
| PSEUDOCHOLINESTERASE, DIBUCAINE INHIBITION | PSEU | PSEU | Enzymatic | Pseudocholinesterase 2900-7100 U/L
Dibucaine GT 75 %
Phenotype |
| PSEUDOCHOLINESTERASE, TOTAL | CHEP | CHEP | Enzymatic | Pseudocholinesterase, Total 2900-7100 U/L |
| PTH, C-TERMINAL WITH CALCIUM | CPTH | CPTH | RIA | Parathormone C-Terminal LT 0.9 ng/mL
Calcium mg/dL
M 0-1 yrs 7.6-11.0
2-18 yrs 8.4-10.5
GT 18 yrs 8.7-10.4
F 0-1 yrs 7.6-11.0
2-18 yrs 8.4-10.5
GT 18 yrs 8.7-10.4 |
| PTH, INTACT, WHOLE MOLECULE | INTACT.PTH | PTHI | ICMA | PTH Intact 10-65 pg/mL
Calcium 8.5-10.5 mg/dL |
| PTH, INTACT, WHOLE MOLECULE, NO CALCIUM | PTHINT | PTHINT | ICMA | PTH, Intact 15-85 pg/mL |
| PTT | PTT | PTT | Electromechanical | PTT, Patient sec
0-1 mo 40-50
2 mos-4 yrs 25-40
5+ yrs 26-36
PTT, Pop.mean 31 sec
Deep venous thrombosis or pulmonary
embolism therapeutic heparin levels
of 0.3 to 0.7 Units/mL anti-factor
Xa levels usually correspond to an
aPTT of 60-85 seconds. Acute cardiac
syndrome therapeutic range based on
heparin levels of 0.2 to 0.5
usually correspond to an aPTT of
55 to 75 seconds. |
| PTT (PRESURGICAL) | PTT | PTT | Electromechanical | PTT, Patient sec
0-1 mo 40-50
2 mos-4 yrs 25-40
5+ yrs 26-36
PTT, Pop.mean 31 sec
Deep venous thrombosis or pulmonary
embolism therapeutic heparin levels
of 0.3 to 0.7 Units/mL anti-factor
Xa levels usually correspond to an
aPTT of 60-85 seconds. Acute cardiac
syndrome therapeutic range based on
heparin levels of 0.14 to 0.34
usually correspond to an aPTT of
50 to 65 seconds. |
| PTT MIXING STUDY | PTTMXS | PTTMXS | Electromechanical | PTT, Patient 0-1 mon 40-50 sec
2 mon-4 yrs 25-60
5+ yrs 26-36
PTT, Patient/ A PTT mix that is not sec
Control Mix within 5 seconds of the
control plasma usually
suggests an inhibitor.
PTT, Control Plasma sec
PTT, Patient Post Incubate sec |
| PURKINJE CELL CYTOPLASMIC ANTIBODY, (REFLEX) | PCCA | PCCA | IFA | Purkinje Cell Cytoplasmic Antibody Negative
|
| PURKINJE CELL CYTOPLASMIC ANTIBODY, SF (REFLEXIVE) | PCCASF | PCCASF | IFA | Purkinje Cell Cytoplasmic Antibody, SF Negative
|
| PYRUVATE KINASE | PKIN | PKIN | Enzymatic | Pyruvate Kinase 9.0-22.0 U/gHgb |
| PYRUVIC ACID | PYRUVIC ACID | PYRACD | Enzymatic | Pyruvic Acid 0.030-0.107 mmol/L
(venous blood) |
| QUANTIFERON TB GOLD IN-TUBE | QFTBG | QFTBG | ELISA | Quantiferon TB GOLD In-Tube Result Negative
Quantiferon TB GOLD In-Tube Note |
| QUETIAPINE, SERUM | QUETQT | QUETQT | GC | Quetiapine, Serum ng/mL
Steady-state peak (1.0-1.5) hours
plasma levels following a tid daily
regimen.
Dose (mg/day) Mean Max Conc (ng/mL)
225 286
450 598
750 828 |
| QUINIDINE | QUINID | QUINID | FPI | Quinidine 1.5-4.5 ug/mL |
| RA, SERUM | RA | RAQ | Nephelometry | RA LT 20 IU/mL |
| RA, SYNOVIAL FLUID | RA.SYN | RASYN | Latex agglutination | RA, Synovial Fluid Negative Titer |
| RABIES ANTIBODY, IGG (VACCINE RESPONSE) | RABIGG | RABIGG | ELISA | Rabies Ab IgG (Vaccine Response) EU/mL
0.50 or greater: Represents adequate
protection against rabies virus
following vaccination. This test is
only intended for vaccine response,
not for diagnosis of infection.
|
| RAJI CELL ASSAY | RAJI | RAJI | FC | Raji Cell Assay LT 33 ugE/mL
|
| RAPID STREP GROUP A SCREEN | RSGA | RSGA | Rapid Immunoassay | Group A Strep Antigen
Negative No Group A Strep antigen detected.
Confirmation by culture recommended.
Positive Presence of Group A Strep
antigen detected. |
| RBC MORPHOLOGY | RMORPH | RMORPH | Microscopy | RBC Morphology |
| RDS RISK PANEL | RDS | RDS | TLC, Enzymatic (IMDS Traceable) | L/S Ratio
Phosphatidylglycerol
Creatinine, AF mg/dL
Creatinine increases with
gestational age.
Appearance
Color
RBC
Risk Comment
For diabetic patients, risk is minimal
when L/S is GT 3.0 and PG is present.
Comment |
| RED BLOOD CELL OSMOTIC FRAGILITY, INCUBATED | FRAGI | FRAGI | Spectrophotometric | RBC Osmotic Fragility, Incubated, Interp
RBC Osmotic Fragility, Incubated, Reviewed By |
| RED CELL COUNT | RBC | RBCCNT | Automated | RBC M/uL
0-3 days 4.00-6.60
3-7 days 3.90-6.30
7-14 days 3.60-6.20
14-30 days 3.00-5.40
30-60 days 2.70-4.90
2-6 mo 3.10-4.50
6-24 mo 3.70-5.30
2-6 yrs 3.90-5.30
6-12 yrs 4.00-5.20
12-18 yrs M 4.50-5.30
18 yrs+ M 4.30-5.70
12-18 yrs F 4.10-5.10
18 yrs+ F 3.80-5.20 |
| REDUCING SUBSTANCES, STOOL | STL.SUGAR | SRS | Colorimetric | Source
Reducing Substances, Stool Negative
Reducing Substances, Stool, Status |
| REDUCING SUBSTANCES, URINE | URED | URED | Clinitest tablets | Reducing Substances, Urine mg/dL
Negative |
| RENAL FUNCTION PANEL | RENALA | RENALA | Colorimetric, Enzymatic, ISE, Enzymatic (IDMS Traceable) | Glucose mg/dL
0-2 days premature 30-80
0-2 days fullterm 40-90
2 days-1 month 60-105
Adult 65-99
Pregnant 65-94
ADA Diagnostic Categories for nonpregnant
adults:
Impaired fasting glucose 100-125 mg/dL
A fasting glucose result of 126 mg/dL or
greater indicates diabetes if the
abnormality is confirmed on a subsequent
day.
A random glucose result of GT 200 mg/dL
indicates diabetes if the abnormality
is confirmed on a subsequent day.
BUN 7-23 mg/dL
Creatinine M 0.50-1.30 mg/dL
F 0.40-1.00
Calcium 8.5-10.5 mg/dL
Phosphorus 0-10 days 4.2-9.6 mg/dL
10 days-24 mo 4.2-7.2
24 mo-12 yrs 4.2-5.9
12-60 yrs 2.5-4.8
60 yrs+ M 2.1-3.9
60 yrs+ F 2.6-4.4
Albumin 0-4 days 2.9-4.6 g/dL
4 days-14 yrs 3.9-5.6
14-18 yrs 3.3-4.7
18-60 yrs 3.5-5.0
60-90 yrs 3.3-4.8
90 yrs+ 3.0-4.7
Sodium 135-145 mmol/L
Potassium 0-30 days 3.9-6.9 mmol/L
1-12 mo 3.6-6.8
1-5 yrs 3.2-5.7
5-10 yrs 3.4-5.4
10 yrs+ 3.5-5.3
Chloride 98-109 mmol/L
C02 0-10 days 13-22 mmol/L
11 days-4 yrs 20-28
5+ yrs 22-31
Anion Gap 7-16 |
| RENIN ACTIVITY [ARUP] | RENARU | RENARU | RIA | Renin, Normal Sodium Diet ng/mL/hr
Adult:
Supine 0.2-1.6
Upright 0.5-4.0
Children Supine:
1-12 mon 2.4-37.0
13 mo-3 yrs 1.7-11.2
4-5 yrs 1.0-6.5
6-10 yrs 0.5-5.9
11-15 yrs 0.5-3.3
Newborn ((1-7 days) 2.0-35.0
Cord Blood 4.0-32.0
Child Upright:
0-3 yrs not available
4-5 yrs 15 or less
6-10 yrs 17 or less
11-15 yrs 16 or less |
| RENIN, PLASMA | REN | RENPER | RIA | Renin with normal sodium intake ng/mL/h
Adult
Random ambulatory 0.8-2.5
Random non-ambulatory 1.5-5.2
Child, supine with normal sodium intake
1-7 days 15-114
7 days-12 mo 18-120
12 mo-3 yrs 13-36
3-5 yrs 7.5-21.1
5-10 yrs 3.8-19.2
10-15 yrs 3.8-10.7 |
| RENIN, SAMPLE 1 | REN.S1 | RN1 | RIA | Renin, #1
Renin with normal sodium intake ng/mL/h
Adult
Random ambulatory 0.8-2.5
Random non-ambulatory 1.5-5.2
Child, supine with normal sodium intake
1-7 days 15-114
7 days-12 mo 18-120
12 mo-3 yrs 13-36
3-5 yrs 7.5-21.1
5-10 yrs 3.8-19.2
10-15 yrs 3.8-10.7
Renin, Site 1 |
| RENIN, SAMPLE 2 | REN.S2 | RN2 | RIA | Renin, #2 ng/mL/h
Renin, Site 2 |
| RENIN, SAMPLE 3 | REN.S3 | RN3 | RIA | Renin, #3 ng/mL/h
Renin, Site 3 |
| RENIN, SAMPLE 4 | REN.S4 | RN4 | RIA | Renin, #4 ng/mL/h
Renin, Site 4 |
| RENIN, SAMPLE 5 | REN.S5 | RN5 | RIA | Renin, #5 ng/mL/h
Renin, Site 5 |
| RENIN, SAMPLE 6 | REN.S6 | RN6 | RIA | Renin, #6 ng/mL/h
Renin, Site 6 |
| REPTILASE (REFLEXIVE) | REPTLS | REPTLS | Electromechanical | Reptilase, Patient 14.8-21.2 sec
Reptilase, Control 14.8-21.2 sec
Reptilase, Pat/Ctl Mix sec |
| RESPIRATORY SYNCYTIAL VIRUS ANTIBODY, IGG & IGM | RSVGM | RSVGM | ELISA | Respiratory Syncytial Virus Ab, IgG IV
0.89 or less Negative-no significant
level of RSV IgG antibody detected.
0.90-1.10 Equivocal-questionable
presence of RSV IgG antibody
detected. Repeat testing in 10-14
days may be helpful.
1.11 or more Positive-IgG antibody
to RSV detected, which may
suggest current or recent infection.
Respiratory Syncytial Virus Ab, IgM IV
0.89 or less Negative-no significant
level of RSV IgM antibody detected.
0.90-1.10 Equivocal-questionable
presence of RSV IgM antibody
detected. Repeat testing in 10-14
days may be helpful.
1.11 or more Positive-IgM antibody
to RSV detected, which may
suggest current or recent infection. |
| RESPIRATORY SYNCYTIAL VIRUS SCREEN | RSVSCR | RSVSCR | DFA | RSV, DFA Screen Negative
RSV, DFA Status |
| RESPIRATORY SYNCYTIAL VIRUS, STAT ONLY | STRSV | STRSV | EIA | Source
Respiratory Syncytial Virus Screen Negative
Report Status |
| RETICULIN ANTIBODY, TOTAL, IGA, IGG & IGM | RETICULIN.AB | RETAB | IFA | Reticulin Ab, Total A,G,M
Negative LT 1:20 |
| RETICULOCYTE COUNT, AUTOMATED | RETCA | RETCA | Automated-New Methylene Blue | Reticulocyte Count %
0-2 days 3.0-7.0
3-6 days 1.0-3.0
7 days-1 mo 0.0-1.0
2 mo-4 yrs 1.0-2.0
5+ yrs 0.4-2.7
Reticulocytes, K/uL
Absolute
5+ yrs 16-123
Immature
Reticulocyte
Fraction
1+ yrs 0.17-0.43 |
| RETICULOCYTE COUNT, AUTOMATED WITHOUT IRF | RETCAW | RETCAW | Automated-New Methylene Blue | Reticulocyte Count %
0-2 days 3.0-7.0
3-6 days 1.0-3.0
7 days-1 mo 0.0-1.0
2 mo-4 yrs 1.0-2.0
5+ yrs 0.4-2.7
Reticulocytes, K/uL
Absolute
5+ yrs 16-123 |
| RETICULOCYTE COUNT, MANUAL | RETICM | RETICM | Microscopic | Reticulocytes %
0-2 days 3.0-7.0
3-6 days 1.0-3.0
7 days-1 mo 0.0-1.0
2 mo-4 yrs 1.0-2.0
5+ yrs 0.9-3.5
Reticulocytes, Absolute K/uL
5+ yrs 20-150
Reticulocytes, Corrected
no longer reported |
| RETICULOCYTES, CELLULAR HEMOGLOBIN | RTCHGB | RTCHGB | Flow Cytometry | Cellular Hemoglobin, Reticulocytes pg
18 yrs and more 28.5-35.0
Reticulocytes %
F 1-3 days 2.1-3.7
4-30 days 0.4-2.0
31-60 days 1.1-2.9
61-180 days 0.9-2.0
0.5-2.0 yrs 0.8-2.1
3-6 yrs 0.8-2.1
7-12 yrs 0.8-2.8
13 yrs & older 0.8-2.7
M 1-3 days 2.2-4.8
4-30 days 0.4-2.7
31-60 days 0.9-3.8
61-180 days 0.8-2.0
0.5-2 yrs 0.8-2.0
3-6 yrs 0.8-2.0
7-12 yrs 0.7-2.2
13 yrs & older 0.8-2.7 |
| RETINOL BINDING PROTEIN | RETBP | RETBP | Nephelometry | Retinol Binding Protein 3.0-6.0 mg/dL |
| RETT SYNDROME (MECP2 DNA ANALYSIS) | REF.RRETT | RRETT | PCR and Sequencing | RETT DNA Analysis |
| RH FACTOR | RH | M2RH | Hemagglutination | RH |
| RH-COMPLETE CDE | COMPRH | COMPRH | Slide/Tube Agglutination | Complete RH Separate Report to Follow |
| RHEUMATOID ARTHRITIS PANEL (REFLEXIVE) | RAPTVM | RAPTVM | Multiplex luminex, Nephelometry, Enzymatic | ANA Negative
A multiplex screen for 11 autoantibodies
(dsDNA, Smith, Ribosomal P, Chromatin, RNP,
SmRNP, Scl-70, Centromere B, SSA, SSB and
J0-1) was performed and no autoantibodies
were detected. A negative multiplex ANA
does not rule out all possibility of a
connective tissue or autoimmune disease,
and further studies should be considered
if clinical suspicion is high.
DSDNA Autoantibody Negative LT 5 IU/mL
Indeterminate 5-9
Positive 10 or more
Smith Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
Ribosomal P Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
Chromatin Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
RNP Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
SMRNP Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
SCL-70 Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
Centromere B Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
SSA (RO) Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
SSB (LA) Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more
JO-1 Autoantibody Negative LT 1.0 AI
antibody Positive 1.0 or more
RA LT 20 IU/mL
CRP 1.5 or less mg/dL
Uric Acid 0-16 years 2.0-5.5 mg/dL
M 17+ yrs 3.1-8.1
F 17+ yrs 2.0-6.7 |
| RIBOSOMAL P AUTOANTIBODY | RIBPMP | RIBPMP | Multiplex luminex | Ribosomal P Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more |
| RICKETTSIA ANTIBODY PANEL | RICABP | RICABP | IFA | Rickettsia Antibody, IgG LT 1:64
Rickettsia Antibody, IgM LT 1:64
Rickettsia Antibody Interpretation
Measurement of antigen-specific IgG
and IgM alows rapid diagnosis of
infection by rickettsial agents. The
Typhus Fever Group of rickettsial
agents includes R. typhi (endemic
or murine typhus), R. prowazekii
(epidemic typhus), and Brill-Zensser
disease caused by reactivation of
latent R. prowazekii.
IgM reactivity in the absence of IgG
reactivity may represent a false-
positive reaction. Recent infection
should be confirmed by demonstrating
either IgG seroconversion or a four-
fold or greater increase in IgG titer
when acute and convalescent sera are
tested in parallel. |
| RICKETTSIA RICKETTSII (RMSF), IGG & IGM | ROCKY MT | RMSFEV | IFA | RMSF, IgG
LT 1:64 Negative-No significant level of Rickettsia
rickettsii IgG Ab detected.
1:64-1:128 Low Positive- Presence of Rickettsia rickettsii
IgG Ab detected, suggestive of current or past
infection.
1:256 or GT Positive-Presence of Rickettsia rickettsii
IgG Ab, suggestive of recent or current infection.
RMSF, IgM
LT 1:64 Negative-No significant level of Rickettsia
rickettsii IgG Ab detected.
1:64 or GT Positive-Presence of Rickettsia rickettsii
IgG Ab detected, which may indicate a recent or
current infection; However, low levels of IgM
antibodies may occasionally persist for more than
12 months post infection. |
| RIFAMPIN | RIFAMPIN | RIFAMP | HPLC | Rifampin mcg/mL
Peak concentration after 600 mg dose
is approximately 7 mcg/mL. |
| RISPERIDONE | RIS | RIS | HPLC/LC/MS/MS | Risperidone ng/mL
9-Hydroxyrisperidone ng/mL
Risperidone & 9-Hydroxyrisperidone
are approximately equieffective,
therefore, the sum of their
concentration is pertinent.
Risperidone & 9-Hydroxyrisperidone ng/mL
Mean steady-state plasma levels of
the total active moiety following
daily regimens:
2 mg/day 14 ng/mL
6 mg/day 45 ng/mL
10 mg/day 73 ng/mL
16 mg/day 110 ng/mL |
| RNP AUTOANTIBODY | RNPMP | RNPMP | Multiplex luminex | RNP Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more |
| ROTAVIRUS | ROTAVIRUS | ROTAAG | EIA | Source
Rotavirus Negative
Rotavirus, Status |
| RPR | RPR | RPR | FLOC | RPR Nonreactive |
| RPR WITH REFLEX TO TITER (REFLEXIVE) | RPRREF | RPRREF | Charcoal Agglutination | RPR Nonreactive
RPR Titer LT 1:2 |
| RUBELLA & RPR | RPR/RUB | RPR, RUBEG | Floc/ICMA | Rubella Ab, IgG IU/mL
LT 5 Presumed non-immune
5-9 Equivocal
10 or greater Presumed immune
RPR Nonreactive |
| RUBELLA ANTIBODY, IGM [ARUP] | RUBMAR | RUBMAR | Chemiluminescent Immunoassay | Rubella Ab, IgM IV
0.89 IV or less Negative
No significant level of detectable
Rubella IgM antibody.
0.90-1.09 IV Equivocal
Repeat testing in 10-14 days may
be helpful.
1.10 IV or more Positive
IgM Ab to Rubella detected which
may indicate a current or recent
infection or immunization.
Testing immediately post-exposure
is of no value without a later
convalescent specimen. While the
presence of IgM Abs suggest current
or recent infection, low levels of
IgM antibodies may occasionally
persist for more than 12 months
post-infection or immunization.
|
| RUBELLA SCREEN, IGG | RUBELLA | RUBEG | ICMA | Rubella Ab, IgG IU/mL
10 or greater Presumed immune
5-9 Equivocal
LT 5 Presumed non-immune
Result flagging will be based on presumed immune status. |
| RUBELLA, IGM (REFLEXIVE) | RUBEM | RUBEM | ELISA | Rubella Ab, IgM Index
LT 0.9 Negative-Indicates absence
of a current or recent (within
previous 6 to 8 weeks) infection.
This does not preclude the
possibility of infection within
the previous 7 days.
0.9-1.1 Indeterminate-The
presence of IgM Ab is equivocal.
Testing of a fresh specimen may
aid in determining the presence
or absence of infection.
GT 1.1 Positive-Indicates Rubella
infection or vaccination within the
previous 3 months. (Low levels of
IgM Ab may occasionally perist for
more than 12 months post infection). |
| RUBEOLA, IGG | RUBEOLA | RUBOG | ELISA | Rubeola IgG ISR
LT 0.91 Negative-No significant level of
IgG Ab to Rubeola virus
detected. Patient may be
susceptible to infection.
0.91-1.09 Indeterminate: Rubeola virus
IgG Ab are equivocal. Cannot
determine the patient's
immune status by this
method.
GT 1.09 Positive-Significant level
of IgG Ab to Rubeola
virus detected. Indicates
current or previous
infection or prior
immunization. |
| RUBEOLA, IGM | RUBEOLA.IGM | RUBEOM | ELISA | Rubeola Ab, IgM AU
0.79 or less Negative-No significant level
of Ab to measles(Rubeola) virus
detected.
0.80-1.20 Equivocal-Repeat testing in 10-14
days may be helpful.
1.21 or more Positive-IgM Ab to measles
(Rubeola) virus detected.
Suggestive of current or recent
infection or immunization.
However, low levels of IgM Abs
may occasionally persist for more
than 12 months post-infection or
immunization. |
| RUBEOLA, MUMPS, RUBELLA IGG ANTIBODIES | MMRG | MMRG | EIA and ICMA | Rubeola IgG ISR
LT 0.91 Negative-No significant level of
IgG Ab to Rubeola virus
detected. Patient may be
susceptible to infection.
0.91-1.09 Indeterminate: Rubeola virus
IgG Ab are equivocal. Cannot
determine the patient's
immune status by this
method.
GT 1.09 Positive-Significant level
of IgG Ab to Rubeola
virus detected. Indicates
current or previous
infection.
Mumps Virus Antibody, IgG IV
0.90 or less Negative-No significant level of
detectable mumps virus Ab.
0.91-1.09 Equivocal-Repeat testing in 10-
14 days may be helpful.
1.10 or more Positive-IgG Ab to mumps virus
detected, which may indicate a current or
previous exposure/immunization to mumps
virus. Positive IgG Ab levels in the absence
of current clinical symptoms may indicate
immunity.
Rubella Ab, IgG IU/mL
LT 5 Presumed non-immune
5-9 Equivocal
10 or greater Presumed immune |
| RUFINAMIDE, SERUM/PLASMA | RUFIS | RUFIS | HPLC | Rufinamide None detected mcg/mL
Maintenance therapy with 45
mg/kg/day rufinaminde resulted
in plasma rufinamide concentrations
ranging from 4.95 to 48.15 mcg/mL |
| SACCHAROMYCES CEREVISIAE ANTIBODY, IGG & IGA | SCABP | SCABP | ELISA | S. cerevisiae Ab, IgG Units
S. cerevisiae Ab, IgA Units
Interpretative Criteria-
S. cerevisiae, IgG/IgA
20.0 or less Negative
21.0-24.9 Equivocal
25.0 or more Positive
Saccharomyces cerevisiae IgG Antibodies
are found in 80% of Crohn's Disease
(CD) patients, but only in 20% of
Ulcerative Colitis (UC) patients.
Saccharomyces cerevisiae IgA antibodies
are found in 35% of CD patients but
less than 1% in UC patient. Detection
of both Saccharomyces IgG and IgA
antibodies in the same serum specimen
is highly specific for CD. |
| SALICYLATES | SAL | SAL | Enzymatic | Salicylates ug/mL
Analgesia 20-100
Anti-inflammatory 100-300
Toxic GT 300
Salicylates mg/dL
Analgesia 2.0-10.0
Anti-inflammatory 10.0-30.0
Toxic GT 30.0
Individuals on chronic administration
may be asymptomatic at levels up to
500 ug/mL. |
| SALMONELLA ANTIBODIES, EIA | SALAB | SALAB | DA | Salmonella H, Type a Negative
Salmonella H, Type b Negative
Salmonella H, Type d Negative
Salmonella O, Type Vi Negative
Salmonella O, Type d Negative
Antibodies to Salmonella flagellar (H) and somatic (O) antigens
typically peak 3-5 weeks after infection. A positive result in
this assay is equivalent to a titer of GT or equal to 1:160 by
tube agglutination (widal). Results should not be considered as
diagnostic unless confirmed by culture.
|
| SCHISTOSOMA ANTIBODY, IGG | SCHAB | SCHAB | FMI | Schistosoma Antibody IgG
LT 1.00 Antibody not detected
1.00 or more Antibody detected
This assay utilizes the microsomal
fraction of adult S. mansoni worms
(MAMA) as antigen, and is thus highly
specific (99%) and sensitive (96%)
for detection of infection caused
by S. mansoni. Although the assay is
also highly specific for infections
caused by other Schistosoma species
(S.japonicum, S.haematobium, S.mekongi),
its sensitivity for these infections
is lower (55%). Antibody levels do
not correlate with intensity of
infection. |
| SCL-70 AUTOANTIBODY | SCLMP | SCLMP | Multiplex luminex | SCL-70 Auto- Negative LT 1.0 AI
antibody Positive 1.0 or more |
| SEDIMENTATION RATE | SED | SED | Westergren | Sed Rate mm/h
M 0-10
F 0-20 |
| SELENIUM, QUANTITATIVE, WHOLE BLOOD | SEL | SELWB | ICP/MS | Selenium, Blood 20-220 mcg/mL |
| SELENIUM, SERUM | SEL.S | SELS | ICP/MS | Selenium, Serum 23-190 ug/L |
| SEMEN EXAMINATION | SEMN | SEMN | | Semen Exam
Appearance Opalescent
Viscosity Normal
Sperm Concentration GT 19 M/mL
Volume 1.5-5.0 mL
Total Sperm Number GT 39 M
Liquifaction Liquified
Motility GT 39% Normal
Activity Grade GT 2+
Morphology GT 29% Normal forms
Leukocytes Absent
Comments Sperm morphology
classification based
on WHO 4th edition.
Reviewed by |
| SEMEN MORPHOLOGY | SEMOPH | SEMOPH | | Morphology GT 29% Normal forms
Leukocytes Absent
Comments Sperm morphology
classification based
on WHO 4th edition.
Reviewed by |
| SEROTONIN | SEROT.S | SER | HPLC | Serotonin 50-220 ng/mL |
| SEROTONIN, BLOOD | SEROT | SERBLD | HPLC | Serotonin, Blood 50-200 ng/mL |
| SERTRALINE | ZOLOFT | SERT | LC/MS | Sertraline Not well established ng/mL
No therapeutic reference range exists for
sertraline. Dosing should begin at 50 mg/d,
not to exceed 200 mg/d. Dosing above 200 mg/d
is associated with increased adverse effects
and decreased efficacy. Dosing of 50-200 mg/d
gives serum values ranging from 30 to 200
ng/mL. |
| SEX HORMONE BINDING GLOBULIN | SHBGL | SHBGL | Enzyme Immunoassay | Sex hormone binding globulin nmol/L
M 1-30 days 13-85
31-364 days 70-250
1-3 years 50-180
4-6 years 45-175
7-9 years 28-190
10-12 years 23-160
13-15 years 13-140
16-17 years 10-60
18 yrs & more 11-80
F 1-30 days 14-60
31-364 days 60-215
1-3 years 60-190
4-6 years 55-170
7-9 years 35-170
10-12 years 17-155
13-15 years 11-120
16-17 years 19-145
18 yrs & more 30-135
Tanner Stages nmol/L
M I 26-286
II 22-169
III 13-104
IV 11-60
V 11-71
F I 30-173
II 16-127
III 12-98
IV 14-151
V 23-165 |
| SICKLE CELL SCREEN (REFLEXIVE) | SICKLE | SICKLE | Solubility | Sickle Cell Screen Negative |
| SILICON, SERUM/PLASMA | SILIS | SILIS | ICP/MS | Silicon Generally LT 0.05 mg/dL
Silicon concentrations are influenced
by diet, especially vegetable intake. |
| SILVER | SIL | SILVER | ICP/MS | Silver LT 5 mcg/mL |
| SILVER, URINE | SILVER.U | SILUR | ICP/MS | Silver, Urine Normal LT 1 ug/L |
| SIROLIMUS, PARENT DRUG ONLY | SIR | SIR | Tandem Mass Spectrometry | Sirolimus 4.0-12.0 ng/mL
A therapeutic range of 4.0-12.0 ng/mL
is proposed, based on a predose (trough)
steady-state specimen, concomitant
cyclosporine, for a kidney transplant
patient in the maintenance phase of
therapy. A range of 12.0-20.0 ng/mL
has been suggested for liver transplant.
The range may vary with other transplant
organs, when used in combination with
drugs other than cyclosporine (or
sirolimus alone). |
| SJOGRENS AUTOANTIBODIES | SJOMP | SJOMP | Multiplex luminex | SSA (RO) Autoantibody Negative LT 1.0 AI
Positive 1.0 or more
SSB (LA) Autoantibody Negative LT 1.0 AI
Positive 1.0 or more |
| SM AUTOANTIBODY | SMMP | SMMP | Multiplex luminex | SM Autoantibody Negative LT 1.0 AI
Positive 1.0 or more |
| SMEAR, AFB | AFB-SM | AFBSM | Truant Fluorochrome Stain | Source
Smear, AFB Negative
Smear, AFB, Status |
| SMEAR, BLOOD PARASITES | BLD-PARA | MAL | Microscopic (thick and thin smears) | Malaria None seen
Infected Cells 0 %
Identification
Reviewed By |
| SMEAR, STAIN & INTERPRETATION | SMEAR | GSSM | Microscopic | Source
Gram Stain Negative
Gram Stain, Status |
| SMRNP AUTOANTIBODY | SMRNMP | SMRNMP | Multiplex luminex | SMRNP Autoantibody Negative LT 1.0 AI
Positive 1.0 or more |
| SODIUM | SOD | NA | ISE | Sodium 135-145 mmol/L |
| SODIUM & POTASSIUM | NA/K | NAK | ISE | Sodium 135-145 mmol/L
Potassium mmol/L
0-30 days 3.9-6.9
1-12 mo 3.6-6.8
1-5 yrs 3.2-5.7
5-10 yrs 3.4-5.4
10 yrs+ 3.5-5.3 |
| SODIUM, FLUID | SODFLD | NAFL | ISE | Sodium, Fluid mmol/L
No reference ranges established
Method not validated for body fluid.
Clinical correlation necessary. |
| SODIUM, STOOL | STLNA | STLNA | ISE | Sodium, Stool mmol/L
No reference range established |
| SODIUM, URINE (QUANTITATIVE) | SOD-U | NAUQ | ISE | Collection Period h
Volume mL
Sodium, Urine 50-225 mmol/24h |
| SODIUM, URINE (RANDOM) | SOD-R | NAUR | ISE | Sodium, Urine, Random mmol/L
No normals established |
| SOLUBLE LIVER ANTIGEN ANTIBODY, IGG | SLAIGG | SLAIGG | ELISA | Soluble Liver Antigen Antibody, IgG
0.0-20.0 U Negative
20.1-24.9 U Equivocal
25.0 or more U Positive
The presence of SLA antibodies has
almost 100% specificity for auto-
immune hepatitis, although only
12-30% have these antibodies. Thus,
a negative SLA IgG test does not
rule out autoimmune hepatitis. |
| SOLUBLE TRANSFERRIN RECEPTOR | STFRC | STFRC | EIA | Soluble Transferrin Receptor LT 1.6 mg/L
Patients with levels equal to or greater than 1.6 may
have iron deficiency anemia (IDA) and/or anemia of
chronic disease (ACD); sensitivity 86.4%, specificity
49.1%.
|
| SPECIFIC GRAVITY | SPG | SPGFL | Colorimetric | Specific Gravity
Exudate 1.015 or greater
Transudate LT 1.015 |
| SPECIFIC GRAVITY, URINE | SPGUD | SPGUD | T/S Meter | Specific Gravity 1.001-1.030 |
| SPERM ANTIBODY IGA, IGG | SPABAG | SPABAG | Immunobeads | Sperm Antibody IgG LT 20% binding
Binding Location IgG
Sperm Antibody IgA LT 20% binding
Binding Location IgA
The incidence of circulating antisperm
antibody (ASA) in the general male
populatio is 10-20%. Vasectomised males
have an increased incidence of sperm
antibody up to 60-80%.
Sperm anti-sperm antibodies are also
found in 10-15% of infertile women
without organic disease. The incidence
of circulating ASA depend on both
specimen source (serum, seminal fluid,
cervical mucus) and the fertility status
of the individual. |
| SPERM COUNT POST VASECTOMY | SPCTPV | SPCTPV | Hemocytometer | Sperm Count None seen M/mL |
| SPINAL MUSCULAR ATROPHY CARRIER TESTING SMA | SMAC | SMAC | Real-Time PCR | SMN1 copy number 2 (reduced carrier risk)
Interpretation |
| SPINAL MUSCULAR ATROPHY, DIAGNOSTIC STUDY | REF.SMAPCR | SMAPCR | PCR and RFLP | Spinal Muscular Atrophy. |
| SRP AUTOANTIBODIES | SRPAUT | SRPAUT | RIPA | SRP Autoantibodies Not detected |
| SSA AUTOANTIBODY | SSAMP | SSAMP | Multiplex luminex | SSA (RO) Autoantibody Negative LT 1.0 AI
Positive 1.0 or more |
| SSB AUTOANTIBODY | SSBMP | SSBMP | Multiplex luminex | SSB (LA) Autoantibody Negative LT 1.0 AI
Positive 1.0 or more |
| SSDNA ANTIBODY, IGG | SSDNA | SSDNA | EIA | ssDNA Antibody, IgG EU
LT 20 Negative
20-25 Borderline Positive
GT 25 Positive |
| STREPTOCOCCAL ANTIBODY (DNASE B) | STREPTO | DNASEB | Enzymatic | Streptococcal Ab-Dnase B U/mL
1-6 yrs 0-70
7-17 yrs 0-170
18+ yrs 0-120 |
| STREPTOCOCCUS PNEUMONIAE ANTIGEN, URINE | SPNAGU | SPNAGU | ICT Assay | Streptococcus pneumoniae Antigen, Urine
Negative
False-positives may occur because of
cross-reactivity with other members
of the S. mitis group. Clinical
correlation is recommended. |
| STREPTOZYME TITER, REFLEX TO ASO | STREP | STRZ | Agglutination/Nephelometry | Streptozyme titer LT 100 Streptozyme Units
ASO titer 250 or less IU/mL |
| STRIATED MUSCLE ANTIBODY, IGG (REFLEXIVE) | STRAB | STRAB | IFA | Striated Muscle Ab, IgG Screen
LT 1:40 No antibody detected
Striated Muscle Ab, IgG Titer |
| STRONGYLOIDES ANTIBODY, IGG | STROAG | STROAG | ELISA | Strongyloides Antibody,IgG IV
1.49 or less Negative-no significant
level of Sronglyoides IgG Ab detected.
1.50-2.10 Equivocal-questionable
presence of Stronglyoides IgG Ab detected.
Repeat testing in 10-14 days may be helpful.
2.11 or more Positive-IgG Abs to
Strongyloides IgG detected, which may
suggest current or past infection. |
| SULFATE, URINE | URSUL | URSUL | Spectrophotometric | Collection time hrs
Total volume mL
Creatinine, Urine mg/dL
Creatinine, Urine 500-2300 mg/day
Sulfate, Urine mmol/L
Sulfate, Urine 6-30 mmol/d |
| SULFONAMIDES | SULFA | SULFA | Spectrophotometry | Sulfonamides mg/dL
Therapeutic 5.0-15.0
Toxic GT 20.0
This test is designed to measure
sulfamethoxazole and sulfisoxazole.
Peak sulfonamide (total) blood levels of
5-15 mg/dL may be considered effective
for most infections, concentrations of
12-15 mg/dL being optimal for serious
infections. Sulfonamide levels should
not exceed 20 mg/dL. |
| SULINDAC | CLIND | CLIND | HPLC/UV | Sulindac (Clinoril) 0.4-1.6 ug/mL |
| SYNOVIAL FLUID PROFILE | SYNFL | SYNFL | | Color
Clarity
RBC M/L
Nucleated Cells M/L
Number of Cells Seen
Segs %
Bands %
Lymphocytes %
Variant Lymphocyte %
Mononuclear Phagocytes %
Eosinophils %
Basophils %
Others %
Non-Heme Cells %
Nucleated RBC /100WBCs
Mesothelial Cells /100WBCs
Note
Reviewed By
Crystals, Synovial Fld
None seen
Crystals, ID
Specific Gravity
Exudate 1.015 or greater
Transudate LT 1.015
Fibrin No longer reported |
| T & B CELLS WITH SUBSETS | TBSUB | TBSUB | Flow Cytometry | Source
WBC K/uL
0 days 9.0-30.0
1-7 days 5.0-21.0
7-30 days 5.0-19.5
1-12 mo 6.0-17.5
1-2 yrs 5.0-15.5
2-4 yrs 6.0-15.5
4-6 yrs 5.0-13.5
6-10 yrs 4.5-13.5
10-14 yrs 5.0-11.0
14-18 yrs 4.5-11.0
18 yrs+ 4.0-11.0
Lymphocytes Newborn 9.0-46.0 %
1-3 days 16.0-46.0
4-7 days 26.0-56.0
8-14 days 33.0-63.0
15-60 days 41.0-71.0
2-11 mo 46.0-76.0
1-4 yrs 35.0-76.0
5-12 yrs 23.0-57.0
13-18 yrs 20.0-50.0
19+ yrs 15.0-45.0
Lymphs, Abs Newborn 2.00-11.00 K/uL
1-3 days 2.00-11.50
4-7 days 2.00-17.00
8-14 days 2.00-17.00
15-60 days 2.50-16.50
2-11 mo 4.00-13.50
1-4 yrs 2.00-10.50
5-12 yrs 1.50-7.00
13-18 yrs 1.20-5.20
19+ yrs 1.00-3.40
CD3 0-3 yrs 55.0-82.0 %
4+ yrs 53.0-91.0
CD3 Absolute 0-5 mo 3500-5000 /uL
6-11 mo 3400-4600
12-17 mo 3200-3900
18-29 mo 2800-3500
30 mo-35 mo 1900-3100
3 yrs 1000-3900
4+ yrs 560-3000
CD4 0-5 mo 50.0-57.0 %
6-11 mo 49.0-55.0
12-17 mo 46.0-51.0
18-23 mo 42.0-48.0
24-29 mo 38.0-46.0
30-35 mo 33.0-44.0
3 yrs 27.0-57.0
4+ yrs 30.0=65.0
CD4 Absolute 0-5 mo 2800-3900 /uL
6-11 mo 2600-3500
12-17 mo 2300-2900
18-23 mo 1900-2500
24-29 mo 1500-2200
30-35 mo 1200-2000
3 yrs 560-2700
4+ yrs 490-1400
CD8 0-2 yrs 8.0-31.0 %
3 yrs 14.0-34.0
4+ yrs 12.0-38.0
CD8 Absolute 0-2 yrs 350-2500
4+ yrs 225-900
CD19 0-2 yrs 11.0-45.0 %
3 yrs 9.0-29.0
4+ yrs 3.0-21.0
CD19 Absolute 0-2 yrs 430-3300 /uL
3 yrs 200-1300
4+ yrs 80-450
CD4/CD8 Ratio 0-2 yrs 1.17-6.22 to 1.0
3 yrs 0.98-3.24
4+ yrs 1.00-3.00
Note
Note |
| T3 (REVERSE) | T3REV | REVT3 | RIA | T3 (Reverse) pg/mL
0-7 days 600-2500
8+ days 90-350 |
| T3 BY ICMA (TBG CORRECTED) | RT3 | RT3 | ICMA | T3 by ICMA TBG Corrected ng/dL
80-200 |
| T3 UPTAKE | T3UP | T3U | ICMA | T3 Uptake 22.5-37.0 % |
| T3, FREE & TOTAL | FREE&TOT.T3 | FRTT3 | ICMA | Free T3 2.3-4.2 pg/mL
T3 by ICMA TBG Corrected 80-200 ng/dL |
| T4 BY ICMA | T4 | T4 | ICMA | T4 ug/dL
M 0-30 days 3.0-14.3
1-12 mo 5.2-16.3
1-5 yrs 5.5-11.4
5-10 yrs 5.3-10.5
10-15 yrs 4.5-10.3
15-18 yrs 4.9-8.8
F 0-30 days 3.0-13.3
1-12 mo 4.6-13.3
1-5 yrs 6.3-12.8
5-10 yrs 5.3-10.8
10-15 yrs 4.9-10.0
15-18 yrs 5.1-10.0
Adults 18 yrs+ 5.0-12.0 |
| TACROLIMUS BY LC-MS/MS | TAC | TAC | Tandem Mass Spectrometry | FK506 5.0-20.0 ng/mL
Therapeutic range is based on a whole blood
specimen drawn 12 hours post dose or prior
to the next dose (the trough). Some other
factors influencing therapeutic range, dose
administered, and result interpretation
include time since transplantation, the
organ transplanted, co-administration of
other immunosuppressants, interaction with
other drugs which may increase or decrease
the tacrolimus concentration, and the
preferences of the transplant centers and
clinicians. |
| TEG MAPPING AND STANDARD TEG | TEGMAP | TEGMAP | Clot Detection, TEG Analyzer | CK R 2-8
CK Angle 55-78
CK MA 51-69
CK CI
CK EPL 0-15
CK LY30 0-8
CKH R 2-8
CKH Angle 55-78
CKH MA 51-69
CKH CI
CKH EPL 0-15
CKH LY30 0-9
% Inhibition 0
ADP
ADP MA
ADP G GT 10
% Inhibition 0
AA
AA MA
AA G GT 10
Interpretation
Note |
| TEICHOIC ACID ANTIBODY | TEICHOIC | TEICH | ID | Teichoic Acid Ab Titer
Normal None detected
1:2 or greater suggestive of infection.
Titers of 1:2 or greater indicate
possible deep-seated S. aureus
infection. |
| TESTICULAR FUNCTION PROFILE | TFP | TFP | ICMA | FSH mIU/mL
M Prepubertal 0-4.5
Pubertal 0.3-9.0
Adult 1.4-11.2
F Prepubertal 0-4.5
Pubertal 0.3-9.0
Follicular 3.2-11.3
Midcycle peak 4.2-19.4
Luteal phase 1.5-6.9
Postmenopausal 23.2-121.3
LH mIU/mL
M Prepubertal 0-1.0
Pubertal 0.4-7.0
Adult 1.7-8.6
F
Prepubertal 0-1.0
Pubertal 0.4-12.0
Follicular 2.4-12.6
Midcycle peak 14.0-95.6
Luteal phase 1.0-11.4
Post menopausal 7.7-58.5
Total Testosterone ng/dL
M Premature 26-28 wks 49-104
Premature 31-59 wks 31-164
Newborn 62-332
1-7 mo Levels
decrease rapidly the first week
to 17-50 ng/dL and then increase
to 50-332 ng/dL between 20-60 days.
Levels then decline to prepubertal
range levels of 2-8 ng/dL by seven
months.
7-9 yrs 0-7
10-11 yrs 2-47
12-13 yrs 6-620
14-15 yrs 27-486
16-17 yrs 154-735
18-39 yrs 332-896
40-59 yrs 291-739
60 yrs + 291-598
Tanner Stage I 0-16
Tanner Stage II 2-124
Tanner Stage III 6-632
Tanner Stage IV 136-709
Tanner Stage V 161-650
F Premature 26-28 wks 4-13
Premature 31-59 wks 4-18
Newborn 17-53
1-7 mo Levels
decrease during the first month
to LT 8 ng/dL and remain at this
level until puberty.
7-9 yrs 0-12
10-11 yrs 2-35
12-13 yrs 5-53
14-15 yrs 7-41
16-17 yrs 7-52
18-30 yrs 9-49
31-40 yrs 9-56
41-51 yrs 7-46
Postmenopausal 5-21
Tanner Stage I 1-13
Tanner Stage II 3-32
Tanner Stage III 8-50
Tanner Stage IV 7-52
Tanner Stage V 8-50
|
| TESTOSTERONE, BIOAVAILABLE & TOTAL + SHBG, BY LC-MS/MS | TESBFC | TESBFC | HPLC/MS/ICMA | Testosterone, LC-MS ng/dL
Bioavailable
F 1-6 yrs LT 1.3 M 1-6 yrs LT 1.3
7-9 yrs 0.3-5.0 7-9 yrs 0.3-2.8
10-11 yrs 0.4-9.6 10-11 yrs 0.1-17.9
12-13 yrs 1.7-18.8 12-13 yrs 1.4-288.0
14-15 yrs 3.0-22.6 14-15 yrs 9.5-337.0
16-17 yrs 3.3-28.6 16-17 yrs 35.0-509.0
18-30 yrs 2.2-20.6 18 yrs & older 130-680
31-40 yrs 4.1-25.5 Tanner Stage I 0.3-13.0
41-51 yrs 2.8-16.5 Tanner Stage II 0.3-59.0
Postmenopausal 1.5-9.4 Tanner Stage III 1.9-296.0
Tanner Stage I 0.3-5.5 Tanner Stage IV 40.0-485.0
Tanner Stage II 1.2-15.0 Tanner Stage V 124.0-596.0
Tanner Stage III 3.8-28.0
Tanner Stage IV 2.8-39.0
Tanner Stage V 2.5-23.0
Testosterone, Free pg/mL
F 1-6 yrs LT 0.6 M 1-6 yrs LT 0.6
7-9 yrs 0.6-1.8 7-9 yrs 0.1-0.9
10-11 yrs 0.1-3.5 10-11 yrs 0.1-6.3
12-13 yrs 0.9-6.8 12-13 yrs 0.5-98.0
14-15 yrs 1.2-7.5 14-15 yrs 3-138.0
16-17 yrs 1.2-9.9 16-17 yrs 38.0-173.0
18-30 yrs 0.8-7.4 18 yrs & older 47-244
31-40 yrs 1.3-9.2 Tanner Stage I 3.7 or less
41-51 yrs 1.1-5.8 Tanner Stage II 0.3-21
Postmenopausal 0.6-3.8 Tanner Stage III 1.0-98.0
Tanner Stage I LT 2.2 Tanner Stage IV 35.0-169.0
Tanner Stage II 0.4-4.5 Tanner Stage V 41.0-239.0
Tanner Stage III 1.3-7.5
Tanner Stage IV 1.1-15.5
Tanner Stage V 0.8-9.2
Testosterone, Total ng/dL
F Premature(26-28 wks) 5-16 M Premature (26-28 wks) 59-125
Premature(31-35 wks) 5-22 Premature (31-35 wks) 37-198
Newborn 20-64 Newborn 75-400
1-7 months: Levels decrease during 1-7 mo: Levels decrease rapidly the first
the first month to LT 10 ng/dL & week to 20-50, and then increase to 60-400
remain at this level until puberty. between 20-60 days. Levels then decline to
7-9 yrs LT 15 prebubertal range levels of 3-10 by 7 months.
10-11 yrs 2-42 7-9 yrs LT 9
12-13 yrs 6-64 10-11 yrs 2-57
14-15 yrs 9-49 12-13 yrs 7-747
16-17 yrs 8-63 14-15 yrs 33-585
18-30 yrs 11-59 16-17 yrs 185-886
31-40 yrs 11-56 18-39 yrs 300-1080
41-51 yrs 9-55 40-59 yrs 300-890
Postmenopausal 6-25 60 yrs & older 300-720
Tanner Stage I LT 17 Tanner Stage I LT 20
Tanner Stage II 4-39 Tanner Stage II 2-149
Tanner Stage III 10-60 Tanner Stage III 7-762
Tanner Stage IV 8-63 Tanner Stage IV 164-854
Tanner Stage V 10-60 Tanner Stage V 194-783
Sex Hormone Binding Globulin nmol/L
F 1-30 days 14-60 M 1-30 days 13-85
31-364 days 60-215 31-364 days 70-250
1-3 yrs 60-190 1-3 yrs 50-180
4-6 yrs 55-170 4-6 yrs 45-175
7-9 yrs 35-170 7-9 yrs 28-190
10-12 yrs 17-155 10-12 yrs 23-160
13-15 yrs 11-120 13-15 yrs 13-140
16-17 yrs 19-145 16-17 yrs 10-60
18 yrs + 30-135 18 yrs & older 11-80
Tanner Stage I 30-173 Tanner Stage I 26-286
Tanner Stage II 16-127 Tanner Stage II 22-169
Tanner Stage III 12-98 Tanner Stage III 13-104
Tanner Stage IV 14-151 Tanner Stage IV 11-60
Tanner Stage V 23-165 Tanner Stage V 11-71 |
| TESTOSTERONE, BIOAVAILABLE FREE & TOTAL + SHBG ( ADULT MALES) | TEBSHB | TEBSHB | Electrochemiluminescent Immunoassay | Testosterone, Bioavailable ng/dL
Adult
M 14-15 yrs 10-337
16-17 yrs 35-509
18 yrs + 131-682
Tanner Stage IV 40-485
Tanner Stage V 124-596
Testosterone, Free pg/mL
M 14-15 yrs 3-138
16-17 yrs 38-173
18 yrs+ 47-244
Tanner Stage IV 35-169
Tanner Stage V 41-239
To convert to pmol/L, multiply
pg/mL by 3.47
The concentration of Free Testosterone
is derived from a mathmatical
expression based on the constant for
the binding of testosterone to sex
hormone binding globulin.
Testosterone, Percentage Free %
M 1.6-2.9
Testosterone, Total ng/dL
M 14-15 yrs 33-585
16-17 yrs 185-886
18-39 yrs 300-1080
40-59 yrs 300-890
60 yrs + 300-720
Tanner Stage IV 165-854
Tanner Stage V 194-783
Sex Hormone Binding Globulin nmol/L
M 1-30 days 13-85
31-364 days 70-250
1-3 yrs 50-180
4-6 yrs 45-175
7-9 yrs 28-190
10-12 yrs 23-160
13-15 yrs 13-140
16-17 yrs 10-60
18 yrs+ 11-80
Tanner Stage I 26-286
Tanner Stage II 22-169
Tanner Stage III 13-104
Tanner Stage IV 11-60
Tanner Stage V 11-71 |
| TESTOSTERONE, FREE | TES.FR | TESTFR | RIA | Testosterone Free pg/mL
20-49 yrs M 5-40
50+ yrs M 5-25
20-39 yrs F 0.2-2.6
40-59 yrs F 0.2-2.0
60-80 yrs F 0.2-1.6
Levels increase during puberty to adult values,
and are related to pubertal stage rather than
age. |
| TESTOSTERONE, FREE & TOTAL + SHBG, MALE | TESBFM | TESBFM | Electrochemiluminescent Immunoassay | Testosterone, Free pg/mL
M 14-15 yrs 3-138
16-17 yrs 38-173
18 yrs+ 47-244
Tanner Stage IV 35-169
Tanner Stage V 41-239
To convert to pmol/L, multiply
pg/mL by 3.47.
The concentration of Free Testosterone
is derived from a mathmatical
expression based on the constant for
the binding of testosterone to sex
hormone binding globulin.
Testosterone, Percentage Free %
M 1.6-2.9
Testosterone, Total ng/dL
M 14-15 yrs 33-585
16-17 yrs 185-886
18-39 yrs 300-1080
40-59 yrs 300-890
60 yrs + 300-720
Tanner Stage IV 165-854
Tanner Stage V 194-783
Sex Hormone Binding Globulin nmol/L
M 1-30 days 13-85
31-364 days 70-250
1-3 yrs 50-180
4-6 yrs 45-175
7-9 yrs 28-190
10-12 yrs 23-160
13-15 yrs 13-140
16-17 yrs 10-60
18 yrs+ 11-80
Tanner Stage I 26-286
Tanner Stage II 22-169
Tanner Stage III 13-104
Tanner Stage IV 11-60
Tanner Stage V 11-71 |
| TESTOSTERONE, TOTAL | TES | TESTOT | ICMA | Total Testosterone ng/dL
M Premature 26-28 wks 49-104
Premature 31-59 wks 31-164
Newborn 62-332
1-7 mo Levels
decrease rapidly the first week
to 17-50 ng/dL and then increase
to 50-332 ng/dL between 20-60 days.
Levels then decline to prepubertal
range levels of 2-8 ng/dL by seven
months.
7-9 yrs 0-7
10-11 yrs 2-47
12-13 yrs 6-620
14-15 yrs 27-486
16-17 yrs 154-735
18-39 yrs 332-896
40-59 yrs 291-739
60 yrs + 291-598
Tanner Stage I 0-16
Tanner Stage II 2-124
Tanner Stage III 6-632
Tanner Stage IV 136-709
Tanner Stage V 161-650
F Premature 26-28 wks 4-13
Premature 31-59 wks 4-18
Newborn 17-53
1-7 mo Levels
decrease during the first month
to LT 8 ng/dL and remain at this
level until puberty.
7-9 yrs 0-12
10-11 yrs 2-35
12-13 yrs 5-53
14-15 yrs 7-41
16-17 yrs 7-52
18-30 yrs 9-49
31-40 yrs 9-56
41-51 yrs 7-46
Postmenopausal 5-21
Tanner Stage I 1-13
Tanner Stage II 3-32
Tanner Stage III 8-50
Tanner Stage IV 7-52
Tanner Stage V 8-50 |
| TESTOSTERONE, TOTAL & FREE | TES.FR&T | TESTF | ICMA | Total Testosterone ng/dL
M Premature 26-28 wks 49-104
Premature 31-59 wks 31-164
Newborn 62-332
1-7 mo Levels
decrease rapidly the first week
to 17-50 ng/dL and then increase
to 50-332 ng/dL between 20-60 days.
Levels then decline to prepubertal
range levels of 2-8 ng/dL by seven
months.
7-9 yrs 0-7
10-11 yrs 2-47
12-13 yrs 6-620
14-15 yrs 27-486
16-17 yrs 154-735
18-39 yrs 332-896
40-59 yrs 291-739
60 yrs + 291-598
Tanner Stage I 0-16
Tanner Stage II 2-124
Tanner Stage III 6-632
Tanner Stage IV 136-709
Tanner Stage V 161-650
F Premature 26-28 wks 4-13
Premature 31-59 wks 4-18
Newborn 17-53
1-7 mo Levels
decrease during the first month
to LT 8 ng/dL and remain at this
level until puberty.
7-9 yrs 0-12
10-11 yrs 2-35
12-13 yrs 5-53
14-15 yrs 7-41
16-17 yrs 7-52
18-30 yrs 9-49
31-40 yrs 9-56
41-51 yrs 7-46
Postmenopausal 5-21
Tanner Stage I 1-13
Tanner Stage II 3-32
Tanner Stage III 8-50
Tanner Stage IV 7-52
Tanner Stage V 8-50
Testosterone Free pg/mL
20-49 yrs M 5-40
50+ yrs M 5-25
20-39 yrs F 0.2-2.6
40-59 yrs F 0.2-2.0
60-80 yrs F 0.2-1.6
Levels increase during puberty to adult values,
and are related to pubertal stage rather than
age. |
| TESTOSTERONE, URINE (QUANTITATIVE) | TES-U | TESUQ | Chemiluminescent Immunoassay | Collection Period hr
Volume mL
Creatinine, Ur mg/dL
Creatinine, Ur mg/d
M 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81+ yrs 600-2000
F 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
81+ yrs 400-1300
Testosterone, Ur ug/d
M 20-125
F 5-34 |
| TESTOSTERONE, WEAKLY BINDING | TESTFW | TESTFW | CL/RIA/ASP | Testosterone, Free ng/dL
M 20-50 yrs 0.95-4.30
GT 50 yrs 0.80-3.50
F Ovulating Up to 0.38
Postmenopausal Up to 0.18
This test result or one or more of
its components was developed and its
performance characteristics determined
by Specialty Lab. It has not been
cleared or approved by the FDA. The
FDA has determined that such clearance
or approval is not necessary.
Testosterone, Bioavailable ng/dL
M 1-5 yrs 1-10
6-9 yrs 1-12
10-11 yrs 2-20
12-14 yrs 4-230
15-17 yrs 88-320
GT 17 yrs 62-512
F 1-5 yrs 1-4
6-9 yrs 1-8
10-11 yrs 2-10
12-14 yrs 4-16
15-17 yrs 2-31
GT 17 yrs 1-37
Testosterone, Total ng/dL
M Prepubertal LT 100
(LT 12 yrs)
12-14 yrs 10-572
15-17 yrs 220-800
GT 17 yrs 241-827
F Prepubertal LT 80
(LT 12 yrs)
12-14 yrs 10-40
15-17 yrs 5-40
GT 17 yrs 14-76 |
| TETANUS ANTIBODY, IGG | TETABG | TETAB | Multi-analyte Fluorescent Detection | Tetanus Antibody, IgG IU/mL
Antibody concentration of 0.10 IU/mL
is usually considered protective.
Responder status is determined
according to the ratio of a one-month
post-vaccination sample to pre-
vaccination concentration of tetanus
IgG antibodies as follows:
1. If the one-month post-vaccination
concentration is LT 1.00 IU/mL, the
patient is considered a non-responder.
2. If the post-vaccination concentra-
tion is GT or equal to 1.00 IU/mL,
a patient with a ratio of LT 1.5 a
non-responder; a ratio of 1.5 to LT
1.3, a weak responder; and a ratio
of 3.0 or greater, a good responder.
3. If the pre-vaccination concentra-
tion is GT 1.00 IU/mL, it may be
difficult to assess the response
based on a ratio alone. A post-
vaccination concentration above
2.50 IU/mL in this case is usually
adequate. |
| THALLIUM, BLOOD | THALLIUM | THALL | ICP/MS | Thallium, Blood 0.0-10.0 ug/L |
| THEOPHYLLINE | THEO | THEO | CMIA | Theophylline ug/mL
Therapeutic 10.0-20.0
Toxic GT 20.0 |
| THIOCYANATE | THIOCYANATE | THIO | Colorimetric | Thiocyante mg/dL
Therapeutic 1.0-2.5 During prolonged
therapy (8 days)
Toxic GT 10.0 |
| THIOPURINE METHYLTRANSFERASE, RBC | TMTR | TMTR | Enzymatic/HPLC | Thiopurine Methyltransferase, RBC. |
| THIORIDAZINE & METABOLITE QUANTITATIVE | THIODZ | THIODZ | GC | Thioridazine ng/mL
100-2600 ng/mL following chronic
400 mg daily dose.
Mesoridazine 100-1400 ng/mL |
| THIOTHIXENE | NAVANE | THIOTH | HPLC | Thiothixene ng/mL
1.0-12.0 The lowest possible plasma
concentration at which therapeutic
effect is exhibited should be sought. |
| THROMBIN TIME & FIBRINOGEN (REFLEXIVE) | TTFIB | TTFIB | Electromechanical | Thrombin Time Patient 15.6-20.0 sec
Thrombin Time Control 15.6-20.0 sec
Thrombin Time PT/CT Mix sec
Thrombin Time PT/PSO4 Mix sec
Fibrinogen 211-419 mg/dL |
| THROMBIN TIME (REFLEXIVE) | XTT | XTT | Electromechanical | Thrombin Time
Patient 15.6-20.0 sec
An abnormal thrombin time may be
found with low levels of fibrinogen
as well s with other abnormalities.
Evaluation of fibrinogen levels and
their studies may be necessary to
interpret abnormal thrombin times.
Control 15.6-20.0 sec
PT/CT Mix sec
PT/PS Mix sec |
| THROMBIN TIME TO FIBRINOGEN (REFLEXIVE) | TTIME | TTIME | Electromechanical | Thrombin Time Patient 15.6-20.0 sec
Thrombin Time Control 15.6-20.0 sec
Thrombin Time PT/CT Mix sec
Thrombin Time PT/PSO4 Mix sec
Fibrinogen 211-419 mg/dL |
| THROMBIN-ANTITHROMBIN COMPLEX | TANTIC | TANTIC | ELISA | Thrombin-Antithrombin Complex LT 5.1 ng/mL |
| THYROGLOBULIN (REFLEXIVE) | THYRO | THYRO | ICMA-Immulite; ICMA-Beckman Coulter | Thyroglobulin Autoantibodies 0.0-40.0 IU/mL
Thyroglobulin 1.2-35.0 ng/mL |
| THYROGLOBULIN (TG) + TGAB [USC] | THRUSC | THRUSC | | TgAb LT 0.4 U/mL
Thyroglobulin ng/mL
Comment |
| THYROGLOBULIN AUTOANTIBODIES | TG.AB | TG | ICMA | Thyroglobulin Autoantibodies 0.0-40.0 IU/mL |
| THYROID PEROXIDASE ANTIBODY | TPO.AB | TPO | ICMA | Thyroid Peroxidase Autoantibodies IU/mL
0.0-35.0 |
| THYROID PROFILE | BTB | BTB | ICMA | FTI 5.0-12.0
T3 Uptake 22.5-37.0 %
T4 ug/dL
M 0-30 days 3.0-14.3
1-12 mo 5.2-16.3
1-5 yrs 5.5-11.4
5-10 yrs 5.3-10.5
10-15 yrs 4.5-10.3
15-18 yrs 4.9-8.8
F 0-30 days 3.0-13.3
1-12 mo 4.6-13.3
1-5 yrs 6.3-12.8
5-10 yrs 5.3-10.8
10-15 yrs 4.9-10.0
15-18 yrs 5.1-10.0
Adults 18 yrs+ 5.0-12.0 |
| THYROID STIMULATING HORMONE 3RD GENERATION | TSH3G | TSH3G | Immunochemiluminometric Assay | TSH 3rd Generation uIU/mL
M 0-30 days 0.520-16.000
1 mo-5 yrs 0.550-7.100
5-18 yrs 0.370-6.000
18 yrs+ 0.400-5.000
F 0-30 days 0.720-13.100
1 mo-5 yrs 0.460-8.100
5-18 yrs 0.360-5.800
18 yrs+ 0.400-5.000 |
| THYROID STIMULATING HORMONE RECEPTOR ANTIBODY TRAB | TSHRAB | TSHRAB | Electrochemiluminescent Immunoassay | TSH Receptor LT or equal to 1.75 IU/L
Positive results are consistent with autoimmune thyroid disease. |
| THYROID STIMULATING IMMUNOGLOBULIN | TSIG | TSIG | Bioassay/Lumo | Thyroid Stimulating Immunoglobulin % Basal Activity
0-139 % of control
Thyroid stimulating immunoglobulin (TSI)
are autoantibodies that recognize the
thyroid stimulating hormone receptor, leading
to activation of cell adenylate
cyclase. TSI activity is measured by
the ability of serum immunoglobulins
to stimulate cyclic adenosine monophosphate
(cAMP) production by a cell line expressing
TSH receptors. Results are expressed
as the % of basal activity, defined as the
response to immunoglobulins from healthy
controls. TSI are responsible for
hyperthyroidism associated with Graves
disease. |
| THYROTROPIN BINDING INHIBITORY IMMUNOGLOBULIN | TBII | TBII | RRA | TBII 16 % or less inhibition % |
| THYROXINE BINDING GLOBULIN | TBG | TBG | ICMA | TBG 13.0-30.0 ug/mL |
| THYROXINE, FREE BY EQUILIBRIUM DIALYSIS/HPLC-TMS | FT4TMS | FT4TMS | Equilibrium Dialysis/HPLC-TMS | Free T4 by Equilibrium Dialysis-TMS ng/dL
25-30 weeks 0.5-3.3
31-36 weeks 1.3-4.7
birth-1 week 2.2-5.3
2-3 weeks 0.9-4.0
1-11 months 1.1-2.2
12 months-18 yrs 1.0-2.0
19 yrs and older 1.1-2.4
Pregnancy:
1st Trimester 0.7-2.0
2nd Trimester 0.7-2.1
3rd Trimester 0.5-1.6 |
| TIAGABINE | TIAGA | TIAGA | LC/MS | Tiagabine ng/mL
Trough levels of 5-70 have been reported
as most probable range for seizure control.
Peak concentrtions and elimination half-life
are affected by fat content of food, time of
day and concomitant medications. |
| TISSUE TRANSGLUTAMINASE ANTIBODY, IGA | TTGIGA | TTGIGA | ELISA | Tissue Transglutaminase Ab, IgA U/mL
Negative LT 4.0
Equivocal 4.0-10.0
Positive GT 10.0
tTG antibody, especially IgA, is
sensitive and specific for untreated
celiac disease. Levels can decrease
significantly in response to a gluten-
free diet. The IgG assay is used
mainly to detect celiac patients who
are IgA-deficient. |
| TISSUE TRANSGLUTAMINASE ANTIBODY, IGG | TTGIGG | TTGIGG | ELISA | Tissue Transglutaminase Ab, IgG U/mL
Negative LT 6.0
Equivocal 6.0-9.0
Positive GT 9.0
tTG antibody, especially IgA, is
sensitive and specific for untreated
celiac disease. Levels can decrease
significantly in response to a gluten-
free diet. The IgG assay is used
mainly to detect celiac patients who
are IgA-deficient. |
| TOBRAMYCIN (PAIRED) | TOB2 | TOBIN | FPIA | Tobramycin Infusion, Start
Tobramycin Infusion, End
Tobramycin, Trough 1.0-2.0 ug/mL
Toxic GT 2.0
Tobramycin, Peak 5.0-10.0 ug/mL
Toxic GT 12.0
|
| TOBRAMYCIN (SINGLE) | TOB | TOBR | FPIA | Tobramycin, Single Dose
Trough 1.0-2.0 ug/mL
Toxic GT 2.0
Peak 5.0-10.0
Toxic GT 12.0 ug/mL
|
| TOBRAMYCIN, PEAK | TOB.PK | TOBRPK | FPIA | Tobramycin, Peak 5.0-10.0 ug/mL
|
| TOBRAMYCIN, TROUGH | TOB.TR | TOBRTR | FPIA | Tobramycin, Trough 1.0-2.0 ug/mL
|
| TOCAINIDE | TOC | TOC | GC | Tocainide mcg/mL
Therapeutic 4.0-10.0
Reported antiarrhythmic concentration. |
| TOPIRAMATE | TOPARP | TOPARP | FPIA | Topiramate Not well established ug/mL
The proposed therapeutic range for
seizure control is 5-20 ug/mL.
Pharmacokinetics varies widely
particularly with c0-medications,
age and/or compromised renal function. |
| TOPIRAMATE BY GC | TOPGCN | TOPGCN | GC | Topiramate ug/mL
Target anti-epileptic range in
refractory patients 2.0-25.0 ug/mL. |
| TORCH TEST, IGG | TORGL | TORGL | CLIA | CMV Ab, IgG Negative LT 0.60 U/mL
Toxoplama Ab, IgG Negative LT 6.0 IU/mL
Rubella Ab, IgG Negative LT 9 IU/mL
HSV I Type Specific Negative LT 0.90 IV
Ab, IgG
HSV II Type Specific Negative LT 0.90 IV
Ab, IgG
TORCH IgG Interp |
| TORCH TEST, IGG & IGM (REFLEXIVE) | TORGML | TORGML | CLIA, EIA, ELISA, ICMA | CMV Ab, IgG Negative LT 0.60 U/mL
Toxoplama Ab, IgG Negative LT 6.0 IU/mL
Rubella Ab, IgG Negative LT 9 IU/mL
HSV I Type Specific Negative LT 0.90 IV
Ab, IgG
HSV II Type Specific Negative LT 0.90 IV
Ab, IgG
CMV Ab, IgM Negative LT 30.0 AU/mL
Toxoplama Ab, IgM Negative LT 8.0 AU/mL
Rubella Ab, IgM Negative LT 0.9 Index
HSV Ab, IgM Negative LT 0.91 OD
TORCH IgG & IgM Interp |
| TORCH TEST, IGM (REFLEXIVE) | TORML | TORML | CLIA, EIA, ELISA | CMV Ab, IgM Negative LT 30.0 AU/mL
Toxoplama Ab, IgM Negative LT 8.0 AU/mL
Rubella Ab, IgM Negative LT 0.9 Index
HSV Ab, IgM Negative LT 0.91 OD
TORCH IgM Interp |
| TOXIC SHOCK SYNDROME ANTIBODY | TSABP | TSABP | MAID | Toxic-Shock Syndrome Toxin 1 Antibody
Negative
SEB Antibody
Negative
Interpretive Criteria
Toxic shock syndrome (TSS) is associated
with strains of Staphylococcus aureus
that produce TSS toxin-1 (TSST-1) and/or
staphylococcal enterotoxin B (SEB). TSST-1
is associated with approximately 65%
of TSS cases, whereas SEB is associated
with 28% of cases. Individuals lacking
autoantibodies to TSST-1 or to SEB
(approximately 10% and 20% of adults
respectively) are presumed to be at
highest risk of TSS. This test is thus
designed to identify antibody-negative
individuals at risk for TSS; it should
not be used as a tool for diagnosing
TSS. |
| TOXIC-SHOCK SYNDROME TOXIN PANEL | TSSTP | TSSTP | Culture and MAID | Toxic-Shock Syndrome Toxin-1 Not detected
SEB Not detected
SEC NOt detected
Toxic shock syndrome (TSS) is associated
with Staphylococcus aureus strains
producing TSST toxin-1 (TSST-1),
enterotoxin B (SEB), or enterotoxin C
(SEC). TSST-1 causes essentially all
menstrual TSS cases and approximately
40% of non-menstrual TSS cases. SEB
and SEC account for most other
non-menstrual TSS cases. |
| TOXOCARA AB, IGG | TOXC | TOXC | ELSIA | Toxocara Ab, IgG IV
Negative 0.8 or less-No significant level of
IgG Toxocara IgG Ab detected.
Equivocal 0.9-1.1-Questionable presence of
Toxocara IgG Ab detected. Repeat
testing in 10-14 days may be
helpful.
Positive 1.2 or more-Presence of IgG Ab to
Toxocara detected, suggestive of
current or past infection. |
| TOXOCARA ANTIBODY | TOXOC | TOXOC | ELISA | Toxocara Antibody LT 1.00 Antibody not detected
Interpretive Criteria
LT 1.00 Antibody not detected
1.00 or more Antibody detected
Results of this assay must be interpreted
with caution, as broad variations in
antibody response occur, and levels
may remain elevated for years after
infection. Further, as with many
parasitic serology assays, antibodies
induced by other parasitic infections
may crossreact in this assay. Although
a negative result (LT 1.00) usually
rules out infection with Toxocara spp.,
parallel testing of serial samples may
prove useful in following patients with
suspected Toxocara infection. |
| TOXOPLASMA ANTIBODY, IGG, CSF | TOXO.CSF | TOXOSF | ICMA | Toxoplasma Ab, IgG IU/mL
No established reference range |
| TOXOPLASMA GONDII ANTIBODY, IGG | TOXOGL | TOXOGL | CLIA | Toxoplasma gondii Ab, IgG IU/mL
LT 6.0 Negative No significant level
of IgG Ab detected.
6.0-7.9 Equivocal Repeat testing of a
second sample in 1-014
days may be helpful to
determine presence or
absence of infection.
8.0 or greater Positive IgG Ab detected. May
indicate a recent or
past infection. |
| TOXOPLASMA GONDII ANTIBODY, IGM (REFLEX) | TOXOML | TOXOML | CLIA | Toxoplasma gondii Ab, IgM AU/mL
LT 8.0 Negative No detectable IgM Abs.
A negative result does
not always rule out acute
toxoplasmosis as the IgM
response is not always
detectable in very early
infection. If exposure to
Toxoplasmosis gondii is
suspected, a second sample
should be collection in 3
weeks.
8.0-9.9 Equivocal Repeat testing in 10-14 days
may be helpful to determine
presence or absence of
infection.
10.0 or greater Positive IgM antibody detected. Possible
recent Toxoplasma infection.
Obtain a second sample in 3
weeks for Toxoplasma IgG and IgM
testing. if the results of this
second specimen remain the same
or if the IgG becomes positive,
both specimens should be sent to
a reference laboratory specializing
in the diagnosis of toxoplasmosis
for further testing. The sample will
be held for 1 month. Please call PAML
client services to arrange the testing.
(509.755.8999 or 800.349.8586). |
| TOXOPLASMA GONDII ANTIBODY,IGG & IGM (REFLEX) | TOXGML | TOXGML | CLIA | Toxoplasma gondii Ab, IgG IU/mL
LT 6.0 Negative No significant level
of IgG Ab detected.
6.0-7.9 Equivocal Repeat testing of a
second sample in 1-014
days may be helpful to
determine presence or
absence of infection.
8.0 or greater Positive IgG Ab detected. May
indicate a recent or
past infection.
Toxoplasma gondii Ab, IgM AU/mL
LT 8.0 Negative No detectable IgM Abs.
A negative result does
not always rule out acute
toxoplasmosis as the IgM
response is not always
detectable in very early
infection. If exposure to
Toxoplasmosis gondii is
suspected, a second sample
should be collection in 3
weeks.
8.0-9.9 Equivocal Repeat testing in 10-14 days
may be helpful to determine
presence or absence of
infection.
10.0 or greater Positive IgM antibody detected. Possible
recent Toxoplasma infection.
Obtain a second sample in 3
weeks for Toxoplasma IgG and IgM
testing. if the results of this
second specimen remain the same
or if the IgG becomes positive,
both specimens should be sent to
a reference laboratory specializing
in the diagnosis of toxoplasmosis
for further testing. The sample will
be held for 1 month. Please call PAML
client services to arrange the testing.
(509.755.8999 or 800.349.8586). |
| TOXOPLASMA GONDII BY PCR | TOXPCR | TOXPCR | PCR | Source
Toxoplasma gondii, PCR Result Negative-Toxoplsma gondii not detected by PCR.
Positive-Toxoplasma gondii detected by PCR.
This test is performed pursuant to an
agreement with Roche Molecular Systems, Inc. |
| TOXOPLASMA GONDII IGG & IGM, CSF | TGONCF | TGONCF | ELISA | Toxoplasma gondii Ab, IgG, CSF LT 0.90
Toxoplasma gondii Ab, IgM, CSF LT 0.90
Interpretive Criteria
LT 0.90 Antibody not detected
0.90-1.09 Equivocal
1.10 or more Antibody detected
Diagnosis of central nervous system
infections can be accomplished by
demostrating the presence of intrathecally-
produced specific antibody. Interpreting
results may be complicated by low
antibody levels found in CSF, passive
transfer of antibody from blood, and
contamination via bloody taps. The
interpretation of CSF results must
consider CSF-serum antibody ratios to
the infectious agent. |
| TP-PA | TPPA | TPPA | HA/Gel Particle Agglutination | VDRL Nonreactive
TP-PA Nonreactive |
| TRAMADOL BY GC/MS | MSTRAM | MSTRAM | GC/MS | Tramadol positive cutoff 100 ng/mL
|
| TRAMADOL SCREEN ( REFLEX) | TRAMU | TRAMU | EIA/Confirmation by GC/MS | Tramadol positive cutoff 200 ng/mL
|
| TRANSFERRIN | TRANSFERRIN | TRF | Nephelometry | Transferrin 214-365 mg/dL |
| TRANSPLANT IMMUNE CELL FUNCTION ASSAY | TICFA | TICFA | Cell Culture/Chemiluminescence | Transplantation ng/mL
Immune Cell Assay
(ATP Level)
226-524 Result is Moderate.
The patient's circulating immune
cells are shoing moderate response
to PHA stimulation.
Risk of infection: Normal
Risk of rejection: Decreased
225 or less Result is Low
The patient's circulating immune
cells are showing low response to
PHA stimulation.
Risk of infection: Increased
Risk of rejection: Decreased
525 or greater Result is Strong
The patient's circulating immune
cells are showing strong response
to PHA stimulation.
Risk of infection: Normal
Risk of rejection: Increased |
| TRAZODONE | TRAZ | TRAZ | HPLC | Trazodone (Desyrel) ug/mL
Therapeutic 0.8-1.6
Toxic GT 3.2 |
| TREPONEMA PALLIDIUM ANTIBODY BY TP-PA | TPALAB | TPALAB | Indirect Hemagglutination | Treponema pallidium Antibody by TP-PA
Nonreactive |
| TREPONEMA PALLIDUM ANTIBODY , IGG BY IFA (CSF) | TPAB | TPAB | Indirect Fluorescent Antibody | Fluorescent Treponema Antibody, CSF ,
Nonreactive |
| TRH STIMULATION, 3 SAMPLES | TRH3 | 3PTRH | ICMA | Baseline TSH uIU/mL
M 0-30 days 0.52-16.00
1 mo-5 yrs 0.55-7.10
5-18 yrs 0.37-6.00
F 0-30 days 0.72-13.10
1 mo-5 yrs 0.46-8.10
5-18 yrs 0.36-5.80
18 yrs+ 0.40-5.00
Post TRH TSH The minimum normal response is an increase
(30 minute) of 1-2 uIU/mL above baseline. The typical
response is an increase of 5 to 10 fold
above baseline. uIU/mL
Post TRH TSH uIU/mL
(60 minute) |
| TRH STIMULATION, 4 SAMPLES | TRH4 | PTRH | ICMA | Baseline TSH uIU/mL
M 0-30 days 0.52-16.00
1 mo-5 yrs 0.55-7.10
5-18 yrs 0.37-6.00
F 0-30 days 0.72-13.10
1 mo-5 yrs 0.46-8.10
5-18 yrs 0.36-5.80
18 yrs+ 0.40-5.00
Post TRH TSH The minimum normal response is
(30 minutes) an increase of 1-2 uIU/mL above
baseline. The typical normal
response is an increase of 5
to 10 fold above baseline. uIU/mL
Post TRH TSH uIU/mL
(45 minutes)
Post TRH TSH uIU/mL
(60 minutes) |
| TRICHINELLA ANTIBODY | TRICH | TRICAB | ELISA | Trichinella Ab None detected |
| TRICHROME STAIN | TRICHROM | TRISM | Microscopic | Source
Trichrome Stain
Trichrome Stain, Status |
| TRICYCLICS, TOTAL | TRICYCLIC.TOTAL | TCT | FPIA | Tricyclics, Total ng/mL
No reference range established
For overdose screening only. Marked
variation in toxic response to TCAs.
Possible toxic cardiac effects at 50-
100 ng/mL. High incidence of cardiac
toxicity at GT 500 ng/mL. Severe,
sometimes fatal effects at GT 1000
ng/mL. |
| TRIFLUOPERAZINE (QUANTITATIVE) | TRI | TRIFLU | GC/NPD | Trifluoperazine ng/mL
Therapeutic levels 20 or less |
| TRIGLYCERIDES | TRIG | TRIG | Enzymatic | Triglycerides mg/dL
LT 150 Normal
150-199 Borderline high
200-499 High
500 or more Very high |
| TRIMETHOPRIM | TRIMETHOPRIM | TRIMET | HPLC | Trimethoprim ug/mL
Therapeutic 10-20
Toxic 40 or greater |
| TRIMIPRAMINE & METABOLITE | TRIMIP | TRIMIP | GC | Trimipramine ng/mL
10-240 ng/mL Observed levels during
chronic oral antidepressant does of
75-150 mg/day.
Trimipramine Metabolite ng/mL
3-380 ng/mL Observed levels during
chronic oral antidepressant doses of
75-150 mg/day. |
| TROPONIN I | TRPI | TRPI | CMIA | Troponin I 0.00-0.29 ng/mL
Critical value GT 0.29 |
| TROPONIN T | TROPT | TROPT | Immunoassay | Troponin T 0.0-0.1 ng/mL |
| TRYPANOSOMA CRUZI ANTIBODY | CHAGAS | CHAGAS | IFA | Trypanosoma cruzi, IgG LT 1:16
Trypanosoma cruzi, IgM LT 1:20
The serodiagnosis of Chagas' disease or
American trypanosomias by IFA is highly
sensitive and specific, although
crossreactions may occur with leishmaniasis.
A T. cruzi IgM (GT or equal to 1:20)
response is observed in acute disease
prior to IgG seroconversion. In chronic
Chagas' disease, IgG is usually
detected at levels GT or equal to 1:64. |
| TRYPSIN, FECAL | TRYPST | TRYPST | Film Digestion | Trypsin, Fecal Negative |
| TRYPSIN-LIKE IMMUNOREACTIVITY | TRYPSN | TRYP | RIA | Trypsin-like Immunoreactivity 10-57 ng/mL
Trypsinogen expected values for
Chronic pancreatitis LT 47.0
Acute pancreatitis 92.0-850.0
Total Pancreatectomy 1.4 or less
. |
| TRYPTASE | TRYPT | TRYPT | FPI | Tryptase 0.4-10.9 ug/mL |
| TSH | TSH | TSH | ICMA | TSH uIU/mL
M 0-30 days 0.52-16.00
1 mo-5 yrs 0.55-7.10
5-18 yrs 0.37-6.00
F 0-30 days 0.72-13.10
1 mo-5 yrs 0.46-8.10
5-18 yrs 0.36-5.80
18 yrs+ 0.40-5.00 |
| TSH (REFLEXIVE) | TSH.R | TSHREF | ICMA | TSH (Reflex) uIU/mL
M 0-30 days 0.52-16.00
1 mo-5 yrs 0.55-7.10
5-18 yrs 0.37-6.00
F 0-30 days 0.72-13.10
1 mo-5 yrs 0.46-8.10
5-18 yrs 0.36-5.80
18 yrs+ 0.40-5.00 |
| UNSATURATED IRON BINDING CAPACITY | UIBCA | UIBCA | Calculation | Unsaturated Iron Binding Capacity ug/dL
155-300 |
| UNSTABLE HEMOGLOBIN | UN.HEM | UNSHGB | Precipitation | Unstable Hemoglobin
Negative |
| UREA CLEARANCE | URCLE | URCLE | Colorimetric and calculation | BUN 7-23 mg/dL
Urea, Urine 12-20 g/24h
Urea Clearance mL/min/1.73m2 |
| UREA, URINE (QUANTITATIVE) | UREA-U | UREAUQ | Colorimetric | Collection Period h
Volume mL
Urea, Urine 12-20 g/24h |
| UREA, URINE (RANDOM) | UREA-R | UREAUR | Colorimetric | Urea, Urine mg/dL
No normals established |
| URIC ACID | UCA | URIC | Enzymatic | Uric Acid mg/dL
M 0-16 yrs 2.0-5.5
17+ yrs 3.1-8.1
F 0-16 yrs 2.0-5.5
17+ yrs 2.0-6.7 |
| URIC ACID, FLUID | UCASYN | URICFL | Enzymatic | Uric Acid, Fluid mg/dL
No reference range established.
Method not validated for body fluid.
Clinical correlation necessary. |
| URIC ACID, URINE (QUANTITATIVE) | UCA-U | URICUQ | Enzymatic | Collection Period h
Volume mL
Uric Acid, Urine 250-750 mg/24h |
| URIC ACID, URINE (RANDOM) | UCA-R | URICUR | Enzymatic | Uric Acid, Urine, Random mg/dL
No normals established |
| URINALYSIS | UA | UA | Colorimetric/Microscopic | Collection Method
Color
Appearance
Glucose Negative mg/dL
Bilirubin Negative
Ketones Negative mg/dL
Specific Grav 1.001-1.030
pH 5.0-7.5
Protein mg/dL
Urobilinogen 0.2-1.0 mg/dL
Nitrite Negative
Blood Negative
Leukocyte Est Negative
Microscopic
WBC LT 6 /hpf
RBC F LT 6 /hpf
M LT 3
Epi None seen
Bacteria None seen
Casts 1 Hyaline /lpf
Crystals /hpf
Crystals, Abnormal /lpf
Other |
| URINALYSIS WITH MICROSCOPIC | UAM | UAM | Colorimetric/Microscopic | Collection Method
Color
Appearance
Glucose Negative mg/dL
Bilirubin Negative
Ketones Negative mg/dL
Specific Grav 1.001-1.030
pH 5.0-7.5
Protein mg/dL
Urobilinogen 0.2-1.0 mg/dL
Nitrite Negative
Blood Negative
Leukocyte Est Negative
UA Micro
WBC LT 6 /hpf
RBC F LT 6 /hpf
M LT 3 /hpf
Epithelial Cells
Bacteria None seen /hpf
Casts /lpf
Crystals /hpf
Crystals, Abnormal /lpf
Other |
| URINALYSIS WITH MICROSCOPIC ANALYSIS | UAXM | UAXM | Flow Cell Digital Imaging/Colorimetric | Color
Appearance
Glucose, Urine Negative mg/dL
Bile, Urine Negative
Ketones, Urine Negative mg/dL
Specific Gravity 1.001-1.030
pH, Urine 5.0-7.5
Protein, Urine Negative mg/dL
Urobilinogen, Urine LT 2.0 mg/dL
Nitrite, Urine Negative
Blood, Urine Negative
Leukocyte Esterase Negative
Reducing Substances Negative mg/dL
WBC LT 6 /hpf
RBC
F LT 6 /hpf
M LT 3
WBC clumps None seen /hpf
RBC clumps None seen /hpf
Bacteria None seen /hpf
Budding yeast None seen /hpf
Hyphae yeast None seen /hpf
Squamous epith cells /lpf
Transitional epit cells None seen /hpf
Renal epith cells None seen /hpf
Oval fat bodies None seen /hpf
Fat None seen /hpf
Mucus None seen /lpf
Sperm None seen /hpf
Trichomonas None seen /hpf
Hyaline casts None seen /lpf
Epith cell casts None seen /lpf
WBC casts None seen /lpf
RBC casts None seen /lpf
Granular casts None seen /lpf
Broad casts None seen /lpf
Fatty casts None seen /lpf
Waxy casts None seen /lpf
Triple phosphaste None seen /hpf
crystals
Calcium oxalate None seen /hpf
crystals
Calcium phosphate None seen /hpf
crystals
Calcium carbonate None seen /hpf
crystals
Uric acid crystals None seen /hpf
Leucine crystals None seen /lpf
Cystine crystals None seen /lpf
Tyrosine crystals None seen /lpf
Amorphous crystals None seen /hpf
Other |
| URINALYSIS, DIPSTICK | DPS | UAD | Colorimetric | Collection Method
Color
Appearance
Glucose, Urine Negative mg/dL
Bile, Urine Negative
Ketones, Urine Negative mg/dL
Specific Gravity 1.001-1.030
pH, Urine 5.0-7.5
Protein, Urine Negative mg/dL
Urobilinogen, Urine 0.2-1.0
Nitrite, Urine Negative
Blood, Urine Negative
Leukocyte Esterase Negative |
| URINALYSIS, DIPSTICK ONLY | UADIP | UADIP | Colorimetric | Color
Appearance
Glucose, Urine Negative mg/dL
Bile, Urine Negative
Ketones, Urine Negative mg/dL
Specific Gravity 1.001-1.030
pH, Urine 5.0-7.5
Protein, Urine Negative mg/dL
Urobilinogen, Urine LT 2.0 mg/dL
Nitrite, Urine Negative
Blood, Urine Negative
Leukocyte Esterase Negative
Reducing Substances Negative mg/dL |
| URINALYSIS, MICROSCOPIC ONLY | UAMIC | UAMIC | Microscopic | WBC LT 6 /hpf
RBC
F LT 6 /hpf
M LT 3
Epithelial Cells
Bacteria /hpf
Casts /lpf
Crystals /hpf
Crystals, Abnormal /lpf
Other |
| URINALYSIS, MICROSCOPIC ONLY(NEW) | UAMCR | UAMCR | Flow Cell Digital Imaging | WBC LT 6 /hpf
RBC
F LT 6 /hpf
M LT 3
WBC clumps None seen /hpf
RBC clumps None seen /hpf
Bacteria None seen /hpf
Budding yeast None seen /hpf
Hyphae yeast None seen /hpf
Squamous epith cells /lpf
Transitional epit cells None seen /hpf
Renal epith cells None seen /hpf
Oval fat bodies None seen /hpf
Fat None seen /hpf
Mucus None seen /lpf
Sperm None seen /hpf
Trichomonas None seen /hpf
Hyaline casts None seen /lpf
Epith cell casts None seen /lpf
WBC casts None seen /lpf
RBC casts None seen /lpf
Granular casts None seen /lpf
Broad casts None seen /lpf
Fatty casts None seen /lpf
Waxy casts None seen /lpf
Triple phosphaste None seen /hpf
crystals
Calcium oxalate None seen /hpf
crystals
Calcium phosphate None seen /hpf
crystals
Calcium carbonate None seen /hpf
crystals
Uric acid crystals None seen /hpf
Leucine crystals None seen /lpf
Cystine crystals None seen /lpf
Tyrosine crystals None seen /lpf
Amorphous crystals None seen /hpf
Other |
| URINE TIME & VOLUME | 1TV | 1TV | | Collection Period h
Volume mL |
| UROBILINOGEN, URINE (QUALITATIVE) | UROB | UROUD | Colorimetric/Dipstick/Modified Ehrlich | Urobilinogen, Urine 0.2-1.0 mg/dL |
| VAGINAL PATHOGENS DNA DIRECT PROBE | VPDNA | VPDNA | Nucleic Acid Probe | Candida species DNA Probe Negative
Gardenella vaginalis DNA Probe Negative
Trichomonas vaginalis DNA Probe Negative
All tests should be correlated with
clinical history. |
| VALPROIC ACID | VALPROIC | VALP | ICMA | Valproic Acid ug/mL
(Peak or Trough)
Therapeutic 50-100
Toxic GT 150 |
| VALPROIC ACID, FREE | VALPROIC.FREE | VALPFR | FPIA | Valproic Acid, Free ug/mL
Normal anti-epileptic range 5-10.
Therapeutic range for the treatment of manic
episodes associated with bipolar disorders:
5-12.5.
Analysis by fluorescence polarization immuno-
assay (FPIA). |
| VANCOMYCIN | VAN | VAN | Turbidimetric | Vancomycin ug/mL
Trough 5.0-15.0 Toxic GT 25.0
Peak 25.0-40.0 Toxic GT 50.0 |
| VANCOMYCIN, PEAK | VAN.PK | VANCPK | Turbidimetric | Vancomycin, Peak 25.0-40.0 Toxic GT 50.0 ug/mL
|
| VANCOMYCIN, PEAK & TROUGH | VAN2 | VANIN | Turbidimetric | Vancomycin, ug/mL
Trough 10.0-20.0 Toxic GT 25.0
Time, Trough
Vancomycin,
Peak 25.0-40.0 Toxic GT 50.0 ug/mL
Time, Peak |
| VANCOMYCIN, TROUGH | VAN.TR | VANCTR | Turbidimetric | Vancomycin, Trough 10.0-20.0 Toxic GT 25.0 ug/mL |
| VANILLYLMANDELIC ACID & HOMOVANILLIC ACID URINE (QUANTITATIVE) | HVVMUQ | HVVMUQ | HPLC | Volume mL
Collection Period hr
VMA 0.0-7.0 mg/d
HVA 0.0-15.0 mg/d
Creatinine, Ur mg/d
Creatinine, Ur mg/dL
M 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
81+ yrs 600-2000
F 0-2 yrs Not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
81+ yrs 400-1300
Interpretation Normal
VMA, Urine mg/gCr
0-2 yrs 0-27
3-5 yrs 0-13
6-17 yrs 0-9
18 yrs + 0-6
HVA, Urine mg/gCr
0-2 yrs 0-42
3-5 yrs 0-22
6-17 yrs 0-15
18 yrs + 0-8 |
| VANILLYLMANDELIC ACID, URINE (QUANTITATIVE) | VMA | VMAUQ | HPLC/Electrochemical Detection | Collection Period h
Volume mL
VMA, Urine ug/mg Cr
0-1 yrs 6.0-24.0
1-8 yrs 2.6-16.0
9-16 yrs 2.0-12.0
17-110 yrs 1.5-7.0 |
| VANILLYLMANDELIC ACID, URINE (RANDOM) | VMA-R | VMAUR | HPLC/Electro Det/Enzymatic (IDMS traceable) | VMA, Urine ug/mgC
0-11 mo 6.0-24.0
1-8 yrs 2.6-16.0
9-16 yrs 2.0-12.0
17-110 yrs 1.5-7.0
Creatinine, Urine, Random No normals established mg/dL
|
| VAP CHOLESTEROL TEST | VAPCT | VAPCT | Ultracentrifugation | Total LDL Cholesterol LT 130 mg/dL
Direct LDL R (Real) Cholesterol LT 100 mg/dL
Direct Lp(a) Cholesterol LT 10 mg/dL
Direct IDL Cholesterol LT 20 mg/dL
Direct Total HDL Cholesterol GT 39 mg/dL
HDL 2 (Large Bouyant, GT 10 mg/dL
Most Protective)
HDL 3 (Small, Dense, GT 30 mg/dL
Least Protective)
Direct Total VLDL Cholesterol LT 30 mg/dL
VLDL 1+2 LT 20 mg/dL
VLDL 3 (Small Remnant) LT 10 mg/dL
Sum Total Cholesterol LT 200 mg/dL
Triglycerides, Direct LT 150 mg/dL
Total Non-HDL Cholesterol LT 160 mg/dL
(LDL + VLDL)
Remnant Lipo (IDL + VLDL3) LT 30 mg/dL
Real LDL Size Pattern A
LDL 4 mg/dL
LDL 3 mg/dL
LDL 2 mg/dL
LDL 1 mg/dL
Total APO B100 Calc LT 109 mg/dL
APO A1 GT 118 mg/dL
APO B100-A1 Ratio LT 0.0 |
| VARICELLA-ZOSTER ANTIBODY, IGG | VZA | VZA | ELISA | Varicella-Zoster Ab IgG
LT 0.91 Negative-No significant level of ISR
IgG Ab to Varicella Zoster virus
detected. Patient may be susceptible
to primary infection.
0.91-1.09 Indeterminate-Varicella zoster virus
IgG antibody status equivocal. Cannot
determine the patient's immune status.
Repeat testing in 10-14 days may be
helpful in determining the presence
or absence of infection.
GT 1.09 Positive-Significant level of IgG Ab
to Varicella Zoster virus detected.
Indicates current or previous
infection or vaccine response. |
| VARICELLA-ZOSTER VIRUS ANTIBODY, IGG & IGM | VZAGM | VZAGM | ELISA | Varicella-Zoster Ab IgG
LT 0.91 Negative-No significant level of ISR
IgG Ab to Varicella Zoster virus
detected. Patient may be susceptible
to primary infection.
0.91-1.09 Indeterminate-Varicella zoster virus
IgG antibody status equivocal. Cannot
determine the patient's immune status.
Repeat testing in 10-14 days may be
helpful in determining the presence
or absence of infection.
GT 1.09 Positive-Significant level of IgG Ab
to Varicella Zoster virus detected.
Indicates current or previous
infection or vaccine response.
Varicella-Zoster Virus Ab, IgM IV
LT 0.91 Negative-no clinically
significant level of
VZV IgM Ab detected.
0.91-1.09 Indeterminate-unable to
determine the presence or
absence of VZV IgM Ab.
GT 1.09 Positive-IgM Ab to VZV
detected. May indicate
current or recent
infection or reactivation. |
| VARICELLA-ZOSTER VIRUS ANTIBODY, IGM | VZVM | VZVM | ELISA | Varicella-Zoster Virus Ab, IgM IV
LT 0.91 Negative-no clinically
significant level of
VZV IgM Ab detected.
0.91-1.09 Indeterminate-unable to
determine the presence or
absence of VZV IgM Ab.
GT 1.09 Positive-IgM Ab to VZV
detected. May indicate
current or recent
infection or reactivation. |
| VARICELLA-ZOSTER VIRUS BY PCR | VZVRTP | VZVRTP | Real-Time PCR | Varicella-Zoster Source
Varicella-Zoster Virus Result
Negative for VZV DNA.
A negative result does not rule out
the presence of PCR inhibitors in the patient
specimen or VZV concentrations below
the level of detection by the assay.
The limit of detection of this assay is 5
copies per microliter of patient specimen. |
| VASCULAR ENDOTHELIAL GROWTH FACTOR | VEGF | VEGF | Chemiluminescent Immunoassay | Vascular Endothelial Growth Factor
9-86 pg/mL
This assay is performed using the
QuantiGlo chemiluminescent EIA kit.
Values obtained with different assay
methods or kits cannot be used
interchangeably. |
| VASOACTIVE INTESTINAL POLYPEPTIDE | VIP | VIP | RIA | VIP LT 75 pg/mL |
| VDRL, CSF | VDRL.CSF | VDRLSF | FLOC | VDRL, CSF Nonreactive |
| VENLAFAXINE & METABOLITE, SERUM/PLASMA | VENLAM | VENLAM | LC-MS/MS | Venlafaxine ng/mL
Steady state peak plasma levels
following a daily regimen occur
at approximately 2 hours for
Venlafaxine:
Dose Range
75 35-79
150 93-334
225 68- 265
450 196-597
Steady state trough plasma levels
following a 150 mg per day regimen:
0-141 ng Venlafaxine/mL.
O-Desmethylvanlafaxine ng/mL
Steady state peak plasma levels
following a daily regimen of
Venlafaxine occur at approximately
2.5 hours for O-Desmethyl-venlafaxine:
Dose Range
75 94-200
150 85-472
225 243-515
450 390-1096
Steady state trough plasma levels
following a 150 mg per day regimen:
5-300 ng O-Desmethylvenlafaxine/mL. |
| VENOUS ACID BASE PROFILE | AC/BASE | VBG | Ion Transfer Electrode/Potentiometry/Co-oximeter | pH 7.31-7.41
PCo2 41-51 mmHg
p02 37-43 mmHg
02 Content 4.5-6.0 Vol %
02 Saturation, Venous 70-76 %
HC03 22-26 mmol/L
Base Excess -2.0 to +2.0 mmol/L
Base Deficit 0.0-2.5 mmol/L
Hemoglobin g/dL
0-3 days 14.5-22.5
3-7 days 13.5-21.5
7-14 days 12.5-20.5
14-30 days 10.0-18.0
30-60 days 9.0-14.0
2-5 mo 10.5-13.5
6-24 mo 11.5-13.5
2-6 yrs 11.5-13.5
6-12 yrs 11.5-15.5
12-18 yrs M 13.0-16.0
18 yrs+ M 13.7-16.7
12-18 yrs F 12.0-16.0
18 yrs+ F 11.6-15.5 g/dL
C0 Hemoglobin 1-3 %
Met Hemoglobin 0.4-1.5 %
02 %
Additional Data |
| VERAPAMIL, SERUM/PLASMA | VERAPA | VERAPA | GC | Verapamil 70-350 ng/mL
Probable therapeutic range. Two or
three fold greater plasma Verapamil
concentrations are required after
oral dosing, as compared to I.V.
dosing, to elicit the same increase
in a-v conduction time. |
| VIRAL CULTURE (REFLEXIVE) | VIRCUL | VIRCUL | Isolation in Tissue Culture | Source
Viral Culture Negative
Viral Culture, Status |
| VIRAL DFA STAIN, REFLEXIVE TO VIRAL CULTURE (REFLEXIVE) | VRDFAR | VRDFAR | DFA Stain | Viral Culture & DFA Stain Negative for DFA screen
No virus isolated
Viral Culture & DFA Stain Status
|
| VISCOSITY | VISC | VISC | Cone and Plate Viscometer | Viscosity Normal 1.1-1.8 cP
Symptoms of hyperviscosity
syndrome may appear with a
viscosity of 4cP, while
a viscosity of between
6cP and 8cP or more is usually
accompanied by symptoms. |
| VISCOSITY, FLUID | VISCFL | VISCFL | Cone and Plate Viscometer | Viscosity, Fluid cP
No normals established |
| VITAMIN A | VIA | VIA | HPLC | Vitamin A (Retinol) Result mg/L
0-30 days 0.18-0.50 mg/L
1 mon-12 yrs 0.20-0.50
13-17 yrs 0.26-0.70
18+ yrs 0.30-1.20 |
| VITAMIN B 12 ASSAY | B12 | B12 | ICMA | B12 Deficient LT 212 pg/mL
Indeterminate 212-246
Normal 247-911 |
| VITAMIN B-1 THIAMINE, PLASMA | VIT B-1 THIAM | VITB1P | HPLC for Thiochrome | Vitamin B-1 Thiamine, 8-30 nmol/L
Plasma |
| VITAMIN B-1, WHOLE BLOOD | VIT B-1.BLD | VITB1B | HPLC | Vitamin B-1 Thiamine, 70-180 nmol/L
Whole Blood
The concentration of thiamine diphosphate
(TDP), the primary active form of vitamin
B1, is measured in this assay. Approximately
90% of vitamin B1 present in the whole blood
is TDP. Thiamine & thiamine monophosphate,
which comprise the remaining 10%, are not
measured. |
| VITAMIN B-6 | VIT B-6 | VITB6P | RIA | Vitamin B-6 5.0-30.0 ng/mL |
| VITAMIN B12 & FOLATE | B12/FOL | B12FOL | ICMA | B12 Deficient LT 212 pg/mL
Indeterminate 212-246
Normal 247-911
Folate ng/mL
Deficient 0.4-3.4
Indeterminate 3.5-5.3
Normal 5.4-24.0 |
| VITAMIN B12 BINDING CAPACITY (UNSATURATED) | UBBC | VB12BC | RIA | Vitamin B12 Binding Capacity, pg/mL
Unsaturated (UBBC) 800-2600 |
| VITAMIN B2, RIBOFLAVIN | VB2 | VB2 | Spectrophotometric | Vitamin B2, Riboflavin Activity Coefficient
1.00-1.30
Values above 1.31 are biochemical evidence of
Riboflavin deficiency. |
| VITAMIN C, PLASMA | VIT.C | VITCP | Spectrophotometric (DNPH) | Vitamin C, Plasma 0.4-2.0 mg/dL |
| VITAMIN D, 1,25-DIHYDROXY | VIDD | VIDD | RIA | Vitamin D 15-75 pg/mL
(1,25-OH) |
| VITAMIN D, 25-HYDROXY | VDOH | VDOH | Chemiluminescent Immunoassay | Vitamin D, LT 20 Suggests a ng/mL
25-Hydroxy deficiency of 25-OH
Vitamin D.
20-29 Suggests a
relative insufficiency
of 25-OH Vitamin D.
30-150 Suggests a sufficient
level of 25-OH Vitamin D.
GT 150 Toxic level of
25-OH Vitamin D.
Blood levels of 25-OH Vitamin D vary
with the extent of sun exposure.
Values tend to be highest in late
summer and lowest in spring. Values
also tend to decrease with age, due
to decreased precursor synthesis in
the skin. |
| VITAMIN D2 D3, 25-HYDROXY BY LC-MS/MS | VITD23 | VITD23 | Tandem Mass Spectrometry | 25-Hydroxyvitamin D2 ng/mL
25-Hydroxyvitamin D3 ng/mL
25-Hydroxyvitamin D Total ng/mL
Reference Ranges for Total Vitamin D
Severe Deficiency LT 10.0 ng/mL
Mild to Moderate Deficiency 10.0-23.9
Optimum Levels 24.0-80.0
Toxicity Possible, Pediatrics (0-18 yrs) 80.0 or greater
Toxicity Possible, Adults (19+ yrs) 150.0 or greater
|
| VITAMIN E | VIE | VIE | HPLC | Vitamin E (alpha-tocopherol) Result mg/L
0-30 days 1.0-3.5 mg/L
1-5 mo 2.0-6.0
6 mo-1 yr 3.5-8.0
2-12 yrs 5.5-9.0
13+ yrs 5.5-21.0 |
| VITAMIN K1 | VITK1 | VITK1 | HPLC | Vitamin K1 0.10-2.20 ng/mL |
| VOLTAGE GATED CALCIUM CHANNEL ANTIBODY | VGCCAB | VGCCAB | Radiobinding Assay | Voltage-gated Calcium Channel Antibody 23000 or less fmol/L |
| VON WILLEBRAND FACTOR ACTIVITY | VON | F08RCO | Electromechanical | VWF Activity GT 40% Activity %
(Ristocetin Cofactor) |
| VON WILLEBRAND FACTOR ANTIGEN | FAC8AG | F08RA | Immuno-turbidimetric Assay | Von Willebrand 50-165% concentration %
Factor Antigen |
| VON WILLEBRAND MULTIMERIC ANALYSIS | VWFMA | VWFMA | Chemiluminensce | Von Willebrand Factor Multimeric
Normal
Interpretation |
| VON WILLEBRAND MULTIMERIC PANEL | VWMUL | VWMUL | Electrophoresis, Western Blot, Clotting MPMIA, Platelet Agg | von Willebrand Multimeric Normal
Factor VIII Activity %
0-6 yrs 56-191
7-9 yrs 76-199
10-11 yrs 80-209
12-13 yrs 72-198
14-15 yrs 69-237
16-17 yrs 63-221
18 yrs + 56-191
von Willebrand Factor Antigen %
0-6 yrs 52-214
7-9 yrs 62-180
10-11 yrs 63-189
12-13 yrs 60-189
14-15 yrs 57-199
16-17 yrs 50-205
18 yrs+ 52-214
von Willebrand Factor Activity %
0-6 yrs 51-215
7-9 yrs 52-176
10-11 yrs 60-195
12-13 yrs 50-184
14-15 yrs 50-203
16-17 yrs 49-204
18 yrs + 51-215 |
| VON WILLEBRAND PANEL | VONP | VONP | Electromechanical & Immuno-turbidimetric | Factor VIII 55-150 %
Von Willebrand Factor Antigen 50-165 %
Von Willebrand Factor Activity GT 40 % |
| WEST NILE VIRUS AB PANEL, IGG & IGM | WNGM | WNGM | ELISA | West Nile Virus, IgG LT 1.30
West Nile Virus, IgM LT 0.90
West Nile Viruse Interpretation
Interpretative Criteria for IgG:
LT 1.30 Antibody not detected
1.30-1.50 Equivocal
GT 1.50 Antibody detected
Interpretative Criteria for IgM:
LT 0.90 Antibody not detected
0.90-1.10 Equivocal
GT 1.10 Antibody detected
West Nile Virus (WNV) IgM is usually
detectable by the time symptoms
appear, but IgG may not be detectable
until day 4 or day 5 of illness.
Although WNV IgM persists for more
than a year in some patients with WNV
encephalitis, detection of WNV IgM
remains a reliable indicator of recent
infection for most patients.
Antibodies induced by WNV infection
show extensive crossreactivity with
other flaviviruses (Dengue, St.
Louis Encephalitis); thus, antibody
detection using this panel is not
diagnostically conclusive for
WNV infection. Final diagnosis should
be based on confirmatory assays, such
as the plaque reduction neutralization
test. |
| WEST NILE VIRUS ANTIBODY, CSF | WNVCSF | WNVCSF | ELISA | West Nile Virus, IgG, CSF LT 1.30
West Nile Virus, IgM, CSF LT 0.90
Interpretation
Interpretative Criteria for IgG:
LT 1.30 Antibody not detected
1.30-1.50 Equivocal
GT 1.50 Antibody detected
Interpretative Criteria for IgM:
LT 0.90 Antibody not detected
0.90-1.10 Equivocal
GT 1.10 Antibody detected
In the very early stages of acute
West Nile Virus (WNV) infection,
IgM may be detectable in CSF before
it becomes detectable in serum.
Antibodies induced by WNV infection
show extensive crossreactivity with
other flaviviruses (Dengue, St.
Louis Encephalitis); thus, antibody
detection using this panel is not
diagnostically conclusive for WNV
infection. Final diagnosis should
be based on confirmatory assays,
such as the plaque reduction
neutralization test.
WNV antibody results for CSF should
be interpreted with caution.
Complicating factors include low
antibody levels found in the CSF,
passive transfer of antibody from
blood, and contamination via bloody
taps. |
| WEST NILE VIRUS RNA BY RT-PCR | WNVPR | WNVPR | RT-PCR | West Nile Virus RNA by RT-PCR
Negative WNV nucleic acid not
detected by RT-PCR.
Positive WNV nucleic acid detected
by RT-PCR.
A negative result does not rule out the
presence of PCR inhibitors in the
patient specimen or WNV nucleic acid
in concentrations below the level of
detection of this assay.
This test is performed pursuant to
an agreement with Roche Molecular
Systems, Inc. |
| WET MOUNT | WET-MNT | WM | Microscopic | Source
WBC /hpf
Epithelial Cells /hpf
Bacteria /hpf
Clue Cells /hpf
Yeast /hpf
Trichomonas /hpf |
| WHITE CELL COUNT | WBC | WBC | Automated | WBC K/uL
0 days 9.0-30.0
1-7 days 5.0-21.0
7-30 days 5.0-19.5
1-12 mo 6.0-17.5
1-2 yrs 5.0-15.5
2-4 yrs 6.0-15.5
4-6 yrs 5.0-13.5
6-10 yrs 4.5-13.5
10-14 yrs 5.0-11.0
14-18 yrs 4.5-11.0
18 yrs+ 4.0-11.0 |
| XYLOSE ABSORPTION TEST, ADULT 25 GM | XYTO25 | XYTO25 | Spectrophotometry | Volume at 5 hours mL
Xylose Dose g
Xylose, Serum at 2 hours mg/dL
17 yrs & older 32-58
Xylose excretion g/5hr
17-64 yrs 4.0-10.0
65 yrs & older 3.5-10.0
Xylose excretion %
17-64 yrs 16-40
65 yrs & older 14-40 |
| XYLOSE ABSORPTION TEST, ADULT 5 GM | XYTO5 | XYTO5 | Spectrophotometry | Volume at 5 hours mL
Xylose Dose g
Xylose, Serum at 2 hours mg/dL
17 yrs and older 5-17
Xylose excretion g/5hr
17 yrs and older 1.2-2.0
Xylose excretion %
17 yrs and older 20-40 |
| XYLOSE ABSORPTION TEST, CHILD | XYTOC | XYTOC | Spectrophotometry | Volume at 5 hours mL
Xylose Dose g
Xylose, Serum at 1 hour mg/dL
0-5 months 15-58
6 mo-16 yrs 20-58
Xylose excretion g/5hr
Xylose excretion %
0-16 yrs 16-40 |
| YERSINIA SPECIES ANTIBODY, IGA & IGG | YERAB | YERAB | Western Blot | Yersinia Species Antibody, IgA
Negative No significant Yersinia
Antibody detected.
Positive IgA Antibody to Yersinia
detected.
Yersinia Species Antibody, IgG
Negative No siginficant Yersinia
Antibody .
Equivocal Questionable presence
of Yersinia IgG Abs
detected. May be an
indication of a recent
infection.
Positive IgA Abs to Yersinia
detected. |
| ZINC | ZINC | ZN | AAS | Zinc ug/dL
60-130
Fasting specimens below 60 ug/dL may
represent deficient zinc status. |
| ZINC PROTOPORPHYRINS | EP-SCR | ZPP | Hematoflourometric | Zinc Protoporphyrins 23-78 mol/mol |
| ZINC, RBC | ZNRBC | ZNRBC | ICP/MS | Zinc, RBC 9.0-14.7 mg/L |
| ZINC, URINE (QUANTITATIVE) | ZNCUQ | ZNCUQ | ICP/MS | Collection Period h
Volume mL
Zinc, Urine 15-120 ug/dL
Zinc, Urine 150-1200 ug/d
Zinc, Urine not established ug/gCr
Creatinine, Ur not established mg/dL
Creatinine, Ur mg/d
M 0-2 yrs not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 500-2300
18-50 yrs 1000-2500
51-80 yrs 800-2100
GT 80 yrs 600-2000
F 0-2 yrs not established
3-8 yrs 140-700
9-12 yrs 300-1300
13-17 yrs 400-1600
18-50 yrs 700-1600
51-80 yrs 500-1400
GT 80 yrs 400-1300 |
| ZIPRASIDONE, SERUM/PLASMA | ZIPRA | ZIPRA | HPLC/LC-MS/MS | Ziprasidone ng/mL
In clinical trials, the following mean
plasma concentrtions (+/-1sd) were reported
in non-fasting subjects at steady-state:
Dose Observed Range
10 mg/day 14.9 +/-6.7
40 mg/day 44.6 +/-48
80 mg/day 118 +/-80
120 mg/day 139 +/-81
Steady-state concentrations occurred
1 to 3 days following initialization
of dosing. |
| ZONISAMIDE | ZONI | ZONI | PETIA | Zonisamide 10.0-40.0 ug/mL
The proposed therapeutic range for
seizure control is 10.0-40.0 ug/mL.
Concentrations that exceed 80.0 ug/mL,
may contribute to adverse effects.
Pharmacokinetics varies widely,
particularly with co-medications and/
or compromised renal function. |
